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Abstract 
Folate mediated one-carbon metabolism is a complex biochemical pathway that is essential to the 
cell. Therefore, any impairments or deficiencies can have serious health consequences. Examination 
of the relationship between folate status and DNA methylation in pregnant women showed 
differential methylation patterns between individuals in the DHFR gene, however, the differences 
observed was not associated with folate status. The 19 bp deletion / insertion polymorphism (DIP) 
within the DHFR gene, an enzyme that catalyses the reduction of dihydrofolate to tetrahydrofolate 
has been studied extensively in association with both neural tube defects and folate metabolites but 
the results are controversial. Screening the DHFR 19 bp DIP in the largest cohort yet to address this 
issue and assessment of the DIP with folate metabolites and folate status showed no association 
between the DIP and the folate metabolites or folate status. DHFRL1 is a newly discovered 
reductase enzyme that participates in thymidylate biosynthesis in the mitochondria. Recombinant 
and endogenous DHFRL1 polymorphisms examined for functionality showed the polymorphisms to 
be capable of altering enzyme activity and to be associated with neural tube defects. By altering 
DHFRL1 expression numerous genes have been shown to be affected. The findings above have 
demonstrated the importance of the genes involved in folate metabolism and their relevance for 
human health and disease. 
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Introduction 
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1.1 Overview 
Nutritional genetics is a field of science, whereby the relationship between the human genome, 
nutrition and health is examined. Research fields mainly focus on how different foods can affect our 
health by altering our genes and how genetic differences between individuals can affect the way we 
respond to the different nutrients we eat, helping us to determine what genetic differences may play 
a role in disease risk. The Parle-Mc Dermott lab focuses on a nutrient called folate, a nutrient that is 
essential for numerous cellular functions and one in which, deficiencies have been associated with a 
broad range of clinical diseases (discussed in Section 1.5). At present, genes / proteins involved in 
the folate mediated one-carbon metabolism are considered to be the prime candidates for disease 
association.    
 
My thesis focuses on exploring the molecular mechanism of the role of folate in human health 
and disease with particular focus on folate-sensitive DNA methylation regions, genetic 
polymorphisms within genes involved in the folate mediated one-carbon metabolism pathway and 
the effects of altered DHFRL1 expression, a newly discovered gene involved in folate metabolism 
(Anderson et al., 2011, McEntee et al., 2011) and their association with disease.   
 
This chapter starts off with a general overview of folate, the folate mediated one-carbon 
metabolism pathway and its association with disease, followed by an overview on the impact of 
nutrition on the epigenome, with particular focus on the relationship between folate and DNA 
methylation, continued by a brief introduction on the DHFR gene family and concludes with the 
aims and objectives of my thesis.  
 
1.2 Folate 
Folate is an essential water soluble B9 vitamin that is involved in numerous important metabolic 
pathways such as DNA replication, DNA repair, DNA methylation and nucleotide biosynthesis 
(Iyer and Tomar, 2009). Folate cannot be synthesised by mammalian cells and therefore, it must be 
obtained through the diet. Folate was first isolated from spinach leaves by Mitchell et al. in 1941. It 
can be found naturally in green leafy vegetables such as spinach and turnip greens, citrus fruits, 
dried beans and peas (Rampersaud et al., 2003, Ifergan and Assaraf, 2008, Ohrvik and Witthoft, 
2011). Folic acid is the synthetic, oxidised, chemically stable form of folate and is found in 
supplements and fortified foods such as bread and breakfast cereals. The Recommended Dietary 
Allowance (RDA), the average daily intake that is recommended to meet the nutrient requirement 
of healthy individuals as approved by the European Union is 400 µg/d of dietary folate equivalents 
 3 
 
(DFE) in adults (McPartlin et al., 1993, (WHO), 2002, Food and Nutrition Boards, 2004), and 600 
µg/d DFE for women who are planning a pregnancy (www.ods.od.nih.gov). However, as these 
requirements were not being met, widespread fortification of many foods has occurred and currently, 
there are 80 countries worldwide that have undertaken mandatory fortification of their flour with 
folic acid (Food Fortification Initiative http://www.ffinetwork.org/). Folate is essential in the body 
and must be converted from dihydrofolate to its biologically active form, tetrahydrofolate (THF), 
before it can be employed in the folate mediated one-carbon metabolism pathway (Fox and Stover, 
2008) (Figure 1.1). 
 
1.3 Folate Metabolism 
Folate mediated one-carbon metabolism is a complex biochemical pathway that is essential 
to the cell and can be divided into two main cycles; the DNA replication and repair cycle and the 
methylation cycle (Figure 1.1) (Fox and Stover, 2008). Both these cycles require THFs. THFs are 
water-soluble B-vitamins and are made up of three different components, a fully reduced pterin ring, 
a p-aminobenzoyl group and a poly-γ-glutamate tail (Figure 1.2) (Shane, 1995). THFs are the active 
form of folates and can be absorbed directly into the small intestine. However, folate found in 
natural foods must be hydrolysed into monoglutamate forms before they can be absorbed. This is 
carried out by an enzyme called gamma-glutamyl hydrolase / human conjugase (Beaudin and 
Stover, 2009). Once hydrolysed, these monoglutamates can be transported across the intestinal 
epithelium by proton-coupled folate transporters, by saturable pH-dependent processes or via a non-
saturable passive diffusion process. Once inside, the monoglutamates as well as folic acid, which 
can be absorbed directly into the intestine, can be reduced to their biologically active form, THF by 
an enzyme called dihydrofolate reductase (DHFR) (Iyer and Tomar, 2009, Stover and Field, 2011).  
 
Folates circulate the body as monoglutamate derivatives and enter the cells via reduced 
folate carrier proteins (Sirotnak and Tolner, 1999), through endocytosis by the folate receptors 
(Antony, 1996) or by passive diffusion (Suh et al., 2001). Once folates have been imported into the 
cell, they are converted into polyglutamate derivatives by the addition of a γ-linked polyglutamate 
peptide, ranging from two to nine glutamate residues by an enzyme called folypoly-γ-glutamate 
synthase (FPGS) to retain the folates in the cell (Zhao et al., 2009).  
 
1.4 Compartmentalisation of Folate Mediated One-Carbon Metabolism 
Folate polyglutamates have been found to be present in all subcellular organelles in all cell 
types, where they are involved in activating one-carbon units. Folate mediated one-carbon 
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metabolism is highly compartmentalised between the cytoplasm, mitochondria and nucleus (Figure 
1.1) in eukaryotes, with the majority of folate polyglutamates been shown to be circulated between 
the cytoplasm and the mitochondria, with low levels also seen in the nucleus (Stover and Field, 
2011). However, the type of folate polyglutamates found in the cytoplasm and the mitochondria are 
different. In the cytoplasm, the majority of folate is found in the form of 5-methyl-tetrahydrofolate, 
whereas in the mitochondria, the majority of folate is found in the form of 10-formyl-
tetrahydrofolate (Tibbetts and Appling, 2010).  
 
In the cytoplasm, folate mediated one-carbon metabolism can be divided into three distinct 
pathways, the de novo purine biosynthesis pathway, the de novo thymidylate (dTMP) biosynthesis 
pathway and the homocysteine re-methylation pathway (Figure 1.1). The three pathways are 
interlocked and compete with each other for folate cofactors. In the mitochondria, folate 
metabolism is required to generate formate, which is utilised in cytoplasmic folate mediated one-
carbon metabolism (Stover and Field, 2011), for the interconversion of glycine and serine (Fox and 
Stover, 2008) and for thymidylate biosynthesis (Anderson et al., 2011), and in the nucleus, it is 
required to synthesise thymidylate from uridylate and serine (Stover and Field, 2011, Anderson et 
al., 2012a). 
 
The methylation cycle is responsible for the regular supply of methionine to the cell by 
homocysteine re-methylation. In the presence of adenosine triphosphate (ATP), methionine is 
adenosylated to S-adenosyl methionine (SAM), a universal methyl donor, which donates methyl 
groups for the majority of the methylation reactions within the cell including those required for the 
correct regulation of epigenetic gene activity (Miranda and Jones, 2007). 
 
The de novo dTMP biosynthesis is responsible for producing thymidylate from the 
conversion of deoxyuridylates (dUMPs) to dTMPs. This reaction is catalysed by three enzymes, 
thymidylate synthase (TYMS), serine hydroxymethyltransferase (SHMT) and dihydrofolate 
reductase (DHFR) (Stover and Field, 2011). Until recently, it had been understood that all dTMP 
biosynthesis took place in the cytoplasm and the nucleus. However, in 2011, Anderson et al. 
showed that a de novo thymidylate biosynthesis pathway exists in the mitochondria, with the newly 
discovered gene, DHFRL1 (Anderson et al., 2011, McEntee et al., 2011) taking the place of DHFR.  
 
Recent findings however, have shown that in the nucleus, localisation of TYMS, SHMT 
and DHFR to the nucleus only occurs during the S and G2/M phase of the cell cycle, indicating that 
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the de novo thymidylate synthesis pathway translocates to the nucleus for DNA replication and 
repair (Anderson et al., 2012a). These enzymes are transported to the nucleus from the cytoplasm 
by a post-translational modification known as sumoylation, which adds a small ubiquitin-like 
modifier (SUMO) to the enzymes (Anderson et al., 2007, Woeller et al., 2007).   
 
Although folate mediated one-carbon metabolism is compartmentalised, the compartments 
are connected through the predominantly unidirectional transport of one-carbon donors such as 
formate, serine and glycine, which are transported across the mitochondrial membrane into the 
cytoplasm, i.e. the majority of the one-carbon units that are required for reactions that take place in 
the cytoplasm are derived from the mitochondria (Tibbetts and Appling, 2010).  
 
1.5 Folate and its Association with Disease Risk 
Folate mediated one-carbon metabolism is essential to the cell, and any impairment or 
deficiency can have serious health consequences. Impairments in folate mediated one-carbon 
metabolism can be caused by a number of different factors such as reduced folate status resulting 
from malnutrition, low intake of folate-containing foods, malabsorption, certain drugs or severe 
alcoholism, polymorphisms in genes that are involved in folate metabolism, and deficiencies in 
secondary micronutrients such as iron and other B vitamins that can alter folate status (Stover and 
Garza, 2002). Folate deficiency has been associated with a broad range of clinical diseases, ranging 
from sub-optimal folate deficiencies such as neural tube defects and cancer as well as severe folate 
deficiencies such as megaloblastic anaemia.  
 
1.5.1 Sub-optimal folate deficiencies 
Sub-optimal folate deficiencies are common in the general population and contribute to 
numerous multi-factorial diseases. Those who have suboptimal folate deficiencies are not folate 
deficient but have folate levels that are slightly below the average. 
 
1.5.1.1 Folate and Neural Tube Defects 
The most commonly known disease associated with folate deficiency are neural tube 
defects (NTDs) (Scott et al., 1994). Neural tube defects are the most frequent congenital 
abnormality of the central nervous system. They are birth defects of the brain and spinal cord and 
occur when the neural tube, the embryonic precursor of the brain and spinal cord, fails to close on 
around day 28 of pregnancy (van der Put et al., 2001). Although several environmental and genetic 
factors are thought to contribute to the development of NTDs, numerous intervention studies have 
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shown that folate status is a major determinant of NTD risk, with peri-conceptional folic acid 
supplementation demonstrated to reduce / prevent the risk of NTDs in the majority of pregnancies 
(1991, Czeizel and Dudás, 1992, Berry et al., 1999). However, the exact mechanism underlying 
how folate reduces the risk of NTDs has not yet been established. 
 
 As pregnancy is a time associated with the growth of an embryo, increased nucleotide 
synthesis is required for cell division and DNA replication to occur. Both of these are one-carbon 
transfer reactions, and therefore, a considerable increase in folate is required during pregnancy in 
order to ensure a sufficient supply. With this in mind, Barber et al. (1999) hypothesised that if 
neuroepithelial cells do not have an adequate internal supply of nucleotides, cellular replication will 
slow down and the development of the neural folds will be retarded.  
 
Folates are also involved in the methylation pathway, and therefore, a disruption in the 
methylation pathway has also been suggested to be responsible for the relation between folate and 
NTDs. Studies in mouse models have shown that by disturbing the methylation cycle in mouse 
embryos by cycloleucine or methionine administration during cranial neurulation resulted in an 
increase prevalence of NTDs (Dunlevy et al., 2006a, Dunlevy et al., 2006b). Chick embryo models 
treated with methylation cycle inhibitors also showed a delay in the closure of the neural tube 
(Afman et al., 2005). However, the cellular, molecular or genetic mechanisms by which methylation 
interferes with neurulation are still largely unknown but recent work from the laboratory identified a 
range of genes that are differentially expressed in the presence of a methylation inhibitor compared 
to control cells (Carroll et al., 2012). 
 
Polymorphisms in genes such as MTHFR, MTHFD1, MTHFD1L involved in the folate-
mediated one carbon metabolism pathway have also been associated with NTD risk (van der Put et 
al., 1995, Botto and Yang, 2000, Brody et al., 2002, Parle-McDermott et al., 2006, Parle-
McDermott et al., 2009). The MTHFR 677 C>T polymorphism is one of the most widely studied 
polymorphisms that is associated with NTDs. The MTHFR 677 C>T SNP causes an alanine to 
valine amino acid substitution, resulting in an enzyme that is ~50-60 % less active in individuals 
who are homozygous TT for the SNP (Yamada et al., 2001). Studies have also shown an elevated 
risk of ~50-70 % for maternal TT genotype and an 80-90 % for fetal genotype (Whitehead et al., 
1995, Shields et al., 1999, Blom et al., 2006). MTHFD1 R653Q polymorphism is another 
polymorphism that has been strongly associated with maternal risk of NTDs. Although the 
functional effect of this polymorphism has not yet been shown, it is thought to increase the risk of 
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NTDs by altering metabolic outcomes as no affect in folate or homocysteine levels have been 
reported, i.e. it may be the result of a negative effect on the de novo nucleotide biosynthesis 
pathway (Parle-McDermott et al., 2006). Therefore, although the exact mechanism underlying how 
folate reduces the risk of NTDs has not yet been established, evidence to date suggests that NTDs 
are a multi-factorial disease, caused by the interaction of gene polymorphisms, nutrients and folate 
enzymes (Moyers and Bailey, 2001, De Marco et al., 2011).  
 
1.5.1.2 Folate and Congenital Heart Defects  
 Congenital heart defects (CHD) are one of the most common types of birth defects and are 
caused by a defect in the structure of the heart and / or vessels, which are present at birth. Numerous 
types of defects can occur, most of which either obstruct blood flow in the heart or vessels near it, 
or cause blood to flow through the heart in an abnormal pattern. The heart’s rhythm can also be 
affected. Numerous studies have shown that folic acid supplementation significantly reduced CHD, 
most obviously in ventricular septal defects and conotruncal defects (Czeizel and Dudás, 1992, 
Czeizel et al., 1996, Botto et al., 2003, Czeizel et al., 2004). Although it is not known how folate 
reduces the risk of CHD, folic acid antagonist drugs that target and inhibit DHFR, an enzyme 
required for DNA synthesis (Figure 1.1) increased the risk of CHD in the children of pregnant 
women (Czeizel et al., 2013) suggesting that an inadequate supply of nucleotides may be a cause of 
CHD. An association between high levels of plasma homocysteine caused by a polymorphism in 
the MTHFR gene and the risk of CHD was also found. Meta-analysis studies showed that both 
infant and maternal MTHFR C677T polymorphisms may contribute to the risk of CHD (van 
Beynum et al., 2006). 
 
1.5.1.3 Folate and Cancer 
The association between folic acid supplementation and cancer is highly controversial, with 
some studies suggesting that folic acid supplementation can increase the risk of cancer, while others 
suggesting that it has a protective role. High folic acid concentrations have been associated with 
certain types of cancer such as prostate, lung and ovarian cancers (Stolzenberg-Solomon et al., 
2006). On the other hand, an association between folate deficiency and the development of certain 
cancers such as colon, breast, ovary, pancreas, brain, lung and cervical cancer (McNulty and Scott, 
2008, Duthie, 2011) as well as cognitive defects (Blount et al., 1997) has been shown. The most 
convincing data are for colorectal cancers with numerous epidemiologic studies suggesting that 
high folate intake may reduce the risk of colorectal cancer (Giovannucci et al., 1998, Choi and 
Mason, 2002, Leahy et al., 2005, Van Guelpen et al., 2006, Pompei et al., 2007), although one 
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intervention trial did show that folic acid supplementation increases the risk of colorectal cancer 
(Cole et al., 2007). Recent meta-analysis study carried out on randomised trials have also found that 
overall folic acid supplementation has no significant effects on total cancer incidence, colorectal 
cancer, gastrointestinal cancer, prostate cancer, genitourinary cancer, lung cancer, breast cancer, 
haematological malignancy and total cancer mortality, although a significantly reduced risk was 
seen for melanoma (Qin et al., 2013). The evidence above suggests folate may have a dual function 
as it seems to both increase the risk in some cases, while having a protective role in others. Animal 
studies that have been carried out also support this theory. They suggest that the effect of folate 
consumption on carcinogenesis may depend on the dose and the timing of folate exposure, with 
folate deficiency enhancing the risk of carcinogenesis in normal healthy cells, while folate 
supplementation enhancing the progression of existing tumour cells (Kim, 2003, Ulrich and Potter, 
2007).   
 
Folate deficiency could influence cancer risk by numerous mechanisms. Severe folate 
deficiency can provoke widespread chromosome damage, fragile site expression, micronucleus 
formation and increased uracil levels in bone marrow cell DNA. When folate is deficient, it has 
been hypothesised that the availability of 5-10 methylenetetrahydrofolate decreases, reducing 
thymidylate synthesis, causing DNA polymerase-mediated uracil misincorporation, resulting in 
DNA strand breaks and chromosome instability (Blount et al., 1997, Giovannucci, 2002). Folate 
deficiency could also result in aberrant DNA methylation patterns, resulting in the altered 
expression of critical proto-oncogenes and tumour suppressor genes (Choi and Mason, 2000). 
Polymorphisms in folate related genes such as MTHFR (Izmirli, 2013) and DHFR (Xu et al., 2007, 
Gemmati et al., 2009) may also influence cancer risk. 
 
1.5.1.4 Folate and Neurological Diseases 
Folate deficiency has also recently been associated with a number of neurological diseases 
such as Alzheimer’s disease (Tchantchou and Shea, 2008), Parkinson’s disease (Mattson and Shea, 
2003) and depression (Bottiglieri, 2005). One study showed that depressed and schizophrenic 
patients receiving 5 mg of methyl-folate per day demonstrate significant improvements in both 
clinical and social recovery (Godfrey et al., 1990). Although the exact mechanism of how folate 
reduces the risk of neurological disease is unknown, it is thought that as there is normally an 
intrinsic balance between folate and homocysteine levels within the cell, when folate is deficient, 
homocysteine, a cytotoxic sulphur containing amino acid cannot be re-methylated back to 
methionine, due to reduced levels of SAM, and therefore, homocysteine levels are high. SAM is a 
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key player in mood enhancement and therefore, folic acid supplementation is thought to reduce 
depression (Iyer and Tomar, 2009). Reduced levels of SAM also results in an increase in 
homocysteine levels. This increase in homocysteine levels can bring about abnormalities in neural 
cell proliferation, which have been related to neurodegenerative conditions (Tchantchou and Shea, 
2008). Plasma homocysteine levels have also been shown to increase in Alzheimer’s disease 
patients, with low levels of folate and SAM observed in the spinal fluid (Mattson and Shea, 2003) 
An accumulation of amyloid β–peptide is a known contributing factor to the development of 
Alzheimer’s disease and there is some evidence to suggest that increased homocysteine 
concentrations can lead to increased amyloid β–peptide concentration leading to neurodegeneration 
(Ho et al., 2001). Parkinson’s disease has also been associated with elevated homocysteine levels. 
In a neuron cell culture model, both folate deprivation and homocysteine made the cells more 
sensitive to damage and death, speeding up the onset and progression of the disease (Duan et al., 
2002). These studies suggest that elevated homocysteine levels are associated with neurological 
diseases. 
 
1.5.1.5 Folate and Cerebrovascular and cardiovascular disease 
Cardiovascular diseases (CVD) are one of the most widespread diseases in the Western 
population and are disorders of the heart and blood vessels. These include diseases such as heart 
attacks, stroke and high blood pressure, as well as cerebrovascular diseases which refer to a group 
of diseases caused by problems in the blood vessels that supply the brain. Numerous factors are 
thought to contribute to the development of CVD. The associations between folate status and CVD 
and cerebrovascular disease have been highly controversial. Many studies have argued that 
inadequate folate intake increases the risk of cerebrovascular and cardiovascular disease, as folate 
deficiency decreases folate-dependent methylation of homocysteine, resulting in elevated levels of 
plasma homocysteine, a cytotoxic sulphur containing amino acid (Blount et al., 1997). High levels 
of homocysteine, however can also be caused by polymorphisms in a number of folate related genes 
such as MTHFR, where individuals with the TT MTHFR 677 C>T genotype have been shown to 
exhibit moderate hyperhomocysteinemia (Dwivedi et al., 2011). High levels of homocysteine have 
been used as an indicator for CVD in the past (Collaboration, 2002). However, recent studies have 
shown that folic acid supplementation does not reduce the risk of cardiovascular disease in 
secondary prevention although it does reduce homocysteine levels (Bazzano et al., 2006, Clarke et 
al., 2012). Nonetheless, there is still no conclusive evidence that links or doesn’t link folic status / 
homocysteine levels with CVD or cerebrovascular disease. 
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1.5.1.6 Effects of Excess Folic Acid on Health and Disease  
Although all of the above diseases seem to be a result of folate deficiency, recent studies 
have suggested that excess folate / folic acid supplementation can also increase the risk of disease, 
raising many concerns. As mentioned earlier (Section 1.5.1.2), randomised clinical trials where 
participants with a recent history of a colorectal adenoma were either given a folic acid supplement 
or a placebo showed that those who took the supplement had a higher risk of having more 
adenomas (Cole et al., 2007). However, a recent study has shown that folic acid supplementation 
has no effect on colorectal cancer (Figueiredo et al., 2011). Similar findings were also seen in the 
case of prostate cancer (Figueiredo et al., 2009, Vollset et al., 2013). Apart from cancer, folic acid 
supplementation during pregnancy has also been linked to the increased risk of asthma in children, 
although results here have also been controversial (Whitrow et al., 2009, Martinussen et al., 2012).  
 
1.5.2 Severe Folate Deficiencies 
1.5.2.1 Folate and Megaloblastic Anaemia 
Megaloblastic anaemia is a disorder, which is characterised by the presence of megaloblasts, 
very large red blood cells in which the inner contents of each cell is not entirely developed. Red 
blood cells have a high turnover rate, and therefore, when folate levels are low, DNA synthesis is 
reduced, resulting in the prolongation of the synthesis phase of cell division. This causes the red 
blood cells to become enlarged. When folate is severely deficient, the megaloblasts accumulate in 
the bone marrow, reducing cell division, as well as the number of white blood cells and platelets 
resulting in anaemia (Bailey and Gregory, 1999).  
 
From the above, we can see that folic acid supplementation can both increase and decrease 
the risk of disease. However, the exact mechanisms of how folate increases / reduces the risk of 
specific diseases is not fully known. Nevertheless, a number of mechanisms such as cell 
proliferation rates, prevention of uracil misincorporation and alteration to DNA methylation 
patterns have been proposed, with the relationship between folate and DNA methylation discussed 
below. 
 
1.6 Epigenetics and DNA Methylation 
Epigenetics is the study of mitotically or meiotically heritable changes in gene expression 
or phenotype that do not result from an alteration in the DNA sequence itself, i.e. regulation post-
DNA level. Epigenetic modifications have been up to recently grouped into three main categories, 
DNA methylation, histone modifications and chromatin remodelling that interplay with each other 
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(Portela and Esteller, 2010). However, in recent times, they have also included non-coding RNA 
and microRNA gene regulation. These epigenetic modifications can change throughout a person’s 
lifetime and can be greatly influenced by environmental factors such as diet, chemical exposures, 
smoking, prenatal and parental care, prenatal nutrition, infectious agents and stress (Anderson et al., 
2012c).  
 
DNA methylation is the most commonly studied form of epigenetic modification and the 
one that is the type of modification that may show trans-generational effects following in utero 
exposure. DNA methylation is the addition of a methyl group to a cytosine residue and is mediated 
by DNA methyltransferases (DNMTs) (Figure 1.3) and usually occurs in CpG islands, i.e. CpG rich 
regions in the promoter region of a given gene. However, recent studies have shown that 
methylation can occur in a non-CpG context and were found to be prevalent in embryonic stem 
cells (Lister et al., 2009b). When DNA is methylated in a region of a gene, it is generally associated 
with the silencing of gene expression, whereas when DNA is not methylated, it is associated with 
activation of gene expression. The precise mechanism of how DNA methylation affects gene 
control has not yet been elucidated but it is thought to involve the interference of methylated 
cytosine residues with the binding of the RNA polymerase complex and associated transcription 
factors through an interaction with chromatin (Klose and Bird, 2006) (Figure 1.4). However, more 
recent studies have shown that DNA methylation is not always associated with transcriptional 
repression (Ball et al., 2009) and that the relationship with gene control is much more complex than 
previously thought. Methylation occurring in the bodies of genes has recently been shown to be 
positively associated with active transcription on the active X chromosome (Hellman and Chess, 
2007, Jones, 2012). The exact function of gene body methylation is yet unknown, but it was 
originally thought to be a mechanism for silencing the transcription of repetitive DNA elements, 
such as retroviruses, LINE1 elements and Alu elements, while allowing gene transcription to 
continue. A number of more recent whole-genome studies have however, shown alternate functions 
for gene body methylation. These studies have shown that exons are more highly methylated than 
introns, and that methylation differences occur at exon–intron boundaries, suggesting that gene 
body methylation plays a role in regulating splicing (Jones, 2012).  
 
It has also recently been found that DNA methylation does not always have to occur in the 
context of a CpG as had been previously thought, but that it can also occur in a non-CpG context. 
This was first shown by Lister et al. in 2009. They examined the DNA methylation patterns of 
human stem cells and fetal fibroblasts and found that non-CpG methylation was mostly enriched in 
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the coding regions of genes in stem cells. However, this non-CpG methylation begun to be lost 
during cellular differentiation and was found to be a specific feature of stem cells. In fibroblasts, 
reduced methylation levels were seen to be associated with lower transcriptional activity for 
specific genes, supporting previous research that showed that DNA hypomethylation does not 
always have to be associated with high transcriptional activity levels (Lister et al., 2009b, Parle-
McDermott and Ozaki, 2011). 
 
DNA methylation can be used in a variety of different ways by cells to control gene 
expression. These range from tissue-specific gene expression to inactivation of imprinted genes, the 
X-chromosome and transposable elements. DNA methylation is best known for its role in imprinted 
genes during differentiation where gene expression is permanently switched on or off. This 
epigenetic mode of regulation is stable and is passed on from parents to offspring (Jirtle and Skinner, 
2007). DNA methylation can also be metastable, subject to change in response to environmental 
factors. No definitive term has been assigned to describe these sites but they are sometimes referred 
to as epialleles (Dolinoy et al., 2007). Due to these, changes in DNA methylation have been 
associated with a number of disease states such as imprinted disorders (Paulsen and Ferguson-Smith, 
2001), tumourigenesis (Esteller, 2005), neurological disorders (Urdinguio et al., 2009), 
cardiovascular disease (Kim et al., 2010) and autoimmune diseases (Richardson, 2003). 
 
1.7 The Methylome 
DNA methylation patterns have been shown to vary between tissues within individuals but 
also between individuals. However, the range and variability of these patterns has not yet been 
established. At present, the Human Epigenome Project (HEP) (Eckhardt et al., 2004) and the NIH 
Roadmap Epigenomics (http://www.roadmapepigenomics.org/) projects are trying to decipher the 
variation in DNA methylation patterns by creating a catalogue of the variety of human epigenetic 
marks including Methylation Variable Positions (MVPs), DNA methylation sites that vary in 
different tissues, between individuals and in disease states. This will hopefully in the not so distant 
future, provide us with an insight into human epigenome patterns. Reviewed in (Parle-McDermott 
and Ozaki, 2011) – See Appendix. 
 
Although 5-methylcytosine (5mC) has always been deemed to be the ‘fifth’ DNA base, a 
‘sixth’ base has recently been discovered in the form of 5-hydroxymethylcytosine (5hmC) 
(Kriaucionis and Heintz, 2009, Tahiliani et al., 2009). 5mC is catalysed to 5hmC by an enzyme 
known as tet methylcytosine dioxygenase 1 (TET1), a 2-oxoglutarate and Fe(II) dependent enzyme, 
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which can bind throughout the genome in embryonic stem cells as well as in neurons and the brain 
and binds particularly at high density CpG sites in the gene promoters and within specific genes 
(Kriaucionis and Heintz, 2009). 5hmC modifications showed a similar pattern to TET1 binding, 
which is in contrast to 5mC, which is primarily found in low density CpG sites. However, 5mC and 
5hmC are similar in that they both play a role in transcriptional silencing (Williams et al., 2011). 
5hmC is also thought to play roles in DNA methylation regulation (Tahiliani et al., 2009), 
prompting DNA de-methylation (Hackett et al., 2013) as well as in the ‘priming’ of specific genes 
for rapid activation (Kriaucionis and Heintz, 2009).  
 
Even though there have been rapid developments made in deciphering the epigenome in 
recent times, comprehending the relevance of these epigenetic marks and how they differ between 
tissues and individuals is not yet understood. Many of the studies that have been carried out to date 
have also only examined the environmental impacts on 5mC although it is likely that 5hmC levels 
are also influenced and altered by environmental factors, due to the fact that the majority of the 
DNA methylation techniques available at present are unable to distinguish the difference between 
5mC and 5hmC. Therefore, these studies may need to be re-evaluated in order to take the newly 
identified ‘sixth’ base into consideration (Parle-McDermott and Ozaki, 2011). 
 
1.8 Fetal Origins of Disease 
DNA methylation patterns of an individual are known to change throughout their lifetime. 
This was first shown by a twin study carried out by Fraga et al. who showed how the epigenome of 
identical twins became divergent as they aged (Fraga et al., 2005). More recently, the evidence 
showing that the human in utero environment can impact on DNA methylation patterns and disease 
risk of the subsequent offspring has been increasing. This relates back to the “fetal origins of adult 
disease” theory originally proposed by Barker (Barker et al., 1989). Barker et al. initially examined 
the association between fetal growth impairment with cardiovascular disease (Barker and Martyn, 
1992, Barker, 1993, Barker, 1997) and the relationship between birth weight and impaired glucose 
tolerance (Hales et al., 1991). From these studies, he proposed the ‘fetal origins of disease’ 
hypothesis, which states that susceptibility to adulthood cardiovascular disease (CVD), non-insulin-
dependent diabetes mellitus (NIDDM), and the insulin resistance syndrome (IRS) is programmed in 
utero in response to fetal under-nutrition.  
 
Different environmental stimuli / constraints such as unbalanced nutrition in early life have 
also been shown to be associated with an increased risk of many other diseases later in adult life and 
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have been shown to cause metabolic and structural alterations that result in phenotypic changes in 
the offspring. These changes and effects caused by environmental stimuli have been examined and 
documented at length in epidemiological studies (Godfrey and Barker, 2001), in whole animals 
(Bertram and Hanson, 2001), in specific cells types (Heywood et al., 2004) and in early embryos 
(Kwong et al., 2000), with a wealth of literature supporting the ‘fetal origins of human disease’ 
concept (Barker et al., 1989).  
 
In addition to the above studies, studies such as the Dutch Hunger Winter, have given us an 
insight into the importance of nutrition status during a critical period of life on long-term effects. 
The Dutch Hunger Winter was a period during the winter of 1944, when the Nazi’s occupied parts 
of the Netherlands. During this time, a famine was forced upon people who were previously well-
nourished. The studies carried out on the Dutch cohort examined the outcomes and consequences of 
maternal under-nutrition on offspring on a long lasting scale. The studies found that in utero 
exposure to famine was associated with increased risks of obesity (men) (Ravelli et al., 1976), 
schizophrenia (Hoek et al., 1996), prevalence of obstructive airways disease (Lopuhaä et al., 2000), 
impaired glucose and lipid homeostasis, coronary heart disease, breast cancer (women) and reduced 
renal function (Roseboom et al., 2006), 4-5 decades later in life, in a manner that is dependent on 
gestational age at the time of exposure to famine. The worst effects were seen in the children who 
were born to mothers who experienced severe under-nutrition during the first trimester of 
pregnancy, suggesting that the first trimester of pregnancy is a particularly vulnerable period that 
can have severe consequences of disease later in adult life. With fetal programming for other 
adulthood diseases being examined subsequent to the original studies, it is now hypothesised that 
the in utero environment has a significant role in an individual’s risk of contracting a number of 
diseases later in their adult life.  
 
However, the molecular mechanism underlying these changes has not yet been identified. 
On the other hand, the mechanisms proposed in relation to how environmental influences / the in 
utero environment can have an effect on an individual’s risk of disease later in life are numerous, 
with DNA methylation as a mediator of these effects being a popular theory. Despite this, studies 
that provide direct evidence to support epigenetic modifications as a mechanism for this theory have 
only recently begun to emerge. These include prenatal exposure to tobacco smoke and exposure to 
airborne polycyclic aromatic hydrocarbons and risk of childhood asthma. Two recent studies have 
also shown a strong link between folate availability in utero and risk of insulin resistance (Yajnik et 
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al., 2008) and childhood asthma (Håberg et al., 2009, Whitrow et al., 2009). However, whether and 
how folate is mediating these effects via changes in DNA methylation has not been studied at length. 
 
1.9 Folate and DNA methylation 
The relationship between folate and DNA methylation in fetal programming was initially 
clearly demonstrated by the classical study of the agouti gene in viable yellow agouti (A
vy
) mice by 
Waterland and Jirtle (Waterland and Jirtle, 2003). The agouti gene is a gene that is expressed in 
mice hair follicles during a short period of hair development and growth and encodes a paracrine 
signalling molecule, which is responsible for the production of the yellow pigment, pheomelanin. In 
normal wild type mice, a yellow band appears on the otherwise brownish hair. A metastable allele 
due to the spontaneous insertion of an intracisternal A particle (IAP) retrotransposon upstream of 
the agouti gene results in the viable yellow agouti mice. A cryptic promoter within the IAP is what 
causes the permanent and constitutive agouti expression in all of the tissues in A
vy
 mice that result in 
the yellow coat. These mice are also extremely obese due to ectopic agouti expression in the 
hypothalamus. This insertion of the IAP into the agouti gene causes epigenetic dysregulation, 
causing inter-individual variability in CpG methylation at the A
vy
 locus. Therefore, within a single 
litter of genetically identical A
vy
/a mice, depending on the methylation status of the 7 CpG 
dinucleotides found in the promoter at the proximal end of the A
vy
 IAP, the agouti gene can produce 
a range of phenotypes, from yellow and obese to brown/black and slim. Waterland and Jirtle tested 
whether the metastable methylation status of the specific transposable element insertion sites in 
agouti mice are epigenetically labile to early methyl donor nutrition. The results showed that a 
maternal diet supplemented with methyl donating dietary vitamins, such as folic acid, vitamin B12, 
choline and betaine during pregnancy can alter the phenotype of their genetically identical offspring 
via increased CpG methylation at the A
vy
 locus. Hypomethylated A
vy
 alleles allowed maximal 
ectopic agouti expression causing the mice to have a yellow coat whereas hypermethylation of the 
A
vy
 alleles silences the ectopic agouti expression in pseudoagouti animals, giving them a brown coat 
(Waterland and Jirtle, 2003) (Figure 1.5). 
 
Similar findings have been confirmed in other experimental models, such as the effect of 
maternal methyl donor supplementation on tail kinking due to the metastable axin-fused epiallele in 
mice (Waterland et al., 2006a) and the effect of a low protein diet during pregnancy on the 
methylation status of the hepatic peroxisome proliferator activated receptor γ and the 
glucocorticoid receptor gene in rats (Lillycrop et al., 2005, Choudhuri et al., 2010). Research that 
has examined the effect of methyl donor deficiencies in the mothers, rather than the offspring, as 
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well as those investigating the effect of post-natal diet have also been carried out. Methyl donor 
deficient diets in both cases showed differences in the methylation status of specific genes, p53 in 
mothers (Pogribny et al., 1995) and Igf2 (Waterland et al., 2006b) in the post-natal diet study. A 
recent study has also looked at the impact of a folate deficient diet on methylation in female mice, 
prior to, during pregnancy and lactation in blood, liver and kidney cells (McKay et al., 2011). 
Methylation changes that were tissue specific were seen. The above findings demonstrate that 
dietary supplementation influences the establishment of epigenetic gene regulation both trans-
generationally, as well as at the organism level in animals and also suggest that dietary 
supplementation may influence the establishment of epigenetic gene regulation in humans.  
 
Apart from the DNA methylation cycle, the DNA synthesis pathway mentioned in Section 
1.3 also uses THF for its reaction and plays an important role in the folate mediated one-carbon 
metabolism pathway. One important enzyme involved in this pathway is DHFR. 
 
1.10 The Dihydrofolate Reductase Gene Family 
DHFR plays an important role in health and disease, and has therefore been researched at 
length and remains to be a gene of great interest. The DHFR gene family consists of five genes, 
which are highly homologous and are dispersed across the genome. DHFR is located on 
chromosome 5 (Chen et al., 1984), DHFRP1 on chromosome 18  (Anagnou et al., 1984, Anagnou et 
al., 1988), DHFRP2 on chromosome 6 (Shimada et al., 1984, Mighell et al., 2000), DHFRP3 on 
chromosome 2 (Shimada et al., 1984) and DHFRP4/DHFRL1 on chromosome 3 (Shimada et al., 
1984, Mighell et al., 2000) (Figure 1.6). The first functional human DHFR gene was characterised 
by Chen et al. in 1983 (Chen et al., 1984). The other four members of the DHFR gene family were 
up until recently thought to be pseudogenes, i.e. genes which are similar to one or more paralogous 
genes, but without any function, i.e. they are not transcribed or translated into a functional protein. 
However, in 2011, the DHFRP4/DHFRL1 gene was in fact shown to be a retrogene - expressed and 
functional (McEntee et al., 2011). 
 
1.11 Dihydrofolate Reductase 
DHFR is an important enzyme that plays an essential role in folate metabolism and is found 
in all eukaryotes and prokaryotes. DHFR catalyses the reduction of dihydrofolate (DHF) and folic 
acid to its biologically active metabolite, THF, which accepts and donates one-carbon groups for 
reactions that are necessary for DNA synthesis, cell proliferation and cellular methylation. This 
vital reaction occurs in the presence of NADPH. The reaction involves the transfer of a hydride ion 
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from NADPH to the C6 atom of the pterin ring of DHF, together with a protonation reaction to 
produce THF (Figure 1.7). Therefore, DHFR plays a central role in maintaining the cellular pools of 
THF and its derivatives, which are required for purine and thymidylate synthesis as well as cellular 
methylation (Schnell et al., 2004). However, there is a limit to the capacity to which DHFR can 
convert folic acid to THF and therefore if folic acid is ingested in doses higher than ~300 µg, 
unmetabolised folic acid appears to be found in the circulation. Although folic acid lacks any 
coenzyme activity, in vitro studies have shown that it can act as an inhibitor of DHFR, further 
restricting its conversion to the biologically active THF. Individuals have also been shown to have 
high variation in their DHFR activity, suggesting that folic acid supplementation could result in 
variable production of folate forms, which in turn could have inconsistent impacts on DNA 
methylation (Bailey and Ayling, 2009). High levels of folic acid in the circulation have also 
recently been found to be associated with colorectal tumorigenesis and prostate cancer, causing 
concern. However, the effect of unmetabolised folic acid on DNA methylation has never been 
investigated to the best of my knowledge.  
 
In normal cells, DHFR expression is tightly controlled at the transcriptional, translational 
and post-translational level. During the cell cycle, DHFR transcription is controlled by the 
transcription factors Sp1 and E2F, with high levels of DHFR expression seen in late G1 / early S 
phase. E2F sites have been shown to repress transcription in the G0 and early G1 phase, whereas Sp1 
sites have been shown to mediate the induction of DHFR transcription in the late G1 phase (Jensen, 
1997). DHFR translation is controlled by the binding of the DHFR protein to its own mRNA, i.e. an 
auto-regulatory mechanism (Tai et al., 2004). DHFR is also subject to post-translational 
modifications, such as monoubiquitination and sumoylation. DHFR has been shown to undergo 
sumoylation in vitro by a protein called SUMO-1. Sumoylation is thought to occur during the S 
phase, and is believed to facilitate the translocation of DHFR to the nucleus, where it is involved in 
the de novo nuclear thymidylate synthesis pathway (Figure 1.1) (Anderson et al., 2007). 
 
As DHFR plays a crucial role in the folate pathway, DHFR has been targeted for many 
different anti-folate drug therapies, as the inhibition of DHFR can limit the growth and proliferation 
of cells that are characteristic of cancer. DHFR inhibition can also kill prokaryotes such as 
Staphylococcus aureus and Mycobacterium, as well as unicellular eukaryotes such as Plasmodium 
falciparum (Hecht et al., 2011). Chemotherapeutic drugs include those such as methotrexate (MTX), 
which has been used in the treatment of leukaemia, non-Hodgkin’s lymphoma, breast cancer, 
osteosarcoma and also the autoimmune disease rheumatoid arthritis (Goto et al., 2001, Schnell et al., 
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2004, Walling, 2006) for over 50 years. Other drugs such as trimethoprim and pyrimethamine target 
bacterial and protozoal DHFR with pyrimethamine being an effective treatment of malaria (Roper 
et al., 2004). However, in response to the extensive use of antibiotics and anti-malarial drugs, 
DHFR has shown that it has the ability to resist / has developed resistance towards many of the anti-
folate drugs in many organisms, via DHFR gene amplifications, mutations in DHFR, a decrease in 
the uptake of drugs among others, rendering them ineffective as chemotherapeutics (Hecht et al., 
2011). 
 
1.12 Dihydrofolate Reductase Like-1  
Recent research has shown that DHFRL1 is in fact a functioning retrogene (Anderson et al., 
2011, McEntee et al., 2011) that localises to the mitochondria and takes the place of DHFR in 
mitochondrial de novo thymidylate biosynthesis (Anderson et al., 2011). DHFRL1 has a 92% 
sequence homology to DHFR and the amino acids required for both catalytic activity and those 
involved in the binding of folate and NADPH in DHFR are also highly conserved in DHFRL1 with 
just three differences at positions 24 (W24R), 54 (K54R) and 81 (V81I). The W24R substitution is 
of significance, as previous studies have shown that a tryptophan at position 24 of DHFR is 
important for substrate binding (Beard et al., 1991, McEntee et al., 2011). 
 
McEntee et al. also showed that recombinant DHFRL1 can complement a DHFR-negative 
phenotype in both bacterial and mammalian cells and that it is has enzyme activity although its 
specific activity was ~30% lower in comparison to DHFR. The Km values for NADPH were similar 
in both enzymes, whereas DHFRL1 has a higher Km for DHF than DHFR. The difference in 
specific activity / Km is thought to be due to the W24R substitution in the catalytic site. Like DHFR, 
DHFRL1 can also regulate its own translation by binding to its own mRNA, resulting in 
translational repression, as well as to the mRNA of DHFR and vice versa. This may have 
implications on the use of anti-folate drugs, particularly if the two enzymes show to have different 
binding affinities for different anti-folate drugs. In comparison, the localisation of DHFRL1 to the 
mitochondria suggests that mitochondrial DHFR activity may be optimal with a lowered affinity for 
DHF and that its primary role is to support mitochondrial DNA synthesis and replication (McEntee 
et al., 2011).  
 
 The literature presented above demonstrates the importance of the different aspects of the 
folate mediated one-carbon metabolism pathway and its association with human health and disease. 
These findings form the basis of my thesis, of which the aims and objectives are outlined below. 
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1.13 Aims & Objectives 
The aim of this project is to explore the molecular mechanism of the role of folate in human health. 
This will be achieved through three specific Aims (Figure 1.8): 
 Investigation of the impact of folic acid supplementation on gene-specific DNA 
methylation patterns during pregnancy. 
 Understanding the functional relevance of specific polymorphisms from the DHFR gene 
family and their relevance for disease.  
 Investigation of the effect of altered DHFRL1 expression on genes / proteins.  
 
The aims will be achieved through the following Objectives (Figure 1.8):  
1. Screening of candidate human folate sensitive DNA methylation sites identified from the 
literature in a folic acid intervention pregnancy study using Methylation Sensitive-High 
Resolution Melting (MS-HRM) curve analysis.  
2. Assessment of DNA methylation changes in the promoter regions of DHFR and DHFRL1 
in a folic acid intervention pregnancy study using Sensitive Melting Analysis after Real 
Time-Methylation Specific PCR (SMART-MSP) analysis. 
3. Correlation of DHFR 19 bp intron polymorphism with circulating metabolites. 
4. Characterisation of endogenous DHFRL1 and its polymorphisms in the mitochondria.  
5. Characterisation of recombinant DHFRL1 and its polymorphisms.   
6. Proteomic analysis of DHFRL1 expression. 
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Figure 1.1 Compartmentalisation of folate mediated one-carbon metabolism.  Folate mediated 
one-carbon metabolism is a complex biochemical pathway that is essential to the cell. It is 
compartmentalised between the cytoplasm, mitochondria and the nucleus. In the cytoplasm, folate 
mediated one-carbon metabolism can be divided into three distinct pathways, the de novo purine 
biosynthesis pathway, the de novo thymidylate (dTMPs) biosynthesis pathway and the 
homocysteine (Hcy) re-methylation pathway (methyl cycle). In the mitochondria, the folate 
mediated one-carbon metabolism pathway is required to generate formate, which is utilised in 
cytoplasmic folate mediated one-carbon metabolism as well as supplying 5,10-methyleneTHF for 
de novo thymidylate synthesis from uridylate (dUMP) and serine and in the nucleus, the pathway is 
required to synthesise thymidylate from dUMP and serine. Image adapted from (Tibbetts and 
Appling, 2010). 
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Figure 1.2 Structure of tetrahydrofolate (THF). THFs are made up of a fully reduced pterin ring, 
a p-aminobenzoyl group (pABA) and a poly-γ-glutamate tail (Glu). Image taken from (Stover and 
Field, 2011). 
 
 
 
 
 
Figure 1.3. Overview of DNA methylation. DNA methylation is the addition of a methyl group 
(CH3) to a cytosine residue. DNMT catalyses the transfer of the methyl group from SAM to the 5-
carbon position of cytosine. Image adapted from (Klose and Bird, 2006). 
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Figure 1.4. The role of CpG island methylation in the control of gene transcription. The 
illustration shows unmethylated and methylated CpG islands (CGI) in the promoter region of a 
given gene. Open circle lollipops indicate unmethylated cytosines, closed circle lollipops indicate 
methylated cytosines. (A) Unmethylated CGIs are usually in a transcriptionally active state. 
Transcription factors (TFs) recognise specific DNA motifs in the promoter and facilitate binding of 
the RNA polymerase II (RNApolII) complex to initiate transcription at the transcription start site 
(curved arrow). (B) Methylated CGIs are associated with a transcriptionally repressed state. This is 
thought to be due to the binding of methyl-binding protein (MBP), which recognises methylated 
cytosines, which subsequently recruit co-repressor complexes that ultimately prevent binding by 
TFs. An alternative mechanism is that methylated cytosines directly prevent binding of TFs (Parle-
McDermott and Ozaki, 2011). Image taken from (Parle-McDermott and Ozaki, 2011). 
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Figure 1.5. Coat colour phenotypes of A
vy
/a offspring whose mothers were supplemented with 
different doses of folic acid. The offspring mice above represent the five coat colour classes used 
to classify the agouti phenotype. The A
vy
 alleles of yellow mice are hypomethylated, allowing 
maximal expression of the agouti gene. When the A
vy
 alleles are hypermethylated, it silences the 
expression of the agouti gene, seen in the pseudoagouti animals, and recapitulates the agouti 
brown/black phenotype. (Image taken from Waterland & Jirtle, Mol Cell Biol,2003Aug; 23, 5293-
300.) 
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Figure 1.6. The location of the members of the human DHFR gene family. There are five genes 
that make up the human DHFR gene family. DHFR is located on chromosome 5, DHFRP1 is 
located on chromosome 18, DHFRP2 is located on chromosome 6, DHFRP3 is located on 
chromosome 2 and DHFRP4/DHFRL1 is located on chromosome 3. The genes in green represent 
functional genes and the genes in purple represent pseudogenes (Image by Parle-McDermott).   
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Figure 1.7. Conversion of Dihydrofolate into Tetrahydrofolate. Dihydrofolate (7,8-DHF) must 
be reduced to 5,6,7,8-THF before it can be utilised in the folate mediated one-carbon metabolism 
pathway. This vital reaction is catalysed by the enzyme called DHFR and occurs in the presence of 
NADPH. The reaction involves the transfer of a hydride ion from NADPH to the C6 atom of the 
pterin ring of DHF, together with a protonation reaction to produce THF (Image adapted from 
(Bailey and Ayling, 2009)).  
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Figure 1.8. A schematic representation of the project carried out. The aim of this project was to 
explore the molecular mechanism of the role of folate in human health and disease and was carried 
out through three specific aims as shown above.  
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Chapter 2 
 
Materials and Methods 
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2.1 Materials 
2.1.1 Reagents 
Solid chemicals were weighed using a MettlerToledo AG204 electronic balance (Mason 
Technology). Gilson pipettes were used for the transfer of liquid volumes of up to 1 mL (Gilson 
S.A., France) and an electronic pipette was used for volumes that were greater than 1 mL with 
disposable plastic tips (Starstedt Ltd., Wexford, Ireland).  
   
Mammalian Cell Culture 
BioSciences Roswell Park Memorial Institute (RPMI) 1640 Medium (Cat No. 21875-034) 
Cruinn Tissue Culture flasks 75cm
2
 (Cat No. 658175CI), Tissue Culture flasks 25cm
2
 (Cat No. 
690175CI) 
Coriell Institute Coriell Lymphoblast Cells: 17201 (Cat No. GM17201), 17243 (Cat No. 
GM17243) 
Gibco  Trypan Blue Stain 0.4% (Cat No. 15250-061) 
Invitrogen Lipofectamine 2000 Reagent (Cat No. 11668500) 
Lennox Puromycin Dihydrochloride Biochemica (Cat No. CA2856.0010) 
Sarstedt 10 mL pipettes, 25 mL pipettes, 6-well plates, 100 mm plates/dishes 
Sigma Aldrich Cell Freezing Medium – DMSO 1X (Cat No. C6164), Dulbecco’s Modified 
Eagle’s Medium (Cat No. D5030), Fetal Bovine Serum (FBS) (Cat No. F9665), G418 Disulfate Salt 
(Cat No. A1720), L-Glutamine Solution (Cat No. G7513), Sodium Pyruvate Solution (Cat No. 
S8636), Trypsin-EDTA Solution (Cat No. T4049-500mL) 
 
Molecular Biology 
Affymetrix  ExoSAP-IT (Cat No. 78250 40 UL) 
Agilent Technologies  QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Cat 
No. 210515), QuikChange II XL Site-Directed Mutagenesis Kit (Cat No. 200522) 
Bioline Alpha-Select Gold Efficiency Cells (Cat No. BIO-85027), ISOLATE Plasmid Mini Kit (Cat 
No. BIO-52026), HyperPAGE Prestained Protein Marker (Cat No. BIO-33065),  
Cambridge BioScience Human Methylated and Non-methylated DNA (Cat No. D5014) 
Coriell Institute African American DNA Samples (Cat No. HD50AA), Caucasian DNA 
Samples (Cat No. HD50CAU) 
Eurofins Sensor and Anchor probes 
 29 
 
Fisher Scientific Acetic Acid (Cat No. 10304980), Glutathione Agarose (Cat No. 16101), 
Methanol (Cat No. 10785484), Pierce 96-well Microplates (Cat No. DIS-210-170F), Protease 
Inhibitor Cocktail I (Cat No. 12801640), TEMED (Cat No. T/P190/04),  
Integrated DNA Technologies Primers, Gene Synthesis (DHFR and DHFRL1) 
Invitrogen  BL21-A1
TM
 One Shot
®
 Cells (Cat No. C6070-03), MAX Efficiency DH5α 
Competent Cells (Cat No. 18258-012), NuPage LDS sample buffer (Cat No. NP0008)  
Merck Millipore Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-3 membrane (Cat No. 
(UFC900324), Coomassie Brilliant Blue G250 (Cat No. 1154440025)  
MyBio Endoproteinase Lys-C  (Cat No. V1071), Runblue Prestained Marker (Cat No. NXA05160), 
Trypsin Gold, Mass Spectrometry Grade (Cat No. V5280)  
New England Biolabs (NEB) BL21 (DE3) Competent E. coli cells (Cat No. C2527H), Quick-
Load 1kB DNA Ladder (Cat No. N0468S), 100bp Ladder (Cat No. N3231) 
Promega dNTP Mix (Cat No. U1515) 
Qiagen EpiTect Fast DNA Bisulfite Kit (Cat No. 59826), FlexiGene DNA Kit (Cat No. 51206). 
Qproteome Mitochondria Isolation Kit (Cat No. 37612) 
Roche Applied Science Lightcycler
®
 480 96 multi-well clear plates (Cat No. 05102413001), 
Lightcycler
®
 480 Genotyping Master 5X (Cat No. 04707524001), Lightcycler
®
 480 High 
Resolution Master (Cat No. 04909631001)  
Sigma Aldrich Acrylamide / bis-acrylamide 40% (Cat No. A9926), Agar (Cat No. A5306), 
Agarose (Cat No. A9539), Ammonium Persulfate (Cat No. A3678-100G), Ampicillin Sodium salt 
(Cat No. A0166), Boric Acid (Cat No. B6768), Bovine Serum Albumin (Cat No. A3294), Bradford 
Reagent (Cat No. B6916), ColorBurst Electrophoresis Marker (Cat No. C1992-1VL), DHFR Assay 
Kit (Cat No. CS0340), Dimethyl Sulfoxide (DMSO) (Cat No. D8418), EDTA (Cat No. EDS), 
Ethanol (Cat No. E7023), Ethidium Bromide (Cat No. E13585), Glycine (Cat No. G8898), HIS-
Select Nickel Affinity Gel (Cat No. P6611), Imidazole (Cat No. I5513), Imprint DNA Modification 
Kit (Cat No. MOD50) Isopropanol (Cat No.  278475-1L), Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (Cat No. I6758), L-Arabinose (Cat No. A3256), Orange G (Cat No. O3756), PCR Core Kit 
with Taq DNA Polymerase (Cat No. CORET), Potassium Chloride (Cat No. P9541), Proteinase K 
(Cat No. P3354), RNA Sample Loading Buffer (R4268), Sodium Chloride (Cat No. S7653), 
Sodium Dodecyl Sulphate (Cat No. 71725), Sucrose (CatNo. 84100), Triton
TM
X-100 (Cat No. 
X100), Trizma Base (Cat No. T1503), Tryptone (Cat No. T7293), Tween
®
 20 (Cat No. P9416-100 
mL), Yeast Extract (Cat No. Y1333), 2-Mercaptoethanol (Cat No. M3148)  
Terumo Neolus Hyperdermin needles (Cat No. NN-2719R).   
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Thermo Scientific Carbenicillin (Disodium Salt) (Cat No. BP2648-5), Coomaisse Brilliant 
Blue G250 Dye (Cat No 20279), PageRuler Plus Prestained Protein Ladder (Cat. No 26619), 
Pierce
® 
BCA Protein Assay Kit (Cat No. 23227), Pierce 1-Step Transfer Buffer (Cat No. 84731), 
PVDF Transfer Membrane (Cat No. 88518), Restore
TM
 PLUS Western Blot Stripping Buffer (Cat 
No. 46430), SuperSignal West Femto Maximum Sensitivity Substrate (Cat No. 34095), Western 
Blotting Filter Paper (Cat No. 84783) 
 
2.1.2 Stock Solutions 
 Bacterial Protein Lysis Buffer – 50 mM Potassium Phosphate (pH 7.8), 400 mM NaCl, 100 
mM KCl, 10 % Glycerol, 0.5 % Triton X-100, 10 mM Imidazole (pH 7.8) 
 Blocking Buffer – 5 g Marvel, 50 μL Tween® 20, 50 mL 10 X TBS, 450 mL dH2O 
 Buffer B – 1.5 M (145.05 g) Tris-HCl, 0.4 % (1 g) SDS, 250 mL dH2O (pH 6.8) 
 Coomaisse Blue De-stain – 100 mL Acetic Acid, 300 mL Methanol, 600 mL dH2O 
 Coomaisse Blue Stain – 2.5 g Coomaisse Brilliant Blue G250 Dye, 100 mL Acetic Acid, 
300 mL Methanol, 600 mL dH2O 
 LB Broth – 2.5 g Tryptone, 2.5 g NaCl, 1.25 g Yeast Extract, 250 mL dH2O 
 LB Agar – 15 g of agar per litre of LB Broth 
 Loading Buffer (Western) (4 X) – 2.4 mL Buffer B, 4 mL Glycerol, 1 g SDS, 4 mg 
Bromophenol blue, 14.4 M (500 µL) beta-mercaptoethanol, 3.1 mL dH2O  
 Orange G (10 X) – 0.1 g Orange G, 20 g Sucrose, 50 mL dH2O 
 PBS (10 X) – 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4, 1 L dH2O (pH7.4) 
 TBE (10 X) – 48.44 g Tris HCl, 12.37 g Boric Acid, 1.5 g EDTA, 500 mL dH2O (pH 8.2) 
 TBS (10 X) – 0.1M (6.06 g) Tris Base, 1.5 M (43.83 g) NaCl, 500 mL dH2O (pH 8)  
 TBST – 250 μL Tween® 20, 50 mL 10 X TBS, 450 mL dH2O 
 Tris – Glycine Running Buffer (10X) – 0.25 M (15.14 g) Tris Base, 1.9 M (71.3 g) Glycine, 
1 % (5 g)  SDS, 500 mL dH2O (pH8.3) 
 Transfer Buffer (1 X) – 100 mL 10 X Transfer Buffer, 200 mL Methanol, 700 mL dH2O  
 4 X Sample buffer – 2.4 mL 1M Tris / HCl (pH 6.8), 4 mL Glycerol, 1 g SDS, 4 mg 
Bromophenol blue, 500 µL betamercaptoethanol, 3.1 mL dH2O (pH 6.8) 
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2.2  Molecular biology methods 
2.2.1 Agarose Gel Electrophoresis 
PCR products were analysed by agarose gel electrophoresis. A 1-2 % w/v agarose gel was 
made by adding 0.5-1 g of agarose powder to 50 mL 1 X TBE buffer. The agarose was dissolved 
completely in the TBE by heating the solution in the microwave for approximately 2 min. The 
agarose solution was then allowed to cool to 55-60
oC and 10 μL ethidium bromide (10 µg/mL) was 
then added and mixed. The gel casting apparatus was prepared in a mould by sealing the ends of the 
gel chamber and the solution was poured onto a gel electrophoresis rig gel plate. Two 8 well combs 
were inserted and any bubbles were removed from the gel using a pipette tip. The gel was left to 
solidify at room temperature for 40 min. The combs were then carefully removed from the gel and 
the gel was submerged in 1 X TBE buffer, with the wells facing the negative terminal. A 2 μL 
volume of 1 kb molecular weight DNA ladder and a 5 μL volume of each sample added to 2 μL of 
10 X Orange G loading dye were loaded into the wells. Electrophoresis was then carried out, 
keeping the voltage constant at 90 V for 45-60 min. The PCR products were then visualised, and 
examined under UV light using a DNR Mini-Bis Pro Bio-Imaging System. Images were taken using 
the VisionworksLS software program and printed on the Fujifilm Thermal Imaging System FTI-500 
for recording in laboratory books and saved as an image file for thesis / publication purposes. 
 
2.2.2 PCR Product Purification / Clean Up 
A 2 μL volume of ExoSAP-IT was added to 5 μL of PCR product in a PCR tube. The tubes 
were centrifuged briefly and incubated in a thermal cycler for 15 min at 37 °C and then for 15 min 
at 80°C. 
 
2.2.3 DNA Isolation from Buffy Coat 
Frozen buffy coat samples were thawed quickly in a 37C water bath. A 20 μL volume of 
proteinase K was added to each sample in order to homogenise the blood clots found in the samples 
before DNA extraction. 
 
The Qiagen
® 
FlexiGene DNA Kit composed of Buffer FG1 (lysis buffer), Buffer FG2 
(denaturation buffer), Buffer FG3 (hydration buffer) and Qiagen protease was used and the protocol 
was carried out according to the manufacturers’ instructions with slight alterations. 
  
A 500 μL volume of Buffer FG1 was pipetted into a 1.5 mL centrifuge tube. A 200 μL 
volume of buffy coat was added and mixed by inverting the tube 5 times. The cells were pelleted by 
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centrifugation at 10,000 X g for 20 s. The supernatant was removed and the tube was left inverted 
on a clean sheet of absorbent paper for 2 min, ensuring that the pellet remained in the tube. A 200 
μL volume of Buffer FG2 / Qiagen protease master mix (Table 2.1) was added to the tube and the 
tube was vortexed immediately until the pellet was completely homogenised. The tube was 
centrifuged for 3-5 s and incubated in a water bath for 10 min at 65C. A 300 μL volume of 100 % 
isopropanol was added to the tube and the tube was mixed by inversion, until the DNA precipitate 
became visible as white threads / clumps. The solution was pelleted by centrifugation at 10,000 X g 
for 3 min. The supernatant was removed and the tube was left inverted on a clean sheet of absorbent 
paper, ensuring that the pellet remained in the tube. A 200 μL volume of 70 % ethanol was added to 
the tube and the tube was vortexed for 5 s. The solution was pelleted by centrifugation at 10,000 X 
g for 3 min. The supernatant was removed and the tube was left inverted on a clean sheet of 
absorbent paper for 5 min, ensuring that the pellet remained in the tube. The DNA pellet was air 
dried for 5 min, until all the liquid had evaporated. A 50 μL volume of Buffer FG3 was added to the 
tube, and the tube was vortexed at low speed for 5 s. The DNA was dissolved by incubating the 
tube in a water bath for 1-2 h at 65C. The DNA samples were analysed by agarose gel 
electrophoresis, as described in Section 2.2.1.  
 
Table 2.1 Buffer FG2 / Qiagen Protease master mix 
 
Component Volume per sample (μL) 
Buffer FG2 200 
Qiagen Protease 2 
 
2.2.4 Quantifying DNA Concentration 
DNA concentrations were measured using the NanoDrop 1000 Spectrophotometer (Thermo 
Scientific). The NanoDrop was blanked with the same buffer that was previously used to dissolve 
the DNA. The DNA parameter was chosen on the NanoDrop instrument and 1 μL of each sample 
was loaded onto the optical pedestal and the sample was then drawn into a column and measured. 
UV-Vis spectrum results were displayed using the NanoDrop 1000 Spectrophotometer software and 
the DNA concentrations were measured as ng/μL with an expected A260/280 ratio of 1.8-2.1, 
indicating acceptable DNA purity within the samples. The samples were then stored at -20°C. 
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2.2.5 Plasmid DNA preparation 
A LB agar plate containing an appropriate selecting agent was streaked overnight at 37°C in 
an incubator with the clone of interest. A 5 mL volume of LB broth containing the appropriate 
selecting agent, which was warmed to room temperature, was pipetted into a 50 mL tube. A single 
colony was isolated / picked from the plate with a sterile pipette tip and grown in the broth at 37°C 
overnight with shaking (220 rpm).  
 
2.2.6 Plasmid DNA Isolation (Small Scale) 
The Isolate Plasmid Mini Kit, composed of re-suspension buffer, lysis buffer P, 
neutralisation buffer, wash buffer AP, wash buffer BP and elution buffer was used to isolate 
plasmid DNA from the bacterial culture. The protocol was carried out according to the 
manufacturers’ instructions with slight alterations (Bioline). 
 
A 5 mL volume of overnight culture was added to a 15 mL tube. The tube was centrifuged 
at 15,000 X g for 10 min and the supernatant was discarded. The pellet was re-suspended in 250 µL 
of re-suspension buffer and was vortexed thoroughly. A 250 µL volume of lysis buffer P was added 
to the tube and the solution was mixed carefully by inversion. A 350 µL volume of neutralisation 
buffer was added to the tube and the solution was mixed by inversion. The tube was centrifuged for 
10 min at 15,000 X g and the supernatant was transferred to a spin column, which was placed in a 2 
mL collection tube. The tube was centrifuged for 1 min at 12,000 X g and the filtrate was discarded. 
A 500 µL volume of wash buffer AP was added and the tube was centrifuged at 12,000 X g for 1 
min. The filtrate was discarded. A 700 µl volume of wash buffer BP was added and the tube was 
centrifuged at 12,000 X g for 1 min. The filtrate was discarded. The tube was centrifuged at 15,000 
X g for 2 min to remove ethanol and the collection tube was discarded. The spin column was placed 
into a 1.5 mL eppendorf tube. A 50 µL volume of molecular grade dH2O was added directly to the 
column membrane and the tubes were incubated at room temperature for 1 min. The tube was 
centrifuged at 12,000 X g for 1 min to elute the plasmid DNA. The isolated DNA was stored at -
20°C. A 1 % w/v agarose gel as described in Section 2.2.1 was run to ensure that DNA was present 
and intact. 
  
2.2.7 Plasmid DNA Isolation (Large Scale) 
The Qiagen Plasmid Maxi Kit, composed of buffer P1, buffer P2, buffer P3, buffer QBT, 
buffer QC, buffer QF and RNase A was used to isolate plasmid DNA from large bacterial cultures. 
The protocol was carried out according to the manufacturers’ instructions with slight alterations. 
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A starter culture of 5 mL of LB broth containing carbenicillin (50 µg/mL) was inoculated 
with a single colony and grown overnight at 37°C with vigorous shaking (300 rpm). The starter 
culture was diluted 1/500 LB broth containing carbenicillin (50 µg/mL), i.e. a 100 mL volume of 
LB broth was inoculated with 100 µl of starter culture.  The culture was grown at 37°C for 12–16 h 
with vigorous shaking (300 rpm). The bacterial cells were harvested by centrifugation at 2,300 X g 
for 30 min at 4°C. The pellet was re-suspended in 4 mL of Buffer P1 and was vortexed thoroughly. 
A 4 mL volume of Buffer P2 was added to the tube and the solution was mixed thoroughly by 
vigorously inverting the tube 4–6 times. The tube was incubated at room temperature for 5 min. A 4 
mL volume of chilled Buffer P3 was added to the tube and mixed immediately and thoroughly by 
vigorously inverting the tube 4–6 times. The tubes were incubated on ice for 15 min. The solution 
was split in 6 x 2 mL tubes and the tubes were centrifuged at ≥20,000 X g for 30 min at 4°C. The 
supernatant containing the plasmid DNA was transferred into new 2 mL tubes promptly. The 
supernatant was centrifuged again at ≥20,000 X g for 15 min at 4°C. The supernatant containing the 
plasmid DNA was removed promptly. A QIAGEN-tip 500 was equilibrated by applying 10 mL of 
Buffer QBT, and allowing the column to empty by gravity flow. The supernatant was applied to the 
QIAGEN-tip and was allowed to enter the resin by gravity flow. The QIAGEN-tip was washed with 
2 x 30 mL of Buffer QC. The DNA was eluted with 5 mL of Buffer QF. The eluate was collected in 
a 15 mL tube. The DNA was precipitated by adding 3.5 mL of room-temperature isopropanol to the 
eluted DNA. The DNA was mixed and centrifuged immediately at 2,300 X g for 90 min at 4°C. The 
supernatant was carefully decanted. The DNA pellet was washed with 2 mL of room-temperature 
70 % ethanol, and transferred into a 2 mL tube. The tube was centrifuged at ≥15,000 x g for 10 min. 
The supernatant was carefully decanted without disturbing the pellet. The pellet was air-dried for 5–
10 min, and the DNA was re-dissolved in 200 µL of dH2O.  
 
2.2.8 Gateway Cloning 
For the His tag expression clones, primers were designed to incorporate a TEV cleavage 
site at the N-terminal and a His tag at the C-terminal as well as att-sites for both DHFR and 
DHFRL1. Primers for the DHFR and DHFRL1 rare codon usage optimised clones were designed to 
incorporate a TEV cleavage site at the N-terminal as well as att-sites. Primers were designed in 
accordance to the Gateway Cloning Manual. Primer sequences are shown in Table 2.2. PCR 
products of the genes of interest were created by amplifying HEK 293 cDNA with the primers. 
Master mix for the amplification is shown in Table 2.3.  
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Table 2.2 Primer Sequences for Gateway Cloning  
 
 
 
 
 
 
 
 
Gene Primer Sequences 
 
 
 
DHFR His TAG 
Fwd: 5′- 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAG
GGGATGGTTGGTTCGCTAAACTG -3′ 
Rev: 5′- 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAATGATGATGATGATG 
ATGATCATTCTTCTCATATACTT -3′ 
 
 
 
DHFRL1 His 
TAG 
Fwd: 5′- 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAG
GGGATGTTTCTTTTGCTAAACTG -3′ 
Rev: 5′- 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAATGATGATGATGATGA
TGATCATCCTTCTCACATACTT -3′ 
 
 
DHFR Optimised 
Fwd: 5′-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAG
GGGATGGTTGGTAGCCTGAACTG-3′ 
Rev: 5′- 
CCCCACCACTTTGTACAAGAAAGCTGGGTCTTAATCGTTCTTTTCATACA
CCT-3′ 
 
 
DHFRL1 
Optimised 
Fwd: 5′-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAG
GGGATGTTTCTGCTGTTAAATG-3′ 
Rev: 5′- 
CCCCACCACTTTGTACAAGAAAGCTGGGTCTTAATCGTCTTTTTCGCACA
CCT-3′ 
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Table 2.3 Master Mix for PCR Amplification  
 
 
A 1 μL volume of a 1/160 dilution of HEK 293 cDNA (100 ng/µL) was used per reaction, 
giving a final volume of 50 μL. A negative-template control using 1 μL H2O instead of DNA was 
also included. Template DNA was initially denatured at 95°C for 3 min, followed by 31 
amplification cycles, in an automated ABI 9700 DNA Thermal Cycler (Applied Biosystems). Each 
cycle consisted of template denaturation (95°C for 1 min), primer annealing (60°C for 1 min) and 
extension (72°C for 2 min). This was followed by an elongation step to complete the amplification 
cycle (72°C for 10 min). Samples were maintained at 4°C. PCR products were run on a 2 % agarose 
gel, as described in Section 2.2.1. 
 
Entry clones were created by carrying out a BP recombination reaction using the PCR 
product and the pDONR™ 211 vector, (See Appendix A for vector map).  
 
Table 2.4 BP Reaction 
 
Component Volume (μL) 
PCR product 4 
pDONR 221 (150 ng/μL) 1 
H2O 13 
BP Clonase 2 
 
The reaction was incubated at 25°C overnight. A 1 μL volume of proteinase K was added to 
the BP reaction to inactivate the enzyme. The BP reaction was then transformed into alpha-select 
gold efficiency cells (F
-
 deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk
+
) supE44 thi-1 phoA 
Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ-). Alpha-select gold efficiency cells were thawed on ice. A 
Component Volume (μL) 
Forward primer (10 pmol/μL) (IDT) 1 
Reverse primer (10 pmol/μL) (IDT) 1 
10X buffer 5 
Taq (5U/μL) 1 
dH₂O  41 
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1 μL volume of the BP reaction was added to a tube containing 50 μL of the cells. The tubes were 
swirled gently and incubated on ice for 30 min. After incubation, the tubes were heat-pulsed in a 
42°C water-bath for 30 s. A 450 μL volume of room temperature LB broth was added to the tubes 
and the tubes were incubated at 37°C for 1 h with shaking at 230 rpm. A 40 μL volume and a 100 
μL volume of each transformation reaction were spread on a LB agar plate containing kanamycin 
(50 μg/mL). The plates were incubated at 37°C overnight. A single colony was isolated and the 
colony was grown overnight in 5 mL of LB broth containing kanamycin (50 μg/mL) in a 50 mL 
tube at 37°C. A 700 μL volume of overnight culture and a 300 μL volume of 50 % glycerol was 
added to a 1.5 mL cryovial tube and stored at -80°C. Plasmid DNA was isolated from the remainder 
of the overnight culture as described in Section 2.2.6. The DNA was sent off for sequencing with 
the M13 forward primer to confirm that the HIS tag and the TEV cleavage site had been inserted. 
 
An expression clone was then created by performing an LR reaction between plasmid DNA 
from the entry clone and the pDEST™ 15 vector, (See Appendix B for vector map).  
 
Table 2.5 LR Reaction 
 
Component Volume (μL) 
Entry Clone (100 ng/μL) 2 
pDEST 15 (150 ng/μL) 1.5 
TE Buffer 4.5 
LR Clonase 2 
 
The reaction was incubated at 25°C overnight. A 1 μL volume of proteinase K was added to 
the LR reaction and was incubated at 37°C for 10 min to inactivate the enzyme. The LR 
recombination reaction was then transformed into Library Efficiency® DH5α cells (F- 
φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk
-
, mk+) phoA supE44 thi-1 gyrA96 
relA1 λ-). Library Efficiency® DH5α cells were thawed on ice. A 1 μL volume of the BP reaction 
was added to a tube containing 50 μL of the cells. The tubes were swirled gently and incubated on 
ice for 30 min. After incubation, the tubes were heat-pulsed in a 42°C water-bath for 30 s. A 450 μL 
volume of room temperature LB broth was added to the tubes and the tubes were incubated at 37°C 
for 1 h with shaking at 230 rpm. A 40 μL volume and a 100 μL volume of each transformation 
reaction were spread on a LB agar plate containing ampicillin (100 μg/mL). The plates were 
incubated at 37°C overnight. A single colony was isolated and the colony was grown overnight in 5 
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mL of LB broth containing ampicillin (1000 μg/mL) in a 50 mL tube at 37°C. A 700 μL volume of 
overnight culture and a 300 μL volume of 50 % glycerol was added to a 1.5 mL cryovial tube and 
stored at -80°C. Plasmid DNA was isolated from the remainder of the overnight culture as described 
in Section 2.2.6. The DNA was sent off for sequencing with the T7 reverse primer to confirm the 
identity of the recombinant plasmid.  
 
2.2.9 Site Directed Mutagenesis (SDM) 
The QuikChange II XL SDM Kit was used to carry out SDM. This kit allows site-specific 
mutation in virtually any double-stranded plasmid and was therefore used. 
 
Primer Design 
Primers were designed according to the QuikChange II XL SDM Kit’s protocol (Agilent 
Technologies). Primer design was also checked using Stratagene’s web-based QuikChange Primer 
Design Program (www.agilent.com/genomics/qcpd) 
 
Table 2.6 Primer Sequences for Site Directed Mutagenesis 
 
 
Mutant Strand Synthesis Reaction 
Once primers were designed, mutant strand synthesis was carried out. The control reaction and 
sample reaction were prepared as indicated in Table 2.7 and Table 2.8 and were thermal cycled.  
 
 
Gene Primer Sequences 
rs17855824 
G->A (Val->Ile) 
Fwd: 5′- TGCCTGAATACCCAGGTATTCTCTCTGATGTCCAG -3′ 
Rev: 5′- CTGGACATCAGAGAGAATACCTGGGTATTCAGGCA -3′ 
rs61739170 
C->G (Pro->Ala) 
Fwd: 5′- CTCAGCAGAGAACTCAAGGAAGCTCCACAAGGAGCTCATTTTC -3′ 
Rev: 5′- GAAAATGAGCTCCTTGTGGAGCTTCCTTGAGTTCTCTGCTGAG -3′ 
Gene Primer Sequences for Optimised DHFRL1 Gene Sequence 
rs17855824 
G->A (Val->Ile) 
Fwd: 5′-  TGCCGGAATACCCGGGCATTCTCAGTGACGTCCAG  -3′ 
Rev: 5′-  CTGGACGTCACTGAGAATGCCCGGGTATTCCGGCA  -3′ 
rs61739170 
C->G (Pro->Ala) 
Fwd: 5′-  GAGTCGCGAACTTAAGGAAGCACCGCAGGGGGCACACTT  -3′ 
Rev: 5′-  AAGTGTGCCCCCTGCGGTGCTTCCTTAAGTTCGCGACTC  -3′ 
 39 
 
Table 2.7 Control Reaction  
 
Component Volume (µL) 
10X Reaction Buffer 5 
pWhitescript 4.5 kb control plasmid (5 ng/µL) 2 
Oligonucleotide control primer #1 [34-mer (100 ng/µL)] 1.25 
Oligonucleotide control primer #2 [34-mer (100 ng/µL)] 1.25 
dNTP mix 1 
QuikSolution Reagent 3 
ddH2O 36.5 
PfuUltra HF DNA polymerase (2.5 U/µL) 1 
 
Table 2.8 Sample Reaction 
  
Component Volume (µL) 
10X Reaction Buffer 5 
dsDNA  1 
Forward primer (100 ng/µL) (IDT) 1.25 
Reverse primer (100 ng/µL) (IDT) 1.25 
dNTP mix 1 
QuikSolution Reagent 3 
ddH2O 37.5 
PfuUltra HF DNA polymerase (2.5 U/µL) 1 
 
The reactions were cycled as follows; 95°C for 1 min, followed by 18 cycles, in an 
automated ABI 9700 DNA Thermal Cycler. Each cycle consisted of 95°C for 50 s, 60°C for 50 s 
and 68°C for 5 min (control) / 7.5 min (sample). This was followed by 68°C for 7 min. Samples 
were maintained at 4°C. Following temperature cycling, a 1 µL volume of the Dpn1 restriction 
enzyme (10 U/µl) was added to each amplification reaction. Each reaction mixture was mixed 
gently and thoroughly by pipetting the solution up and down several times. The reaction mixture 
was spun down at 12,000 X g in a microcentrifuge for 1 min. The reactions were incubated 
immediately at 37°C for 1 h to digest the parental supercoiled dsDNA. 
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2.3 Protein Purification Methods 
2.3.1 Transformation into XL10 Cells (SDM Plasmid DNA) 
XL10 Gold Ultra competent cells (Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 Tn10 (Tetr) Amy Camr]) were 
thawed on ice. A 45 µL volume of the cells were aliquoted to chilled 1.5 mL eppendorf tubes. A 2 
µL volume of 2-Mercaptoethanol was added to the tube and the contents of the tubes were swirled 
gently. The tubes were then incubated on ice for 10 min, swirling gently every 2 min. A 2 µL 
volume (10 ng) of DpnI treated DNA was then added to the tube containing the cell aliquot. The 
transformation reaction was swirled gently and was incubated on ice for 30 min. LB broth was pre-
heated in a 42°C water-bath. After incubation, the tubes were heat-pulsed in a 42°C water-bath for 
30 s and then incubated on ice for 2 min. A 0.5 mL volume of the pre-heated LB broth was added to 
the tube and the tubes were incubated at 37°C for 1 h with shaking at 230 rpm. A 250 µL volume of 
each transformation reaction was plated on a LB agar plate containing ampicillin (100 µg/mL). The 
plates were incubated at 37°C overnight. A single colony was isolated and the colony was grown 
overnight in 5 mL of LB broth containing ampicillin (100 µg/mL) in a 50 mL tube at 37°C. A 700 
µL volume of overnight culture and a 300 µL volume of 50 % glycerol was added to a 1.5 mL tube 
and stored at -80°C. Plasmid DNA was isolated from the remainder of the overnight culture as 
described in Section 2.2.6. The DNA was sent off for sequencing to Source BioScience to confirm 
the identity of the recombinant plasmid.  
 
2.3.2 Transformation into BL21-AITM One Shot® Cells 
A 5 µL volume (10 ng) of plasmid DNA from the expression clones and from each of the 
transformed clones were added to a vial of BL21-AI
TM
 One Shot 
®
 Cells (F
-
ompT hsdSB (rB
-
mB
-
) 
gal dcm araB::T7RNAP
-
tetA) and were incubated on ice for 30 min. After incubation, the cells were 
heat-shocked for 30 s at 42
O
C and were then transferred immediately back on to the ice. A 250 µL 
volume of LB broth was added to the tubes and the tubes were incubated at 37°C for 1 h with 
shaking at 230 rpm. A 100 µL volume of cells were spread on a set of LB plates containing 
ampicillin (100 µg/mL). The plates were incubated at 37°C overnight. Plates were then stored at 
4°C. 
 
2.3.3 Transformation into BL21 (DE3) Competent E. Coli Cells 
BL21 (DE3) Competent E. Coli cells (fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3  λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 ) were thawed on ice for 10 
min. A 1-5 µL volume (100 ng) of plasmid DNA from the expression clone and from each of the 
 41 
 
transformed clones was added to a vial of BL21 (DE3) Competent E. Coli cells. The tubes were 
flicked 4-5 times to mix the DNA with the cells and the tubes were then incubated on ice for 30 min. 
After incubation, the cells were heat-shocked for 10 s at 42°C and were then transferred 
immediately back on to the ice for 5 min. A 950 µL volume of S.O.C. media was added to each of 
the tubes and the tubes were incubated at 37°C for 1 h with shaking at 250 rpm. A 50 µL volume 
and a 150 µL volume of cells were spread on a set of LB plates containing carbenicillin (50 µg/mL). 
The plates were incubated at 37°C overnight. Plates were then stored at 4°C.  
 
2.3.4 Induction of recombinant proteins with L-Arabinose / IPTG 
Single colonies were isolated from plates and the colonies were grown overnight with 
shaking in LB broth containing carbenicillin (50 µg/mL) at 37°C. The overnight cultures were 
diluted by 1/20 by adding fresh LB broth containing carbenicillin (50 µg/mL). This was left to grow 
at 37ºC with shaking at 220 rpm for ~ 2 h, until an OD600 of 0.4 (optimal growth stage) was reached. 
Each culture was then split in two. L-arabinose / IPTG was added to one culture to give a final 
concentration of 0.04 % (v/v) (L-arabinose) or 50 µM (IPTG) to induce recombinant protein 
expression. A sample of both cultures was taken at various time points. At each time point, the cells 
were centrifuged for 5 min at 4470 X g, the supernatant was removed, and the pellets were weighed 
and were then frozen at -20 º C.  
 
2.3.5 Sample Fractionation  
Once pellets had been obtained for all time points, each pellet was thawed and lysed in 
bacterial lysis buffer (ratio of 0.4 g to 8 mL of bacterial lysis buffer used). Once the pellets were re-
suspended, they were put through a needle (0.4 x 20 mm) and syringe in order to lyse the cells. The 
cells were then separated into soluble and insoluble fractions by freezing the samples in liquid 
nitrogen and thawing in a 42
o
C water bath three times. The lysed cells were then centrifuged for 10 
min at 4470 X g at 4
o
C, to pellet insoluble proteins. The supernatant was transferred into 50 mL 
tubes. The insoluble fractions were lysed with 5 mL lysis buffer. The protein lysates were stored at -
20ºC or -80ºC. 
 
2.3.6 SDS-PAGE Gel Preparation 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out 
in order to separate the proteins within each sample according to molecular weight (size). A 10 % 
(v/v) separating gel was composed of 3.5 mL 40 % Acrylamide, 2.5 mL Tris-HCL (pH 8.8), 100 μL 
10 % (w/v) SDS, 100 μL 10 % (w/v) fresh Ammonium Persulfate (APS), 4 μL N, N, N’, N’ 
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tetramethylethylenediamine (TEMED) and the volume was brought up to a total of 10 mL with 
dH2O. TEMED initiates the polymerisation reaction and therefore is added just before the gel is 
poured. Before adding the TEMED, the plates for the gel were prepared by cleaning them with 
isopropanol in one direction, placing the seal onto the plate with the lip facing upwards and by 
fastening the two plates together using bulldog clips. Once the TEMED was added, the gel was 
mixed and poured between the two plates using a Pasteur pipette up to 2/3 full. Ethanol was then 
applied to the top of the separating gel to remove any air bubbles and to stop atmospheric oxygen 
from inhibiting the polymerisation reaction. The gel was left to polymerise for 30 min. The stacking 
gel is cast over the separating gel and has larger pores. The stacking gel was made up with 830 µL 
40 % Acrylamide, 630 µL Tris-HCL (pH 6.8), 50 μL 10 % (w/v) SDS, 50 μL 10 % (w/v) fresh APS 
and 5 μL TEMED and the volume was brought up to a total of 5 mL with dH2O. Before adding 
TEMED, and when the separating gel was fully polymerised, the ethanol layer was poured off onto 
a tissue and the stacking gel was then overlaid on top of the separating gel. A 12 tooth comb was 
introduced into the stacking gel and the gel was allowed to polymerise for 30 min. Once 
polymerised, the bulldog clips and seal were removed and the gel was transferred to an 
electrophoresis tank and fixed, ensuring that the grooved side of the gel is placed facing towards the 
inside of the chamber. The central chamber was then filled with 1X Tris-Glycine running buffer. 
The comb was then removed, the wells straightened and blown out, using a Gilson pipette and a 
needle. Air bubbles were also removed from the base of the gels by tilting the apparatus to one side 
and refilling the central chamber.  
 
2.3.7 Protein Sample Preparation 
An 18 µL volume of protein sample was added to 6 µL of NuPage 4X LDS sample buffer / 
4 X sample buffer and the mixture was heated for 5 min at 99ºC. A 5 µL volume of Protein Marker 
was applied to the first well and 20 µL of each sample was applied to the wells. The gels were run 
at 140 V until the dye front had electrophoresed off the end of the gel (~ 90 min). The gel was then 
removed carefully. 
 
2.3.8 Protein Transfer to PVDF 
Following the separation of the protein samples in a SDS-PAGE gel, the gels were carefully 
disassembled with a scalpel and were transferred to polyvinylidene fluoride (PVDF) membranes. 
One piece of PVDF membrane and two pieces of MM filter paper were cut to the appropriate size. 
The PVDF membrane was dipped into 100 % methanol for 30 s to activate it and then rinsed in cold 
1 X transfer buffer. The MM filter papers, the PVDF membrane, along with the two sponges were 
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soaked in cold 1 X transfer buffer for 30 min. The SDS-PAGE gel was also soaked in cold 1 X 
transfer buffer. The transfer cassette was prepared by loading the transfer pad with a MM filter 
paper, then the PVDF membrane, followed by the gel containing the electrophoresed proteins, 
which were then covered with the remaining MM filter paper. The two pads, filter papers, gel and 
membrane were then sandwiched together, making sure there was no air bubbles caught between 
any of the layers. The transfer cassette was placed into the holder with the black plates facing 
towards the centre. The transfer apparatus (Mini-Trans Blot Cell, BioRad) was filled with cold 1 X 
transfer buffer. The electrophoretic transfer of proteins was performed by transferring the gels at 
100 V at maximum Amps for 1 h, ensuring that the membrane was placed at the anode end, the gel 
at the cathode. The transfer was performed with cooling and buffer circulation. A representative 
semi-dry transfer layout is shown in Figure 2.1.  
 
 
Figure 2.1. Representative layout of the semi-dry transfer. The base of the transfer apparatus 
was pre-soaked in 1 X transfer buffer. A pre-soaked filter paper was placed on top of this, followed 
by the methanol-activated, transfer buffer soaked PVDF membrane. The polyacrylamide gel was 
placed directly on top of this, followed by pre-soaked filter paper. The direction of protein transfer 
occurs from the gel (cathode) to the membrane (anode). 
 
  Anode              
                                                                                          buffer-soaked filter paper 
       Direction                                                                        PVDF membrane  
        of        Polyacrylamide gel 
        transfer           
                             
   
                                                                                            buffer-soaked filter paper 
 
Cathode                                                                           
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2.3.9 Transfer of proteins using the G2 Fast Blotter (Thermo Scientific Pierce) 
Following the separation of the protein samples in a SDS-PAGE gel, the gels were carefully 
disassembled with a scalpel and were transferred to PVDF membranes. Four sheets of 0.83 mm 
thick western blotting filter paper and one sheet of PVDF membrane were cut to the same size. The 
PVDF membrane was dipped into 100 % methanol for 30 s to activate it and then the filter papers 
and the PVDF membrane were equilibrated in Thermo Scientific Pierce 1-step transfer buffer for at 
least 5 min. After electrophoresis, the gel was removed from the cassette and briefly placed into the 
tray containing the transfer buffer to ensure even wetting, to facilitate in proper gel placement and 
to improve gel contact with the membrane. The cassette was then assembled as before, with the 
anode on the bottom of the cassette. A blot roller was used to remove any trapped air bubbles. The 
top of the cassette (cathode) was locked into place and was slid into the cassette unit. The pre-
programmed method was selected, as well as the number of gels, the molecular weight and the start 
button was pressed. 
 
2.3.10 Staining gels with Coomassie Brilliant Blue 
Following protein electrophoresis and the transfer of proteins, gels were stained in 
Coomassie brilliant blue and de-stained in Coomassie de-stain until the protein bands were clearly 
visible and background staining had been fully eliminated. The gel was then visualised under white 
light using a DNR Mini-Bis Pro Bio-Imaging System. 
 
2.3.11 Western Blotting  (Immunoblotting / Antibody binding) 
Following the transfer of proteins, membranes were blocked with 50 mL blocking buffer 
for 2 h at room temperature on a rotating platform. Following this, the blocking solution was 
discarded. The membrane was then incubated in primary antibody, diluted in blocking buffer (See 
Table 2.9 for antibody concentrations) in a total volume of 10 mL and left overnight at 4°C with 
gentle agitation on a rotating platform. It was ensured that the membrane was completely covered 
so that it does not dry out. Following incubation, the membrane was washed three times for 15 min 
each in TBST on a rotating platform. The secondary antibody, (See Table 2.9 for antibody 
concentrations) was prepared in 20 mL TBST. The membrane was placed in the secondary antibody 
solution at room temperature for 1 h on a rotating platform. After incubation, the membrane was 
washed three times for 15 min each in TBST on a rotating platform. The SuperSignal West Femto 
Reagents were used to detect the HRP-labelled secondary antibody. Equal volumes of reagent A 
and reagent B were mixed together. The blot was placed on a sheet protector with the outside clean 
and the inside free of air bubbles and the reagent mixture was applied to the membrane. The excess 
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liquid was removed from the blot and the blot was imaged using the Gene Genome instrument 
(SynGene). 
 
Table 2.9. Antibody Concentrations used for Western blotting 
Primary Antibody Primary 
Antibody 
Concentration 
Secondary 
Antibody 
Secondary 
Antibody 
Concentration 
DHFR 
Abcam (Cat No. ab49881) 
1:10,000 HRP conjugated anti-
rabbit 
1:50,000 
DHFR 
(mitochondrial fractions) 
1:5,000 HRP conjugated anti-
rabbit 
1:25,000 
DHFRL1 
Abcam (Cat No. ab171837) 
1:250 HRP conjugated anti-
rabbit 
1:50,000 
GST 
Sigma Aldrich (Cat No. G7781) 
1:2,000 HRP conjugated anti-
rabbit 
1:200,000 
GAPDH 
Sigma Aldrich (Cat No. G8795) 
1:1,000 HRP conjugated anti-
rabbit 
1:10,000 
PDH 
MitoSciences (Cat No. 110330) 
1:1,000 HRP conjugated anti-
mouse 
1:100,000 
 
2.3.12 Concentrating and Clarifying Protein Samples  
Protein lysates were concentrated using 30 kDa centricons. Protein samples were spun in 
the centricons at 4470 X g for 1 h at 4 
o
C. This was carried out not only to concentrate the protein 
samples but also to eliminate free GST and small proteins. Protein lysates were then diluted 1 in 5 
in bacterial protein lysis buffer and was filtered through a 0.45 µM filter in order to clarify the 
protein. 
 
2.3.13 Protein Purification of GST-tagged Protein Using a Gravity Free Column 
 Once protein expression had been confirmed by SDS-PAGE analysis / Western blot 
analysis, protein purification was carried out. All samples were kept on ice at all times. The column 
was first washed with 1 X PBS. The column was then packed with 1 mL of Glutathione Agarose 
and the storage buffer was drained from the resin by gravity flow. Once the storage buffer had been 
drained off, the volume of resin was reduced by half. The column was then equilibrated with 10 
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resin bed volumes (10 mL) of Equilibration / Wash Buffer (50 mM Tris, 150 mM NaCl, pH 8.0), 
allowing the buffer to drain from the resin at a flow rate of 0.5 mL/min. Protein samples were 
prepared by diluting the protein lysates 1 in 2 in Equilibration / Wash Buffer. The prepared protein 
lysates were then added to the column using a Pasteur pipette, ensuring not to disturb the resin. The 
flow through was collected in 50 mL tubes and was re-applied to the column to maximise binding. 
The resin was washed with 10 resin bed volumes (10 mL) of Equilibration / Wash Buffer and the 
flow through was collected. This step was repeated using new collection tubes until the absorbance 
of the flow through fraction at 280 nm approaches baseline. The GST-tagged protein was then 
eluted from the resin with two resin-bed volumes (2 mL) of Elution Buffer (50 mM Tris, 150 mM 
NaCl, pH 8.0 containing 10 mM reduced glutathione). This step was carried out twice. Each 
fraction was collected in separate tubes. The protein elution was monitored by measuring the 
absorbance of the fractions at 280 nm. All purification fractions were analysed by SDS-PAGE and 
Western blot.  
 
2.3.14 Protein Purification of HIS-tagged Protein 
Once protein expression had been confirmed, protein purification was carried out. Samples 
were kept on ice at all times. A 50 µL volume of HIS-Select Nickel Affinity Gel suspension was 
added to a microcentrifuge tube and centrifuged for 30 s at 5,000 X g. The supernatant was 
removed and discarded. A 200 µL volume of Equilibration / Wash buffer (50 mM sodium 
phosphate, pH 8.0, 0.3 M sodium chloride) was added to the tube and mixed well. The tube was 
centrifuged for 30 s at 5,000 X g and the supernatant was discarded. A 100 µL volume of clarified 
protein was added to the tube and mixed gently for 1 min. The mixture was centrifuged for 30 s at 
5,000 X g and the supernatant was saved for analysis. The affinity gel was washed twice with 500 
µL of Wash buffer by mixing the affinity gel for 10 s and centrifuging for30 s at 5,000 X g. The 
supernatant (washes) were saved for analysis. The target protein was eluted with a 50 µL volume of 
Elution buffer (50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, 250 mM imidazole). All 
purification fractions were analysed by SDS-PAGE and Western blot. 
 
2.3.15 Mitochondrial Isolation from Eukaryotic Cell Lysates 
The Qiagen
® 
Qproteome Mitochondria Isolation Kit composed of lysis buffer, disruption 
buffer, mitochondrial storage buffer and protease inhibitor solution was used to extract 
mitochondria from Cell Lines. The protocol was carried out according to the manufacturers’ 
instructions with slight alterations. All steps were carried out at 4°C. Lysis buffer and disruption 
buffer were supplemented with protease inhibitor solution. 
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A cell suspension containing 5 x 10
6
 to 2 x 10
7
 cells were transferred into 25 mL tubes and 
were centrifuged at 500 X g for 10 min at 4°C. The supernatant was discarded. A 1 mL volume of 
sterile PBS was added to the pellet and the pellet was re-suspended in order to wash the cells. The 
solution was transferred into 1.5 mL eppendorf tubes and was centrifuged at 500 X g for 3 min. The 
supernatant was discarded. A 500 μL volume of ice-cold lysis buffer was added to the tube and the 
pellet was re-suspended by pipetting up and down. The tube was incubated on ice for 10 min with 
gentle mixing every 30 s. The lysate was centrifuged at 1000 X g for 10 min at 4°C and the 
supernatant was removed to a clean eppendorf tube. This is the cytosolic fraction. A 500 μL volume 
of ice-cold disruption buffer was added to the pellet and the pellet was re-suspended by pipetting up 
and down. Cells were the completely disrupted using a blunt-ended needle (0.4 x 20 mm) and a 
syringe by drawing the lysates into the syringe slowly and ejecting the lysates in one stroke. This 
was repeated 10 times. The lysate was then centrifuged at 1000 X g for 10 min at 4°C and the 
supernatant was transferred into a clean eppendorf tube. The supernatant was centrifuged at 6000 X 
g for 10 min at 4°C and the supernatant was discarded. A 1 mL volume of mitochondrial storage 
buffer was added to the pellet and the pellet was re-suspended by pipetting up and down. The tube 
was then centrifuged at 6000 X g for 20 min at 4°C. The mitochondrial pellet was re-suspended in 
100 μL of mitochondrial storage buffer and was stored at -20°C.  
 
2.3.16 Protein Concentration Quantification by BCA Assay 
The Pierce
® 
BCA Protein Assay Kit composed of Bicinchoninic Acid (BCA) Protein Assay 
Reagent A (an alkaline bicarbonate solution), BCA Protein Assay Reagent B (a copper sulphate 
solution) and Albumin Stranded Ampules (2 mg/mL) was used and the protocol was carried out 
according to the manufacturers’ instructions. 
 
Preparation of Standards and Working Reagent 
Preparation of Diluted Bovine Serum Albumin (BSA) Standards 
A range of standards from 25 – 2000 µg of BSA was made. The dilution scheme for the Standard 
Microplate Procedure is shown in Table 2.10. dH₂O was used as the diluent. 
 
Preparation of the BCA Working Reagent (WR) 
The following formula was used to determine the total volume of WR required.  
(# standards + # unknowns) x (# replicates) x (volume of WR per sample) = total volume of WR 
required. WR was prepared by mixing 50 parts of Reagent A with 1 part of Reagent B.  
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2.3.17 Microplate Procedure 
A 10 μL volume of each standard and 10 μL of unknown sample replicate was pipetted into 
a 96-well microplate well. A 100 μL volume of WR was then added to each well and the plate was 
mixed on a rotating platform. The plate was covered with tinfoil and incubated at 37°C for 30 min. 
The plate was then cooled to room temperature and the absorbance was measured at a wavelength 
of 562 nm on the Tecan i600 spectrophotometer. The average 562 nm absorbance measurement of 
the blank standard replicates was subtracted from the average 562 nm absorbance measurements of 
all the other standards and unknown samples. A standard curve was then prepared by plotting the 
average blank-corrected 562 nm absorbance measurement for each BSA standard vs. concentration 
in μg/mL. The equation of the line (y = mx + c) was then used to determine the protein 
concentration of each of the unknown samples, where x is the unknown concentration of the sample, 
y is the absorbance of the sample, m is the slope of the line and c is a constant.  
 
Table 2.10. Dilution Scheme for BSA 
 
 
 
Vial Volume of Diluent Volume and Source of BSA Final BSA Conc. 
A 0 300 μL of stock 2,000 μg/mL 
B 125 μL 375 μL of stock 1,500 μg/mL 
C 325 μL 325 μL of stock 1,000 μg/mL 
D 175 μL 175 μL of vial B 750 μg/mL 
E 325 μL 325 μL of vial C 500 μg/mL 
F 325 μL 325 μL of vial E 250 μg/mL 
G 325 μL 325 μL of vial F 125 μg/mL 
H 400 μL 100 μL of vial G 25 μg/mL 
I 400 μL 0 0 μg/mL 
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2.3.18 Protein Concentration Quantification by Bradford Assay 
The Sigma Bradford Reagent was used in order to determine the concentration of protein 
samples in which the background interfered with the Pierce
® 
BCA Protein Assay Kit. A set of 
standards were prepared as described above in Table 2.10. 
 
2.3.19 Microplate Procedure 
A 5 μL volume of each standard, unknown sample and background medium was pipetted 
into a 96-well microplate well. All samples were carried out in duplicate. A 250 μL volume of 
Bradford Reagent was then added to each well and the plate was mixed on a rotating platform for 
30 s. The plate was covered with tinfoil and incubated at room temperature for 10 min. The 
absorbance was measured at a wavelength of 595 nm using the Tecan i600 spectrophotometer. The 
protein concentration of each of the unknown samples was determined as described in Section 
2.3.17. 
 
 
2.3.20 Protein Concentration Quantification using Image J 
Image J software (http://rsb.info.nih.gov/ij/index.html) was used to compare the density of 
the bands observed on the Western blots in order to quantify protein concentrations for Enzyme 
analysis.  
 
2.3.21 Enzyme Activity Measurement for Endogenous and Recombinant Protein 
Enzyme activity was tested using a Dihydrofolate Assay Kit. The assay was performed 
according to manufacturer’s instructions, with slight alterations. All volumes in the protocol were 
divided by two in order to have enough protein to carry out the experiments. Assays were 
performed in 1 ml UVette cuvettes. In order to examine enzyme activity, methotrexate stock 
solutions were made up and used to ensure that any enzyme activity that is observed is due to 
DHFR and not any other enzymes in the cells or from the GST tag that use NADPH as a cofactor, 
i.e. methotrexate was used to remove any background activity. Methotrexate concentrations that 
were four fold higher than the concentration used for inhibition reactions of the purified enzyme 
was used. Samples were prepared as shown in Table 2.11 and Table 2.12. The samples were mixed 
after each component was added by covering the cuvette with parafilm and inverting.  
 
The substrate was added just before enzyme activity was measured on a spectrophotometer. 
The absorbance was read at 340 nm using the kinetic mode reading every 15 s for 2.5 - 5 min. One 
unit of enzyme is defined as the amount which reduces 1 µmol of dihydrofolate per minute based on 
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the molar extinction coefficient of 12,300 M
-1
cm
-1
 at 340 nm. A graph was then prepared by 
plotting the 340 nm absorbance measurement vs. time in s. The decrease in ΔOD over time was 
measured as ΔOD/min and the specific activity was calculated using the following equation:  
Units / mg P = (ΔODmin. sample – ΔODmin. blank) x d 
    12.3 x V x mg P / ml 
 Where d = dilution factor of the enzyme sample  
                   12.3 = extinction coefficient reaction at 340 nm 
           V = volume of enzyme used in ml 
           mg P / ml = concentration of enzyme of the original sample 
       Units / mg P = specific activity in µmol/min/mg protein 
 
However, for the endogenous protein, the final value was multiplied by 1000 to obtain the 
specific activity value in nmol/min/mg protein. Also in contrast to purified protein, the exact 
concentration of your protein of interest in cell lysates / cytoplasmic / mitochondrial fractions is 
unknown and therefore the total concentration of the fractions was used in the calculations. 
 
Table 2.11. Sample preparation for the DHFR control assay 
 
Table 2.12. Sample preparation for the sample assay 
 
 
 
 
 
 
  Blank A (µL) 
Blank B 
(µL) 
DHFR Control 
(µL) 
DHFR + MTX 
(µL) 
1 X Assay Buffer 492.6 493.1 490.1 488.1 
DHFR 4.4 4.4 4.4 4.4 
MTX 40 nM 0 0 0 2 
NADPH 3 0 3 3 
DHF 0 2.5 2.5 2.5 
  Mt Fraction (µL) Mt Fraction + MTX (µL) 
1 X Assay Buffer 449.5 447.5 
Protein Sample 45 45 
MTX 40 nM 0 2 
NADPH 3 3 
DHF 2.5 2.5 
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2.4 Methylation Methods 
2.4.1 Bisulfite Treatment for MS-HRM 
The Imprint
®
 DNA Modification Kit composed of DNA modification powder, DNA 
modification solution, balance solution, capture solution, cleaning solution and elution solution was 
used to bisulfite treat DNA samples and the protocol was carried out according to the manufacturers’ 
instructions with slight alterations. 
 
A 1.1 mL volume of DNA modification solution was added to a vial of DNA modification 
powder. The vial was vortexed for 2 min until the solution was clear. A 40 μl volume of balance 
solution was added to the vial and vortexed briefly. DNA with a concentration of 500 ng was added 
to a 1.5 mL micro-centrifugation tube, adjusting the total volume to 10 μL with dH2O. A 110 μL 
volume of the prepared DNA modification solution was added into the tube. The tube was 
incubated at 99°C for 6 min, immediately followed by incubation at 65°C for 90 min. A spin 
column was placed into a capless 2 mL collection tube for each sample that was modified. A 300 
μL volume of capture solution was added to the column and the solution was allowed to sit on the 
column for 1 min. The modified DNA solution was utilised onto the column already containing the 
capture solution. The column was centrifuged at 12,000 X g for 45 s. The flow through was 
discarded. A 200 μL volume of the ethanol-diluted cleaning solution was added to the column and 
the column was centrifuged at 12,000 X g for 45 s. A 50 μL volume of balance/ethanol wash 
solution was added to the bottom of the column, ensuring that no air bubbles were impeding the 
liquid flow to the column filter. The column was incubated at 8 min at room temperature. After 
incubation, the column was centrifuged at 12,000 X g for 45 s and the flow-through was discarded. 
A 200 μL volume of 90 % ethanol solution was added to the column and the column was 
centrifuged at 12,000 X g for 45 s and the flow-through was discarded. A 200 μL volume of 90 % 
ethanol solution was added to the column and the column was centrifuged at 12,000 X g for 1 min. 
The column was placed into a 1.5 mL collection tube and the capless collection tube was discarded. 
A 15 μL volume of elution solution was added to the bottom of the column. The solution was 
allowed to incubate for 1 min. The column was centrifuged at 12,000 X g for 45 s. The column was 
removed and discarded. The eluted solution is the modified DNA, which was stored at -20°C. 
 
2.4.2 Methylation-Sensitive High-Resolution Melting (MS-HRM) 
MS-HRM curve analysis was carried out in Lightcycler
®
 480 96 multi-well clear plates on 
the Lightcycler
®
 480. A master mix of PCR reagents was prepared per sample as described in Table 
2.13. Primer sequences and annealing temperatures are shown in Table 2.14. 
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A 1 μL volume of bisulfite treated DNA (500 ng concentration) was used per reaction, 
giving a final volume of 10 μL. A negative-template control using 1 μL H2O instead of DNA was 
also included. Template DNA was initially denatured at 95°C for 10 min, followed by 45 
amplification cycles, followed by high-resolution melting analysis on the Lightcycler
®
 480. Each 
cycle consisted of template denaturation (95°C for 10 s), primer annealing (Tm for 15 s) and 
extension (72°C for 15 s). This was followed by high-resolution melting analysis. High-resolution 
melting settings consisted of 95°C for 1 min, 40°C for 1 min, 70°C for 5 s and continuous 
acquisition to 95°C (ramp rate 0.02 °C/s), followed by cooling at 40°C for 10 s. Melting 
temperature for the DNA samples were assigned automatically by the Lightcycler 
®
 480 Software. 
 
 
Table 2.13. Master Mix for MS-HRM 
 
Table 2.14. Primer sequences and annealing temperatures used for MS-HRM 
 
 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 0.4 
Reverse primer (5 ρmol/μL) (IDT) 0.4 
25mM MgCl2 1.2 
Lightcycler
®
 480 HRM Master Mix 5 
dH₂O 2.0 
Gene Primer Sequences Annealing Temp. 
 
ATM 
Fwd: 5′-CGAAGAGGGTGGGTGAGAGTTT-3′ 
Rev: 5′-ACGCCATATCCACCAATAACCAAC-3′ 
58°C  
 
RASSF1 
Fwd: 5′-GTTTTAGATGAAGTCGTTATAGAGGT-3′ 
Rev: 5′-CCCCACGACAACTAATCCCTAA-3′ 
58°C 
 
EIF2C3 
Fwd: 5′-TTAGGAAGGAGGGTGGTTTTATT-3′ 
Rev: 5′-AAACTTACCTAAAAAATAACCTACCTAAAA-3′ 
52°C 
 
ATP5F1 
Fwd: 5′- CGTTGGGGGCGGTATAGGGG-3′ 
Rev: 5′-CCGAACTATCCCCAACCCTACCC-3′ 
60°C 
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2.4.3 Bisulfite Treatment for SMART-MSP 
The Qiagen Epitect Fast Bisulfite Conversion Kit composed of Bisulfite Solution, DNA 
Protect Buffer, RNase-Free Water, MinElute Spin Columns, Collection Tubes, Buffer BL, Buffer 
BW, Buffer BD, Buffer EB and Carrier RNA was used to bisulfite treat DNA samples. The protocol 
was carried out according to the manufacturers’ instructions with slight alterations. Bisulfite 
reactions were prepared in PCR tubes per sample as described in Table 2.15. 
 
Table 2.15. Bisulfite Reaction 
 
The PCR tube was closed and the reaction was mixed thoroughly. DNA bisulfite 
conversion was carried out on a thermal cycler. DNA was denatured at 95°C for 5 min, followed by 
incubation at 60°C for 10 min, denaturation at 95°C for 5 min, incubation at 60°C for 10 min and an 
indefinite hold at 20°C. The bisulfite converted DNA was then cleaned up. The PCR tube was 
centrifuged briefly and the reaction was transferred to a 1.5 ml eppendorf tube. A 310 μL volume of 
Buffer BL was added and the solution was mixed by vortexing. A 250 μL volume of 100 % ethanol 
was added and the sample was mixed by pulse vortexing for 15 s and centrifuged briefly. A 
MinElute DNA spin column was placed into a 2 mL collection tube and the entire solution from the 
tube was transferred into the column. The column was centrifuged at 15,000 X g for 1 min and the 
flow-through was discarded. A 500 μL volume of Buffer BW was added to the column, the column 
was centrifuged at 15,000 X g for 1 min. and the flow-through was discarded. A 500 μL volume of 
Buffer BD was added to the column, the lid was closed (to avoid acidification) and the column was 
incubated at room temperature for 15 min. The column was centrifuged at 15,000 X g for 1 min and 
the flow-through was discarded. A 500 μL volume of Buffer BW was added to the column, the 
column was centrifuged at 15,000 X g for 1 min and the flow-through was discarded. This step was 
repeated. A 250 μL volume of 100 % ethanol was added to the column and the column was 
centrifuged at 15,000 X g for 1 min. The column was transferred into new 2 mL collection tubes 
and centrifuged at 15,000 X g for 1 min. The column was placed into 1.5 mL eppendorf tube and 
the capless collection tube was discarded. A 10 μL volume of Buffer EB was added onto the centre 
Component Volume (μL) 
DNA Sample (500 ng) 1-40 
RNase-free water 40 - DNA sample 
Bisulfite solution 85 
DNA Protect Buffer 15 
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of the column membrane, the lid was closed and the column was incubated at room temperature for 
1 min. The column was centrifuged at 15,000 X g for 1 min to elute the DNA. The modified DNA 
was stored at -20°C. 
 
2.4.3 Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP) 
SMART-MSP curve analysis was carried out in Lightcycler
®
 480 96 multi-well white 
plates. A master mix of PCR reagents was prepared per sample as described in Table 2.16 and 2.17. 
Primer sequences and annealing temperatures are shown in Table 2.18.  
 
A 2.5 μL volume (25 ng) of bisulfite treated DNA (theoretical amount) was used per 
reaction, giving a final volume of 10 μL. A positive 100 % methylated control and negative-
template control using 2.5 μL H2O instead of DNA was also included. All samples were carried out 
in duplicate. Template DNA was initially denatured at 95°C for 10 min, followed by 45 
amplification cycles, followed by high-resolution melting analysis on the Lightcycler
®
 480. Each 
cycle consisted of template denaturation (95°C for 10 s), primer annealing (Tm for 15 s) and 
extension (72°C for 15 s). This was followed by high-resolution melting analysis. High-resolution 
melting settings consisted of 95°C for 1 min, 40°C for 1 min, 70°C for 5 s and continuous 
acquisition to 95°C (ramp rate 0.02 °C/s), followed by cooling at 40°C for 10 s. Crossing point (Cp) 
values and melting temperature for the DNA samples were assigned automatically by the 
Lightcycler 
®
 480 Software. Cp values were averaged and methylation values were quantified using 
the 2
(-ΔΔCp)
 quantification approach. 
 
Table 2.16. Master Mix for COL2A1 SMART-MSP 
 
 
 
 
 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 0.8 
Reverse primer (5 ρmol/μL) (IDT) 0.8 
25mM MgCl2 1 
Lightcycler® 480 HRM Master Mix 5 
dH₂O 0.5 
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 Table 2.17. Master Mix for DHFR and DHFRL1 SMART-MSP 
 
Table 2.18. Primer sequences and annealing temperatures used for MS-HRM 
 
2.5 Genotyping Methods  
2.5.1 DHFR 19bp Genotyping Assay – Melt Curve Analysis 
Melt curve analysis was carried out in Lightcycler 
®
 480 96 multi-well clear plates on the 
Lightcycler
®
 480. A master mix of reagents was prepared as shown in Table 2.19. Primer and probe 
sequences are shown in Table 2.20. 
 
A 1-4 μL volume of DNA (100 ng) was used per reaction, giving a final volume of 20 μL. 
Template DNA was initially denatured at 95°C for 10 min, followed by 45 amplification cycles, 
followed by melt curve analysis on the Lightcycler
®
 480. Each cycle consisted of template 
denaturation (95°C for 10 s), primer annealing (59°C for 15 s) and extension (72°C for 15 s). This 
was followed by melt curve analysis. Melt curve settings consisted of 95°C for 1 min, 30°C for 1 
min and 75°C for continuous (ramp rate 0.1 °C/s), followed by cooling at 40°C for 30 s. Genotypes 
for the DNA samples were assigned automatically by the Lightcycler 
®
 480 Software and manually 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 0.4 
Reverse primer (5 ρmol/μL) (IDT) 0.4 
25mM MgCl2 1.2 
Lightcycler® 480 HRM Master Mix 5 
dH₂O 0.5 
Gene Primer Sequences Annealing Temp. 
 
COL2A1 
Fwd: 5′-GTAATGTTAGGAGTATTTTGTGGGTA-3′ 
Rev: 5′-CTACCCCAAAAAAACCCAATCCTA-3′ 
 
63°C 
 
DHFR 
Fwd: 5′-GAGGGTTTTCGTTTTCGTTCG-3′ 
Rev: 5′-CAAATAAACCCTAACGCTACAACG-3′ 
 
54°C  
 
DHFRL1 
Fwd: 5′-GGGTTAGGGTTAAAGCGATTTTCGT-3′ 
Rev: 5′-AAACAAAAACCGCACAAACGCG-3′ 
 
58°C 
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Table 2.19. Master Mix for DHFR 19bp deletion Melt Curve Analysis   
 
Table 2.20. DHFR 19bp deletion primer and probe sequences 
 
2.5.2 DHFRL1 rs17855824 SNP Melt Curve Analysis 
Melt curve analysis was carried out in Lightcycler 
®
 480 96 multi-well clear plates on the 
Lightcycler
®
 480. A master mix of reagents was prepared as shown in Table 2.21. Primer and probe 
sequences are shown in Table 2.22. 
 
Table 2.21. Master Mix for DHFRL1 rs17855824 SNP Melt Curve Analysis   
 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 2 
Reverse primer (5 ρmol/μL)  (IDT) 1 
Sensor probe (10 ρmol/μL) (Eurofins) 1 
Anchor probe (10 ρmol/μL) (Eurofins) 1 
Lightcycler
® 
480 Genotyping Master 5X 4 
dH₂O 10 
 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 3 
Reverse primer (5 ρmol/μL) (IDT) 1 
Sensor probe (10 ρmol/μL) (Eurofins) 1 
Anchor probe (10 ρmol/μL) (Eurofins) 1 
DMSO 3 
Lightcycler 
® 
480 Genotyping Master 5X 4 
dH₂O 3-6 
Forward primer 5′-TGGGCATCGGCAAGAAC-3′ 
Reverse primer 5′-TCTGGCCCCATCCTCTC-3′ 
Sensor probe 5′-CCAGGTACCCCGACCGTG- Fluorescein -3′ 
Anchor probe 5′- BODIPY 630/650 - CAGCCTGCGCCCGTTTGGG- Phosphate -3′ 
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A 1 μL volume of DNA was used per reaction, giving a final volume of 20 μL. Template 
DNA was initially denatured at 95°C for 10 min, followed by 45 amplification cycles, followed by 
melt curve analysis on the Lightcycler
®
 480. Each cycle consisted of template denaturation (95°C 
for 10 s), primer annealing (52°C for 15 s) and extension (72°C for 15 s). This was followed by 
melt curve analysis. Melt curve settings consisted of 95°C for 1 min, 40°C for 1 min and 75°C for 
continuous (ramp rate 0.1 °C/s), followed by cooling at 40°C for 30 s. Genotypes for the DNA 
samples were assigned automatically by the Lightcycler
®
 480 Software. 
 
Table 2.22. DHFRL1 SNP 1 (rs17855824) primer and probe sequences 
 
Forward primer 5′-GGAAGCCATGAATCACCTAG-3′ 
Reverse primer 5′-TACTTCAAATTTGTACTTGATGTGTTT-3′ 
Sensor probe 5′-ACATCAGAGAGAACACCTGGGTA- Fluorescein -3′ 
Anchor probe 5′- BODIPY 630/650 - 
CAGGCAGAAGTTTATATTTCTCCAAGTCAATTTCT- Phosphate -3′ 
 
2.5.3 Genotyping by Gel Electrophoresis 
DHFRL1 Polymorphisms 
A master mix of PCR reagents was prepared per sample as described in Table 2.23. 
DHFRL1 primer sequences are shown in Table 2.24.  
 
Table 2.23. Master Mix for DHFRL1 SNP Polymorphisms 
 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 1 
Reverse primer (5 ρmol/μL) (IDT) 1 
10X buffer 2.5 
2.5mM dNTPs 2 
MgCl2  1.5 
Taq (5U/μL) 0.1 
dH₂O  15.9 
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A 1 μL volume of DNA (100 ng) was used per reaction, giving a final volume of 25 μL. A 
negative-template control using 1 μL H2O instead of DNA was also included. Template DNA was 
initially denatured at 95°C for 3 min, followed by 30 amplification cycles, in an automated ABI 
9700 DNA Thermal Cycler. Each cycle consisted of template denaturation (94°C for 30 s), primer 
annealing (51°C for 1 min) and extension (72°C for 1 min). This was followed by an elongation 
step to complete the amplification cycle (72°C for 5 min). Samples were maintained at 4°C 
overnight. PCR products were run on a 2 % agarose gel, as described in Section 2.2.1. 
 
Table 2.24. DHFRL1 polymorphism primer sequences  
 
2.6 Cell Culture Methods 
2.6.1 Cell Culture 
All cell culture was carried out in a laminar flow hood whilst adhering to strict sterile 
techniques. The hoods were switched on at least 15 min before use. All medium, flasks, pipettes, 
tips and the inside of the hoods were sprayed and wiped down with ethanol (70 % v/v) before and 
after use to maintain aseptic conditions in the work area.  
 
2.6.2 Cell Lines 
Coriell cell lines, Epstein Barr Virus (EBV) transformed lymphoblastoid cultures from 
peripheral human blood mononuclear cells and human embryonic kidney (HEK) cells were used.   
 
2.6.3 Maintenance of Cell Lines  
2.6.3.1 Coriell Cell Lines 
All Coriell cell lines were maintained in Roswell Park Memorial Institute (RPMI) 1640 
medium containing 2 mM L-Glutamine, and supplemented with heat-inactivated Fetal Bovine 
Serum (FBS) (15 % v/v) (hereafter known as complete medium). The cells were grown in 25 cm
2
 
Gene Primer Sequences 
 
rs17855824 
Fwd: 5′- GGAAGCCATGAATCACCTAG -3′ 
Rev: 5′- TACTTCAAATTTGTACTTGATGTGTTT -3′ 
 
rs61739170 
Fwd: 5′- AATCTGGTGATTATGGGTAGGA -3′ 
Rev: 5′- AGTTTAAGATGGCCTAGGTGATT -3′ 
 
rs114936057 
Fwd: 5′- AACCGCTGCTGTCATGTTTCTTT -3′ 
Rev: 5′- CAGTAAGTTTTAAGGCATCATCCAAA -3′ 
 59 
 
vented sterile tissue culture flasks in an upright position in an incubator at 37°C with 5 % CO₂, 
95 % humidified air. 
  
2.6.3.2 HEK 293 Cell Lines 
All HEK 293 cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with heat-inactivated FBS (10 % v/v), 2 mM L-Glutamine and 1 mM sodium 
pyruvate (hereafter known as complete medium). The HEK 293 DHFRL1 stably transfected 
overexpressed cell pools were grown in complete supplemented with 500 µg/mL G418. The HEK 
DHFRL1 shRNA down-regulated cell pools were grown in complete medium supplemented with 5 
µg/mL puromycin, which are then treated with 500 µM IPTG. The HEK 293 cells were grown in 75 
cm
2
 vented sterile tissue culture flasks in a horizontal position in an incubator at 37°C with 5 % CO₂, 
95 % humidified air.  
 
2.6.4 Cell Line Subculture 
2.6.4.1 Coriell Cell Line Subculture 
Coriell cell lines were inspected daily, manually and via cell count (Section 2.6.7) using a 
haemocytometer and an Olympus CKX31 inverted microscope. All culture reagents were heated to 
37°C before use unless otherwise stated. Cells were sub-cultured or re-fed with fresh medium every 
couple of days depending on how fast the cell line grew. The cell suspension was transferred into a 
20 mL tube and the cells were spun down at 500 X g for 5 min. The cells were re-suspended in a 
volume of complete media to yield a minimum concentration of 200,000 viable cells / ml. Once 
cells had been sub-cultured three times, they could be used for experiments. 
 
2.6.4.2 HEK 293 Cell Line Subculture 
HEK 293 cell lines were inspected daily using an Olympus CKX31 inverted microscope. 
Once cell cultures had reached 60-70 % confluency, they were either used in experiments or were 
sub-cultured. All culture reagents were heated to 37°C before use unless otherwise stated. The 
residual growth medium was poured off from the flasks into a waste bottle. A 2 mL volume of 
trypsin-EDTA was added to the flask, in order to rinse the cells. The trypsin was removed from the 
flask and a 3 mL volume of trypsin-EDTA was added to the flask, in order to detach the cells from 
the flasks. The flasks were incubated at 37°C until the cells had detached from the flask surface 
(~10 min). Trypsin was inactivated by the addition of 5 mL of complete medium. To ensure a single 
cell suspension, cells were re-suspended thoroughly using a pipette. The cell suspension was 
transferred into a 20 mL tube and the cells were spun down at 500 X g for 5 min. The cells were re-
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suspended in a volume of complete medium based on the cell density required. A 9 mL volume of 
complete medium was then added into a new cell culture flask and 1 mL of the cell suspension was 
added. Cells were maintained at 37°C in CO₂ 5 %, humidified air 95 %.  
 
2.6.5 Preparation of Frozen Stocks 
Coriell cell line stocks were maintained and stored as follows. Cell clumps were dissociated 
by trituration and the number of viable cells was counted. The cell suspension was transferred into a 
20 mL tube and the cells were pelleted by centrifugation at 500 X g for 5 min. The supernatant was 
discarded. The cell pellet was re-suspended in the appropriate volume of cold (4-10°C) freeze 
medium (RPMI 1640 with 20 % FBS and 6 % DMSO) to yield five million viable cells/mL. The 
cell suspension was dispensed in 1 mL aliquots into sterile, labelled cryotubes. The samples were 
stored at - 20°C for 20 min and then stored at - 80°C overnight. The samples were then transferred 
into liquid nitrogen. 
  
HEK 293 cell line stocks were maintained and stored as follows. Cells were collected by 
trypsinisation as described in Section 2.6.4. The entire cell suspension was transferred into a 20 mL 
tube, and the cells were pelleted by centrifugation at 500 X g for 5 min. The supernatant was 
discarded. The cell pellet was re-suspended in the appropriate volume of cold cell freezing medium 
to yield 1 X 10
6
 viable cells/mL. The cell suspension was dispensed in 1 mL aliquots into sterile, 
labelled cryotubes. The samples were stored at - 20°C for 20 min and then stored at - 80°C 
overnight. The samples were then transferred into liquid nitrogen. 
 
2.6.6 Reconstitution of Frozen Cell Stocks 
The cryovials containing Coriell cells were removed from the liquid nitrogen and the frozen 
cells were thawed out with agitation as quickly as possible in a water bath at 37°C. The cells were 
then transferred into sterile 20 mL tubes and 5 mL complete medium was added to the tube. Cells 
were counted, seeded and maintained in an upright position at 37ºC with CO₂ 5 %, humidified air 
95 % in 25 cm
2
 tissue culture flasks. When cell lines reached confluency, they were passaged as 
described in Section 2.6.4. 
 
The cryovials containing HEK cells were removed from the liquid nitrogen and the frozen 
cells were thawed out with agitation as quickly as possible in a water bath at 37°C. The cells were 
then transferred into sterile 20 mL tubes and 5 mL complete medium was added to the tube. Cells 
were spun down at 500 X g for 5 min and the supernatant was discarded. The pellet was re-
suspended in 5 mL of complete medium and the cells were counted, seeded and maintained in a 
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horizontal position at 37ºC with CO₂ 5 %, humidified air 95 % in 25 cm2 or 75 cm2 tissue culture 
flasks. When cell lines reached confluency, they were passaged as described in Section 2.6.4. 
 
2.6.7 Cell Enumeration  
The trypan blue dye exclusion test is based on the ability of viable cells to actively exclude 
dye, due to an intact cell membrane. As dead cells are unable to exclude the trypan blue dye, they 
appear blue, rather than clear, when examined under the microscope. A 500 μL volume of cells 
were transferred to a 1.5 mL tube eppendorf tube. A 100 μL volume of trypan blue was added to the 
cell suspension. The solution was mixed by vortexing and was left to sit for 5 min. After 5 min, the 
cell suspension was vortexed and a 10 μL volume was applied to the counting chamber of a 
haemocytometer (Hausser Scientific, PA, USA). The cells were then counted under 40 X 
magnification. The number of cells in the 4 outer chambers, made up of 16 squares each and the 
cells on 2 sides were counted. Four independent determinations were carried out and the mean was 
used to calculate the mean cell culture density. 
 
Cell density was determined using the following formula: 
 Cells/mL = (N/4) x 1.2 x 10⁴  
Where, 
N =cell number counted  4 = number of fields counted 
1.2 = dilution factor   10⁴ = constant 
 
2.6.8 Transfection of HEK 293 cells using Lipofectamine 
Cells were seeded at a cell density of 2 x 10
5
 cells per well in complete medium in a 6-well 
plate and incubated at 37°C for 24 h. Plasmid DNA (4 µg) was added to a final volume of 50 µL of 
serum free medium in an eppendorf tube. A 10 µL volume of Lipofectamine 2000 was added to 40 
µL of serum free medium in an eppendorf tube. Both tubes were incubated at room temperature for 
5 min. The two tubes were mixed together and the mixture was incubated at room temperature for 
20 min. The tubes were mixed well by vortexing and the mixture was added drop wise into the well. 
The plate was incubated at 37°C for 48 h. The transfection complexes were removed and replaced 
with 2 mL of medium containing the selection agent.   
 
2.6.9 RNA Isolation from Cultured Cells 
The Bioline Isolate II RNA Mini Kit composed of Lysis Buffer RLY, Wash Buffer RW1, 
Wash Buffer RW2, Membrane Desalting Buffer (MEM), Reaction Buffer for DNase I (RDN), 
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DNase I and RNase-free Water was used to isolate RNA from cultured cells. The protocol was 
carried out according to the manufacturers’ instructions with slight alterations. 
 
A total number of 5 X 10
6
 mammalian cells were trypsinised and the pellets were collected 
by centrifugation. A 350 µL volume of lysis buffer RLY and 3.5 µL of β-ME were added to the cell 
pellet, and the cell pellet was re-suspended with a pipette and vortexed vigorously. The ISOLATE 
II Filter was placed in a collection tube and the lysate was loaded and centrifuged for 1 min at 
11,000 X g. The ISOLATE II Filter was discarded and 350 µL of 70 % ethanol was added to the 
homogenised lysates. The lysate was mixed by pipetting up and down 5 times. The ISOLATE II 
RNA Mini Column was placed in a collection tube and the lysate was loaded on to the column. The 
column was centrifuged for 30 s at 11,000 X g. The column was placed into a new collection tube. 
A 350 µL volume of MEM was added and the column was centrifuged at 11,000 X g for 1 min. A 
DNase I reaction mixture was prepared by adding 230 µL of water to the DNase I and incubating at 
room temperature for 1 min. A 10 µL volume of reconstituted DNase I was added to 90 µL of RDN 
and was mixed by gentle flicking. A 95 µL volume of the DNase I reaction mixture was loaded 
directly on to the centre of the silica membrane and incubated at room temperature for 15 min. A 
200 µL volume of Wash Buffer RW1 was added to the ISOLATE II RNA Mini Column and 
centrifuged for 30 s at 11,000 X g. The column was then placed into a new collection tube. A 600 
µL volume of Wash Buffer RW2 was added to the ISOLATE II RNA Mini Column and centrifuged 
for 30 s at 11,000 X g. The flow through was discarded and the column was placed back into the 
collection tube. A 250 µL volume of Wash Buffer RW2 was added to the ISOLATE II RNA Mini 
Column and centrifuged for 2 min at 11,000 X g. The column was placed into a nuclease-free 1.5 
mL collection tube. A 50 µL volume of RNase-free water was added directly to the column and the 
tubes were incubated at room temperature for 1 min. The tube was then centrifuged at 11,000 X g 
for 1 min. The isolated RNA was stored at -80°C. 
 
2.6.10 Quantifying RNA Concentration 
RNA concentrations were measured using the NanoDrop 1000 Spectrophotometer (Thermo 
Scientific). The NanoDrop was blanked with RNase-free water that was previously used to elute the 
RNA. The RNA parameter was chosen on the NanoDrop instrument and 1 μL of each sample was 
loaded onto the optical pedestal and the sample was then drawn into a column and measured. UV-
Vis spectrum results were displayed on the computer and the RNA concentrations were measured as 
ng/μL with an expected A260/280 ratio of 2, indicating acceptable RNA purity within the samples. 
The samples were then stored at -80°C. 
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2.6.11 DNase Treatment of RNA 
  A 2 µg concentration of RNA was added to nuclease-free water to give a final volume of 8 
µL in a PCR tube. A 1 µL volume of Sigma 10 X reaction buffer and a 1 µL volume of Sigma 
amplification grade DNase I was added to the tube. The reaction solution was mixed gently by 
flicking and the tube was then incubated at room temperature for 15 min. A 1 µL volume of Sigma 
stop solution was added to the reaction in order to bind calcium and magnesium ions and to 
inactivate the DNase I. The reaction was then incubated at 70 °C for 10 min on a thermal cycler.  
The reaction was then chilled on ice / stored at -20 °C. 
 
2.6.12 RNA Sample Preparation for Agarose Gel Electrophoresis 
RNA samples were kept on ice at all times. A 1 µg concentration (one volume) of RNA 
sample was added to two volumes of RNA sample loading buffer in a PCR tube. The tubes were 
then heated to 65°C for 10 min in a thermal cycler to denature the RNA. Samples were then loaded 
onto as agarose gel was as described in Section 2.2.1. 
 
2.6.13 Reverse Transcription Polymerase Chain Reaction (cDNA Synthesis) 
High quality RNA was reverse transcribed to cDNA by the following method. A 1 µg (5.5 
µL) concentration of DNase treated RNA was transferred into a PCR tube. A 2 μL volume of 
Bioline random hexamers primer mix (50 ng/μL) and 4 µL of Bioline Oligo (dT) 18 primer mix (50 
µM) was added to each sample and the tubes were centrifuged briefly to ensure that the solution 
was mixed. The samples were then heated at 70°C for 5 min on the thermal cycler to denature the 
RNA. The samples were then cooled on ice for at least 1 min. A master mix of reverse transcription 
reagents was prepared per sample as described in Table 2.25.  
 
Table 2.25. Master Mix for reverse transcription 
Component Volume (μL) 
Nuclease free H₂O 1.5 
RNAsin (RNaseOUT Ribonuclease Inhibitor) (40μg/μL)  1 
10 mM dNTPs 1 
5 x Reaction Buffer 4 
BioScript (Reverse Transcriptase Enzyme) (200U/µL) 1 
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An 8.5 μL volume of master mix was added to each sample. The samples were centrifuged 
briefly to homogenise the mixture. cDNA synthesis was then carried out on a thermal cycler. The 
samples were heated to 25°C for 10 min, followed by 42°C for 60 min and 70°C for 15 min. 
Samples were stored at 4°C. 
 
2.6.14 Genomic Contamination of RNA Samples Test – MTHFD1 R653Q PCR Assay 
The MTHFD1 R653Q assay is an intron spanning assay, producing a PCR product of 330 
bp when amplifying genomic DNA and a PCR product of 232 bp when amplifying cDNA. A master 
mix of PCR reagents was prepared per sample as described in Table 2.26. Primer sequences are 
shown in Table 2.27.  
 
Table 2.26. Master Mix for MTHFD1 R653Q PCR Assay 
 
 Table 2.27. MTHFD1 R653Q Polymorphism Primer sequences 
 
A 1 μL volume of cDNA / genomic DNA was used per reaction, giving a final volume of 
50 μL. A negative-template control using 1 μL H2O instead of DNA was also included. Template 
DNA was initially denatured at 95°C for 3 min, followed by 35 amplification cycles, in an 
automated ABI 9700 DNA Thermal Cycler. Each cycle consisted of template denaturation (94°C 
for 30 s), primer annealing (58°C for 1 min) and extension (72°C for 1 min). This was followed by 
Component Volume (μL) 
Forward primer (5 ρmol/μL) (IDT) 0.3 
Reverse primer (5 ρmol/μL) (IDT) 0.4 
10X buffer 5 
2.5mM dNTPs 4 
25 mM MgCl2  3 
Taq (5U/μL) 0.2 
dH₂O  36.1 
Gene Primer Sequence 
MTHFD1 R653Q Fwd: 5′- CACTCCAGTGTTTGTCCATG -3′ 
Rev: 5′- GCATCTTGAGAGCCCTGAC -3′ 
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an elongation step to complete the amplification cycle (72°C for 10 min). Samples were maintained 
at 4°C overnight. PCR products were run on a 2 % agarose gel, as described in Section 2.2.1. 
 
2.6.15 Real Time – quantitative Polymerase Chain Reaction 
RT-qPCR assays were carried out in Lightcycler
®
 480 96 multi-well white plates on the 
Lightcycler
®
 480 and were designed using the Universal Probe Library (Roche). Primer and probe 
sequences are shown in Table 2.28. A master mix of PCR reagents was prepared per sample as 
described in Table 2.29. 
 
Table 2.28 Primer sequence and probe number for RT-qPCR 
  
Table 2.29. Master Mix for RT-qPCR assay 
 
A 1 μL volume of cDNA was used per reaction, giving a final volume of 15 μL. All 
samples were run in triplicate. A negative-template control using 1 μL H2O instead of DNA was 
also included. Template DNA was initially denatured at 95°C for 5 min, followed by 45 
amplification cycles. Each cycle consisted of template denaturation (95°C for 30 s), primer 
annealing (60°C for 30 s) and extension (72°C for 1 s), with signal acquisition. Results were 
calculated by applying the comparative E-method (Tellmann, 2006) to measure the fold change in 
target gene expression relative to the reference gene.  
Assay Target Primer Sequences 
DHFRL1 Fwd: 5ʹ- CGGACCTTAGAAAGTCACACATC-3ʹ 
Rev: 5 ʹ-TCACAGGAGAATCACTTCAACC-3ʹ 
Probe #89 
GAPDH Fwd: 5ʹ-CTCTGCTCCTCCTGTTCGAC-3ʹ 
Rev: 5ʹ-ACGACCAAATCCGTTGACTC-3ʹ 
Probe #60 
Component Volume (μL) 
Forward primer (20 ρmol/μL) (IDT) 0.16 
Reverse primer (20 ρmol/μL) (IDT) 0.16 
Probe 0.16 
SensiMixII 8 
dH₂O 5.52 
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2.6.16 Proteomics Analysis 
Label-free LC-MS Analysis was carried out by our collaborators, Dr. Paula Meleady and 
Mr. Michael Henry from the National Institute for Cellular Biology (NICB) in DCU. 
 
2.6.16.1 Sample Preparation 
Cell pellets were lysed with 300 µL of lysis buffer (7 M urea, 2M thiourea, 30 mM Tris, 4 % 
CHAPS, pH 8.5) and were homogenised by passing the samples through a 20 gauge needle five 
times. Samples were then placed on a shaker for 1 h to allow extraction to take place. Samples were 
then centrifuged at 10,000 X g for 15 min at 4°C to remove any insoluble material. The supernatant 
was transferred into a new tube and protein concentrations were determined using the thiourea-
compatible Quick Start Bradford Assay. A100 µg concentration of the samples was then cleaned 
using the Ready Prep 2-D clean up kit to remove any trace of detergents. The cell pellet was then 
re-suspended in detergent free buffer (6M urea, 2 M thiourea, 10 mM Tris, pH 8.0). Protein 
concentrations were determined again using the thiourea-compatible Quick Start Bradford Assay. 
Protein concentrations were adjusted to a concentration of 2 µg/µL using the detergent free buffer. 
Proteins were then digested by adding 10 µg of protein (5 µL) to 35.4 µL of 50 mM ammonium 
bicarbonate and 0.5 µL of 1 % Protease MAX Surfactant. The proteins were reduced with DTT 
(final concentration of 5 mM) by incubating the samples at 56°C for 20 min and then allowing them 
to cool to room temperature for 20 min. Samples were alkylated by adding Iodoacetamide (final 
concentration 15 mM) and incubating the samples at room temperature in a dark room for 15 min. 
Digestion was carried out with sequence grade Lys-C at a ratio of 1:20 (w/w) Lys-C:Protein at 37°C 
for 6 h, followed by a second digestion with sequence grade trypsin at a ratio of 1:25 (w/w) 
Trypsin:Protein at 37°C overnight. The digestion was stopped by adding 2 µL of a 50 % 
trifluoroacetic acid (TFA) / 50 % water solution. Samples were then cleaned up using Pep-clean 
C18 spin column dried under a vacuum and stored at -80°C. Prior to mass spectrometry, the dried 
peptides were re-suspended in 50 µL of 0.1 % TFA in 2 % acetonitrile (CAN), vortexed and 
sonicated to ensure an even suspension. 
 
2.6.16.2 Label-free LC-MS Quantitative Profiling 
Nano LC-MS/MS analysis was carried out using an Ultimate 3000 nano LC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; 
Thermo Fisher Scientific). A 5 µL volume of digest was loaded onto a C18 trap column (C18 
PepMap, 300 µm ID x 5 cm, 5 µm particle size, 100 Å pore size; Thermo Fisher) and desalted for 
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10 min using a flow rate of 25 µL/min in 0.1 % TFA. The trap column was then switched online 
with the analytical column (PepMap C18, 75 µm ID x 500 mm, 3 µm particle and 100 Å pore size; 
Thermo Fisher) and peptides were eluted with the following binary gradients of solvent A and B: 0-
25 % solvent B in 240 min and 25-50 % solvent B in a further 60 min, where solvent A consisted of 
2 % CAN and 0.1 % formic acid in water and solvent B consisted of 80 % CAN and 0.08 % formic 
acid in water. Column flow rate was set to 300 nL/min. Data was acquired with Xcalibur software, 
version 2.0.7 (Thermo Fisher Scientific). The mass spectrometer was operated in data-dependent 
mode and externally calibrated. Survey MS scans were acquired in the Orbitrap in the 300-2000 m/z 
range with the resolution set to a value of 60,000 at m/z 400. Up to seven of the most intense ions 
(1+, 2+ and 3+) per scan were CID fragmented in the linear ion trap. A dynamic exclusion window 
was applied within 40 s. All tandem mass spectra were collected using a normalised collision 
energy of 35 %, an isolation window of 3 m/z, and one microscan. 
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Chapter 3 
 
Examination of Candidate Folate 
Sensitive Differentially Methylated 
Regions (FS-DMRs) in the FASSTT 
study 
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3.1 Introduction 
 DNA methylation is the most commonly studied form of epigenetic modification in the 
mammalian genome and is thought to play a part in regulating gene expression. The aim of this 
chapter is to identify candidate folate-sensitive differentially methylated regions (FS-DMR) in the 
literature that have previously been shown to be subjected to DNA methylation changes due to 
changes in one carbon metabolism markers and to screen these candidate sites in a folic acid 
intervention trial of pregnant women. This will be carried out in order to assess whether prolonged 
exposure to folic acid supplementation during pregnancy can result in changes in DNA methylation 
patterns. This will be carried out using a technique known as MS-HRM. The folic acid intervention 
study will also be assessed for the DNA methylation patterns in the promoter regions of DHFR and 
DHFRL1, two important genes that are involved in de novo thymidylate biosynthesis in the folate 
mediated one-carbon metabolism pathway (Figure 1.1) (See Section 1.11 and 1.12). DHFR is 
involved in de novo thymidylate biosynthesis /folate metabolism in both the nucleus and the 
cytoplasm whereas DHFRL1 localises to the mitochondria and takes the place of DHFR in de novo 
thymidylate biosynthesis in the mitochondria. Promoter methylation will be assessed using a 
technique known as SMART-MSP.  
 
3.1.1 Nutrition and DNA Methylation 
Nutrition is well-known to play a major role in health and disease, with a wealth of 
literature supporting the “fetal origins of disease” hypothesis (Gluckman et al., 2008) that proposes 
that the in utero environment has a significant role in an individual’s risk of a number of diseases 
later in their adult life (Barker et al., 1989). Although the mechanism behind how the in utero 
environment can influence disease is yet unknown, DNA methylation has been a proposed 
mechanism. However, DNA methylation is a new area of research, and therefore nutrition sensitive 
methylation sites in humans have only recently begun to be identified (Parle-McDermott and Ozaki, 
2011). 
 
Studies such as the Dutch Hunger Winter study provide an excellent opportunity to 
examine the effects of nutrition on health and disease (Lumey et al., 1993). The Dutch Hunger 
Winter was a time during the end of World War II, when food restrictions were put in place in the 
western part of the Netherlands. In spite of this, excellent medical records were kept, allowing those 
who were exposed to the famine prenatally to be traced (Schulz, 2010). Research carried out on this 
cohort of samples by Heijmans et al. (2008), showed that those individuals who were exposed to the 
famine prenatally had significantly less DNA methylation at the imprinted Igf2 gene in comparison 
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to their unexposed, same sex siblings 60 years later. However, individuals who were exposed to the 
famine during the late gestation period showed to have no effect, suggesting that it is an early 
developmental effect (Heijmans et al., 2008). Another study examined additional loci on this same 
cohort of samples (Tobi et al., 2009). This study found that the INSIGF gene had decreased 
methylation, while the IL10, LEP, ABCA1, GNASAS and MEG3 genes had increased methylation in 
those individuals who were exposed to the famine prenatally. However, late gestational exposure 
only showed DNA methylation changes in the GNASAS and LEP genes in men only (Tobi et al., 
2009). These studies indicate that nutritionally induced changes are not just limited to the peri-
conceptional period, and show both increases and decreases in methylation as well as displaying 
some sex-specificity (Parle-McDermott and Ozaki, 2011).  
 
Aside from the Dutch Hunger Winter study, a number of other observational and 
intervention studies have been carried out, which have mostly focused on methyl donors. 
Correlations have been found between folate status and global DNA methylation levels in 
peripheral blood mononuclear DNA (Friso et al., 2002). The study showed that individuals who 
have the MTHFR 677 TT genotype have a significantly lower level of global DNA methylation in 
comparison to those who have the MTHFR 677 CC genotype. As the MTHFR 677C>T 
polymorphism is a well-known disease associated variant that converts 5, 10-
Methylenetetrahydrofolate to 5-Methyltetrahydrofolate at a slower rate when folate status is low, it 
was thought that the supply of methyl groups may be compromised in individuals with the MTHFR 
677 TT genotype and this was shown to correlate with global DNA methylation patterns (Friso et 
al., 2002, Parle-McDermott and Ozaki, 2011). Other folic acid intervention studies have also found 
differences in global DNA methylation status (Jacob et al., 1998, Rampersaud et al., 2000), as well 
as DNA methylation changes in specific genes such as Igf2 (Steegers-Theunissen et al., 2009).   
 
The most relevant study to our project has been carried out by Fryer et al. (2011), who 
examined human cord blood samples using the Illumina Infinium Methylation 27K BeadArray, a 
large step towards genome wide analysis. They also measured serum folate and homocysteine levels, 
an inverse indicator of folate status and methyl supply. They analysed 27,578 CpG loci that were 
associated with 14,496 genes. Similar to previous findings, they found that the majority of CpGs 
within the CpG islands were hypomethylated while those outside of the CpG islands were 
methylated. From their analysis, they identified that DNA methylation of 12 genes (EIF2C3, 
ZBTB11, BDH2, ZNF187, RUNX1T1, C9orf64, PDE2A, MGC33486, AMN, ZPBP2, FBN3 and 
PVRL2) was directly correlated to homocysteine levels, while DNA methylation of five genes 
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(ATP5F1, CYP26C1, FSTL3, MDS032 and BMX) was inversely correlated (Fryer et al., 2011). As 
the cord blood samples were taken at birth, it suggests that late gestation could be an important 
period where nutrition can influence / induce DNA methylation changes.  
 
Despite the fact that the numbers of studies that have been carried out to date in order to 
identify nutrient sensitive DMRs in humans have been restricted, due to the availability of samples 
and to ethical issues, a number of observational and intervention studies have reported changes in 
DNA methylation in response to nutrient status, with the above studies revealing how folate status 
can play a role in influencing the pattern of DNA methylation both in utero and in adults. Although 
a number of candidate methylation sites have emerged from these studies, we are only beginning to 
decipher the human epigenome and identify those DNA methylation sites that are altered by 
nutrition. However, the pattern that seems to be emerging from the studies carried out to date, is that 
nutrient mediated DNA methylation changes are gene specific, site specific, tissue specific and age 
specific. In light of this, it is therefore, much more significant to examine specific known regions of 
the genome or to carry out a genome wide screen rather than measuring global DNA methylation 
patterns, measuring the methylation levels of multiple DNA repetitive sites, which seems to have 
been the case in most of the previous studies carried out to date, which have limited relevance. 
Technologies such as DNA microarray based technology, next generation sequencing after sodium 
bisulfite treatment, SMART-MSP and MS-HRM have now been developed and are available to 
measure genome wide or gene specific DNA methylation patterns. Therefore, the identification of 
nutrient-sensitive DMRs is likely to explode in the coming years (Parle-McDermott and Ozaki, 
2011). We aim to begin to assess the impact of folic acid supplementation on DNA methylation 
patterns using a candidate gene / region approach. 
 
3.1.2 The FASSTT Study 
It is well known that folate supplementation pre-conception and during the first term of 
pregnancy reduces the risk of NTDs (1992). However, no official folic acid recommendations exist 
after the first trimester of pregnancy. Therefore, McNulty et al., (2013) carried out a study in order 
to investigate the effect of continued folic acid supplementation after the first trimester of 
pregnancy on maternal folate and homocysteine responses and related effects in the new born 
(McNulty et al., 2013). The study was carried out on the Folic Acid Supplementation during the 
Second and Third Trimester (FASSTT) samples, a 26 week, double blind, randomised placebo 
controlled intervention trial of pregnant women during the second and third trimester of pregnancy, 
and consists of a total of 357 blood samples. This study was led by Prof. Helene McNulty and Dr. 
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Kristina Pentieva of the Northern Ireland Centre for Food and Health, School of Biomedical 
Sciences, University of Ulster, Northern Ireland. Women who took part in this study were between 
18-35 years of age with singleton pregnancies with no known complications between 2005 and 
2006. All women took folic acid supplements in the first trimester of their pregnancy. A total 
number of 119 women completed the study. After the first trimester, the women were divided into 
two groups. A total of 59 women received 400 µg of folic acid supplement per day and a total of 60 
women received a placebo. Blood samples were taken at baseline (after the first trimester) and post-
intervention (week 36) as well as from the cord blood at delivery (Figure 3.1). McNulty et al., 
(2013) found that those women who did not continue on with the folic acid supplementation after 
the first trimester had a decrease in their serum folate levels and an increase in their plasma 
homocysteine levels, whereas those women who were on the supplementation had a significant 
increase in their red blood cell folate levels. Cord blood folate levels were also found to be 
significantly higher in the folic acid supplementation group when compared to the placebo group. 
Whether these effects have benefits for pregnancy outcomes or early childhood still needs to be 
determined (McNulty et al., 2013). 
 
In our study, genomic DNA samples were isolated from the buffy coats of all the blood 
samples and the DNA samples were used to screen candidate FS-DMRs, as well as DHFR and 
DHFRL1 by two different DNA methylation analysis methods as described below (Section 3.1.3 
and Section 3.1.4).  
 
3.1.3 Methylation Sensitive - High Resolution Melting (MS-HRM) 
MS-HRM is a PCR based assay that has been specifically adapted to study DNA 
methylation following sodium bisulfite treatment (Wojdacz et al., 2008). High resolution melting is 
a technique that was initially developed for genotyping by comparing the melting profiles of 
sequences that differ in their nucleotide composition. Each double-stranded DNA molecule has a 
specific melting temperature, a temperature at which the DNA helix separates into two single 
strands. During high resolution melting, the PCR products, which are bound to an intercalating dye, 
are exposed to an increasing temperature gradient, emitting fluorescence. When the melting 
temperature of the PCR product is reached, the DNA separates into two single strands, preventing 
the binding and fluorescing of the dye. This results in a sharp drop in fluorescence, allowing the 
melting profile of the PCR products to be determined (Wittwer et al., 2003).   
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In MS-HRM, sodium bisulfite treatment, a chemical modification that converts all the 
unmethylated cytosine residues to uracil, while leaving the methylated cytosines as cytosines has to 
take place before high resolution melting (Figure 3.2) as methylation marks are removed from 
genomic DNA by DNA polymerase during PCR amplification. Therefore, bisulfite treatment 
introduces specific changes in the DNA sequence that depends on the methylation status of the 
individual cytosine residues. As methylated and unmethylated DNA acquire different sequences 
after bisulphite treatment, this results in PCR products with noticeably different melting 
temperatures and profiles (Wojdacz et al., 2008).  
 
Before PCR amplification can take place, PCR primers need to be designed carefully in 
order to ensure unbiased amplification of either the methylated or the unmethylated DNA. This is 
critical, as preferential amplification of either template (PCR bias) will lead to misinterpretation of 
the results. Amplification of DNA standards should result in one PCR product that is relatively rich 
in GC content originating from the methylated DNA, where methylated cytosines are kept and one 
PCR product that has little GC content, originating from unmethylated templates where all the 
cytosines have been converted into uracils. Once the PCR product is amplified, melt curve analysis 
can take place. MS-HRM allows the melt curve of your DNA of interest to be compared to a 
standard curve of DNA methylation standards so that the methylation status of your sample can be 
determined (Wojdacz et al., 2008). 
 
3.1.4 Sensitive Methylation Analysis after Real Time-Methylation Specific PCR  
 Sensitive methylation analysis after real time–methylation specific PCR (SMART-MSP) is 
also a probe free PCR based assay that detects the level of DNA methylation at a single locus 
following sodium bisulfite treatment (Figure 3.2). However, in contrast to MS-HRM, SMART-MSP 
quantifies the levels of methylation using the data obtained from the real-time PCR, rather than that 
obtained from the melting profiles of the DNA samples, although the melting profiles are used to 
evaluate the amplicon; to identify false positives due to incomplete bisulfite conversion or false 
priming, i.e. the methylation levels are quantified based on the crossing point (Cp) values, the 
number of cycles required for the fluorescent signal to cross the threshold (Kristensen et al., 2008, 
Kristensen et al., 2009).   
 
 In the same way as MS-HRM, PCR primers for SMART-MSP must be designed carefully 
before PCR amplification can take place. In contrast to MS-HRM primers, where the primers are 
designed to amplify the target, independent of its methylation status, SMART-MSP primers must be 
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designed to only amplify up methylated DNA templates during PCR amplification. This can be 
achieved by including CpG sites at the 3ʹ end of the primers.  
 
3.1.5 Objectives 
In our study, assessment of candidate FS-DMRs, DHFR and DHFRL1 in the FASSTT 
study was examined using the following methodology. 
 Examination of the literature and choosing folate-sensitive gene candidates.  
 Generation of MS-HRM assay for the candidate folate-sensitive genes.  
 DNA extraction from the buffy coats of the FASSTT samples. 
 Screening of FASSTT samples for all candidate FS-DMRs using MS-HRM. 
 Generation of SMART-MSP assays for DHFR and DHFRL1.  
 Screening of FASSTT samples for DHFR and DHFRL1 using SMART-MSP. 
 
3.2 Results 
3.2.1 Examination of the literature and choosing folate-sensitive gene candidates  
A literature survey was carried out on all human methylation sites that were reported to 
change in response to any environmental stimuli and a number of those that had been reported to 
change in response to folate-related markers were chosen to be examined. The FS-DMRs that were 
chosen were: 
 RASSF1A – ras association domain family member 1 alpha 
o Folic acid supplementation increases RASSF1A methylation levels in blood samples 
(Vineis et al., 2011) (Examined by pyrosequencing).  
 EIF2C3 -  eukaryotic translation initiation factor 2C, 3 
o DNA methylation levels directly correlated with homocysteine levels in cord blood 
(Fryer et al., 2011) (Examined by Illumina bead array). 
 ATP5F1 – ATP synthase H+ transporting, mitochondrial F0 complex, subunit B1
 
 
o DNA methylation levels inversely correlated with homocysteine levels in cord 
blood (Fryer et al., 2011) (Examined by Illumina bead array). 
 
As the MS-HRM assays proved to be quite difficult to develop and optimise, a MS-HRM 
assay was firstly optimised for the ATM – ataxia telangiectasia mutated gene, a gene whose primers 
had been previously designed by Wojdacz et al. (2008) to examine tumour methylation by MS-
HRM (Wojdacz et al., 2008). While ATM is not considered to be a candidate FS-DMR, the 
feasibility of adopting the MS-HRM method to our laboratory could be assessed through this assay. 
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3.2.2 DNA extraction from buffy coats 
DNA was extracted from the buffy coats of a total of 255 samples. Buffy coats are a 
fraction of whole blood that lies between the red blood cells and the plasma once the whole blood 
has been spun down and contain the white blood cells and platelets. DNA was extracted from the 
buffy coats using the Qiagen
® 
FlexiGene DNA Kit as described in Section 2.2.3. The DNA proved 
to be difficult to extract as the buffy coats obtained were highly viscous. In order to ensure we had 
extracted clean DNA, all samples were run on a 1 % agarose gel (Figure 3.3) and were also 
nanodropped in order to determine the concentration of the DNA. 
 
3.2.3 Screening of Candidate FS-DMR genes by MS-HRM 
3.2.3.1 Generation of MS-HRM assays for the candidate folate-sensitive genes  
The first step of MS-HRM assay development was to design primers that allow correction 
for PCR bias as the quantity of amplification achieved by methylated and unmethylated DNA 
controls can be compromised by PCR bias due to the fact that they have different base compositions. 
Wojdacz et al. (2008) showed that the inclusion of a limited number of CpGs into the primer 
sequence and optimisation of the annealing temperature compensates for PCR bias towards the 
unmethylated GC-poor strand in most cases by enabling selective binding of the primer to the 
methylated sequence, therefore enabling compensation for PCR bias that would otherwise normally 
favour amplification of the unmethylated template. Inserting CpGs into the primer also increases the 
sensitivity of the melting assay. Therefore, primers with a limited number of CpGs were designed 
carefully and in accordance to the guidelines given by Wojdacz et al. (2008) in order to ensure 
unbiased amplification of either the methylated or unmethylated DNA. 
 
Primers for ATM, RASSF1A, EIF2C3 and ATP5F1 were designed in the proximal promoter 
CpG islands of each gene according to the guidelines (See Table 2.7 for primer sequences and 
Appendix C-F for primer sites in the proximal promoter CpG islands). Once primers were designed, 
methylated and unmethylated DNA standards were bisulfite treated using the Sigma Imprint DNA 
Modification Kit. To ensure that the primers were designed correctly and that the DNA standards 
had been bisulfite treated and could be amplified, the bisulfite treated DNA standards were 
amplified with ATM primers (Figure 3.4) (See Section 2.4.2) 
 
Once amplification was confirmed, a range of methylation concentrations (0 %, 5 %, 10 %, 
50 % & 100 %) were made up by a series of dilutions, mixing the relevant volume of methylated 
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DNA template to unmethylated DNA template to be used for the standard curve. All assays were 
optimized initially for annealing temperature (Ta), then for primer and MgCl2 concentration (See 
Section 2.4.2). The most important aspect for optimization was for the amplification to be specific 
and therefore, lower primer concentrations worked best.   
 
Although Wojdacz et al. (2008) had published the sequence of the ATM primers they had 
used in their study, optimal conditions for the MS-HRM assay were not given and therefore, had to 
be optimised in the lab. An optimised standard curve of the ATM MS-HRM assay is shown in 
Figure 3.5, with five different methylation concentrations (0 %, 5 %, 10 %, 50 % & 100 %). The 
RASSF1A assay was also optimised using the same five different methylation concentrations. An 
optimised standard curve of the RASSF1A MS-HRM assay is shown in Figure 3.6. The EIF2C3 
assay was also optimised using the five different methylation concentrations. However, the lower 
methylation ranges of 5 % and 10 % proved difficult to reproduce and were therefore left out of 
subsequent standard curves. An optimised standard curve of the EIF2C3 MS-HRM assay is shown 
in Figure 3.7. The ATP5F1 assay was also initially optimised using the five different methylation 
concentrations. However, the lower methylation ranges of 5 % and 10 % also proved difficult to 
reproduce and were therefore left out of the standard curve. An optimised standard curve of the 
ATP5F1 MS-HRM assay is shown in Figure 3.8.  
 
3.2.3.2 Screening of FASSTT samples for all candidate folate-sensitive genes 
A total of 95 FASSTT Study samples, including samples taken from both pre- and post-
folic acid intervention and those who had been given folic acid and those who had been given a 
placebo after the first trimester of pregnancy were chosen and were examined. A 500 ng 
concentration of DNA from each sample was bisulfite treated as described in Section 2.4.1 and the 
methylation levels of the ATM, RASSF1A, EIF2C3 and ATP5F1 gene were examined by MS-HRM 
(Figures 3.9-3.13). All samples were screened along with three methylation standards (0 % 
methylated, 50 % methylated and 100 % methylated) in order to produce a DNA methylation 
standard curve. This allowed us to determine the methylation status of the FASSTT samples by 
comparing the melt curve of the FASSTT samples to the standard curve of DNA methylation 
standards. 
 
FASSTT samples, including both pre- and post-intervention samples with those given a 
placebo and those given a daily folic acid supplementation were screened for all four genes (the 
ATM gene, the RASSF1 gene, the EIF2C3 gene and the ATP5F1 gene) by MS-HRM. All samples 
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were found to be unmethylated for the ATM gene, the RASSF1 gene and the EIF2C3 gene (Figure 
3.9 – Figure 3.11). The FASSTT samples that were screened for the ATP5F1 gene by MS-HRM 
were also found to be mostly unmethylated (Figure 3.12). However, a slight methylation was seen 
in a few of the samples as can be seen by the small methylation peaks seen in Figure 3.13. On the 
other hand, the small peaks seen may also be due to background noise. These need to be confirmed 
by sequencing. 
 
3.2.4 Screening of DHFR and DHFRL1 promoters by SMART-MSP  
DHFR and DHFRL1 promoters were screened by a method known as SMART-MSP as 
described in Section 3.1.4. SMART-MSP was chosen as the method of choice, as MS-HRM assays 
proved to be difficult to design and optimise as described above. 
 
3.2.4.1 Generation of SMART-MSP assays for a control gene  
The first step of SMART-MSP assay development was to develop a control assay. A 
control assay is required in order to account for the amount of input DNA going into the PCR after 
bisulfite treatment, so that we can normalise for the DNA input for each of our samples during 
quantification. The COL2A1 gene was the gene chosen for our control assay as it had previously 
been used as a control gene for SMART-MSP and primers for this assay had been designed by 
Kristensen et al. (2008). The primers were designed so that any bisulfite treated DNA would be 
amplified regardless of its methylation status, i.e. this is a control gene for the amount of input DNA 
for subsequent normalisation. The COL2A1 assay was initially optimized for melting temperature 
(Tm), then for primer and MgCl2 concentration using bisulfite treated methylated and un-
methylated DNA controls (See Section 2.4.4). Once these parameters had been optimised, the 
COL2A1 assay was optimised using four different methylation concentrations (0 %, 10 %, 50 % & 
100 %) in order to determine the sensitivity of the assay. A negative control was also included in 
the assay (See Section 2.4.4). All samples were carried out in duplicate. The Cp values of an 
optimised COL2A1 SMART-MSP assay are shown in Table 3.1. Cp values are inversely 
proportional to the amount of DNA present in the sample, i.e. the lower the Cp value, the greater the 
amount of DNA in the sample. The COL2A1 assay was initially optimised using methylated and un-
methylated DNA standard samples. The melting curves of an optimised COL2A1 SMART-MSP 
assay is shown in Figure 3.14., where a clean single melting peak is observed as expected for both 
methylated and un-methylated control DNA samples. 
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3.2.4.2 Generation of SMART-MSP assays for DHFR and DHFRL1 genes  
The first step of SMART-MSP assay development was to design primers that are selective 
as much as possible for methylated DNA templates, so that only methylated DNA templates will be 
amplified during PCR amplification. This was achieved by the inclusion of at least two CpGs, of 
which at least one was located at or near the 3ʹ end of the primer sequence. Non-CpG cytosines 
were also included near the 3ʹ end of the primer sequences in order to select against incompletely 
converted sequences. The primer sequences were also examined to ensure that no single nucleotide 
polymorphisms (SNPs) were present within the sequence as SNPs can interfere with the melting 
profile of the PCR product (Kristensen et al., 2008). 
  
Primers for the DHFR gene were designed in the 5ʹ upstream and exon 1 region (promoter 
region) of the DHFR gene proximal promoter in accordance to the guidelines mentioned above. 
(See Table 2.7 for primer sequences and Appendix G for primer sites). Primers for the DHFRL1 
gene were designed by firstly examining the difference between the two DHFRL1 transcripts (See 
Appendix H). The two transcripts differ in their 5ʹ UTRs but both produce the same protein 
sequence. Although transcript 1 is 111 bp longer than transcript 2, transcript 1 is missing 123 bp in 
a region of exon 1, which may be of importance as previous data generated in the lab has shown 
that DHFRL1 transcript 2 is the transcript, which is being more highly expressed (McEntee et al., 
2011). Therefore, SMART-MSP primers for DHFRL1 were designed in this 123 bp region in 
accordance to the guidelines mentioned above. (See Table 2.7 for primer sequences and Appendix 
H for primer sites).  
 
Once primers were designed, the assays were initially optimized for Ta, then for primer and 
MgCl2 concentration using bisulfite treated methylated and unmethylated DNA controls. The most 
important aspect for optimization was to ensure that only methylated DNA templates were being 
amplified. Once the assay was optimised, a range of methylation concentrations (0%, 10%, 50% & 
100%) were made up by a series of dilutions, mixing the relevant volume of methylated DNA 
template to unmethylated DNA template. These were then used to assess the quantitative properties 
and sensitivity of the assays.  
 
The DHFR assay was optimised using four different methylation concentrations (0 %, 10 %, 
50 % & 100 %). Although we did try lower methylation concentrations, we found that the 
reproducibility of samples with low levels of DNA methylation was not great and that sometimes 
only one of the replicates amplified. Therefore, we used a 10 % cut off point as our level of % 
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methylation detection. A negative control was also included in the assay. The Cp values of an 
optimised DHFR SMART-MSP assay are shown in Table 3.2. The DHFR assay was initially 
optimised using methylated and unmethylated DNA standard samples. The amplification and 
melting curves of an optimised DHFR SMART-MSP assay are shown in Figure 3.15. All 
methylated samples are represented by a clean singe peak at the same melting temperature as 
expected. 
 
The DHFRL1 assay was optimised using four different methylation concentrations (0 %, 
10 %, 50 % & 100 %). A negative control was also included in the assay. The Cp values of an 
optimised DHFRL1 SMART-MSP assay are shown in Table 3.3. The DHFRL1 assay was initially 
optimised using methylated and unmethylated DNA standard samples. The amplification and 
melting curves of an optimised DHFRL1 SMART-MSP assay are shown in Figure 3.16. All 
methylated samples are represented by a clean singe peak at the same melting temperature as 
expected. 
 
3.2.4.3 Screening of FASSTT samples for COL2A1, DHFR and DHFRL1 
A total of 252 FASSTT Study samples, including samples taken from both pre- and post-
folic acid intervention and those who had been given folic acid and those who had been given a 
placebo after the first trimester of pregnancy were chosen and were examined. These samples were 
chosen so that we could compare the pre- and post-intervention methylation level differences within 
each woman, i.e. their A versus B sample. We felt that this was important due to the likely 
methylation differences between individuals and therefore thought it would be better to analyse the 
difference between pre- and post-intervention first, rather than grouping the methylation analyses of 
all the A’s together and comparing it to the methylation analyses of all the B’s grouped together. A 
1 µg concentration of DNA from each sample was bisulfite treated using the Qiagen EpiTect Fast 
Bisulfite Kit as described in Section 2.4.3 and the methylation levels of the COL2A1, DHFR and 
DHFRL1 gene were examined by SMART-MSP. All samples were carried out in duplicate. An 
example of each of these assays is shown in Figures 3.17 - 3.19 (See Appendix I & J for raw Cp 
values). All samples were screened along with the 100 % methylation standard as well as a negative 
control in order to ensure that the assay was working correctly and suitable for methylation 
quantification. Samples were screened twice for the COL2A1 assay in order to ensure that similar 
results were being obtained, regardless of what day / what plates the samples were being run on.  
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3.2.4.4 Analysis of SMART-MSP data for COL2A1, DHFR and DHFRL1 in the FASSTT 
samples 
Out of the total 252 FASSTT samples screened for the COL2A1, DHFR and DHFRL1 gene, 
a total of 66 samples were excluded from the analysis as either the pre- or post-intervention samples 
were missing, the concentration of DNA of the sample was too low to bisulfite treat or as the assay 
replicates could not be repeated. Therefore, our final analysis included a total of 196 samples (98 
people).  
 
The methylation levels for each of the samples for each gene was quantified relative to the 
methylated DNA template using the 2
-ΔΔCp
 real-time PCR quantification approach (Kristensen et al., 
2008), where ΔΔCp = unknown sample (Cptarget gene – Cpcontrol gene) – 100 % methylated DNA (Cptarget 
gene – Cpcontrol gene). This value was then put into the 2
-ΔΔCp
 equation and multiplied by 100 to get the 
methylation percentage of each sample (See Appendix I & J for raw analysis).   
 
3.2.4.4.1 Analysis of SMART-MSP data for DHFR in the FASSTT samples 
Methylation levels were found to differ highly between individuals for the promoter region 
of the DHFR gene that we examined, pre- and post-intervention as expected (Figure 3.20-3.21). 
Therefore, for our analysis, it was decided to examine the difference in methylation % between 
individuals in their pre- and post-intervention samples. A 10 % methylation cut off was used and 
the samples were grouped into one of three categories, 1) above a 10 % increase in methylation 
change after intervention, 2) no change in % methylation after intervention (-10 ≤x ≤ +10) and 3) 
above a 10 % decrease in methylation change after intervention (Figure 3.22). These categories 
were chosen in order to take into account the limits of the SMART-MSP assay for methylation 
detection. 
 
The samples were then divided up into those who were given a placebo after intervention 
and those who were given a daily folic acid supplement after intervention. The two groups were 
then subdivided into the three categories as above (Figure 3.23-3.24). 
 
The samples that showed a methylation change of over 10 %, either an increase or a 
decrease after intervention were plotted as a graph in order to determine whether prolonged 
exposure to folic acid supplementation during pregnancy can result in changes in DNA methylation 
patterns (Figure 3.25-3.26). The bar charts indicated that prolonged exposure to folic acid 
supplementation during pregnancy does not result in changes in DHFR DNA methylation patterns 
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as differential methylation is seen regardless whether the women were given a placebo or a daily 
folic acid supplement after intervention (p-value 0.404), suggesting that DNA methylation patterns 
for DHFR differ between individuals irrespective of folic acid status.  
 
3.2.4.4.2 Analysis of SMART-MSP data for DHFRL1 in the FASSTT samples 
Methylation for the DHFRL1 gene was analysed in a similar fashion to that of the DHFR 
gene. The % methylation change pre- and post-intervention was calculated. However, when this 
was carried out, all samples regardless of whether the women were given a placebo or a daily folic 
acid supplement after intervention were found to lie in the no change category (Figure 3.27 - 3.28). 
The scatter plot and the bar chart indicate that the DHFRL1 gene is most likely un-methylated in the 
region examined and that prolonged exposure to folic acid supplementation during pregnancy does 
not result in changes in DHFRL1 DNA methylation patterns as no change in methylation is seen 
regardless of whether the women were given a placebo or a daily folic acid supplement after 
intervention. 
 
3.3 Discussion 
The in utero environment has been shown to have a significant role in influencing an 
individual’s risk of a number of diseases later in their adult life (Barker et al., 1989). However, the 
mechanism behind how the in utero environment can impact on the risk of disease has yet to be 
deciphered but DNA methylation is thought to play a key role, with nutrition sensitive DMRs in 
humans beginning to be identified in recent years. The first aim of our study was to investigate the 
impact of folic acid supplementation during pregnancy on DNA methylation patterns by examining 
previously identified FS-DMRs in DNA from women who consumed a daily folic acid throughout 
their entire pregnancy and those who only consumed folic acid for the first trimester of pregnancy. 
  
From examining the literature, we chose to examine the DNA methylation patterns of three 
genes, RASSF1, EIF2C3 and ATP5F1 in maternal DNA taken from both pre- and post-folic acid 
intervention, including both those who were given a daily folic acid supplement and those who were 
given a placebo after the first trimester of pregnancy. Although ATM had not previously been 
identified as a FS-DMR, it was also chosen to be examined as MS-HRM assays proved to be 
difficult to optimise and primers for the ATM region had previously been described (Wojdacz et al., 
2008). Optimisation of the MS-HRM assays proved to be a difficult task, with optimisation of 
numerous variables (primer sequence, primer concentration, annealing temperature, MgCl2 
concentration) requiring to be optimised. The choice of gene region and primer design also caused a 
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lot of trouble and required a lot of optimisation. Primers had to be redesigned a couple of times in 
order to ensure that there were no non-specific peaks on the high resolution melting scans as well as 
to eliminate bias towards either the methylated or unmethylated DNA sequences.  
 
Once the MS-HRM assays had been optimised, we analysed the methylation status of 95 
FASSTT DNA samples, taken from both pre- and post-folic acid intervention, including both those 
who were given a daily folic acid supplement and those who were given a placebo after intervention, 
across the four genes (ATM, RASSF1A, EIF2C3 and ATP5F1), with ATM used as a control assay. 
RASSF1A is a gene that has been associated with a tumour suppressor function and is required for 
death receptor-dependent apoptosis. RASSF1A interacts with a protein called CDC20, which is an 
activator of the anaphase-promoting complex. The interaction between RASSF1A and CDC20 
results in the inhibition of APC activity and mitotic progression, resulting in the inhibition of cell 
proliferation by negatively regulating cell cycle progression at the G1/S phase transition (Amin and 
Banerjee, 2012). EIF2C3 is a gene that encodes a member of the Argonaute family of proteins and 
is thought to play a role in short-interfering-RNA (siRNA) mediated gene silencing (Carmell et al., 
2002). ATP5F1 is a gene that encodes a subunit of mitochondrial ATP synthase. ATP5F1 catalyses 
the synthesis of ATP from ADP in the presence of an electrochemical gradient of protons across the 
inner membrane during oxidative phosphorylation. 
 
From our analysis, we found that there was no change in the DNA methylation patterns in 
both groups, pre- and post-folic acid intervention. All the samples examined were also found to be 
unmethylated in the regions examined in the ATM, RASSF1A and EIF2C3 gene (Figure 3.9-3.11). 
However, the ATP5F1 gene proved to be somewhat interesting. Although the majority of the 
samples were also unmethylated in the ATP5F1 gene region examined (Figure 3.12), there were a 
few samples that were seen to be slightly methylated in the ATP5F1 region examined indicated by 
the small methylated peaks, (Figure 3.13) suggesting that it may be folate sensitive and affected by 
folic acid supplementation. However, the minor methylation patterns seen in these samples may 
also be due to background noise. This gene nonetheless, may be of interest and needs to be 
investigated further, possibly by sequencing a number of the methylated and non-methylated 
samples by Sanger sequencing. Apart from these few samples, the rest of the samples were found to 
be unmethylated for all four of the gene regions examined. Therefore, in order to preserve the 
precious sample set and to keep costs down, it was decided that the remaining FASSTT samples 
would not be screened and analysed. 
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Although the other genes investigated in our study were previously shown to be potentially 
folate sensitive in other studies (Fryer et al., 2011, Vineis et al., 2011), they showed no changes in 
DNA methylation pattern in our study. This could have been due to a possible number of reasons. 
Firstly, Fryer et al. (2011) examined methylation patterns in cord blood samples whose mothers 
were either on a folic acid supplemented diet or a non-folic acid supplemented diet during 
pregnancy and not the methylation patterns of the mothers before, during or after pregnancy. 
Therefore we do not know if folic acid supplementation had / has an effect on the DNA methylation 
patterns of mothers who are taking folic acid or whether the effect of folic acid supplementation is 
an in utero effect and only impacts on the DNA methylation pattern of their offspring. Another 
recent finding has also shown an association between pregnant women whom consumed folic acid 
supplement after their first trimester and epigenetic changes in the cord blood samples, with 
increased DNA methylation observed in the paternal copy of the IGF2 gene and decreased 
methylation in the paternally imprinted PEG3 gene (Haggarty et al., 2013). As we only examined 
the maternal FASSTT DNA samples, the changes in DNA methylation patterns seen by Fryer et al. 
(2011) in the cord blood samples may not have been seen. Examining the FASSTT cord blood 
samples may give us an insight into this and this may possibly be done as a future step of our 
research. Secondly, Fryer et al. (2011) assessed the methylation patterns of the genes using the 
Infinium Methylation 27K beadchip assay. However, the methylation patterns observed by the 
Infinium Methylation 27K beadchip were not confirmed by another method and therefore, these 
genes require further validation, especially as they only examined 12 cord samples in total, which 
increases the risk of false positive results. Thirdly, Vineis et al. (2011) examined DNA methylation 
patterns in blood samples from both lung cancer subjects and controls together and found that 
RASSF1A DNA methylation increased in response to folic acid supplementation in individuals who 
have never smoked. This indicates that DNA methylation patterns may be influenced by a number 
of dietary / lifestyle factors acting together and also on the blood sample type taken, i.e. blood from 
cancer patients vs. healthy subjects. RASSF1A is also a gene whose loss or altered expression is 
associated with the pathogenesis of a variety of different cancers, suggesting that it has a tumour 
suppressor function. The inactivation of this gene has been shown to be correlated with 
hypermethylation of its promoter region. As our samples were all healthy individuals, this may in 
part be another explanation as to why no methylation was found in any of our samples. Lastly, as 
the Infinium Methylation 27K beadchip only examines ~ 2 CpG sites per CpG island and the region 
examinable by MS-HRM only covers a small region of the gene, ~ 8-14 CpG sites, (See Appendix 
C-F), the CpG sites in the genes of interest that we examined may not have covered the same region 
examined by Fryer et al. (2011). The CpG sites examined by Fryer et al. (2011) are not indicated in 
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their paper and therefore we could not determine whether the regions they examined overlapped the 
regions we examined. In the case of the RASSF1A gene, the CpG sites examined by Vineis et al. 
(2011) differ to those we examined. This may explain the difference in the methylation patterns 
observed between the different samples. However, the methylation patterns of the genes observed 
above are in concordance with those within the literature, who have proposed that the genes above 
are hypomethylated in their promoter regions (Kristensen et al., 2012). No methylation was 
observed in the RASSF1A promoter region in normal peripheral blood mononuclear cells 
(Kristensen et al., 2012).    
 
In conclusion, we can conclude that the region of the four genes (ATM, RASSF1, EIF2C3 
and ATP5F1) that we examined do not show any change in DNA methylation patterns between the 
pre- and post-folic acid intervention, including both those who were given folic acid and those who 
were given a placebo after the first trimester of pregnancy. In the future, we could examine 
subsequent genes that have been shown to be potential folate sensitive genes to further investigate 
the impact of folic acid supplementation on DNA methylation patterns, however, the quantity of 
DNA that was available to us was limiting and therefore could not be carried out as part of my 
project. 
 
The second aim of our study was to investigate the effect of folic acid supplementation 
during pregnancy on the DNA methylation patterns in the promoter regions of DHFR and DHFRL1, 
two important genes that are involved in the folate mediated one-carbon metabolism pathway in 
DNA from women who consumed a daily folic acid throughout their entire pregnancy and those 
who only consumed folic acid for the first trimester of pregnancy. 
 
As mentioned in Section 1.11, DHFR is an important enzyme in the folate mediated one 
carbon metabolism pathway and catalyses the reduction of DHF and folic acid to its biologically 
active metabolite, THF, in both the cytoplasm and the nucleus. THF can then accept and donate 
one-carbon groups for reactions that are necessary for DNA synthesis, cell proliferation and cellular 
methylation. On the other hand, DHFRL1 localises to the mitochondria and takes the place of 
DHFR in mitochondrial de novo thymidylate biosynthesis as mentioned in Section 1.12 (Figure 1.1). 
As both these enzymes play an important role in the folate pathway, we wanted to determine 
whether prolonged exposure to folic acid would have an effect on the methylation patterns of these 
two genes. This was carried out by a method known as SMART-MSP. 
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For the SMART-MSP assays, we had to use a control assay, the COL2A1 assay, an assay 
which is designed so that all bisulfite treated DNA will be amplified in order to normalise for the 
amount of input DNA after bisulfite conversion as the concentration of bisulfite treated DNA 
cannot be quantified by nanodrop. In order to ensure that the COL2A1 assay is a true representation 
of the amount of input DNA, bisulfite treated FASSTT DNA samples were screened for this assay 
twice, on different plates and on different days in order to ensure that similar results were being 
obtained for both runs. The sensitivity of the SMART-MSP assays was tested using a standard 
dilution series of methylated DNA into unmethylated DNA. Although some papers have reported 
that their SMART-MSP assays are sensitive to as low as 0.1 % and 0.05 % DNA methylation 
(Kristensen et al., 2012), our assays proved to differ. We found that the reproducibility of the 
samples with low levels of DNA methylation were inconsistent and that sometimes only one of the 
replicates amplified. Therefore, we used a 10 % cut off point as our level of % methylation 
detection.  
 
Once the SMART-MSP assays had been optimised, we analysed the methylation status of 
255 FASSTT DNA samples, taken from both pre- and post-folic acid intervention, including both 
those who were given a daily folic acid supplement and those who were given a placebo after 
intervention, across the two genes (DHFR and DHFRL1). From our analysis, we found that the 
methylation patterns did change in the individuals’ pre- and post-folic acid intervention, in both 
those who were given a placebo and those who were given a daily folic acid supplementation for 
the DHFR gene (Figure 3.20-3.21). However, as we expected methylation levels to differ between 
individuals, we worked out the percentage methylation difference in the pre- versus post-
intervention sample for each individual first i.e., each woman’s post-intervention DNA sample was 
only compared to her own pre-intervention DNA sample. 
 
The DHFR SMART-MSP results (Figure 3.22-3.24) indicate that different individuals have 
different levels of % DNA methylation change in the promoter of their DHFR gene. Regardless of 
whether the women were given a placebo or a daily folic acid supplement after intervention, 
changes in the percentage of promoter DHFR methylation were seen between individuals in both 
the intervention and placebo groups suggesting that folic acid status does not affect DHFR DNA 
methylation patterns. Although, the exact reason for the difference in DNA methylation patterns 
observed is unknown, there are many factors that could have attributed to the differences observed. 
It may be due to defects in methyl metabolism or may just simply be due to the environment which 
can affect DNA methylation patterns (Kaminsky et al., 2009). As regions in the genome can also 
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autonomously determine DNA methylation states, this may be the cause of the differences seen 
(Lienert et al., 2011). The methylation observed in this region may also not be functional and what 
we are observing may just be passive methylation differences, DNA methylation that is a 
consequence of gene regulation (Gutierrez-Arcelus et al., 2013). The differences in the blood cell 
type between each sample may also be of concern as DNA methylation variation in human 
populations have recently showed that genetic variation can influence DNA methylation levels in 
different cell types (Gibbs et al., 2010, Bell et al., 2011) and therefore, the differences which we 
observed may simply be differences in blood cell type.  
  
Previous studies carried out to determine the methylation status of the DHFR gene have 
shown that DHFR is under-methylated at its 5ʹ-end promoter region, while completely methylated 
throughout the rest of the gene (Stein et al., 1983, Shimada and Nienhuis, 1985). The DNA 
methylation patterns observed were found to be similar in both sperm and all somatic tissue, a 
contrast to many of the tissue-specific genes that are highly methylated in sperm DNA and under-
methylated in the tissues in which they are expressed. However, as DHFR is a key enzyme that is 
involved in the biosynthesis of purines and pyrimidines, it would be expected to be active and 
expressed in all cells and it has been shown to be constitutively expressed at low levels in all cell 
types. Although DNA methylation has been associated with transcriptional silencing, DHFR has 
been shown to be completely methylated throughout its coding regions and 3ʹ-end, and is still 
actively expressed in all cells. This suggests that DNA methylation most likely exercises its major 
effects on sites that can be altered, with those located at and around the 5ʹ promoter region / exon 1 
of the gene, i.e. promoter methylation can inhibit subsequent gene expression, whereas methylation 
of the coding region does not have an effect on transcription. This is consistent in other genes, such 
as the human gamma globin gene, which shows a strong correlation between its activity in certain 
differentiated cell types and the degree of demethylation around their 5ʹ sequences (Stein et al., 
1983). The level of expression is said to be modulated during the cell cycle, increases with growth 
stimulation and decreases with terminal cell differentiation when the cells cease to proliferate 
(Hendrickson et al., 1980). As described in Section 1.6, the gene body could also be methylated as 
methylation occurring in the bodies of genes has recently been shown to be positively associated 
with active transcription (Hellman and Chess, 2007, Lister et al., 2009a, Jones, 2012).  
  
 However, our results suggest that the DHFR gene is in fact methylated at low percentages 
in the 5ʹ promoter region. However, SMART-MSP assays can only analyse a small number of CpG 
sites and therefore, we would have to design numerous assays in order to determine the methylation 
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status of the whole promoter. Sanger sequencing could also be used to determine the methylation 
status of all of the CpG residues in the DHFR promoter region.   
 
The DHFRL1 SMART-MSP results (Figure 3.27-3.28) indicate that all the individuals who 
took part in the FASSTT study have similar levels of DHFRL1 methylation and that no change in 
methylation patters were found in both groups, pre- or post-folic acid intervention, regardless of 
whether the women were given a placebo or a daily folic acid supplement after intervention. All the 
FASSTT samples examined were also found to be practically unmethylated in the region examined 
pre- and post-intervention. This suggests that folic acid status does not have an effect on DHFRL1 
DNA methylation patterns. As DHFRL1 plays a key role in mitochondrial de novo thymidylate 
biosynthesis, it is likely to be constitutively active in all cells and therefore, one would expect to see 
no methylation in its 5ʹ promoter region. 
 
From the methylation studies carried out above by both MS-HRM and SMART-MSP, we 
can conclude that folic acid supplementation during the second and third trimester of pregnancy did 
not alter the DNA methylation patterns of individuals in the gene regions we examined, with most 
of the genes we examined being unmethylated pre- and post-intervention. However, this is not to 
say that folic acid supplementation does not result in DNA methylation pattern changes and it does 
have the potential to alter DNA methylation patterns in different genes / in different regions of the 
genes we examined and needs to be investigated further.    
 
 
 88 
 
Pregnant women end 1st
trimester
N=119
Controls
Placebo
N=60
Intervention
400ug FA/day
N=59
Pre-Intervention 
Sample
Post-Intervention 
Sample
Cord Blood 
Sample
Week 36
Delivery
FASSTT Study
 
 
Figure 3.1. Overview of the FASSTT study. All women took folic acid supplements throughout 
their first trimester of pregnancy. Intervention began at the beginning of the second trimester, where 
one group was given 400 µg of folic acid per day, whereas the other group was given a placebo. 
Blood samples were taken at baseline and at week 36 and also from the cord blood at the time of 
delivery. Image adapted from Breige McNulty et al., unpublished. 
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Figure 3.2. An overview of sodium bisulfite treatment. Bisulfite treatment converts the 
unmethylated cytosines to uracils while keeping the methylated cytosines as cytosines so that 
methylated and unmethylated cytosines can be distinguished after PCR amplification. 
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Figure 3.3. Gel electrophoresis of an example of the DNA extracted from buffy coats on a 1 % 
agarose gel. Lane 1 – 1 kb DNA ladder, Lane 2 – DNA Sample 1, Lane 3 – DNA Sample 2, Lane 4 
– DNA Sample 3, Lane 5 – DNA Sample 4, Lane 6 – DNA Sample 5. 
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Figure 3.4. Gel electrophoresis of bisulfite treated DNA standards (500 ng) amplified with 
ATM primers on a 2 % agarose gel. Lane 1 – 100 bp DNA ladder, Lane 2 - methylated DNA 
standard, Lane 3 – unmethylated DNA standard, Lane 4 – negative control. Clear bands of the 
correct band (85 bp) were seen indicating that DNA amplification had occurred, confirming that the 
DNA standards had been bisulfite treated and that the primers were designed correctly. 
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Figure 3.5. Standard MS-HRM curve for the ATM gene. The single blue peak represents non-
methylated (0 % methylated) DNA, the two red peaks represent 5 % methylated DNA, the two 
green peaks represent 10 % methylated DNA, the two pink peaks represent 50 % methylated DNA 
and the single grey peak represents 100 % methylated DNA. The annealing temperature used for the 
ATM assay was 58°C.   
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RASSF1A MS-HRM STANDARD 
CURVE
0% methylated -
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Figure 3.6. Standard MS-HRM curve for the RASSF1A gene. The single blue peak represents 
non-methylated (0 % methylated) DNA, the two red peaks represent 5 % methylated DNA, the two 
green peaks represent 10 % methylated DNA, the two pink peaks represent 50 % methylated DNA 
and the single grey peak represents 100 % methylated DNA. The small peaks seen prior to the non-
methylated and methylated peaks may be due to background noise. The annealing temperature used 
for the RASSF1 assay was 58°C.   
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Figure 3.7. Standard MS-HRM curve for the EIF2C3 gene. The single blue peak represents non-
methylated (0 % methylated) DNA, the two red peaks represent 5 % methylated DNA, the two 
green peaks represent 50 % methylated DNA and the single grey peak represents 100 % methylated 
DNA. The small peaks seen prior to the non-methylated and methylated peaks may be due to 
background noise. The annealing temperature used for the EIF2C3 assay was 52°C.   
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Figure 3.8. Standard MS-HRM curve for ATP5F1. The single blue peak represents non-
methylated (0 % methylated) DNA, the two red peaks represent 50 % methylated DNA and the 
single green peak represents 100 % methylated DNA. The annealing temperature used for the 
ATP5F1 assay was 60°C.   
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Figure 3.9. ATM MS-HRM for FASSTT Samples. The single blue peak represents the non-
methylated (0 % methylated) DNA standard, the two red peaks represent the 50 % methylated DNA 
standard and the single green peak represents the 100 % methylated DNA standard. The single lime 
green peaks seen represent the FASSTT samples that were screened. All FASSTT samples were 
unmethylated in the ATM region examined. The annealing temperature used for the ATM assay was 
58°C   
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Figure 3.10. RASSF1A MS-HRM for FASSTT Samples. The single red peak represents the non-
methylated (0 % methylated) DNA standard, the two green peaks represent the 50 % methylated 
DNA standard and the single blue peak represents the 100 % methylated DNA standard. The single 
purple peaks seen represent the FASSTT samples that were screened. All FASSTT samples were 
unmethylated in the RASSF1 region examined. The annealing temperature used for the RASSF1 
assay was 58°C.   
 
  
 
 
 
 
 
 98 
 
 
 
Figure 3.11. EIF2C3 MS-HRM for FASSTT Samples. The single blue peak represents the non-
methylated (0 % methylated) DNA standard, the two red peaks represent the 50 % methylated DNA 
standard and the single green peak represents the 100 % methylated DNA standard. The single light 
blue peaks seen represent the FASSTT samples that were screened. All FASSTT samples were 
unmethylated in the EIF2C3 region examined. The annealing temperature used for the EIF2C3 
assay was 52°C.   
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Figure 3.12. ATP5F1 MS-HRM for FASSTT Samples. The single blue peak represents the non-
methylated (0 % methylated) DNA standard and the single green peak represents the 100 % 
methylated DNA standard. The single orange peaks seen represent the FASSTT samples that were 
screened. FASSTT samples were unmethylated in the ATP5F1 region examined. The annealing 
temperature used for the ATP5F1 assay was 60°C.   
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Figure 3.13. ATP5F1 MS-HRM for FASSTT Samples. The single blue peak represents the non-
methylated (0 % methylated) DNA standard, the two red peaks represent the 50 % methylated DNA 
standard and the single green peak represents the 100 % methylated DNA standard. The single light 
blue peaks seen represent the FASSTT samples that were screened. Some of the FASSTT samples 
were seen to be slightly methylated in the ATP5F1 region examined. The annealing temperature 
used for the ATP5F1 assay was 60°C.   
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Figure 3.14. Standard SMART-MSP melting peaks  for the COL2A1 gene. The green peak 
represents non-methylated (0 % methylated) DNA, the orange peaks represent 50% methylated 
DNA, the pink peaks represent 100 % methylated DNA and the blue line represents the negative 
control. The same clean single melting peak is observed as expected for both methylated and un-
methylated control DNA samples.The annealing temperature used for the COL2A1 assay was 63°C.   
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Figure 3.15. Standard SMART-MSP amplification curve and melting peaks for the DHFR 
gene. The top figure represents the amplification curves for the DHFR gene, with all samples being 
carried out in duplicate. The bottom figure represents the melting peaks for the DHFR gene. The 
blue peak represents non-methylated (0 % methylated) DNA, the red peaks represent 10 % 
methylated DNA, the purple peaks represent 50 % methylated DNA, the brown peak represents 
100 % methylated DNA and the green peak represents the negative control. The same clean single 
melting peak is observed for all the methylated control DNA samples as expected. The annealing 
temperature used for the DHFR assay was 54°C.   
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Figure 3.16. Standard SMART-MSP amplification curve and melting peaks for the DHFRL1 
gene. The top figure represents the amplification curves for the DHFRL1 gene, with all samples 
being carried out in duplicate. The bottom figure represents the melting peaks for the DHFRL1 
gene. The blue peak represents non-methylated (0 % methylated) DNA, the red peaks represent 
10 % methylated DNA, the purple peaks represent 50 % methylated DNA, the brown peak 
represents 100 % methylated DNA and the green line represents the negative control. The same 
clean single melting peak is observed for all the methylated control DNA samples as expected. The 
annealing temperature used for the DHFRL1 assay was 58°C.   
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Figure 3.17. SMART-MSP Screen of FASSTT Samples for the COL2A1 gene. The red peaks 
represent the 100 % methylated DNA control sample, the green peaks represent the FASSTT 
samples and the blue peak represents the negative control. The melting temperature used for the 
COL2A1 assay was 63°C.   
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Figure 3.18. SMART-MSP Screen of FASSTT Samples for the DHFR gene. The red peaks 
represent the 100 % methylated DNA control sample, the light blue peaks represent the FASSTT 
samples and the blue peak represents the negative control. The melting temperature used for the 
DHFR assay was 54°C.   
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Figure 3.19. SMART-MSP Screen of FASSTT Samples for the DHFRL11 gene. The red peak 
represents the 100 % methylated DNA control sample, the light blue peaks represent the FASSTT 
samples and the blue line represents the negative control. The melting temperature used for the 
DHFRL1 assay was 58°C.   
 
 
 
 
 
 
 
 
 
 
 107 
 
  
 
Figure 3.20. DHFR % Methylation pre-intervention in all of the FASSTT Samples. The 
starting % methylation of all the FASSTT samples was plotted as a scatter plot. % methylation 
differs highly between individuals.  
 
 
 
Figure 3.21. DHFR % Methylation post-intervention in all of the FASSTT Samples. The % 
methylation of all the FASSTT samples after intervention was plotted as a scatter plot. % 
methylation differs highly between individuals.  
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Figure 3.22. Change in DHFR % Methylation after Intervention in all of the FASSTT 
Samples. The samples were grouped into three categories depending on whether the methylation 
change after intervention increased by over 10 %, no change (-10 ≤x ≤+10) and methylation change 
decreased over 10 %. The majority of samples fell in the no change category. 
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Figure 3.23. Change in DHFR % Methylation after Intervention in the Placebo FASSTT 
Samples. The placebo samples were grouped into three categories depending on whether the 
methylation change increased by over 10 %, no change (-10 ≤x≤ +10) and methylation change 
decreased over 10 %.    
 
 
  
Figure 3.24. Change in DHFR % Methylation after Intervention in the Intervention FASSTT 
Samples. The intervention samples were grouped into three categories depending on whether the 
methylation change increased by over 10 %, no change (-10 ≤x≤ +10) and methylation change 
decreased over 10 %.      
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Figure 3.25. Change in DHFR % Methylation in the Placebo FASSTT Samples that have a 
Difference of over 10 % Methylation. Differential DHFR DNA methylation changes are seen 
regardless of the fact that all these women were given a placebo after intervention. 
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Figure 3.26. Change in DHFR % Methylation in the Intervention FASSTT Samples that have 
a Difference of over 10 % Methylation. Differential DHFR DNA methylation changes are seen 
regardless of the fact that all these women were given a daily folic acid supplement after 
intervention. 
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Figure 3.27. Scatter Plot of the Change in DHFRL1 % Methylation in all of the FASSTT 
Samples. All samples, regardless of whether they were given a placebo or a daily folic acid 
supplement after intervention showed no difference (-10 ≤x≤ +10) in % methylation change before 
and after intervention. 
 
 
 
Figure 3.28. Change in DHFRL1 % Methylation in all of the FASSTT Samples. The samples 
were grouped into three categories depending on whether the methylation change after intervention 
increased by over 10 %, no change (-10 ≤x≤ +10) and methylation change decreased over 10 %. All 
samples, regardless of whether they were given a placebo or a daily folic acid supplement after 
intervention showed no difference (-10 ≤x≤ +10) in % methylation change before and after 
intervention. 
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Table 3.1 Cp values obtained from the COL2A1 Standards 
 
DNA Standards Cp Value Cp Value Mean Cp Value Standard Deviation 
0 % Methylated 30.80 30.45 30.62 0.24 
50 % Methylated 33.24 32.35 32.80 0.62 
100 % Methylated 31.80 31.15 31.47 0.46 
Negative Control - - - - 
 
 
Table 3.2 Cp values obtained from the DHFR Standards 
 
DNA Standards Cp Value Cp Value Mean Cp Value Standard Deviation 
0 % Methylated 38.64 40 39.32 0.96 
10 % Methylated 31.46 31.71 31.585 0.18 
50 % Methylated 29.39 29.46 29.425 0.05 
100 % Methylated 28.11 28.18 28.145 0.06 
Negative Control 38.3 40 39.15 1.2 
 
 
Table 3.3 Cp values obtained from the DHFRL1 Standards 
 
DNA Standards Cp Value Cp Value Mean Cp Value Standard Deviation 
0 % Methylated 40 37.8 38.9 1.55 
10 % Methylated 30.31 30.65 30.48 0.24 
50 % Methylated 28.46 28.12 28.29 0.24 
100 % Methylated 27.07 27.16 27.115 0.07 
Negative Control 38.23 - 38.23  
 
 
 
 
 
 114 
 
 
 
Chapter 4 
 
Investigation of the impact of the 
DHFR 19 bp deletion / insertion 
polymorphism on circulating folate 
metabolites 
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4.1 Introduction 
DHFR is an important enzyme that plays an essential role in folate mediated one-carbon 
metabolism (Fox and Stover, 2008). A 19 bp deletion /insertion polymorphism (rs70991108) within 
this DHFR gene and its association with circulating folate metabolites has been an area of great 
interest. However, there has been a lot of controversy around the results found (Johnson et al., 2004, 
Parle-McDermott et al., 2007, van der Linden et al., 2007). The aim of this chapter is to genotype 
the 19 bp deletion / insertion polymorphism by Melting Curve analysis and to elucidate the decisive 
impact of the DHFR 19 bp deletion / insertion polymorphism on circulating folate metabolites in a 
cohort of healthy individuals from the Trinity Student Study, the largest cohort (n= 2,507) to 
address this issue to date.  
 
4.1.1 Dihydrofolate reductase (DHFR) 
DHFR, as mentioned in Section 1.10 and 1.11 is an important enzyme that is expressed in 
all organisms and plays an essential role in folate metabolism (Fox and Stover, 2008, Litwack, 
2008). It is located on chromosome 5q11.2-13.2 and is about 30 kb in length, consisting of six 
exons, which are separated by five introns. However, the DHFR coding sequence is only 564 
nucleotides in length. DHFR is expressed in three mRNA isoforms that differ in their 3’ 
untranslated regions (UTRs). These three mRNA species are of 800, 1,000 and 3,800  nucleotides in 
length (Morandi et al., 1982). DHFR is regulated by a TATA-less promoter at the level of 
transcription. This promoter is controlled by a number of different transcription factors, including 
Sp1 and E2F, which are key for its regulation during the cell cycle (Askari and Krajinovic, 2010). 
DHFR catalyses the reduction of DHF and folic acid to its biologically active metabolite, THF, 
which accepts and donates one-carbon groups for reactions that are necessary for DNA synthesis 
and homocysteine re-methylation (Fox and Stover, 2008) (Figure 1.1).  
 
As DHFR plays a vital role in health and disease, it has been studied extensively and 
remains to be a gene of great interest. Due to this, many DHFR polymorphisms have been identified 
and examined (Goto et al., 2001, Mishra et al., 2006, Mishra et al., 2007, Parle-McDermott et al., 
2007), with many thought to be functional, having the ability to alter / influence DHFR gene 
expression / activity. Although polymorphisms can occur within both the coding region and non-
coding regions of genes, no polymorphisms have been found within the coding region of the DHFR 
gene (Litwack, 2008) . This may be due to the fact that DHFR plays a critical role in the folate 
mediated one-carbon metabolism pathway (Blakley and Sorrentino, 1998, Banerjee et al., 2002). 
However, polymorphisms found within the non-coding region of a gene have the ability to change 
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the expression of a gene, affect its RNA splicing or RNA stability, have the potential to influence 
disease and some have been found to be associated with disease susceptibility, mainly cancer 
(Litwack, 2008). Therefore, DHFR polymorphisms that are associated with increasing the levels of 
DHFR expression may play a role in the protection of cancer due to higher levels of 5,10-methylene 
THF needed for thymidylate synthesis. On the other hand, a change in the 5-methyl-THF pool may 
alter methylation reactions and subsequently increase the risk of cancer through epigenetic 
regulation. Variations in the gene could also alter the effect of therapeutic responses to antifolates, 
resulting in reduced responses to drugs / treatment (Askari and Krajinovic, 2010). 
 
4.1.2 DHFR Polymorphisms 
A number of DHFR polymorphisms have been identified in the DHFR gene (Figure 4.1), 
with several of them found to be located in the 3ʹ UTR of the gene. The 3ʹ UTR is located after the 
translation termination codon and contain poly(A) tails. The 3ʹ UTR functions principally to 
regulate RNA stability and translational efficiency but also function to protect the RNA from being 
degraded by 3ʹ to 5ʹ exonucleases, and are required for export from the nucleus (Day and Tuite, 
1998). One of the first polymorphisms to be discovered in the DHFR 3ʹ UTR was the 829 C>T SNP 
(rs1677669), located 233 base pairs downstream of the stop codon and positioned between the first 
and second polyadenylation site. The 829 C>T polymorphism was shown to influence DHFR 
expression (Goto et al., 2001, Mishra et al., 2007) by RT-qPCR, with those with the 829 T/T 
genotype producing the highest DHFR mRNA expression. Although the polymorphism was 
examined in leukaemia and control patients, no significant association was found between disease 
susceptibility and the polymorphism. However, the study did show that the 829 C>T polymorphism 
is associated with a positive role in gene expression, i.e. increased the levels of DHFR mRNA 
expression and provides evidence that the 829 C>T SNP located in the 3ʹ UTR of the DHFR gene is 
a functional SNP that is involved in gene expression (Goto et al., 2001). The increased mRNA 
levels caused by the 829 C>T SNP was shown to be due to better RNA stability, resulting in higher 
levels of DHFR protein in DHFR deficient Chinese hamster cell lines by comparing cells that were 
transfected with the DHFR 829 TT variant and those transfected with the DHFR 829 CC variant 
(Mishra et al., 2006). Further research carried out on this polymorphism at a later stage, showed that 
this increase in DHFR gene expression also affects the efficiency of MTX, with those with the 829 
TT genotype having a higher resistance to MTX (Mishra et al., 2007). In addition, the SNP was 
found to be located near the microRNA (miR) -24 3’ UTR binding site. The 829 C>T 
polymorphism influences the expression of DHFR by interfering with the function of miR-24. Cells 
with the T allele were found to bind miR-24 less efficiently, causing the half-life of DHFR mRNA 
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to increase, resulting in higher DHFR mRNA and protein levels. This in turn has an impact on 
MTX sensitivity, with cells with the T allele being 4-fold more resistant to MTX in comparison to 
those without the allele (Mishra et al., 2007). Other polymorphisms identified in the DHFR 3ʹ UTR 
include 35289 A>G (rs1232027) (Chandran et al., 2010) and 1171 A>T (rs7387) (Sharma et al., 
2009), both of which have been shown to negatively affect (decrease) the response to MTX 
treatment in psoriatic arthritis and rheumatoid arthritis respectively. A 9 bp repeat polymorphism 
(rs3045983) has been reported in the 5ʹ upstream region of the DHFR gene that partially overlaps 
with the 5ʹ UTR. The impact of this polymorphism is not known but it is thought that it may affect 
mRNA stability or the efficiency of translation (Gellekink et al., 2007). A number of 
polymorphisms have also been shown in the upstream region from the minor promoter transcription 
initiation site, 317 A>G (rs408626) and 1610 C>G/T (rs1650694). Both these polymorphisms have 
been shown to be associated with worse acute lymphoblastic leukaemia, most likely due to higher 
levels of DHFR expression (Dulucq et al., 2008). Polymorphisms have also been identified in intron 
3 of the DHFR gene, 8890 A>G (rs1643659) and 10372 A>C (rs1677639), both of which have been 
associated with a decrease in colorectal cancer risk in non-users of multivitamin supplements 
(Levine et al., 2010). Two recent studies have also identified rare coding mutations (not 
polymorphisms) in DHFR as causative for megaloblastic anaemia and cerebral folate deficiency 
(Banka et al., 2011, Cario et al., 2011). However, no non-synonymous polymorphisms have been 
identified within the coding region of the DHFR gene to date.  
 
4.1.3 DHFR 19 bp deletion / insertion polymorphism  
The most extensively studied DHFR polymorphism is a 19 bp deletion / insertion 
(rs70991108) polymorphism. This 19 bp deletion / insertion polymorphism in intron-1 of the DHFR 
gene, located 60 bases from the splice donor site (Figure 4.2) has been associated with maternal risk 
of NTDs (Johnson et al., 2004, van der Linden et al., 2007, Parle-McDermott et al., 2007). NTDs 
are a group of common birth defects of the brain and spinal cord, with a prevalence of 1 per 1,000 
in Europe and the USA, caused by the failure of the neural tube to close and include spina bifida 
and anencephaly. As neural tube closure takes place during a period of rapid cellular proliferation, 
DHFR activity is most likely to be crucial in maintaining optimal DNA synthesis during this time. 
As previous studies have shown and it is now well known that low serum folate and high 
homocysteine levels are associated with an increased risk of NTDs, (van der Put et al., 2001) it is 
not surprising that changes / polymorphisms in the DHFR gene has been considered as a candidate 
for association with NTDs. However, the association of the 19 bp deletion/insertion polymorphism 
with NTDs and the biological function of this polymorphism are highly controversial. In 2004, 
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Johnson et al. (2004) reported that the DHFR 19 bp deletion allele in mothers is associated with an 
increased risk of having a baby born with spina bifida in a heterogeneous cohort of n=35 as the Sp1 
transcription factor binding site is located in the deletion sequences (Johnson et al., 2004). As 
mentioned in Section 1.11, Sp1 sites mediate the induction of DHFR transcription in the late G1 
phase of the cell cycle (Jensen et al., 1997). Therefore, deletion of this site could alter DHFR 
transcription, altering the level of DHFR expression, which could result in an increased risk of 
having a baby born with NTDs. On the other hand, Parle-McDermott et al. (2007) suggested that 
the 19 bp deletion allele has a protective effect in a larger cohort (n = 283), decreasing the risk of 
having a baby with spina bifida while others have proposed that it has no effect at all (n = 101) (van 
der Linden et al., 2007).  Thus, whether the DHFR 19 bp deletion allele is associated with NTDs 
remains to be elucidated. However the DHFR 19 bp deletion allele has been shown to have a 
protective role in adult acute lymphoblastic leukaemia (ALL) patients (n = 245) (Gemmati et al., 
2009) and has also been shown to be a risk of breast cancer in multivitamin users (n = 1062) (Xu et 
al., 2007).  
 
A number of studies have also been carried out that examine the impact of the 19 bp 
deletion / insertion polymorphism on circulating folate metabolites, with conflicting results. One 
study who examined 20 individuals ranging from 20-90 years of age reported a 2.5 % and a 14.4 % 
decrease in total plasma homocysteine (tHcy) for the heterozygous and homozygous genotypes 
respectively in comparison to the wild type genotype (p = 0.016) but no differences were seen with 
serum or red blood cell (RBC) folate levels, with adjustments for age and sex not changing the 
result (Gellekink et al., 2007), whereas another group found the 19 bp deletion (del/del) genotype to 
be modestly associated with elevated levels of RBC and serum folate in women but not in men, 
with no differences seen in tHcy levels, although the effects were annulled by smoking 
(Stanisławska-Sachadyn et al., 2008). They carried out the study on 430 young Northern Irish adults 
ranging from 20-26 years of age. Although only small samples numbers were used in both these 
studies, both these findings suggest that the deletion allele may have a protective effect against 
NTDs as maternal low folate / high homocysteine levels have previously been shown to be 
associated with the increased risk of NTDs in offspring (Mills et al., 1995). In contrast, another 
group who investigated the effect of the 19 bp deletion / insertion polymorphism and plasma 
concentrations of circulating folic acid with plasma total homocysteine, total folate and RBC folate 
concentrations reported that the functional effect of the DHFR polymorphism depends on the level 
of folic acid intake (Kalmbach et al., 2008). They examined 1215 individuals from the Framingham 
Offspring Study and reported that folic acid intake of ≥500 μg/d increased the level of high 
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circulating unmetabolised folic acid in individuals who had the deletion (del/del) genotype (47.0%) 
in comparison to those who had the heterozygous (WT/del) genotype (21.4%) and the insertion 
(WT/WT) genotypes (24.4%) (P = 0.03). An interaction between the DHFR polymorphism and 
folic acid intake was also seen with respect to RBC folate (P = 0.01). When folic acid intake was 
<250 μg/d, the del/del genotype was associated with signiﬁcantly lower RBC folate (732.3 nmol/L) 
compared to the WT/WT genotype (844.4 nmol/L). No interaction was found between the DHFR 
genotype and folic acid intake with tHcy and plasma total folate.  
 
The larger two studies described above (Kalmbach et al., 2008, Stanisławska-Sachadyn et 
al., 2008) suggest that the DHFR deletion allele may have an impact on circulating unmetabolised 
folic acid and RBC folate but that folic acid intake and sex may also need to be considered. The aim 
of our study is to elucidate the decisive impact of the DHFR 19 bp deletion / insertion 
polymorphism on circulating folate metabolites in the Trinity Student Study, the largest cohort (n= 
2,507) to address this issue to date. This Chapter is in collaboration with Prof. Anne Molly from 
Trinity College Dublin and Dr. James Mills from the NIH. 
 
4.1.4 The TSS Study 
The Trinity Student Study (TSS) is a study, which is funded by the National Institute of 
Health in the USA and the Health Research Board of Ireland. Young males and females between 
the ages of 19 and 36, attending Trinity College Dublin were recruited between February 2003 and 
2004. A total of 3569 students primarily took part in the study. Of these 3569 students, the 2524 
individuals who had Irish grandparents and no major medical problems at the time were invited to 
continue with the study. Blood samples were taken from the subjects and they were also asked to 
fill out a questionnaire (lifestyle and nutritional information). Of these subjects, complete blood 
data could not be obtained for 2 students and 15 students failed to return the questionnaire and were 
therefore excluded from the data analysis. This left a total of 2507 subjects for the study. All 
samples were made anonymous before analysis. Ethical approval was attained from the Dublin 
Federated Hospitals Research Ethics Committee, which is associated with the University of Dublin, 
Trinity College, and the study was reviewed by the Office of Human Subjects Research at the 
National Institutes of Health. Written informed consent was also obtained from the participants 
when they enrolled. 
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4.1.5 Melt Curve Analysis 
Melt curve analysis was the method chosen to genotype our DNA samples, mainly based on 
instrument availability. Melt curve analysis is a method that is based on looking at the fluorescence 
of the sensor and anchor probes and is principally designed to genotype SNPs. In melting curve 
genotyping experiments, labelled sequence-specific probes are added to the PCR reaction, and are 
allowed to anneal to the reaction products during the amplification procedure. Melting curves are 
acquired by heating the probe-amplicon heteroduplex and measuring the changes in fluorescence 
that occurs. Even a single mismatch between the probe and amplicon can show a reduced melting 
temperature when compared to the perfect match (Lyon and Wittwer, 2009). The fluorescence data 
acquired from the melting curves are converted into melting peaks by the LightCycler Data 
Analysis software that compensates for colour and removes the background fluorescence and plots 
the negative derivative of fluorescence with respect to temperature (Pont-Kingdon and Lyon, 2003) 
(Figure 4.3). The information obtained from the melting peaks can be used to identify which SNP 
base is present on the allele, and can therefore be used in applications such as clinical diagnosis and 
monitoring.   
 
In our study, we used HybProbes to design our melt curve genotyping assays. HybProbes 
are based on fluorescence resonance energy transfer (FRET), whereby two sequence-specific 
oligonucleotide probes labelled with different dyes, a sensor (donor) probe labelled with 
Fluorescein and an anchor (acceptor) probe labelled with BODIPY 630/650, are added to the 
reaction mix along with the PCR primers. The sensor probe binds to the region including the 
variable target sequence, with the adjacent anchor probe having a distinctly higher melting 
temperature. During the annealing phase, the HybProbes bind to the target DNA sequence in a 
head-to-tail fashion, causing the two dyes to be in close proximity to each other. The donor dye 
(Fluorescein) is excited by the blue LED (absorption wavelength of 495 nm, emission wavelength 
of 520 nm), which in turn excites the acceptor dye (BODIPY 630/650) (absorption wavelength of 
620 nm, emission wavelength of 640 nm) as long as the two dyes are close to each other (within 15 
nucleotides), which then emits fluorescent light at a different wavelength. At low temperature, the 
probe hybridises to both alleles but as the temperature increases, the probe first denatures from the 
mismatched allele, then from the perfect matched allele. The fluorescence is directly proportional to 
the amount of target DNA generated during PCR. HybProbe probes are displaced during the 
elongation and denaturation steps. (Figure 4.4) 
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4.1.6 Objectives 
Assessment of the DHFR 19 bp deletion / insertion polymorphism in the Trinity Student Study 
samples was examined using the following methodology. 
 Development of a genotyping assay on the LightCycler 480 for the DHFR 19 bp 
deletion / insertion polymorphism.  
 Screening the DHFR 19 bp deletion / insertion polymorphism in the TSS samples. 
 Correlation analysis of the DHFR 19 bp deletion / insertion polymorphism with 
folate metabolites and folate intake in the TSS samples. 
 
4.2 Results 
4.2.1 Development of a genotyping assay for the 19 bp deletion / insertion polymorphism.  
The DHFR 19 bp deletion/insertion polymorphism was genotyped using melt curve 
analysis with HybProbes on the Roche Lightcycler 480. As melting curve genotyping is principally 
designed for SNPs, it was necessary to develop a novel assay in order to genotype the DHFR 19 bp 
deletion / insertion polymorphism. For this assay, the sensor probe was designed so that it would 
bind directly to the alleles with the 19 bp insertion, resulting in alleles with the insertion to have a 
higher melting temperature in comparison to those with the deletion alleles due to greater 
complementary base pairing between them (Figure 4.5). 
 
Once the HybProbes had been designed to incorporate the deletion / insertion 
polymorphism, primers were also designed. A multi-sequence analysis of the DHFR gene family 
was carried out using clustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and primers were 
designed to ensure that only the DHFR gene was being amplified (See Table 2.9 for primer and 
probe sequences and Appendix K for DHFR gene sequence analysis and primer and probe location). 
Once probes and primers were designed, the 19 bp deletion / insertion assay, was optimised by 
running primer and probe curves to determine the optimal concentrations required as well as 
altering annealing temperatures. As the polymorphism is located in a GC-rich area of the gene, the 
assay proved to be difficult to optimise, and in the end required the use of DMSO. The DHFR 19 bp 
deletion / insertion genotyping assay was developed and optimised successfully (Figure 4.6).  
 
4.2.2 Screening the DHFR 19 bp deletion/insertion polymorphism in the TSS study 
Once the 19 bp deletion / insertion polymorphism genotyping assay had been developed 
and optimised, ~ 2500 TSS DNA samples were screened and analysed for the polymorphism. 
Approximately 10 % of the DNA samples were repeated in order to ensure that the assay was 
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working efficiently and that the software was calling the correct genotypes consistently. The 
genotype (numbers and percentages) results as well as the allele frequencies obtained are shown in 
Table 4.1. Genotypes were analysed for both males and females together as well as separately.   
 
The genotypes and allele frequencies obtained from the TSS DNA samples were similar to 
those seen previously in an Irish population, (Allele 1 = 0.55, Allele 2 = 0.45) (Parle-McDermott et 
al., 2007), a mixed ethnicity population (Allele 1 = 0.55, Allele 2 = 0.45) (Johnson et al., 2004) and 
a Dutch population (Allele 1 = 0.57, allele 2 = 0.42) (van der Linden et al., 2007) and did not differ 
significantly from the expected frequencies based on the Hardy-Weinberg principle, which states 
that in a large randomly breeding population, the allelic frequencies will remain the same from 
generation to generation, assuming that there is no mutation, gene migration, selection or genetic 
drift. The Hardy-Weinberg principle is illustrated as follows: p2 + 2pq + q2 = 1, where p2 is the 
frequency of the WT genotype, 2pq is the frequency of the HET genotype and q2 is the frequency 
of the DEL genotype. Figures for genotype frequency are shown in Table 4.1. From this, the 
expected number of individuals for each genotype could be calculated. In our population, the 
expected numbers for each genotype was as follows: 
 WT - 0.33 *(2503) = 826 
 HET - 0.48 *(2503) = 1201 
 DEL - 0.19 *(2503) = 476 
 
To test whether a population is in Hardy-Weinberg Equilibrium, the chi-squared test (χ2) can be 
used. 
χ2 = Σ [(observed value – expected value)2 / expected value]  
 
In our population, the calculation was as follows: 
χ2 = [(829-826)2/826] + [(1204-1201)2/1201] + [(470-476)2/476] 
    = 0.09 
 
The critical chi-square value for a p-value of 0.05 (5 %) significance cut off value with one 
degree of freedom is 3.841. Our chi-squared value of 0.09 falls below the 0.05 significance cut off 
value of 3.841 and therefore, we can conclude that the differences observed are caused by chance 
and that our population does not differ significantly from what we would expect, indicating that our 
population is in Hardy-Weinberg Equilibrium.  
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4.2.3 DHFR 19 bp deletion / insertion polymorphism is not associated with folate 
metabolites and/or folate intake 
  The 19 bp deletion / insertion polymorphism results that were obtained were assessed with 
three folate metabolites, red cell folate (RCF), serum folate and total plasma homocysteine (tHcy), 
whose measurements had previously been obtained from the TSS.  
 
The characteristics of the participants in the TSS are shown in Table 4.2. As males and 
females differ with respect to several of the biochemical and lifestyle variables, analyses were 
performed separately for males and females. Information regarding age, sex, weight and smoking 
was previously collected using questionnaires. 
 
To determine the correlation between the DHFR 19 bp deletion / insertion polymorphism 
and the folate metabolites, the mean serum folate, the mean RCF and the mean tHcy levels were 
analysed with respect to DHFR genotype (Table 4.3). Furthermore, as sex was shown to appear to 
influence the DHFR 19 bp deletion / insertion correlations with serum and RBC folate in a previous 
study (Stanisławska-Sachadyn et al., 2008), the association between the DHFR 19 bp deletion / 
insertion polymorphism with the folate metabolites was also analysed separately for males and 
females (Table 4.4 and Table 4.5). ANOVA analysis was carried out on the log transformed data in 
order to generate the p-values. From the tables / p-values, we can see that no association was 
observed between DHFR genotype and any of the three folate metabolites, even when analyses 
were carried out separately for males and females. Mean RCF, serum folate and tHcy values were 
similar regardless of DHFR genotype or sex. 
 
In order to determine whether folate intake has an influence on genotype correlations as 
previously reported (Kalmbach et al., 2008), each individual was firstly categorised by total folic 
acid intake per week into one of four groups. The first group was comprised of individuals who had 
no folic acid intake per week, and the remainder of the groups was subdivided into three equal 
groups, defining the categories as low, those individuals who had a folic acid intake of 128.57 
µg/week or lower, medium, those individuals who had a folic acid intake of between 128.58 
µg/week ≤x≤ 200 µg/week and high, those individuals who had a folic acid intake of over 200 
µg/week. Out of a total of 2,503 people, 76.07 % of the individuals had no folate intake, 8.03 % had 
low folate intake, 8.03 % had medium folate intake and 7.87 % had high folate intake. These 
subgroups were then analysed in correlation with the DHFR 19 bp deletion / insertion 
polymorphism (Table 4.6).  
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These groups were then analysed with mean RCF, serum folate and tHcy levels (Table 4.7-
4.9). From Table 4.7, we can see that RCF levels roughly correlate with folate intake as expected, 
with increased levels of RCF as the levels of folate intake increase. However, no association was 
seen between genotype, folate intake and red cell folate. From Table 4.8, we can see that serum 
folate levels also roughly correlate with folate intake as expected, with increased levels of serum 
folate as the levels of folate intake increase. However, no association was seen between genotype, 
folate intake and serum folate. From Table 4.9, we can see that tHcy levels are roughly inversely 
correlated with folate intake as expected, with decreased levels of tHcy as the levels of folate intake 
increase. However, no association was seen between genotype, folate intake and tHcy.  
 
4.3 Discussion  
The DHFR 19 bp deletion / insertion polymorphism is one of the most widely studied 
DHFR polymorphisms. Although the polymorphism has been associated with a number of different 
cancers (Kalmbach et al., 2008, Xu et al., 2007), there has been a lot of controversy surrounding its 
association with NTDs (Johnson et al., 2004, Parle-McDermott et al., 2007, van der Linden et al., 
2007) and its association with circulating folate metabolites (Gellekink et al., 2007, Stanisławska-
Sachadyn et al., 2008, Kalmbach et al., 2008) and its exact role has yet to be determined. DHFR 
plays a major role in the folate mediated one-carbon metabolism pathway and is the only known 
enzyme that is capable of reducing folic acid. Therefore the activity of this enzyme is of great 
importance, especially due to widespread worldwide mandatory and voluntary folic acid 
fortification that has occurred in order to prevent the risk of NTDs (Czeizel and Dudás, 1992). 
However, a recent study has shown that DHFR activity in the human liver varies highly between 
individuals and that it has a limited ability to reduce folic acid (Bailey and Ayling, 2009). Therefore, 
it has been hypothesized that any polymorphisms within the DHFR gene will alter its ability to 
reduce folic acid, thereby reducing the assimilation of folic acid into the endogenous forms of folate 
(Kalmbach et al., 2008).  
 
The location of the 19 bp deletion / insertion polymorphism within the DHFR gene 
sequence also suggests that this polymorphism may be functional. The DHFR 19 bp deletion / 
insertion polymorphism is located in intron 1, a non-coding region of the DHFR DNA sequence  
(Johnson et al., 2004). This region has previously been reported to be an important site for 
transcription, translation and other regulatory functions in other genes (Takayanagi et al., 1992, 
Guérin et al., 1995, Clark et al., 1997). This suggests that the DHFR 19 bp deletion genotype may 
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alter the levels of DHFR mRNA and subsequently alter the amount of enzyme. Studies that have 
been carried out to investigate the functionality of the DHFR polymorphism have shown a dose-
dependent relationship between the DHFR deletion allele and DHFR mRNA levels, with those with 
the deletion genotype to have a 1.5-fold increase in DHFR mRNA levels in healthy individuals 
(Parle-McDermott et al., 2007) and a 4.8-fold increase in DHFR mRNA levels in breast cancer 
patients (Xu et al., 2007) in comparison to those with the insertion genotype.  
 
The DHFR intron-1 has also been shown to contain transcriptional factor binding sites for 
transcriptional factors such as Specificity Protein 1 (Sp1), Sp3 and estrogen receptor 1 (ESR1), 
which may be involved in the regulation of DHFR transcription. The DHFR 19 bp insertion 
contains the binding sites for Sp1 and Sp3, whereas the 19 bp deletion contains ESR1 sites 
(Kalmbach et al., 2008). The Sp1 site is thought to be involved in growth / cell cycle regulation 
during DHFR transcription, through the recruitment and interactions with co-activators and 
repressors and therefore, the removal of the Sp1 transcription factor binding site may increase or 
decrease transcription (Kalmbach et al., 2008). ERS1 is a ligand-activated transcription factor and is 
composed of several domains that are important for hormone binding, DNA binding and 
transcriptional activation (Jensen et al., 1997).  
 
In order to finally resolve the issue as to whether the DHFR 19 bp deletion / insertion 
polymorphism is associated with circulating folate metabolites, we examined the relationship and 
the effect of the DHFR 19 bp deletion / insertion genotype on serum folate, red cell folate and total 
homocysteine in the largest human sample set yet to be examined. In order to do this, we first had to 
design an assay that would be able to detect the genotype of the DHFR polymorphism in a large 
study set in an optimal manner. The method of choice was a melt curve assay and this was 
successfully designed and optimized for genotype detection (Figure 4.5). For validation purposes, 
we could have also validated the genotypes by gel electrophoresis or by sequencing of th PCR 
products and a genotyping assay by gel electrophoresis has been developed for the DHFR 19 bp 
deletion / insertion polymorphism.   
 
The results from the analyses presented above indicate that the DHFR 19 bp deletion / 
insertion polymorphism is not associated with any of the three folate metabolites examined, serum 
folate, red cell folate or total homocysteine in the TSS study, whether the data from the males and 
females was analysed in combination or separately, which is in contrast to the studies which have 
been carried out previously (Gellekink et al., 2007, Kalmbach et al., 2008, Stanisławska-Sachadyn 
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et al., 2008). Although previous groups have reported the 19 bp deletion to be associated with lower 
tHcy levels in both males and females and elevated RBC and serum folate levels in women, the 
numbers of participants in their studies were much smaller in comparison to the number of 
individuals in our study, which may have influenced the results obtained, resulting in false-positive 
outcomes. The previous studies also suggest that the differences seen are gender dependent, while 
others not, resulting in conflicting results. The differences in the age of the participants may have 
also been a contributable factor to the difference in results obtained between our study and previous 
studies carried out by Gellekink et al. (2007), however Stanisławska-Sachadyn et al. (2008), used 
subjects of similar age and therefore the discrepancies seen between the results cannot be attributed 
to age difference. Another study also found that the functional effect of the DHFR polymorphism 
depends on the level of folic acid intake. We also examined the effect of folic acid intake on the 
DHFR genotype (Table 4.6) as well as analysing them with respect to each of the three folate 
metabolites (Table 4.7-4.9) but did not observe any associations in our population. In conclusion, 
our results indicate that the DHFR 19 bp deletion / insertion polymorphism does not have an impact 
on circulating folate metabolites. 
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Figure 4.1. An Overview of the DHFR Polymorphisms. The schematic above shows the rough 
positions of the DHFR polymorphisms on the DHFR gene. The table above shows the allele change 
and the locations of the different DHFR polymorphisms. Although there are numerous DHFR 
polymorphisms, none are located within the coding region of the gene.  
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Figure 4.2. Structure and location of the DHFR 19 bp deletion / insertion polymorphism. The 
DHFR gene consists of six exons, indicated as red boxes above. The 19bp deletion / insertion 
polymorphism is located in intron 1, 60 bases downstream of the splice donor site. The nucleotide 
sequence of the 19bp deletion / insertion is also shown (Image taken from Parle-McDermott et al., 
unpublished). 
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Figure 4.3. Overview of Melt Curve Analysis. Melt curve analysis analyses SNPs on specific 
alleles by melting in the presence of sequence-specific labelled probes that bind with different 
affinities to different alleles in the region containing the SNP. The raw data from the melting curves 
are generally represented by plotting fluorescence against temperature. This data is often converted 
into the negative first derivatives (-dF/dT) for convenience, which allows the melting temperatures 
to be seen as peaks. Data derived from homozygous wild types (single blue peaks), homozygous 
mutants (single red peaks), and heterozygous samples (two green peaks) differ in their peak number 
and positions. Matching colours for samples with the same genotype (peaks) allow for easy 
visualisation and interpretation of the results. (Image taken from www.roche-applied-science.com)  
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Figure 4.4. Overview of how HybProbes Function. (1) The sensor (donor) probe is labelled with 
a dye called Fluorescein (blue circle) at its 3’ end and the anchor (acceptor) probe is labelled with a 
dye called BODIPY 630/650 (red circle) at its 5’end. No hybridisation occurs during PCR 
denaturation and therefore, no energy transfer takes place between the two dyes. (2) During the 
annealing phase, the HybProbes bind to the target DNA sequence in a head-to-tail fashion, causing 
the two dyes to be in close proximity to each other. The donor dye is excited by the blue LED light, 
which in turn excites the acceptor dye, which then emits fluorescent light at a different wavelength. 
(3) HybProbe probes are displaced during the elongation. (Images adapted from www.roche-
applied-science.com)  
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Figure 4.5. Schematic diagram of the approach taken to design the genotyping assay for the 
DHFR 19bp deletion / insertion polymorphism. The 19 bp deletion / insertion is highlighted in 
yellow. The sensor probe is represented in pink; while the anchor probe is represented in green (A) 
Perfect match between the sensor probe and the allele with the insertion. (B) Mismatch between the 
sensor probe and the allele with the deletion. Due to the greater complementary base pairing 
between the sensor probe and the insertion allele, those with the insertion allele will have a higher 
melting temperature than those with the deletion allele. 
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Figure 4.6. Melt curve analysis of the DHFR 19 bp deletion/insertion polymorphism. The 
single green peak at 40.5°C represents the homozygous deletion genotype. The single red peak at 
54.5°C represents the homozygous insertion genotype. The two blue peaks at 40.5°C and 54.5°C 
represent the heterozygous genotype.  
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Table 4.1. Genotypes of the DHFR 19 bp deletion / insertion polymorphism in the TSS 
study analysed for both males and females together and separately. 
 
DHFR Total [n (%)] Males [n (%)] Females [n (%)] 
WT 829 (33.1) 340 (32.8) 489 (33.3) 
HET 1204 (48.1) 507 (48.9) 697 (47.5) 
DEL 470 (18.9) 189 (18.2) 281 (19.2) 
Allele 1 (WT) 2862 (57.2) 1187 (57.3) 1675 (57.1) 
Allele 2 (DEL) 2144 (42.8) 885 (42.7) 1259 (42.9) 
 
 
Table 4.2. Characteristics of the student who took part in the TSS study 
 
  Males (n=1036) Females (n=1472) 
Age 22.63 22.32 
BMI 23.4 22.69 
Creatine 75.1 59.6 
Total FA Intake 247.87 266.44 
Haemoglobin 15.38 13.44 
Smoking [n (%)]     
Yes 335 (32.4) 450 (30.7) 
No 700 (67.6) 1018 (69.3) 
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Table 4.3. DHFR Genotype & Mean RCF, Serum folate & tHcy levels [mean±SD] in all samples. 
DHFR RCF Serum folate tHcy 
WT 1083±432.21 33.92±20.68 8.71±2.96 
HET 1081±432.11 34.37±20.66 8.66±2.95 
DEL 1055±432.30 34.83±20.68 8.55±2.96 
p-value 0.405 0.975 0.330 
 
Table 4.4. DHFR Genotype & Mean RCF, Serum folate & tHcy levels [mean±SD] in males 
DHFR RCF Serum folate tHcy 
WT 1108±414.65 33.02±17.18 9.35±3.32 
HET 1095±414.19 31.63±17.16 9.59±3.31 
DEL 1091±414.48 34.09±17.21 9.13±3.33 
p-value 0.211 0.546 0.057 
 
Table 4.5. DHFR Genotype & Mean RCF, Serum folate & tHcy levels [mean±SD] in females. 
DHFR RCF Serum folate tHcy 
WT 1066±443.70 34.54±22.76 8.27±2.54 
HET 1070±443.65 36.37±22.73 7.98±2.54 
DEL 1031±443.07 35.33±22.74 6.67±2.54 
p-value 0.355 0.399 0.301 
 
Table 4.6. DHFR Genotype and Total Folate Intake [n (%)] 
 Total Folate Intake 
DHFR None Low Medium High 
WT 628 (32.98) 63 (31.34) 75 (37.31) 63 (31.98) 
HET 915 (48.06) 104 (51.74) 89 (44.28) 96 (48.73) 
DEL 361 (18.96) 34 (16.92) 37 (18.41) 38 (19.29) 
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Table 4.7. RCF [mean±SD] by DHFR Genotype and total folate intake 
RCF (nM) Total Folate Intake 
DHFR None Low Medium High 
WT 1049±391.17 1130±425.37 1214±414.68 1221±511.63 
HET 1041±425.12 1170±425.33 1200±456.38 1257±512.19 
DEL 1015±413.71 1184±425.82 1172±423.20 1207±509.95 
All  1035±410.00 1161±425.51 1195±431.42 1228±511.26 
  
Table 4.8. Serum Folate [mean±SD] by DHFR Genotype and total folate intake 
Serum Folate (nM) Total Folate Intake 
DHFR None Low Medium High 
WT 32.03±16.99 36.34±17.84 40.05±18.29 42.94±39.29 
HET 32.07±17.21 36.18±17.84 42.08±20.80 47.27±39.03 
DEL 33.17±19.23 39.63±17.86 39.97±18.43 41.32±39.02 
All  32.42±17.81 37.38±17.85 40.70±19.17 43.84±39.11 
 
Table 4.9. tHcy [mean±SD] divided by DHFR Genotype and total folate intake 
tHcy (µM) Total Folate Intake 
DHFR None Low Medium High 
WT 8.92±3.66 8.22±2.72 7.93±3.36 8.07±2.71 
HET 8.84±2.69 8.02±2.72 8.15±2.10 8.01±2.70 
DEL 8.72±3.14 8.03±2.72 7.39±2.98 8.59±2.70 
All  8.88±2.95 8.10±2.95 7.82±2.96 8.22±2.70 
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Chapter 5 
 
Identification of DHFRL1 
polymorphisms, functionality testing 
and their relevance in human health 
and disease 
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5.1 Introduction 
DHFRL1 or Dihydrofolate reductase like-1 is a gene that belongs to the DHFR gene family. 
Until recently, DHFRL1 was thought to be a pseudogene but has now been characterised to be 
expressed and functional (Anderson et al., 2011, McEntee et al., 2011). As DHFR plays such an 
important role in folate mediated one-carbon metabolism, no non-synonymous polymorphisms have 
been found within the coding region of the gene. However, non-synonymous polymorphisms have 
been found to be present in the DHFRL1 gene. These may contribute to health and disease. The aim 
of this chapter is to identify and validate DHFRL1 polymorphisms and to determine their 
functionality and relevance in human health and disease.  
 
5.1.1 DNA Polymorphisms 
The human genome contains millions of different DNA polymorphisms (Sachidanandam et 
al., 2001). DNA polymorphisms are differences in the DNA sequence when compared to a 
reference standard, and are found to be present in at least 1-2 % of the population. They can range 
from a change in a single nucleotide to thousands of bases. Known polymorphisms include SNPs, 
insertions/deletions, short tandem repeats (1-8bp), variable number tandem repeats (8 to >50bp) and 
copy number variations in nucleotide repeat motifs. These polymorphisms may or may not have a 
phenotypic effect, depending on their position within the DNA sequence (Schork et al., 2000). 
 
The most common type of polymorphism is a SNP, the change of a single nucleotide. SNPs 
can act as a landmark / marker for locating other genes / genetic regions and are often used to form 
dense genetic maps. However, they also have the potential to be functional and are often associated 
with both common and complex genetic diseases, as well as playing a role in altering an 
individual’s response to drugs. SNPs that are located within the coding region of a gene can 
introduce variations that result in missense substitutions or stop codons, resulting in premature 
termination of the gene product, while SNPs that are located in the non-coding regions can 
influence gene expression by altering specific regulatory elements (Goto et al., 2001). Therefore, it 
is important to identify SNPs in the human genome and to evaluate the role they play in gene 
expression and drug response. 
 
5.1.2 DHFRL1 and its polymorphisms  
In 2011, DHFRL1, a member of the DHFR gene family, located on chromosome 3 was 
found to be functional (Anderson et al., 2011, McEntee et al., 2011) with similar properties to 
DHFR, with the ability of complementing a DHFR negative phenotype in both bacterial and 
mammalian cells. Like DHFR, DHFRL1 can also regulate its own translation by binding to its own 
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mRNA. Although DHFR and DHFRL1 share many characteristics, they also have distinct 
differences. DHFRL1 has a lower binding affinity for dihydrofolate (DHF) and is localized to the 
mitochondria (McEntee et al., 2011), the site of energy production in eukaryotic cells. In the 
mitochondria, DHFRL1 takes the place of DHFR in the de novo thymidylate synthesis pathway 
(Anderson et al., 2011). As DHFR has been shown to play a key role in health and disease (Section 
1.10 and 1.11), DHFRL1 is also thought to have the possibility of playing a vital role in health and 
disease. Therefore, it is important to examine the functional characteristics not only of DHFRL1 but 
also to examine the functional characteristics of any polymorphisms within the DHFRL1 gene 
sequence.  
 
Numerous synonymous (those that do not change the amino acid sequence of the protein) 
and non-synonymous (those that alter the amino acid sequence of the protein) DHFRL1 
polymorphisms have been identified and entered into the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/SNP). Of these, three non-synonymous polymorphisms, rs17855824, 
rs61739170 and rs114936057 within the coding region of the gene were chosen to be examined. 
The rs17855824 polymorphism results in a valine to isoleucine change, located at position 166 in 
the amino acid sequence. The rs61739170 polymorphism results in a proline to alanine change, 
located at position 83 in the amino acid sequence. The rs114936057 polymorphism results in a 
methionine to isoleucine change, located at position 38 in the amino acid sequence (Figure 5.1). 
Although none of the amino acids that are involved in the polymorphisms are located in the active 
site of DHFRL1, the changes in amino acids could alter the structure of the protein, causing 
differences in enzyme activity, resulting in alterations in the function of the enzyme. An Irish NTD 
(Section 5.1.3) was also screened for a number of DHFRL1 polymorphisms, some of which are 
located in the coding region and others which are located both upstream and downstream of the 
coding regions, in order to determine the relevance of DHFRL1 polymorphisms in health and 
disease.  
 
5.1.3 Irish Neural Tube Defect (NTD) cohort 
 The Irish NTD cohort are a set of DNA samples from NTD affected triads (mother, father 
and their NTD-affected child) that were recruited throughout Ireland from 1993-2005 with the 
assistance of the Irish Association for Spina Bifida and Hydrocephalus (Shields et al., 1999, Brody 
et al., 2002, Parle-McDermott et al., 2009). The complete Irish NTD case population consists of a 
total of 586 families. However, triad families were not always complete as samples from all three 
family members were not always available. The NTD cohort consists of 442 full family triads, 53 
case–mother pairs, 5 case–father pairs, 46 cases only and 40 families with parents or single parent 
 139 
 
only. The control population are samples that were obtained from 56,049 pregnant women who did 
not give birth to an NTD-affected child and had no previous history of an NTD-affected pregnancy 
and were attending one of the three main maternity hospitals, The National Maternity Hospital 
Holles Street, The Coombe Women’s Hospital or The Rotunda Hospital in Dublin between 1986-
1990 (Kirke et al., 1993, Daly et al., 1995, Mills et al., 1995). These NTD samples and a random 
sample of the control samples were used in our study in order to determine the relevance of 
DHFRL1 polymorphisms in health and disease.    
 
5.1.4 Objectives 
As mentioned earlier, recombinant DHFRL1 (McEntee et al., 2011) and endogenous 
DHFRL1 in cancer cells (Anderson et al., 2011) has been shown to localise to the mitochondria. We 
wanted to assess the presence of endogenous DHFRL1 in the mitochondria of non-cancerous cells, 
and to determine whether or not endogenous DHFRL1 and DHFRL1 polymorphisms harbour 
enzyme activity in the mitochondria in order to test for functionality. DHFRL1 polymorphisms will 
also be screened in an NTD cohort in order to determine their relevance in health and disease. 
 
Assessment of the functionality of DHFRL1 polymorphisms were examined using the following 
methodology 
 Validation of candidate DHFRL1 polymorphisms by gel electrophoresis and 
sequencing. 
 Development of a genotyping assay on the LightCycler 480 for the DHFRL1 SNPs.  
 Screening the DHFRL1 rs17855824 SNP in a panel of Coriell DNA samples. 
 Culturing of Coriell and HEK 293 cell lines. 
 Extraction of cytoplasmic and mitochondrial protein fractions from the cell lines. 
 Confirmation of endogenous mitochondrial DHFRL1 and its variants by Western blot. 
 Enzyme kinetic analysis of endogenous mitochondrial DHFRL1 and its polymorphisms. 
 Screening and analysis of DHFRL1 polymorphisms in an Irish NTD cohort   
 
5.2 Results 
5.2.1 Validation of candidate DHFRL1 polymorphisms 
The NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp) was examined in order to 
determine what polymorphisms had been reported in the DHFRL1 gene. Four polymorphisms 
within the coding region of the DHFRL1 gene had been identified when we examined the database 
early in 2011. Of these four DHFRL1 polymorphisms, three were non-synonymous polymorphisms, 
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the DHFRL1 rs17855824 SNP (G->A), the rs61739170 SNP (C->G) and the rs114936057 (G->T). 
These three SNPs were chosen to be examined (Figure 5.1).  
 
In order to validate these polymorphisms, a multi-nucleotide sequence analysis of the 
DHFR gene family was first carried out using clustalW to facilitate primer design (Figure 5.2) (See 
Appendix L for full clustalW alignment). ClustalW alignment showed high similarity / homology 
between DHFRL1 and all of the other genes in the DHFR gene family. As there are not many 
differences between all of the genes, validation of the polymorphisms proved to be a big challenge. 
Primers had to be designed specifically for each of the non-synonymous polymorphisms (Table 
2.10) (See Appendix L for primer location), ensuring that the primers only amplified the regions of 
the DHFRL1 gene under investigation, without the possibility of amplifying other homologous 
regions in the DHFR gene or the other pseuodogenes in the DHFR gene family.  
 
A set of Coriell DNA samples (DNA from human lymphoblasts) from both African 
American and European American descent as well as a number of DNA samples from different 
cancer cell lines were chosen to be examined and were amplified by PCR. Once PCR conditions 
had been optimized, amplification was firstly confirmed by running the PCR products on a 2 % 
agarose gel (Figure 5.3 – 5.5). The PCR products were then cleaned up with ExoSAP-IT, a reagent 
which removes any unconsumed dNTPs or primers remaining in the PCR product mixture as 
described in Section 2.2.2. The PCR products were then sent off for Sanger sequencing (Source 
BioScience). Due to the homology between the members of the DHFR gene family, the 
chromatograms had to be analysed with a fine tooth comb and the sequences were aligned and 
examined to determine the genotype of the DNA samples (Table 5.1) (See Appendix M for 
sequence alignments). An example of a ‘dirty’ sequencing run, a trace that not only picks up the 
DHFRL1 gene but also other members of the DHFR gene family (Figure 5.6) and that of a clean 
sequencing run, one that picks up only the DHFRL1 gene (Figure 5.7) are shown below (See 
Appendix N for Chromatograms of each of the three polymorphisms). 
 
Although one of our assays, the DHFRL1 rs61739170 (C->G) assay seemed to be 
susceptible to producing a ‘dirty’ assay, the mixed signal was not coming from the SNP and 
therefore, after careful analysis of the traces, we concluded that the three polymorphisms were ‘real’ 
variants. However, direct sequencing and chromatogram analysis of the samples for the DHFRL1 
rs114936057 (G>T) polymorphism found this polymorphism not to be frequent. Therefore, we 
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focused our analysis on the two common variants DHFRL1 rs61739170 and rs17855824, both of 
which result in an amino acid change. 
 
5.2.2 Development of a genotyping assay for two DHFRL1 polymorphisms. 
Once the DHFRL1 polymorphisms had been confirmed to be real variants, we first had to 
develop a genotyping assay for the DHFRL1 SNPs using melt curve analysis with HybProbes on 
the Roche Lightcycler
®
 480 as described in Section 4.1.5 and 4.2.1 in order to be able to screen a 
large panel of DNA samples accurately. This would allow us to identify the genotype of the DNA 
samples so that the polymorphisms could be characterised. The rs61739170 SNP is located in a 
region of high homology with other members of the DHFR gene family and although primers and 
probes were designed carefully in order to try and only amplify up the region of the SNP, a 
genotyping assay on the Roche Lightcycler could not be designed. However, a genotyping assay 
was successfully designed and optimised for the rs17855824 SNP (Figure 5.8). The sensor probe 
was designed so that it would bind fully complementary to the wild type alleles, resulting in those 
with the wild type alleles having a higher melting temperature in comparison with those who had 
the alleles with the polymorphism due to greater complementary base pairing between them. 
 
5.2.3 Screening and analysis of the DHFRL1 rs17855824 polymorphism in a panel of Coriell 
DNA samples. 
Once the DHFRL1 rs17855824 polymorphism genotyping assay had been developed and 
optimised on the LightCycler
®
 480, a panel of 169 Caucasian and African American Coriell DNA 
samples were screened for the polymorphism. Samples were genotyped twice in order to ensure that 
the assay was working efficiently and that the software was calling the correct genotypes as we had 
issues with contamination in our negative controls. The genotype results (numbers and percentages) 
as well as the allele frequencies obtained from the samples are shown in Table 5.2. 
 
5.2.4 Examination of the presence of endogenous mitochondrial DHFRL1 
Previous work carried out in the lab had determined the presence of recombinant DHFRL1 
in the mitochondria (McEntee et al., 2011). Therefore, the presence of endogenous DHFRL1 in the 
mitochondrial needed to be determined before examining the functionality of the DHFRL1 
rs17855824 polymorphism endogenously. HEK 293 and DHFRL1 over-expressed HEK 293 cells 
were cultured as described in Section 2.6.4.2. Mitochondrial and cytoplasmic protein fractions were 
extracted from the HEK 293 and DHFRL1 over-expressed HEK 293 cells, pooling four 75 cm
3
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flasks together as described in Section 2.3.15 in order to obtain enough mitochondrial protein to 
carry out the experiments.  
 
A Bradford assay (as described in Section 2.3.18) was carried out on a set of standard 
protein samples (Table 5.3, Figure 5.9) and the extracted mitochondrial and cytoplasmic protein 
fractions in order to determine the concentration of the extracted protein fractions. An example of 
the concentrations observed from the mitochondrial and cytoplasmic protein fractions obtained are 
shown in Table 5.4.  
 
SDS-PAGE gels were then run and Western blots were carried out on the cytoplasmic and 
mitochondrial fractions in order to determine the presence or absence of DHFRL1 in the 
mitochondria and DHFR in the cytoplasm (Figure 5.10-5.11). In order to ensure that our 
mitochondrial protein fractions were clean, i.e. did not contain any cytoplasmic protein, the 
mitochondrial protein fractions were probed with GAPDH, a positive control for cytoplasmic 
protein. Cytoplasmic protein samples were also probed for GAPDH at the same time in order to 
ensure the antibody was working sufficiently. No bands were seen in our mitochondrial protein 
fractions confirming that the mitochondrial protein fractions were clean. An example of both 
cytoplasmic and mitochondrial protein fraction samples probed with the GAPDH antibody is shown 
in Figure 5.10. Once it was confirmed that our mitochondrial protein fractions were pure, both 
cytoplasmic and mitochondrial protein fractions were examined for the presence of DHFR in the 
cytoplasm and DHFRL1 in the mitochondria (a 21 kDa band). Figure 5.11 shows an example of a 
Western blot carried out on the cytoplasmic protein fractions and Figure 5.12 shows an example of 
a Western blot carried out on the mitochondrial protein fractions. The Western blots (Figure 5.11-
Figure 5.12) showed that DHFR is present in the cytoplasmic protein fractions and that DHFRL1 is 
present in the mitochondrial protein fractions. As Figure 5.9 confirms that the mitochondrial protein 
fractions are clean, we can confirm that the DHFRL1 bands seen in the mitochondrial protein 
fractions are real and are not contaminated with any cytoplasmic protein. 
 
5.2.5 Examination of endogenous mitochondrial DHFRL1 enzyme activity  
 Once the presence of endogenous DHFRL1 in the mitochondria was confirmed by Western 
blot, the presence / absence of endogenous DHFRL1 enzyme activity in the mitochondria was 
examined. In order to determine DHFRL1 enzyme activity in the mitochondria, the Dihydrofolate 
Assay Kit was used as described in Section 2.3.21. The DHFR control and blanks were tested first 
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in order to confirm that all the reagents were working correctly within the region of detection by the 
spectrophotometer (Figure 5.13-5.16).  
 
Once it was confirmed that the reagents and the assay was working well, the assay was 
carried out on the mitochondrial protein fractions. The assay was carried out on both HEK 293 and 
DHFRL1 over expressed mitochondrial protein samples. An example of each is shown in Figure 
5.17–5.20. Assays were repeated twice with different batches of mitochondrial protein extracted 
from the cells at different times. The decrease in ΔOD / min (the decrease in absorbance per 
minute) was then calculated for each of the samples. In order to obtain the true ΔOD of DHFR / 
DHFRL1, the ΔOD / min of the sample + MTX was taken away from the ΔOD / min of the sample. 
This is to work out the proportion of NADPH loss that is due to DHFR activity in endogenous 
samples.  After deduction, the true ΔOD / min of DHFRL1 in HEK 293 cells was determined to be 
0.0089. The specific activity was then calculated as mentioned in Section 2.3.21. The specific 
activity of DHFRL1 in HEK293 cells was found to be 14.88 nmol/min/mg protein, indicating the 
presence of endogenous DHFRL1 activity in the mitochondria of normal human cell lines. The true 
ΔOD / min of DHFRL1 was also calculated in the DHFRL1 over-expressed HEK 293 cells and was 
determined to be 0.01, indicating the presence of endogenous DHFR / DHFRL1 mitochondrial 
activity. The specific activity was then calculated as mentioned in Section 2.3.21. The specific 
activity of DHFRL1 in DHFRL1 over-expressed HEK293 cells was found to be 14.11 nmol/min/mg 
protein, also indicating the presence of endogenous DHFRL1 activity in the mitochondria of normal 
human cell lines. 
 
5.2.6 Examination of the presence of endogenous mitochondrial DHFRL1 in Coriell Cell 
Lines 
Once the genotypes of the Coriell DNA samples had been identified by melt curve analysis, 
two Coriell cell lines for each of the DHFRL1 rs17855824 genotypes were cultured as mentioned in 
Section 2.6.4.1. Mitochondrial and cytoplasmic protein fractions were extracted from the Coriell 
cell lines, pooling six to eight 25 cm
3
 flasks together. Protein concentrations were determined by 
Bradford assay as before. However, the protein concentration values that were obtained from the 
Coriell mitochondrial protein fractions were less than half, and in some samples, less than a quarter 
of that when compared to those obtained for the HEK 293 and DHFRL1 over-expressed HEK 293 
mitochondrial protein fractions. Nonetheless, Western blots were carried out on the mitochondrial 
protein fractions and were probed with both the DHFR and GAPDH antibodies as before (Figure 
5.21-5.22).   
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No bands were seen in our mitochondrial protein fractions when they were probed with the 
GAPDH antibody, confirming that the mitochondrial protein fractions were clean, indicating that 
the DHFRL1 bands seen in the Coriell mitochondrial protein fractions are real for all three of the 
DHFRL1 rs17855824 genotypes. 
 
5.2.7 Examination of endogenous mitochondrial DHFR / DHFRL1 enzyme activity in the 
Coriell samples  
 Once the presence of endogenous DHFRL1 was confirmed in the Coriell mitochondrial 
protein fractions by Western blot, the presence / absence of endogenous DHFRL1 enzyme activity 
in the Coriell mitochondrial protein fractions was examined in order to try and determine whether 
the DHFRL1 rs17855824 polymorphism causes a change in DHFRL1 enzyme activity. In order to 
determine DHFRL1 enzyme activity in the mitochondria, the Dihydrofolate Assay Kit was used as 
described in Section 2.3.21. As before, the DHFR control and blanks were tested first in order to 
confirm that all the reagents were working correctly within the region of detection by the 
spectrophotometer.  
 
Once it was shown that the controls were working correctly, enzyme kinetic analysis was 
carried out on the Coriell mitochondrial protein fractions. As mentioned above (Section 5.2.6), the 
protein concentrations of the Coriell mitochondrial protein fractions were very low in comparison to 
those of the HEK 293 and DHFRL1 over-expressed HEK 293 mitochondrial protein fractions. 
Therefore, when enzyme activity analysis was carried out on the different Coriell mitochondrial 
protein samples, no enzyme activity could be detected in any of the mitochondrial protein samples. 
We did however; generate recombinant protein versions of the polymorphisms and this is described 
in Chapter 6. 
 
5.2.8 Examination of DHFRL1 polymorphisms within an NTD cohort 
Although, the enzyme activity of the different genotypes of the rs17855824 polymorphism 
could not be determined due to the concentration of the mitochondrial fractions being too low, the 
fact that polymorphisms existed within the DHFRL1 gene was interesting in itself and therefore, 
DHFRL1 polymorphisms, including the rs17855824 SNP were examined and screened in an NTD 
cohort by our collaborators Dr. Faith Pangilinan and Dr. Larry Brody at the National Human 
Genome Research Institute–National Institutes of Health (NHGRI-NIH) and Prof. Anne Molloy in 
TCD. This was carried out in order to determine whether or not any of the DHFRL1 polymorphisms 
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are associated with NTDs in an Irish cohort. All the analyses described below were carried out by 
our collaborators.  
 
Seven DHFRL1 polymorphisms (rs10454213, rs11927165, rs17855824, rs61739170, 
rs7644176, rs7645522 and rs7653521) were genotyped in the Irish NTD cohort as well as the 
controls. The genotype frequency results (numbers and percentages) for each of the DHFRL1 
polymorphisms are shown in Table 5.5. 
 
After careful analysis, three of the DHFRL1 polymorphisms, rs7645522, rs10454213 and 
rs17855824 were found to be in linkage disequilibrium with each other, i.e. the alleles were non-
randomly associated at the three loci, in the Irish NTD cohort, with an r
2
 value of 1 (Table 5.6). 
Linkage disequilibrium was also found in the Irish controls, with the rs7645522, rs10454213 and 
rs17855824 DHFRL1 polymorphisms having an r
2 
value of > 0.99, while the rs11927165 and 
rs7644176 polymorphism had an r
2
 value of 0.93. The positions of the DHFRL1 polymorphisms are 
also shown in Table 5.6. The rs7645522 and rs10454213 SNPs are located ~ >10 kb and ~ 5 kb 
from the DHFRL1 gene, while the rs17855824 SNP is located within the coding regions of the 
DHFRL1 gene. 
 
A transmission disequilibrium test (TDT), a family based association test for the presence 
of genetic linkage between a genetic marker and a trait was then carried out on the data. The TDT 
test showed that the rs7645522, rs10454213 and rs17855824 DHFRL1 polymorphisms are in high 
linkage disequilibrium with each other and that they are associated with NTDs, with significant p-
values (Table 5.7). No significant p-values were observed for the other DHFRL1 polymorphisms. 
The table also shows the allele which is being over-transmitted for all seven DHFRL1 
polymorphisms 
 
5.3 Discussion 
The aim of this chapter was to identify and validate DHFRL1 polymorphisms and to 
determine their functionality and relevance in human health and disease. By examining the dbSNP 
database, we were able to identify a number of DHFRL1 polymorphisms within the coding region 
of the DHFRL1 gene. DHFRL1, a member of the DHFR gene family, which was until recently 
thought to be a pseudogene is highly homologous to DHFR. DHFR has been studied extensively 
and no polymorphisms have been found within its coding regions (Litwack, 2008).Therefore, the 
identification of polymorphisms within the DHFRL1 coding region was of great interest to us.     
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Three DHFRL1 polymorphisms found within the coding region of DHFRL1 were validated 
via PCR amplification and Sanger sequencing in both Coriell DNA and DNA from various cancer 
cell lines. From this, it was detected that two of the polymorphisms were common in the population 
and therefore of most interest to us. In order to functionally characterise these polymorphisms, we 
wanted to examine these polymorphisms endogenously. Although recombinant DHFRL1 was 
previously examined in the lab (McEntee et al., 2011), we first had to demonstrate endogenous 
mitochondrial DHFRL1 activity in our cell lines of interest.  
 
HEK 293 and DHFRL1 over-expressed HEK 293 cell lines were cultured and both 
cytoplasmic and mitochondrial protein fractions were extracted. Western blots carried out on the 
samples detected DHFR in the cytoplasm and DHFRL1 in the mitochondria. The extracted 
mitochondrial protein fractions were shown to be pure, with no cytoplasmic contamination by 
immunoblotting against GAPDH, a positive control for cytoplasmic protein, indicating that 
DHFRL1 is present in the mitochondria. Enzyme kinetic analysis carried out on the mitochondrial 
fractions showed that DHFRL1 has enzyme activity in the mitochondria in these cell lines. 
 
Therefore, we wanted to determine whether the DHFRL1 rs17855824 polymorphism could 
alter DHFRL1 enzyme activity. A genotyping assay was successfully designed to determine the 
genotypes of a large cohort of Caucasian and African American Coriell DNA. This was carried out 
so that the different rs17855824 genotypes could be identified and so that Coriell cell lines with the 
different genotypes could be cultured. Western blots carried out on the extracted mitochondrial 
protein fractions confirmed again that DHFRL1 is present in the mitochondria. However, due to the 
low protein concentrations obtained for the Coriell mitochondrial protein fractions, no enzyme 
activity could be detected in any of the Coriell samples. 
 
In order to obtain enough mitochondrial protein (~ the same concentrations that were being 
obtained from the HEK 293 and DHFRL1 over-expressed HEK 293 cells) from the Coriell cell 
lines, we would have had to quadruple the amount of cells that were cultured in order to carry out 
the enzyme kinetic analysis experiments. As six - eight 25 cm
3 
flasks were already being pooled 
together, it was not practical to grow 32 flasks for each of the genotypes in order to just carry out 
the experiment just once. Cost restraints would have also prevented us to carry this out. The low 
protein concentrations observed for the Coriell cell lines may be due to a number of reasons. Coriell 
cells lines are suspension cells unlike the adherent HEK 293 cells and are also typically grown in 25 
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cm
3
 flasks. Therefore, in the future, it may be possible to adapt the Coriell cell lines so that they 
would grow in 75 cm
3
 flasks, so that a larger number of cells could be collected, hopefully resulting 
in higher protein concentrations. 
   
The sensitivity of the DHFR assay kit was also unknown and therefore, even if enough 
mitochondrial protein could have been obtained, the DHFR assay kit may not have been specific 
enough to measure the difference in enzyme activity between the different DHFRL1 rs17855824 
polymorphism genotypes, as the SNP only results in a single base change with unknown enzyme 
impact. Enzyme analysis carried out on the HEK 293 and DHFRL1 over-expressed HEK 293 cells 
showed that DHFRL1 is not the only enzyme in the mitochondria that utilises NADPH as part of 
their reaction system as a decrease in absorbance was still observed even after methotrexate, an 
inhibitor of DHFR was added to the reaction, indicating the presence of other enzymes that utilise 
NADPH (as expected). Therefore, if the Coriell cell lines could be adapted to grow in larger 
volumes and larger amounts of mitochondrial protein could be collected, one could purify out the 
DHFRL1 protein from the mitochondrial fractions by immunoprecipitation, allowing us to carry out 
the enzyme kinetic analysis on a purified endogenous protein. However, high concentration yields 
would be required. In order to carry out immunoprecipitation, one requires ~300-500 µg of total 
protein. As the protein yield obtainable from the mitochondrial extraction kit is 20-80 µg of total 
protein from 5 X 10
6
 - 2 X 10
7
 cells, pooling of large amounts of mitochondrial protein fractions 
would be required in order to obtain enough protein to carry out immunoprecipitation.  
 
 Another alternative method that could be used in the future to examine the functionality of 
polymorphisms could be using newer technologies such as genome editing with engineered 
nucleases (GEEN). GEEN is a form of engineering in which DNA can be inserted, replaced or 
removed from a genome using artificially engineered nucleases. These nucleases are programmable 
and function by creating specific double-stranded breaks (DSBs) at the location of interest in the 
genome and then make use of the cells endogenous mechanisms to repair the induced break by 
natural processes such as homologous recombination (HR) and non-homologous end-joining 
(NHEJ) (Kim and Kim, 2014). HR relies on a homologous sequence to repair the DSBs. By 
exploiting this system, a sequence of interest can be inserted within a sequence that is homologous 
to the flanking sequences of a DSB, leading to the formation of the desired change within the 
genomic region of interest (Rouet et al., 1994). NHEJ uses a variety of enzymes to directly join the 
DNA ends in a DSB. NHEJ is error prone and has been shown to cause mutations at the repair site 
in ~ 50 % of DSBs. Therefore, if one could create a DSB at a desired region of the gene in multiple 
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samples, it would be very likely for the mutation to be generated at the region of interest in at least 
some of the samples (Bibikova et al., 2002). In this way, if one can create specific DSBs at specific 
locations, the cell’s own repair system can be exploited to insert specific mutations at regions of 
interest (Figure 5.23).  
 
Engineered nucleases include zinc finer nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), RNA-guided engineered nucleases (RGENs) and engineered 
meganuclease re-engineered homing endonucleases. ZFNs, TALENs and RGENs are all based on 
the same principal and work by the same mechanism; they cleave the DNA in a site-specific manner, 
which then triggers the cells endogenous repair mechanisms resulting in targeted genome 
modification (Kim and Kim, 2014). The choice of nuclease and their success rate depends on the 
cell type and delivery method, i.e. transient transfection by electroporation, liposome transfection, 
microinjection, lentivirus vectors, adenoviruses etc. However, to date, there are no reliable rules to 
predict which nuclease will work best before experimental confirmation. 
 
These new methods could be used to try and edit the endogenous sequence in order to 
incorporate our polymorphism of interest into HEK 293 cells, which would allow us to produce and 
extract higher protein concentrations, enabling us to both purify and carry out enzyme kinetic 
analysis on the mitochondrial protein fractions, allowing us to determine whether different 
genotypes alter the enzyme activity of a specific gene.  
  
Although we could not obtain enough mitochondrial protein to carry out enzyme kinetic 
analysis in order to determine the effect of the DHFRL1 rs1785824 polymorphism, we have 
confirmed that endogenous DHFRL1 is present in the mitochondria in both HEK 293 and Coriell 
cell lines and that it has enzyme activity in normal human cells (HEK 293 cells). Endogenous 
mitochondrial DHFRL1 enzyme activity has been previously shown in HepG2 cells, a cancerous 
liver cell line (Anderson et al., 2011). Anderson et al., treated HepG2 cells with scrambled control 
siRNA and siRNA specific to the 5ʹ UTR of DHFRL1 that is not present in the DHFR transcript. 
They showed that HepG2 mitochondrial protein extracted from the cells that had been treated with 
the control siRNA had a DHFR enzyme activity of 32.4±4.0 nmol/min/mg protein, while those 
which had been treated with the siRNA that was specific to DHFRL1 had an activity of 
0.17±0.0008 nmol/min/mg protein, indicating that DHFRL1 is active in the mitochondria. The 
activity was significantly different with a p value of 0.0002 (n=3). Likewise to our experiments, 
extracted mitochondrial protein fractions were tested for purity by immunoblotting against Lamin A 
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(nuclear) and GAPDH (cytoplasmic) and mitochondrial protein samples were shown to exhibit no 
nuclear or cytoplasmic contamination. Mitochondrial protein fractions that were collected from the 
cells which had been treated with the siRNA specific to DHFRL1, i.e. in which DHFRL1 had been 
knocked down, no DHFRL1 protein was found to be present, with COXIV being used as a positive 
mitochondrial control. DHFR activity was examined in the cytoplasmic protein fractions from those 
extracted from both the scrambled and DHFRL1 specific siRNA treatment cells and were found to 
be unaffected by the siRNAs with specific activities of 4.5 ± 2.6 and 4.5 ± 2.8 µmol/min/mg protein 
observed, indicating that the DHFRL1 knockdown did not affect DHFR activity.  
 
Although enough mitochondrial protein could not be obtained from the Coriell cell lines in 
order to determine the effect of the DHFRL1 rs1785824 polymorphism on enzyme activity, 
genotyping of the Irish NTD cohort with seven DHFRL1 polymorphisms carried out by our 
collaborators in the NHGRI-NIH and TCD have shown that three out of the seven DHFRL1 
polymorphisms analysed, including the rs17855824 polymorphism are in high linkage 
disequilibrium and are associated with the risk of NTDs in an Irish population, which is of great 
interest. How the DHFRL1 polymorphisms are affecting NTD risk is yet unknown and further 
analyses will have to be carried out in order to elucidate the exact mechanism as to how these 
DHFRL1 polymorphisms affect NTDs.   
 
Our findings have shown that HEK 293 cells and DHFRL1 over-expressed HEK 293 cells 
harbour enzyme activity with an enzyme activity of 14.88 nmol/min/mg protein and 14.11 
nmol/min/mg protein respectively. The enzyme activity observed in our mitochondrial protein 
fractions is lower than that found for the HepG2 mitochondrial protein fractions by Anderson et al. 
However, Anderson et al. examined DHFRL1 activity in HepG2 cells, a cancerous liver cell line, 
and therefore, one would expect it to have a higher proliferation rate than that of normal human cell 
lines, and therefore, most likely to have a higher enzyme activity. This is the first time that it has 
been shown that endogenous DHFRL1 is functionally active in the mitochondria of normal healthy 
human cells. Although DHFRL1 has been shown to be active, the exact function that DHFRL1 
plays in the mitochondria is yet unknown, however, it could be one of great importance in human 
health and disease especially as DHFRL1 polymorphisms have been shown to be associated with 
NTDs.  
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Figure 5.1. An overview of the DHFRL1 polymorphisms. The schematic above shows the rough 
positions of the four DHFRL1 polymorphisms on the DHFRL1 gene. The three polymorphisms 
above the black line represent non-synonymous polymorphisms while the polymorphism below the 
black line is synonymous. The table shows the characteristics of each of the polymorphisms. The 
rs114936057 SNP results in a methionine to isoleucine change at position 38, the rs61739170 SNP 
results in a proline to alanine change at position 83, and the rs17855824 SNP results in a valine to 
isoleucine change at position 166. 
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Figure 5.2. ClustalW alignment of the DHFR gene family.  The clustalW alignment shows that 
there is high homology with very little differences between DHFRL1 and all of the other genes in 
the DHFR gene family. The rs61739170 SNP is shown in dark yellow, while the primers for the 
rs61739170 SNP are shown in light blue. Primers were designed so that they would only amplify up 
the region of interest. 
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Figure 5.3. Gel electrophoresis of DNA samples amplified by specific DHFRL1 primers 
designed to amplify the region containing the rs17855824 polymorphism. Lane 1 – 100 bp 
DNA ladder, Lane 2 - Coriell sample 17229, Lane 3 - Coriell sample 17214, Lane 4 – Coriell 
sample 17147, Lane 5 – Coriell sample 17146, Lane 6 Coriell samples 17234, Lane 7 – negative 
control. The gel shows bands of the correct size (178 bp), indicating that the DNA samples have 
been amplified by the primers. 
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Figure 5.4. Gel electrophoresis of DNA samples amplified by specific DHFRL1 primers 
designed to amplify the region containing the rs61739170 polymorphism. Lane 1 – 100 bp 
DNA ladder, Lane 2 - Coriell sample 17265, Lane 3 - Coriell sample 17133, Lane 4 – Coriell 
sample 17219, Lane 5 – Coriell sample 17102, Lane 6 Coriell samples 17259, Lane 7 – negative 
control. The gel shows bands of the correct size (257 bp), indicating that the DNA samples have 
been amplified by the primers. 
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Figure 5.5. Gel electrophoresis of DNA samples amplified by specific DHFRL1 primers 
designed to amplify the region containing the rs114936057 polymorphism. Lane 1 – DNA 
ladder, Lane 2 - Coriell sample 17206, Lane 3 – SW480, Lane 4 – Coriell sample 17145, Lane 5 – 
Coriell sample 17158, Lane 6 Coriell samples 17165, Lane 7 – negative control. The gel shows 
bands of the correct size (317 bp), indicating that the DNA samples have been amplified by the 
primers. 
 
 
 
 
 
 
 
 
 
 155 
 
 
 
Figure 5.6. An example of a dirty chromatogram from a Sanger sequencing run of one of the 
rs61739170 (C>G) polymorphism DNA samples. The navy arrow indicates the location of the 
polymorphism, showing that this individual is heterozygous for the DHFRL1 rs61739170 (C->G) 
polymorphism. However, we can see that the trace not only picks up the DHFRL1 gene but also 
other members of the DHFR gene family, indicated by the two peaks observed at the orange arrow. 
The chromatogram shows evenly spaced peaks, with little baseline noise, indicating that our 
template and primers were good, as well as allowing us to determine the base at each of the 
polymorphisms.   
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Figure 5.7. An example of a clean chromatogram from a Sanger sequencing run of one of the 
rs17855824 (G>A) polymorphism DNA samples. The navy arrow indicates the location of the 
polymorphism, showing that this individual is heterozygous for the DHFRL1 rs17855824 (G->A) 
polymorphism. This trace only picks up the DHFRL1 gene as indicated by the single peaks 
observed at each base The chromatogram shows evenly spaced peaks, with little baseline noise, 
indicating that our template and primers were good, as well as allowing us to determine the base at 
each of the polymorphisms.   
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Figure 5.8. Melt curve analysis of the DHFRL1 rs17855824 Val->Ile polymorphism. The single 
green peak at 55.5°C represents the homozygous polymorphism A/A genotype. The single blue 
peak at 63.5°C represents the homozygous wild type G/G genotype. The two red peaks at 55.5°C 
and 63.5°C represent the heterozygous G/A genotype.  
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Figure 5.9. Bovine Serum Albumin (BSA) Standard Curve. The BSA Standard Curve was 
obtained by plotting the protein standards against the absorbance measured at 595 nm. 
Mitochondrial and cytoplasmic protein concentrations were obtained from the standard curve using 
the equation of the line. An R
2
 value of over 0.98 indicated good linearity of the assay and precision 
of the standard preparation. .   
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Figure 5.10. Western blot of HEK 293 and DHFRL1 over-expressed cytoplasmic and 
mitochondrial protein fractions probed with the GAPDH antibody. Lane 1 – protein ladder, 
Lane 2 –HEK 293 cytoplasmic protein fraction, Lane 3 – HEK 293 mitochondrial protein fraction, 
Lane 4 – DHFRL1 over-expressed HEK 293 cytoplasmic protein fraction, Lane 5 – DHFRL1 over-
expressed HEK 293 mitochondrial protein fraction. All samples were equally loaded as determined 
by Bradford assay (Table 5.3). Bands of the correct size (40 kDa) were seen for all of the 
cytoplasmic protein samples. 
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Figure 5.11. Western blot of HEK 293 and DHFRL1 over-expressed HEK 293 cytoplasmic 
protein fractions probed with the DHFR antibody. Lane 1 – protein ladder, Lane 2 –HEK 293 
cytoplasmic protein fraction, Lane 3 – DHFRL1 over-expressed HEK 293 cytoplasmic protein 
fraction, Lane 4 - HEK 293 cytoplasmic protein fraction, Lane 5 – DHFRL1 over-expressed HEK 
293 cytoplasmic protein fraction. All samples were equally loaded. Bands of the correct size (21 
kDa) were seen for all of the cytoplasmic protein samples. 
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Figure 5.12. Western blot of HEK 293 and DHFRL1 over-expressed HEK 293 mitochondrial 
protein fractions probed with the DHFR antibody. Lane 1 – protein ladder, Lane 2 – HEK 293 
mitochondrial protein fraction, Lane 3 – DHFRL1 over-expressed HEK 293 mitochondrial protein 
fraction. All samples were equally loaded. Bands of the correct size (21 kDa) were seen for all of 
the mitochondrial protein samples. 
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Figure 5.13. DHFR Control without DHF (substrate). The graph above was obtained by plotting 
the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that there is 
no DHFR activity, indicated by the roughly straight horizontal line, i.e. when one of the key 
components of the reaction, DHF, which is the substrate for DHFR, is absent, the reaction cannot 
take place.   
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Figure 5.14. DHFR control without NADPH (cofactor). The graph above was obtained by 
plotting the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that 
there is no DHFR activity, indicated by the straight horizontal line, i.e. when one of the key 
components of the reaction, NADPH, which is a cofactor for DHFR, is absent, the reaction cannot 
take place.   
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Figure 5.15. DHFR Control. The graph above was obtained by plotting the 340 nm absorbance 
measurement vs. time in s. From the graph, it can be confirmed that once all the necessary 
components that are involved in the DHFR pathway are present, there is DHFR activity, indicated 
by the decrease in absorbance over time. The decrease in ΔOD over the 2.5 min was measured as 
ΔOD/min. An R2 value of over 0.98 indicated good linearity of the assay and precision of the 
standard preparation. 
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Figure 5.16. DHFR control plus methotrexate. The graph above was obtained by plotting the 340 
nm absorbance measurement vs. time in s. From the graph, it can be confirmed that methotrexate is 
inhibiting DHFR activity and that the concentration of methotrexate used is high enough to inhibit 
all DHFR enzyme activity, indicated by the straight horizontal line.  
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Figure 5.17. HEK 293 Mitochondrial Fraction. The graph above was obtained by plotting the 
340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that there is 
enzyme activity occurring in the mitochondria, indicated by the decrease in absorbance over time. 
The decrease in ΔOD over the 2.5 min was measured as ΔOD/min. An R2 value of over 0.98 
indicated good linearity of the assay and precision of the standard preparation. 
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Figure 5.18. HEK 293 Mitochondrial Fraction plus Methotrexate. The graph above was 
obtained by plotting the 340 nm absorbance measurement vs. time in s. The graph above 
demonstrates the background activity present in the mitochondrial samples, as the enzyme activity 
caused by DHFR / DHFRL1 should be inhibited by the methotrexate. An R
2
 value of over 0.98 
indicated good linearity of the assay and precision of the standard preparation. 
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Figure 5.19. DHFRL1 Over-Expressed HEK 293 Mitochondrial Fraction. The graph above was 
obtained by plotting the 340 nm absorbance measurement vs. time in s. From the graph, it can be 
confirmed that there is enzyme activity occurring in the mitochondria, indicated by the decrease in 
absorbance over time. The decrease in ΔOD over the 2.5 min was measured as ΔOD/min. An R2 
value of over 0.98 indicated good linearity of the assay and precision of the standard preparation. 
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Figure 5.20. DHFRL1 Over-Expressed HEK 293 Mitochondrial Fraction plus Methotrexate. 
The graph above was obtained by plotting the 340 nm absorbance measurement vs. time in s. The 
graph above demonstrates the background activity present in the mitochondrial samples, as the 
enzyme activity caused by DHFR / DHFRL1 should be inhibited by the methotrexate. An R
2
 value 
of over 0.98 indicated good linearity of the assay and precision of the standard preparation. 
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Figure 5.21. Western blot of Coriell mitochondrial protein fractions probed with the DHFR 
antibody. Lane 1 – protein ladder, Lane 2 – Coriell 17205 mitochondrial protein fraction (G/G 
genotype, wild type), Lane 3 – Coriell 17189 mitochondrial protein fraction (G/A genotype, 
heterozygous), Lane 4 - Coriell 17234 mitochondrial protein fraction (A/A genotype, variant). 
Bands of the correct size (21 kDa) were seen for all of the mitochondrial protein samples. 
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Figure 5.22. Western blot of Coriell mitochondrial protein fractions probed with the GAPDH 
antibody. (A). Lane 1 – protein ladder, Lane 2 – Coriell 17205 mitochondrial protein fraction (G/G 
genotype, wild type), Lane 3 – Coriell 17189 mitochondrial protein fraction (G/A genotype, 
heterozygous), Lane 4 - Coriell 17234 mitochondrial protein fraction (A/A genotype, variant). 
(B). ). Lane 1 – protein ladder, Lane 2 – Coriell 17205 cytoplasmic protein fraction (control) 
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Figure 5.23. Genome Editing using Programmable Nucleases. Nuclease-induced DSBs can lead 
to sequence insertions, nucleotide correction or change (red box) through HR in the presence of a 
donor DNA or a single-stranded oligodeoxynucleotide (ssODN), both of which contain homology 
arms. DSBs can also be repaired through error-prone NHEJ, which does not require donor DNA or 
ssODN and consequently often leads to small insertions and deletions (indels). Image and legend 
taken from (Kim and Kim, 2014).  
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Table 5.1. Genotyping results from sequence and chromatogram analyses for each of the three 
DHFRL1 polymorphisms 
 
Samples Sequenced G->A (rs17855824) C->G (rs61739170)  G->T (rs114936057)  
Coriell 17229 G/A C/C G/G 
Coriell 17214 G/G C/C G/G 
Coriell 17147 G/G C/C G/G 
Coriell 17146 G/G C/G G/G 
Coriell 17234 G/G C/G G/G 
Coriell 17265 G/G C/C G/G 
Coriell 17133 G/G C/C G/G 
Coriell 17219 G/G C/C G/G 
Coriell 17102 G/G C/G G/G 
Coriell 17259 G/G C/G G/G 
Coriell 17206 G/A C/G G/G 
SW480 G/G C/C  G/G 
Coriell 17145 G/G C/C G/G 
Coriell 17158 G/G C/C G/G 
Coriell 17165 G/G C/C G/G 
Coriell 17291 G/G C/C G/G 
Coriell 17218 G/A C/C G/G 
BT474 G/G C/G G/G 
NCI-H1299 G/G C/C G/G 
HT29 G/G C/C G/G 
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Table 5.2. Genotypes of the DHFRL1 rs17855824 polymorphism in a panel of Coriell DNA 
Samples 
  
rs17855824 Genotype Total [n (%)] 
G/G (wild type) 
G/A (heterozygous) 
A/A (polymorphism) 
144 (85.2) 
23 (13.6) 
2 (1.18) 
Allele 1 (WT) 
Allele 2 (SNP) 
311 (92) 
27 (8) 
 
Table 5.3. Protein Standard Concentration and Absorbance Values  
 
Concentration (mg/mL) Absorbance 
Average 
Absorbance 
Average – 
Blank 
0 0.3071 0.3103 0.3087 0 
0.25 0.3858 0.38415 0.384975 0.076275 
0.5 0.47819999 0.4859 0.482049995 0.173349995 
0.75 0.54729998 0.5592 0.55324999 0.24454999 
1 0.63120002 0.6847 0.65795001 0.34925001 
1.25 0.70209998 0.7544 0.72824999 0.41954999 
 
Table 5.4. Mitochondrial and Cytoplasmic Protein Absorbance and Concentration Values  
 
+
Over-expressed 
 
Sample Absorbance 
Average 
Absorbance 
Average 
- Blank 
Protein 
Concentration 
(mg/mL) 
HEK 293 Cytoplasmic 0.7134 0.7731 0.74325 0.4369 1.291457286 
HEK 293 Mitochondrial 0.71249 0.7188 0.715645 0.409795 1.211336092 
DHFRL1 OE
+
 Cytoplasmic 0.7993 0.8311 0.8152 0.50885 1.504138339 
DHFRL1 OE Mitochondrial 0.4923 0.5048 0.49855 0.1927 0.56961277 
Lysis Buffer 0.305 0.3077 0.30635 
  Storage Buffer 0.3068 0.3049 0.30585 
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Table 5.5. DHFRL1 polymorphism genotyping results in NTD triads (fathers, mothers 
and cases) and controls. 
 
DHFRL1 rs7653521 SNP 
 Fathers Mothers Cases Controls 
 n % N % n % N % 
CC 91 20.00 86 17.10 97 18.95 182 18.69 
CT 200 43.96 234 46.52 248 48.44 468 48.05 
TT 164 36.04 183 36.38 167 32.62 324 33.26 
Total 455  503  512  974  
 
rs10454213 
 Fathers Mothers Cases Controls 
 n % n % n % N % 
AA 339 74.83 380 74.80 404 77.99 732 75.78 
GA 105 23.18 121 23.82 108 20.85 215 22.26 
GG 9 1.99 7 1.38 6 1.16 19 1.97 
Total  453  508  518  966  
 
rs7644176 
 Fathers Mothers Cases Controls 
 n % n % n % N % 
GG 434 94.55 480 93.93 495 95.19 910 93.43 
TG 24 5.23 31 6.07 25 4.81 64 6.57 
TT 1 0.22 0 0.00 0 0.00 0 0.00 
Total  459  511  520  974  
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rs11927165 
 Fathers Mothers Cases Controls 
 N % n % n % N % 
CC 2 0.43 0 0.00 0 0.00 0 0.00 
CT 23 4.99 31 6.03 26 4.97 67 6.88 
TT 436 94.58 483 93.97 497 95.03 909 93.33 
Total  461  514  523  976  
 
rs61739170 
 Fathers Mothers Cases Controls 
 N % n % n % N % 
CC 24 5.38 26 5.17 25 4.96 57 5.91 
CG 149 33.41 179 35.59 179 35.52 344 35.65 
GG 273 61.21 298 59.24 300 59.52 564 58.45 
Total  446  503  504  965  
 
rs17855824 
 Fathers  Mothers Cases  Controls 
 N % n % n % N % 
CC 339 75.67 374 74.35 395 79.16 724 76.29 
CT 101 22.54 123 24.45 99 19.84 211 22.23 
TT 8 1.79 6 1.19 5 1.00 14 1.48 
Total  448  503  499  949  
 
rs7645522 
 Fathers  Mothers Cases  Controls 
 N % n % n % N % 
AA 337 74.56 377 73.92 403 77.95 736 75.64 
GA 106 23.45 126 24.71 109 21.08 222 22.82 
GG 9 1.99 7 1.37 5 0.97 15 1.54 
Total  452  510  517  973  
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 Table 5.6. Location of each of the DHFRL1 polymorphisms and the linkage 
disequilibrium test results carried out on the DHFRL1 polymorphisms. 
 
 
 
Table 5.7. TDT analysis for the DHFRL1 polymorphisms.  
 
Name Over-transmitted T:U Chi square P value 
DHFRL1_rs7645522 A 107:71 7.281 0.007 
DHFRL1_rs11927165 T 24:19 0.581 0.4458 
DHFRL1_rs10454213 A 105:66 8.895 0.0029 
DHFRL1_rs17855824 C 97:62 7.704 0.0055 
DHFRL1_rs61739170 C 130:125 0.098 0.7542 
DHFRL1_rs7644176 G 25:18 1.14 0.2858 
DHFRL1_rs7653521 C 177:158 1.078 0.2992 
 
 
 
 
Irish NTDs CHR Position_b36 Region HapMap CEU 
rs7645522.25 3 95257618 DHFRL1_10kb r^2=1 with rs10454213 
rs11927165.25 3 95258101 DHFRL1_5kb r^2=1 with rs7644176 
rs10454213.25 3 95259426 DHFRL1_5kb r^2=1 with rs7645522 
DHFRL1_start 3 95262482 DHFRL1_start   
rs17855824.25 3 95262550 DHFRL1 r^2=1 
rs61739170.25 3 95262799 DHFR1 
 DHFRL1_end 3 95263045 DHFRL1_end   
rs7644176.25 3 95266787 DHFRL1_5kb r^2=1 with rs11927165 
rs7653521.25 3 95267249 DHFRL1_10kb Singleton 
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Chapter 6 
 
Investigation of the impact of DHFRL1 
polymorphisms on the activity of 
recombinant enzyme 
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6.1 Introduction 
Non-synonymous polymorphisms have been identified in the coding region of the DHFRL1 
gene as previously mentioned (Section 5.1.2). In Chapter 5, we have shown that endogenous 
DHFRL1 is present in the mitochondria and that it harbours enzyme activity. The presence of 
polymorphisms within the DHFRL1 coding region was also confirmed. This in itself is highly 
interesting as no common polymorphisms are known to exist within the coding region of its 
paralogous gene, DHFR. Although the enzyme activity of the DHFRL1 rs17855824 polymorphism 
could not be determined endogenously, due to low mitochondrial concentration yields, the two 
DHFRL1 polymorphisms that we have identified could alter the activity of the enzyme, which could 
be of great importance and may contribute to health and disease. As the DHFRL1 rs17855824 
polymorphism, along with two other DHFRL1 polymorphisms (rs7645522 and rs10454213) 
showed to be associated with NTDs in Chapter 5, it is of great interest to try and determine the 
function of these DHFRL1 polymorphisms. Therefore, the aim of this chapter was to assess the 
enzyme activity of recombinant DHFRL1, which was generated by Gateway Cloning and its 
recombinant variants, which were generated by Site Directed Mutagenesis, in order to complement 
our findings found in endogenous mitochondrial protein as well as to try and determine the function 
of the DHFRL1 polymorphisms. 
 
6.1.1 Gateway Cloning 
 Gateway cloning is a universal cloning technology that is based on the integration of the 
site-specific recombination properties of bacteriophage lambda into the E. coli. chromosome, 
relying on the switch between the lytic and lysogenic pathways (Landy, 1989, Ptashne, 1992). 
Lambda integration into the E. coli chromosome occurs via intermolecular DNA recombination that 
is mediated by a mixture of lambda and E. coli encoded recombination proteins. Recombination 
proteins involved differ depending on whether lambda utilises the lytic or lysogenic pathway. 
Lambda recombination occurs between specific attachment (att) sites on the interacting DNA 
molecules, i.e. the DNA segments flanking the recombination sites are switched, and after 
recombination, the att sites are hybrid sequences comprised of sequences donated by each parental 
vector (e.g. attL sites are comprised of sequences from attB and attP sites). The strand exchange 
occurs within a core region that is common to all att sites and the recombination can occur between 
DNAs of any topology, i.e. supercoiled, linear or relaxed. Lambda recombination is conservative 
(there is no net gain or loss of nucleotides) and requires no DNA synthesis 
(https://tools.lifetechnologies.com/content/sfs/manuals/gatewayman.pdf.)   
   
 180 
 
In Gateway cloning, the components of the lambda recombination system have been 
modified in order to improve the specificity and efficiency of the system (Bushman et al., 1985). 
Mutations have been made to the core regions of the att sites to eliminate stop codons and to ensure 
specificity of the recombination reactions to maintain orientation and reading frame as well as to the 
short (5 bp) regions flanking the 15 bp core regions of the attB sites to minimise secondary structure 
formation in single stranded forms of attB plasmids. A 43 bp portion of the attR site has also been 
removed to make the in vitro attL x attR reaction irreversible and more efficient (Bushman et al., 
1985). Site specific point mutations have also been made to some att sites in order to increase 
recombination efficiency.   
  
Gateway cloning involves three main steps. 1) Designing attB PCR primers and amplifying 
up the sequence of interest, 2) BP recombination reaction with the attB PCR product and a donor 
vector to generate an entry clone and 3) LR recombination reaction with the entry clone and a 
Gateway destination vector to generate an expression clone. These reactions are carried out by 
proteins that mediate the recombination reaction (Clonase
TM
 enzyme mix, which contain a mixture 
of lambda and E. coli encoded recombination proteins) (Figure 6.1). 
   
6.1.2 Site Directed Mutagenesis (SDM) 
SDM is a molecular technique that is used to introduce a specific mutation at a specific site 
in the DNA. This will allow the relationship between protein structure and function to be 
determined. Site-directed mutagenesis functions by utilising a supercoiled double-stranded DNA 
vector with the insert of interest and two synthetic primers, both of which contain the desired 
mutation. The primers are complementary to opposite strands of the vector and are extended by 
PfuUltra high fidelity DNA polymerase during elongation, generating a mutated plasmid containing 
staggered nicks. Once the mutated plasmid is produced, it is digested with Dpn I, an endonuclease 
that is specific for methylated and hemimethylated DNA, and is used to digest the parental DNA 
and select for mutation-containing synthesized DNA. (DNA isolated from almost all E. coli strains 
is dam methylated and therefore susceptible to Dpn I digestion) (Figure 6.2). Once the vectors 
containing the mutations are produced, they are transformed into XL10 Gold Ultracompetent cells 
(Section 2.3.1). 
 
6.1.3 Objectives 
Assessment of enzyme activity in DHFRL1 and its polymorphisms was examined using the 
following methodology. 
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 Prediction of DHFRL1 and variant DHFRL1 protein structures 
 Generation of DHFRL1 variant GST tagged proteins via site-directed mutagenesis.  
 Production and optimisation of DHFRL1 and DHFRL1 variant GST tagged 
proteins.  
 Generation of GST and His tagged DHFR, DHFRL1 and DHFRL1 variant 
expression clones by Gateway Cloning and site-directed mutagenesis. 
 Production and optimisation of DHFR, DHFRL1 and DHFRL1 variant GST and 
His tagged proteins.  
 Rare codon optimisation of DHFR and DHFRL1. 
 Generation of rare codon optimised GST tagged DHFR and DHFRL1 expression 
clones by Gateway Cloning. 
 Production and optimisation of rare codon optimised GST tagged DHFR and 
DHFRL1 proteins.  
 Purification of DHFRL1 proteins. 
 Production and optimisation of recombinant DHFRL1 variant proteins. 
 Purification of DHFRL1 variant proteins. 
 Enzyme kinetic analysis of purified DHFRL1 and its polymorphisms. 
 
6.2 Results 
6.2.1 Protein Structure Prediction 
The predicted tertiary structures of DHFRL1, DHFRL1 rs17855824 and DHFRL1 
rs61739170 polymorphisms were generated using the Protein Structure Prediction Server software 
from the Molecular Bioinformatics Centre, National Chiao Tung University (Chen et al., 2006) and 
the STRAP-NT software (Figure 6.3), which predicts the structure of the protein from an amino 
acid sequence. By comparing the structures of DHFRL1, DHFRL1 rs17855824 and DHFRL1 
rs61739170 to each other, we can see that all three proteins are highly similar, with all major α 
helices and β sheets present but there are slight differences in the folding of their loops and coils.   
 
6.2.2 Generation of recombinant DHFRL1 GST tagged variant clones 
A DHFR and DHFRL1 recombinant protein had previously been generated in the lab by 
recombining a PCR product that had been amplified from HEK 293 cDNA into a pDONR™ 211 
vector, to form an entry clone. Plasmid DNA from the entry clone was then cloned into the 
Gateway Cloning vector pDEST 15 (Invitrogen), which contains a glutathione S-transferase (GST) 
tag (26kDa) at its N terminus. Clones were verified by Sanger sequencing. The pDEST 15 vectors 
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uses the pET system to induce high levels of recombinant protein expression in Escherichia coli (E. 
coli) by taking advantage of the high activity and specificity of the bacteriophage T7 RNA 
polymerase to control expression (Studier et al., 1990). The DHFR and DHFRL1 ORF was inserted 
into the vector at position 799 (Figure 6.4), with the region between position 799 and 2482 of the 
original vector sequence being removed to allow entry. As the DHFRL1 ORF is only 564 bases 
long, it altered the overall size of pDEST 15 from 7013bp to 5893bp. A tobacco etch virus (TEV) 
recognition site was also included upstream of the DHFRL1 protein but downstream of the GST tag 
at this stage. The vector construct was then transformed into DH5α E-coli cells, as described in 
Section 2.2.8 which can be used to maintain a library of the clone.  
  
DHFR and DHFRL1 clones were streaked out onto LB agar plates with carbenicillin and 
plasmid DNA was extracted from the DHFR and DHFRL1 overnight cultures (Section 2.2.6) and 
were run on a 1 % w/v agarose gel to ensure that DNA was present (Figure 6.5). Once the presence 
of DNA was confirmed, SDM was carried out (Section 2.2.9). Primers were designed according to 
the QuikChange II XL SDM Kit (Section 2.2.9) to incorporate the rs17855824 and rs61739170 
polymorphisms respectively and SDM was carried out. Once the vector containing the mutations 
was produced, they were transformed into XL10 Gold Ultracompetent cells, cells which can be used 
to maintain a library of the clone (Section 2.3.1) and plasmid DNA was extracted (Section 2.2.6). 
To confirm the presence of DNA and to verify that the correct mutation had been inserted, the 
purified plasmid DNA was run on a 1 % w/v agarose gel (Figure 6.6.) and Sanger sequenced 
(Figure 6.7) (See Appendix O for complete mutant clone chromatograms). 
 
6.2.3 Production  of recombinant DHFRL1 and DHFRL1 polymorphism proteins 
DHFRL1 WT, DHFRL1 rs17855824 and DHFRL1 rs61739170 recombinant DNA samples 
were used to transform BL21-AI E-coli cells. This cell line has been modified to ensure that the 
protein of interest is expressed optimally by exploiting the use of an inducer system. Transformed 
BL21-AI cells were induced using L-arabinose to give a final concentration of 0.04 % as described 
in Section 2.3.4. T7 expression is controlled by the araBAD promoter, which in turn is controlled by 
araC, a transcriptional regulator which can form a complex with L-arabinose. When L-arabinose 
binds to araC, it activates the T7 RNA polymerase, which activates the araBAD genes, releasing the 
protein. Therefore, L-arabinose acts as an inducer of recombinant DHFRL1 in this system. An 
overnight culture was sub-cultured and grown until an OD600 of 0.4 was reached. The culture was 
then induced with L-arabinose and the protein was harvested at specific time points (0 h, 2 h, 4 h, 6 
h and 24 h) and fractionated into soluble and insoluble fractions by multiple freeze thaw cycles. 
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SDS-PAGE analysis was carried out to make sure that the protein of interest was expressed, to 
determine at which time point the protein was best induced at and to ensure that the protein of 
interest was present in the soluble fraction. The 24 h time point showed the best results, with a 
strong band seen in the induced in comparison to the un-induced sample (Figure 6.8). 
 
Results shown in Figure 6.8 illustrate a strong band at ~ 48 kDa in the induced 24 hr time 
point in the DHFRL1 and polymorphism protein samples and show that the protein of interest is 
both strongly expressed and present in the soluble fraction allowing protein purification to take 
place. A strong band is also seen at ~ 33 kDa in all of the induced proteins, indicating that other 
proteins may also be induced by this inducer system or it may be a truncated version of the fusion 
protein. Once it was confirmed that the protein of interest was present in the soluble fraction, the 
GST tagged protein was purified by binding the GST tag to glutathione agarose. GST-tagged fusion 
proteins can be purified by binding its substrate glutathione. When reduced glutathione (GSH) is 
immobilized by binding to a solid support, such as glutathione agarose beads, it can be used to 
capture GST-tagged proteins via the enzyme-substrate binding reaction. The purified protein was 
eluted using 35mM glutathione, which competitively displaces the GST to bind to the glutathione 
agarose, allowing the fusion protein to emerge from the affinity column. The protein purification 
fractions were analysed by 10 % w/v SDS-PAGE. Results are shown in Figure 6.9. Bands of the 
correct size in the elution fraction were seen at 48 kDa, indicating that GST-tagged fusion protein is 
present. Results shown in Figure 6.9 illustrate that the protein of interest at ~ 48 kDa is being 
purified out. However, the ~ 33 kDa band is also being co-purified out. This was of concern as the 
band at ~ 33 kDa is stronger than that of our protein of interest.    
 
6.2.4 Optimisation of recombinant DHFRL1 & DHFRL1 polymorphism proteins: 
Elimination and identification of the 33 kDa band 
Although the protein of interest at 48 kDa was being induced and could be purified out, a 
strong 33 kDa band was also seen to be induced at the same time and on repetition, the 33kDa was 
stronger than that of the band of interest at 48 kDa (Figure 6.10). 
 
In order to try and eliminate this band at ~ 33 kDa, the cultures were grown at different 
temperatures in order to try and optimise the growth of the cultures so that the protein of interest 
would be produced most optimally. Cultures were grown at 25°C, 30°C and 37°C for 24 h. The 
protein fractions were fractionated as before and were analysed by 10 % w/v SDS-PAGE (Figure 
6.11). Strong bands were still observed at ~33 kDa 
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6.2.5 Generation of GST and His tagged recombinant DHFR, DHFRL1 and DHFRL1 
variant clones. 
The strong band seen at ~ 33 kDa was initially thought to be a truncated version of the 
protein of interest and therefore, in order to only purify out the full length protein, a His tag was 
added to the C-terminus of the protein. This was carried out by designing primers that would 
incorporate a TEV cleavage site at the N-terminus and a His tag (6 x histidine amino acids) at the 
C-terminus as well as att-sites for both DHFR and DHFRL1 (Section 2.2.8) (Figure 6.12) and by 
PCR amplification with these primers using HEK 293 cDNA as a template (Figure 6.13). Once the 
PCR product was obtained, recombinant DHFR and DHFRL1 protein was generated by Gateway 
cloning (Section 2.2.8). Generated clones were plasmid prepped and verified by Sanger sequencing 
(Figure 6.14) (See Appendix P-W for sequences and chromatograms). 
 
Once the His tag had been incorporated, SDM was carried out on the DHFRL1 plasmid 
DNA as before in order to generate the recombinant DHFRL1 polymorphisms (See Section 2.2.9). 
Generated clones were plasmid prepped and verified by Sanger sequencing (Figure 6.15) (See 
Appendix X-AA for sequences and chromatograms).  
 
6.2.6 Production and optimisation of DHFR and DHFRL1 GST and His tagged proteins  
Once the correct clones had been obtained, the proteins were induced as before and the 
protein was purified using a His column (Section 2.3.14). The protein samples were then run on 
10 % w/v SDS-PAGE gels (Figure 6.16). However, two bands, one at 48 kDa, the size of the 
protein of interest and one at 33kDa or just one band at the lower size was observed, depending on 
the protein sample.  
 
Therefore, in order to try and eliminate the lower strong band at ~ 33 kDa, L-Arabinose 
concentrations were re-optimised, time points were altered, the temperature at which the culture 
were grown were altered. The cell strain in which the cells were transformed into was also changed 
from BL21-AI cells to BL21 (DE3) cells. The BL21 (DE3) E. coli cells contain the DE3 lysogen 
that carries the gene for the T7 RNA polymerase, which unlike the BL21-AI cells is under the 
control of the lacUV5 promoter, and therefore IPTG, rather than L-Arabinose is required to induce 
the expression of the T7 RNA polymerase. However, changing the growth conditions caused more 
problems and eventually induced bands could only be obtained in certain samples and no 
consistency could be observed on the SDS-PAGE gels (Figure 6.17). 
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6.2.7 Identification of 33 kDa band 
In order to try and determine what was happening with our samples and in order to try and 
identify what the initial two strong bands were, a Western blot was carried out on those samples that 
had previously shown the two strong induction bands and those samples in which induction did not 
occur at all. As the samples had not been purified, a Bradford assay (See Section 2.3.17) was 
carried out on the samples in order to determine the concentration of the protein samples. A serial 
dilution of one of the protein samples was carried out and run on an SDS-PAGE gel in order to 
determine the best concentration to use for Western blot analysis. The gel was run so that the two 
strong bands would be separated as much as possible, i.e. the lower bands of the ladder were run off 
the gel (Figure 6.18).  
 
Figure 6.18 shows that when the bands were separated out, the two strong induction bands 
seen previously were in actual fact made up of numerous bands rather than a single strong band. 
From Figure 6.18, we can also determine that the best concentration of protein to use for Western 
blot analysis is ~ 2.82 µg of total protein. Once the best concentration was determined, the GST and 
DHFR primary and secondary antibodies were optimised by varying the concentration of the 
antibodies (Figure 6.19).  
 
Once the Western blots had been optimised, a Western blot was carried out on those 
samples that had previously shown the two induction bands and those samples in which induction 
did not occur at all. All lanes were equally loaded for protein (Figure 6.20). Figure 6.20 shows no 
33 kDa band in any of the samples indicating that the 33 kDa bands observed in the SDS-PAGE 
gels (Figure 6.16) are not our protein of interest nor is it a truncated version of our protein. The 
Figure also shows that our protein of interest is not only present in the induced fraction samples but 
also in the un-induced fraction samples. This is most likely due to a leaky promoter.   
 
6.2.8 Rare codon optimisation of DHFR and DHFRL1 
We ruled out that the 33kDa protein was a truncated version of our fusion protein. Our 
main difficulty was the inconsistency in the induction of our fusion protein from one experiment to 
the next. From our Western blots, (Figure 6.20), we can conclude that the clones were originally 
producing our protein of interest, but that the clones stopped producing DHFR and DHFRL1 for an 
unknown reason. One cause could be attributed to the fact that different colonies were picked from 
the LB agar plates each time the experiment was carried out, indicating that the production of the 
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recombinant protein could be colony specific, with some colonies producing the protein while 
others not, although this is not known for sure. Therefore, we decided to optimise our DHFR and 
DHFRL1 clones for rare codon usage in bacteria by generating another set of recombinant clones. 
The DHFR and DHFRL1 genes were optimised for codon usage in bacteria using the IDT codon 
optimisation web tool (https://eu.idtdna.com/CodonOpt) and the GenScript rare codon analysis tool 
(http://www.genscript.com/cgi-bin/tools/rare_codon_analysis). Sequences optimised for rare codon 
usage were obtained from the IDT website and the optimised sequences were analysed for the best 
fit using the GenScript website. The best DHFR sequence optimised for rare codon usage obtained 
from the IDT website is shown in Figure 6.21, with the characteristics for the best fit shown in 
Figure 6.22–6.24. The best DHFRL1 sequence optimised for rare codon usage obtained from the 
IDT website is shown in Figure 6.25, with the characteristics for the best fit shown in Figure 6.26–
6.28. 
 
6.2.9 Generation of rare codon optimised GST tagged DHFR and DHFRL1 expression 
clones by Gateway Cloning 
Once the DHFR and DHFRL1 genes were optimised for rare codon usage in E. coli, the 
optimised gene was synthesised by IDT using their Gene Synthesis Technology. Primers were then 
designed to amplify up the optimised DHFR and DHFRL1 gene. Once the PCR product was 
obtained (Figure 6.29), recombinant DHFR and DHFRL1 protein was generated by Gateway 
cloning (Section 2.2.8). Generated clones were plasmid prepped and verified by Sanger sequencing 
(See Appendix AB-AI for whole sequences and chromatograms). 
 
6.2.10 Production and optimisation of rare codon usage optimised GST tagged DHFR and 
DHFRL1 proteins  
Once the correct DHFR and DHFRL1 clones had been obtained, the plasmid DNA was 
transformed into BL21 (DE3) cells (Section 2.3.3) and were sub-cultured and grown as before. The 
cultures were then optimised for time (0 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h and 24 h), 
IPTG concentration (0 µM, 10 µM, 25µM, 50µM and 500 µM) and temperature (37°C, 30°C and 
20°C). Samples were harvested for each optimisation step. Protein samples were then lysed with 
bacterial lysis buffer, put through a needle and syringe, and the samples were fractionated into 
soluble and insoluble fractions by multiple freeze thaw cycles using liquid nitrogen. Samples were 
then run on SDS-PAGE gels and Western blot analysis was carried out to make sure that the protein 
of interest was expressed, to determine at which time point the protein was best induced at and to 
ensure that the protein of interest was present in the soluble fraction. Proteins had to be confirmed 
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by Western blot analysis as although a band of the correct size was sometimes seen on the SDS-
PAGE gel, there are numerous proteins of the same size as our protein of interest that are induced 
under our conditions (Figure 6.30). Although stronger bands were always observed in our insoluble 
fractions for all our proteins (Figure 6.31–6.34), the goal of our optimisation steps was to obtain the 
highest possible amount of our protein of interest in the soluble fraction. For the DHFR clone, the 
induced 1 h time point at 30°C showed the best results, with a strong band observed at 48 kDa 
(Figure 6.31). For the DHFRL1 clone, the un-induced 1 h time point at 30°C showed the best results 
(Figure 6.32), with the un-induced samples producing higher amounts of protein in the soluble 
fractions in comparison to the induced samples. This may be due to as mentioned earlier, (Section 
6.2.6), a leaky promoter and / or the fact that as the new clones have been optimised for bacteria, 
they are producing the protein too fast when the protein is induced, resulting in the formation of 
protein aggregates (inclusion bodies), which are located in the insoluble protein fraction. 
 
For the DHFRL1 polymorphisms clones, we went back to our original GST clones and re-
optimised them using the BL21 (DE3) cells. For the DHFRL1 rs61739170 (C->G) clone, the un-
induced 4 h time point at 30°C showed the best results, with a strong band seen (Figure 6.33) and 
for DHFRL1 rs17855824 (G->A) clone, the induced (final concentration 50 µM IPTG) 4 h time 
point at 30°C showed the best results (Figure 6.34). 
 
6.2.11 Purification of DHFR and DHFRL1 proteins 
Once the clones had been optimised for expression in a small scale culture (50-100 mL), 
large scale cultures (2 L) were then carried out to ensure that the expression of the protein did not 
change. Once this had been confirmed, the protein samples were spun down in 30 kDa centricons at 
4°C for ~ 1 h at 4470 X g in order to concentrate the protein as well as to eliminate small proteins. 
The protein samples were then clarified in lysis buffer and put through a 0.45 µM filter. The GST 
tagged protein was then purified as described in Section 2.3.13. The eluted fractions were then 
pooled together and concentrated using the 30 kDa centricons by centrifugation at 4°C for ~ 30 min 
at 4470 X g. The protein purification fractions were run on a 10 % w/v SDS-PAGE and Western 
blot analysis was carried out to ensure our protein of interest had been purified (Figure 6.35–6.37). 
Bands of the correct size in the elution fraction were seen at 48 kDa, indicating that the GST-tagged 
fusion protein is present and purified. 
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6.2.12 Enzyme kinetic analysis of purified DHFRL1 and its polymorphisms 
Once the presence of the protein of interest was confirmed by Western blot analysis, the 
eluted concentrated protein of interest was quantified. Protein concentrations could not be 
quantified by Bradford assay as when the SDS-PAGE gel corresponding to the Western blot was 
analysed via Coomassie blue, a strong glutathione band (~ 28 kDa) as well as our band of interest 
(48 kDa) as well as other bands were observed (Figure 6.38). Therefore, the concentration of our 
protein of interest was quantified using our Western blot images via Image J, a semi-quantitative 
method for determining protein concentration (Figure 6.39) (Table 6.1). The concentrations of our 
purified recombinant proteins were determined by loading a known concentration (176 ng) of the 
DHFR control onto each of the gels and normalising against the control. The DHFR control also 
allowed us to estimate the amount of protein required for the enzyme activity assays and to ensure 
that the same amount of protein was being used for each enzyme assay. This was important for 
calculating accurate specific activity values. Image J quantifications indicated that we had 4.4 ng of 
protein/µL for the DHFRL1 protein, 3.5 ng of protein/µL for the rs61739170 polymorphism protein 
and 5.55 ng of protein/µL for the rs17855824 polymorphism protein (Table 6.1). 
 
Enzyme kinetic analyses were then carried out on the purified recombinant WT DHFRL1, 
DHFRL1 rs17855824 and DHFRL1 rs61739170 polymorphisms in order to determine the specific 
activity of each of the proteins. Specific activity measures the amount of product formed by the 
enzyme per min per milligram of total protein i.e. how efficient the enzyme is at breaking down the 
substrate. The higher the specific activity of the enzyme, the more efficient the enzyme is at 
breaking down the substrate.  
 
In order to determine the enzyme activity of our purified protein, the Dihydrofolate Assay 
Kit, a colorimetric assay, was used as described in Section 2.3.21. The assay kit functions on the 
basis that the absorbance at 340 nm will decrease over time, due to the decrease in NADPH 
concentration (cofactor) as it is utilised by the enzyme, with DHF acting as the substrate for the 
reaction. The DHFR control and blanks were tested first in order to confirm that all the reagents 
were working correctly within the region of detection by the spectrophotometer (Figure 6.40-6.43).  
 
Once it was confirmed that the reagents and the assay was working well, the assay was 
carried out on the purified protein fractions. An example of each is shown in Figure 6.44–6.49. It 
was important to carry out the enzyme assays with our purified protein with the methotrexate in 
order to ensure / eliminate any possible involvement of the GST tag, which may lead to 
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overestimation of the specific activity of the enzyme. The decrease in ΔOD / min was then 
calculated for each of the samples. In order to obtain the true ΔOD of the protein samples, the ΔOD 
/ min of the sample + MTX (the background activity, which was practically zero in our case) was 
taken away from the ΔOD / min of the sample. The specific activity was then calculated as 
mentioned in Section 2.3.21. The specific activity measurements are based on the molar extinction 
coefficient of 12,300 M
-1
cm
-1
 at 340nm. As mentioned earlier, it is crucial that protein 
concentrations are estimated correctly in order to calculate the specific activity of the proteins. The 
specific activity measurements showed that both the DHFRL1 polymorphisms were more efficient 
at breaking down the substrate than the WT. The specific activity calculations showed the 
recombinant DHFRL1 protein to have a specific activity of 2.11 µnmol/min/mg protein, the 
DHFRL1 rs61739170 protein to have a specific activity of 7.10 µnmol/min/mg protein and the 
DHFRL1 rs17855824 protein to have a specific activity of 3.45 µnmol/min/mg. The specific 
enzyme activity fold difference was then calculated between the DHFRL1 wild type and the 
polymorphisms. The DHFRL1 rs61739170 protein showed to have a 3.36 fold increase and the 
DHFRL1 rs17855824 protein showed to have a 1.64 fold increase in specific enzyme activity when 
normalised to the DHFRL1wild type (Figure 6.50). 
 
6.3 Discussion 
The discovery of DHFRL1 as a functional gene in 2011 (McEntee et al., 2011) has great 
implications and may offer us further insights not only into folate-mediated one carbon metabolism 
but may also have serious implications for disease risk as shown in Chapter 5. We generated 
recombinant DHFRL1 and DHFRL1 polymorphism proteins via Gateway cloning in combination 
with SDM and optimised them for protein expression. Although the DHFRL1 polymorphisms only 
differ from the DHFRL1 wild type protein by a single base / amino acid, optimisation conditions for 
protein expression seemed to have varied between all three proteins, indicating that the proteins 
may have different effects.  
 
A lot of optimisation was required in order to produce enough recombinant DHFRL1 
protein and variant DHFRL1 proteins in the soluble fraction of the cells to carry out the enzyme 
kinetic analysis. It appeared that if the bacterial cultures were grown at too high a temperature or if 
the cultures were grown for too long, our proteins of interest moved into the insoluble fractions of 
the cells. Localisation of the proteins from the soluble fraction into the insoluble fraction is most 
likely caused by the protein being produced too quickly, resulting in the aggregation of the proteins, 
which will then result in the likelihood of the protein being mis-folded. This would then most likely 
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affect our downstream experiments of both protein purification and enzyme kinetic analysis as 
protein mis-folding could result in the GST tag being mis-folded, preventing binding to the GST 
column as well as altering the activity of the protein. Even after optimisation, a lot of the 
recombinant protein appeared to remain in the insoluble fraction, however, enough remained in the 
soluble fraction to carry out an assessment of the specific activity but not enough to calculate the 
Km.  
 
We examined the effect of two non-synonymous polymorphisms within the DHFRL1 gene 
on enzyme activity. Although the two polymorphisms chosen are not located in the regions required 
for catalytic activity or are the residues known to be important for folate, NADPH and/or MTX 
binding (Figure 6.51), the results above demonstrate that they have an impact on enzyme activity. 
On the other hand, our predicted protein structures for DHFRL1 and its variants showed slight 
differences in the folding of their loops and coils, (Figure 6.3) suggesting that the polymorphisms 
may have a potential effect on the 3D structure of the protein, resulting in enzyme activity 
differences.  
 
The DHFRL1 rs61739170 polymorphism, a non-synonymous polymorphism, which results 
in a proline to alanine amino acid change, showed that it can efficiently bind to the co-factor 
NADPH but also showed to have a much greater specific activity in comparison to the WT 
DHFRL1, indicating that it is much more efficient at reducing DHF. Proline and alanine are both 
linker molecules and can alter the stability of proteins as well as having an effect on protein fold 
rates (George and Heringa, 2002). However, there are many characteristic differences between the 
two amino acids. Prolines are the only amino acids whose side chain is connected to the protein 
backbone twice, and therefore does not allow for much flexibility. As a result, this restricts proline 
to occupy many of the main chain conformations that are easily adapted by all the other amino acids. 
This causes proline residues to have rigid structures, and therefore they often either act as scaffolds 
to prevent unfavourable interactions between folding domains or they function to introduce kinks 
into alpha helices, as it is unable to adopt a normal helical conformation. On the other hand, alanine 
is a much more flexible amino acid, allowing for movement within the helices (Solan et al., 2002). 
Therefore this proline to alanine amino acid change in the DHFRL1 rs61739170 polymorphism 
may be what is having an effect on the specific activity and the binding affinity of the protein.  
 
The DHFRL1 rs17855824 polymorphism, a non-synonymous polymorphism, which results 
in a valine to isoleucine amino acid change also showed that it can efficiently bind to the co-factor 
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NADPH and also showed to have a higher specific activity in comparison to the WT DHFRL1, 
although to a far lesser extent to that of the DHFRL1 rs61739170 polymorphism. In contrast to the 
amino acids involved in the DHFRL1 rs61739170 polymorphism, valine and isoleucine are both 
aliphatic hydrophobic amino acids and have very similar characteristics. They are both C-beta 
branched and contain two non-hydrogen substituents attached to its C-beta carbon, making them 
bulky near the protein backbone. Although valine and isoleucine seem to have similar properties, 
differences in protein structure can been seen from the predicted structures in Figure 6.3, implying 
that it may have an effect on functional impact. In Chapter 5, an association between the DHFRL1 
rs17855824 polymorphism and NTDs was observed. The association may be linked with the 
differences observed between the specific activity of the DHFRL1 WT and that of the DHFRL1 
rs17855824 polymorphism but will need to be investigated further.  
 
Although the exact function of these two polymorphisms is yet unclear and unknown, they 
seem to impact the activity of the enzyme and should be explored further. DHFR has been 
associated with many different diseases such as NTDs and cancer, and with DHFRL1 been 
previously shown to have similar properties to DHFR, it may also have implications in disease risk. 
When the specific activity and affinity for the substrate were examined in DHFR and DHFRL1, 
DHFR was shown to have a much higher specific activity and binding affinity in comparison to 
DHFRL1 (McEntee et al., 2011). However, both the DHFRL1 rs61739170 C->G polymorphism 
(proline to alanine change) and the DHFRL1 rs17855824 G->A polymorphism (valine to 
isoleucine) seems to increase the specific activity and binding affinity of DHFRL1, suggesting that 
it may be a significant factor in terms of disease risk. As the rs61739170 G allele and the 
rs17855824 A allele have been found to be frequent within the European population (approximately 
15 % and 7.5 % respectively), a large number of the population may be exhibiting increased activity 
levels of DHFRL1, which in turn may be increasing / decreasing their risk of disease by altering the 
folate-mediated one carbon metabolism pathway resulting in people who harbour this 
polymorphism to be at an increased / decreased risk of disease.  
 
In the future, two other specific kinetic measurements could be examined Vmax and Km, in 
order to determine the enzymatic properties of the WT DHFRL1 protein and each of the DHFRL1 
polymorphisms, which would hopefully allow us to understand better the function of the proteins. 
Vmax is the maximum rate of reaction that can be achieved by the enzyme and measures the 
amount of time it takes for the substrate to bind all the enzymes active sites. Km (Michaelis-Menten 
constant) measures the substrate concentration required to reach half the Vmax. The Km 
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characterises the enzyme’s affinity for the substrate. The higher the Km of the enzyme, the lower 
it’s affinity for its substrate (Figure 6.52). The Km and Vmax values for the substrate DHF could be 
determined by keeping the cofactor, NADPH constant at 60 µM, a concentration that was suggested 
by the DHFR assay kit and varying the concentration of DHF. However, in order to carry out these 
enzyme kinetic analyses, one would require a much higher concentrations of total recombinant 
protein than what we were obtaining. At present, we are obtaining ~ 3.5 µg of total protein from a 2 
L bacterial culture based on our Image J quantifications and in order to carry out the enzyme 
kinetics to obtain the Km and Vmax values; one would require at least three times the amount. In 
order to try and obtain higher protein concentration yields, one could try and solubilise the insoluble 
protein aggregates (inclusion bodies) and then re-fold the protein in order to obtain a functionally 
active protein. Protein solubilisation could be carried out by using denaturants such as urea or 
guanidine hydrochloride at high concentrations, in combination with reducing agents such as β-
mercaptoethanol. Once the protein is solubilised, it can be re-folded by the slow removal of the 
denaturing agent in the presence of an oxidising agent, which removes the secondary structures, 
resulting in the formation of an active protein (Sirawaraporn et al., 1993, Singh and Panda, 2005).   
 
In order to produce higher yields of purified recombinant protein, one could also try 
expressing the protein of interest in a mammalian expression system, such as Chinese hamster 
ovary (CHO) cells, which have been adapted into growing in suspension. A target protein sequence 
encoded with a signalling sequence for secretion could be transfected into the CHO cells and grown 
until a desired cell density is obtained. Extracellular production of the protein of interest would 
allow the recovery of the protein from the supernatant during the collection process. This method 
has been used routinely in biopharmaceutical companies for the last few decades in order to obtain 
high yields of protein with low cellular protein contamination (Lory, 1992, Wurm, 2004).  
 
As previously mentioned, Bailey et al. found that there was a high variability of DHFR 
activity among individuals, however the cause of this variability is yet unknown. Polymorphisms 
within the non-coding region of DHFR, have been thought to be related to the variability of DHFR 
activity (Bailey and Ayling, 2009) although no definitive cause has yet been discovered. In our 
study, we found that both the DHFRL1 polymorphisms that we examined had an impact of enzyme 
activity. This suggests that if variability of DHFRL1 activity is also found between different 
individuals, that these polymorphisms may be the cause of the differences observed.  
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DHFRL1 has also been shown to localise to the mitochondria, suggesting that 
polymorphisms in the DHFRL1 gene may have an effect on mitochondrial diseases, such as Rett 
Syndrome, Sudden Infant Death syndrome, Leigh Syndrome and Diabetes Mellitus and Deafness. If 
these two polymorphisms prove to be functional, they could have a huge impact on disease 
especially as they are located within the coding region of the DHFRL1 gene and no polymorphisms 
have been found in the coding region of the DHFR gene to date.  
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Figure 6.1. Gateway Recombination Reactions. A. The BP Reaction. The BP reaction facilitates 
the recombination of an attB substrate (attB-PCR product) with an attP substrate (donor vector) to 
create an attL-containing entry clone. This reaction is catalysed by the BP Clonase
TM 
enzyme mix, 
which contains the bacteriophage lambda integrase (Int) and the E. coli integration host factor (IHF) 
proteins. B. The LR Reaction. The LR reaction facilitates the recombination of an attL substrate 
(entry clone) with an attR substrate (destination vector) to create an attB-containing expression 
clone. This reaction is catalysed by the LR Clonase
TM
 enzyme mix, which contains the 
bacteriophage lambda integrase (Int) and Excisionase (Xis) and E. coli integration host factor (IHF) 
proteins. The BP and LR enzymes bind to the specific att sites, bring together the target sites, cleave 
them and covalently attach the DNA (Figure taken from the Gateway Technology Manual, 
Invitrogen). 
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Figure 6.2. Overview of Site-Directed Mutagenesis. Site-directed mutagenesis functions by 
utilising a supercoiled double-stranded DNA vector with the insert of interest and two synthetic 
primers, both of which contain the desired mutation. The primers are annealed to the DNA and are 
extended by PfuUltra high fidelity DNA polymerase during elongation, generating a mutated 
plasmid. Once the mutated plasmid is produced, it is digested with Dpn I, an endonuclease that 
digests parental methylated and hemimethylated DNA. Mutant DNA is transformed in to XL10 
Gold Cells (Image taken from www.genomics.agilent.com).   
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Figure 6.3. Tertiary Protein Structures of wild type DHFRL1, DHFRL1 rs61739170 (Pro-
>Ala) polymorphism and DHFRL1 rs17855824 (Val->Ile) polymorphism. (A). Protein 
structures were generated using the Protein Structure Prediction Server software from the Molecular 
Bioinformatics Centre, National Chiao Tung University. All three proteins are highly similar, with 
all main α helices and β sheets present but there are slight differences in the folding of their loops 
and coils. These differences may have an impact on the enzyme activity of the proteins, which in 
turn may have an impact on function. (B). Protein structures were generated using STRAP-NT 
software (http://www.charite.de/bioinf/strap/). The green circles indicate the location of the SNPs. 
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Figure 6.4. Sequence of the pDEST 15 vector. The highlighted region above shows the position 
where the DHFR / DHFRL1 ORF was inserted into the vector (at position 799) and the region of the 
original sequence which was removed to allow for the entry of the DHFRL1 ORF. The position at 
which the original vector sequence joins to the end of the DHFRL1 ORF is also marked (at position 
2482). (Image taken from www.invitrogen.com)  
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Figure 6.5. Gel electrophoresis of DHFRL1 plasmid DNA. Lane 1 – 1 kb DNA ladder, Lane 2 - 
DHFRL1 clone 1, Lane 3 – DHFRL1 clone 2, Lane 4 – DHFR clone 1, Lane 5 – negative control. 
The bands seen on the gel indicates that DNA is present and that it has been extracted correctly.  
 
 
Figure 6.6. Gel electrophoresis of plasmid DNA. Lane 1 – 1 kb DNA ladder, Lane 2 - DHFRL1 
rs17855824 clone 1, Lane 3 – DHFRL1 rs17855824 clone 2, Lane 4 – DHFRL1 rs17855824 clone 
3, Lane 5 – 1 kb DNA ladder, Lane 6 -  DHFRL1 rs61739170 clone 1, Lane 7 – DHFRL1 
rs61739170 clone 2, Lane 8 - DHFRL1 rs61739170 clone 3. The bands seen on the gel indicates 
that DNA is present and that it has been extracted correctly.  
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Figure 6.7. An example of a chromatogram from a sequencing run of one the successful 
mutant clones (reverse sequence). The arrow indicates confirmation of the base change of the 
rs61739170 polymorphism resulting in a C->G (Proline to Alanine amino acid) change. The 
chromatograms show evenly spaced peaks, with little baseline noise, indicating that our templates 
were of good quality. Direct sequencing and chromatogram results confirmed that the correct 
mutation had been inserted into the correct site. 
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Figure 6.8. SDS-PAGE analysis of BL21-AI soluble fraction after 24 h. Protein was isolated 
from both induced and un-induced samples at 24 h and was separated into soluble and insoluble 
fractions after incubation at 37°C overnight. The soluble fraction was run on a 10 % w/v SDS-
PAGE gel. Lane 1 – PageRuler pre-stained protein ladder, Lane 2 – DHFRL1 WT un-induced 
sample at 24 h, Lane 3 – WT induced sample at 24 h, Lane 4 - DHFRL1 C->G (rs61739170) 
polymorphism un-induced sample at 24 h, Lane 5 - DHFRL1 C->G (rs61739170) polymorphism 
induced sample at 24 h, Lane 6 - DHFRL1 G->A (rs17855824) polymorphism un-induced sample 
at 24 h and Lane 7 DHFRL1 G->A (rs17855824) polymorphism induced sample at 24 h. The 
protein of interest is clearly present at 48 kDa in the induced samples after 24 h and not in the un-
induced samples. 
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Figure 6.9. SDS-PAGE analysis of protein purification fractions. The GST tagged protein was 
purified by binding the GST tag to glutathione agarose. The purified protein was eluted using 35 
mM glutathione and the samples were analysed by running the samples on a 10 % w/v SDS-PAGE 
gel. (A) GST-DHFRL1 WT purification. Lane 1 – PageRuler pre-stained protein ladder, Lane 2 - 
flow-through, Lane 3 - wash step, Lane 4 - elution. (B) GST-DHFRL1 C->G (rs61739170) 
polymorphism purification. Lane 1 - PageRuler pre-stained protein ladder, Lane 2 - flow-through, 
Lane 3 - wash step, Lane 4 - elution 1. (C) GST-DHFRL1 G->A (rs17855824) polymorphism 
purification. Lane 1 - PageRuler pre-stained protein ladder, Lane 2 - flow-through, Lane 3 - wash 
step, Lane 4 - elution 1. Clear bands of the protein of interest can be seen at 48 kDa in the elution 
steps.  
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Figure 6.10. SDS-PAGE analysis of BL21-AI soluble fraction after 24 h. Protein was isolated 
from both induced and un-induced samples at 24 h and was separated into soluble and insoluble 
fractions after incubation at 37°C overnight. The soluble fraction was run on a 10 % w/v SDS-
PAGE gel. Lane 1 – Colorburst Electrophoresis Marker protein ladder, Lane 2 – DHFRL1 WT un-
induced sample at 24 h, Lane 3 – WT induced sample at 24 h, Lane 4 - DHFRL1 C->G 
(rs61739170) polymorphism un-induced sample at 24 h, Lane 5 - DHFRL1 C->G (rs61739170) 
polymorphism induced sample at 24 h. The protein of interest is clearly present at ~ 48 kDa in the 
induced samples after 24 h and not in the un-induced samples, however, a strong band is also seen 
below the 48 kDa band at ~ 33 kDa. 
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Figure 6.11. SDS-PAGE analysis of DHFRL1 BL21-AI soluble fraction after 24 h grown at 
different temperatures. Protein was isolated from both DHFRL1 induced and un-induced samples 
at 24 h and was separated into soluble and insoluble fractions after incubation at different 
temperatures overnight. The soluble fraction was run on a 10 % w/v SDS-PAGE gel. Lane 1 – 
Colorburst Electrophoresis Marker protein ladder, Lane 2 – DHFRL1 WT un-induced sample at 
25°C after 24 h, Lane 3 – DHFRL1 WT induced sample at 25°C after 24 h, Lane 4 - DHFRL1 WT 
un-induced sample at 30°C after 24 h, Lane 5 - DHFRL1 WT induced sample at 30°C after 24 h. 
Lane 6 - DHFRL1 WT un-induced sample at 37°C after 24 h, Lane 7 - DHFRL1 WT induced 
sample at 37°C after 24 h. The protein of interest is clearly present at ~ 48 kDa in the induced 
samples after 24 h and not in the un-induced samples, however, a strong band is still  present below 
the 48 kDa band at ~ 33 kDa. 
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ACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGTTTC
TTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGG
ACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAAC
TTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAAC
TCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAA
CTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTGGCA
GTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGG
ATCATGCAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAA
ACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACATCAAGT
ACAAATTTGAAGTATGTGAGAAGGATGATCATCATCATCATCATCATTAGGACCCA
GCTTTCTTGTACAAAGTGGT 
 
Figure 6.12. Primer design for His tag incorporation for the DHFRL1 clone. The letters in bold 
represent the forward and reverse primers. The att sites are represented in green, the TEV cleavage 
site in blue, the His tag in pink and the stop codon in yellow. 
 
 
Figure 6.13. Gel electrophoresis of PCR products amplified with specific DHFR and DHFRL1 
primers designed to incorporate a TEV cleavage site and a His tag using HEK 293 cDNA as a 
template. Lane 1 – 100 bp DNA ladder, Lane 2 – DHFR PCR product, Lane 3 –DHFRL1 PCR 
product. The gel shows bands of the correct size, 646 bp indicating that the target products have 
been amplified. 
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Figure 6.14. An example of a chromatogram from a Sanger sequencing run of one of the HIS 
incorporated DHFR recombinant plasmid DNA samples. The chromatogram shows evenly 
spaced peaks, with little baseline noise, indicating that our template and primers were good.   
 
 
 
Figure 6.15. An example of a chromatogram from a sequencing run of one the successful 
mutant clones. The arrow indicates confirmation of the base change (G->A) of the rs17855824 
polymorphism resulting in a Valine to Isoleucine amino acid change. The chromatogram shows 
evenly spaced peaks, with little baseline noise, indicating that our template and primers were of 
good quality. This demonstrated that the site directed mutagenesis was successful.   
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Figure 6.16. SDS-PAGE analysis of protein purification fractions. The GST and His tagged 
protein was purified by binding the His tag to a nickel affinity gel. The purified protein was eluted 
using 250 mM imidazole and the samples were analysed by running the samples on a 10 % w/v 
SDS-PAGE gel. (A) GST-DHFRL1 WT and GST-DHFRL1 C->G (rs61739170) polymorphism 
purification. Lane 1 –PAGE Ruler plus prestained protein marker protein ladder, Lane 2 – WT 
flow-through, Lane 3 – WT wash step, Lane 4 – WT elution 1, Lane 5 – WT elution 2, Lane 6 – 
blank, Lane 7 – BSA control, Lane 8 – C->G flow-through, Lane 9 – C->G wash step, Lane 10 – C-
>G elution 1, Lane 11 – C->G elution 2. (B) GST-DHFRL1 G->A (rs17855824) polymorphism 
purification. Lane 1 - Colorburst Electrophoresis Marker protein ladder, Lane 2 – G->A flow-
through, Lane 3 – G->A wash step, Lane 4 – G->A elution 1, Lane 5 – G-> elution 2. A clear but 
faint band of the protein of interest can be seen at 48 kDa in the elution steps with a stronger band 
seen at the lower 33 kDa size. 
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Figure 6.17. SDS-PAGE analysis of recombinant clones expressed in BL21-AI separated into 
soluble and insoluble fractions after 24 h. Protein was isolated from both induced and un-induced 
samples at 24 h and was separated into soluble and insoluble fractions after incubation at 37°C 
overnight. The soluble fraction was run on a 10 % w/v SDS-PAGE gel. Lane 1 – Colorburst 
Electrophoresis Marker protein ladder, Lane 2 – DHFRL1 WT un-induced sample at 24 h, Lane 3 – 
WT induced sample at 24 h, Lane 4 - DHFRL1 C->G (rs61739170) polymorphism un-induced 
sample at 24 h, Lane 5 - DHFRL1 C->G (rs61739170) polymorphism induced sample at 24 h, Lane 
6 - DHFRL1 G->A (rs17855824) polymorphism un-induced sample at 24 h and Lane 7 DHFRL1 
G->A (rs17855824) polymorphism induced sample at 24 h.. The protein of interest at ~ 48 kDa is 
only clearly induced in Lane 5, however, the 33 kDa is strongly induced in all of the induced 
samples after 24 h. 
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Figure 6.18. SDS-PAGE analysis of serial dilution of the rs61739170 (C->G) induced and un-
induced protein samples. Lane 1 – PAGE Ruler plus protein ladder, Lane 2 - 11.3 µg of C->G 
induced sample, Lane 3 - 11.3 µg of C->G un-induced sample, Lane 4 - 5.6 µg of C->G induced 
sample, Lane 5 - 5.6 µg of C->G un-induced sample, Lane 6 - 2.8 µg of C->G induced sample, 
Lane 7 - 2.8 µg of C->G un-induced sample, Lane 8 - 1.4 µg of C->G induced sample, Lane 9 - 1.4 
µg of C->G un-induced sample, Lane 10 - 0.7 µg of C->G induced sample, Lane 11 - 0.7 µg of C-
>G un-induced sample. 
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Figure 6.19. Optimisation of GST antibody by Western blot analysis on 2.8 µg of total protein. 
Lane 1 - C->G induced sample, 1:2,000 primary and 1:100,000 secondary antibody, Lane 2 - C->G 
un-induced sample, 1:2,000 primary and 1:100,000 secondary antibody Lane 3 - C->G induced 
sample, 1:3,000 primary and 1:100,000 secondary antibody, Lane 4 - C->G un-induced sample, 
1:3,000 primary and 1:100,000 secondary antibody, Lane 5 - C->G induced sample, 1:2,000 
primary and 1:150,000 secondary antibody, Lane 6 - C->G induced sample, 1:2,000 primary and 
1:150,000 secondary antibody, Lane 7 - C->G induced sample, 1:2,000 primary and 1:200,000 
secondary antibody, Lane 8 - C->G induced sample, 1:2,000 primary and 1:200,000 secondary 
antibody.  
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Figure 6.20. Western blot analysis of soluble protein samples expressing recombinant DHFR / 
DHFRL1 where induction was observed or not observed (by Coomassie staining), probed with 
the GST antibody. Lane 1 – PAGE Ruler plus protein ladder, Lane 2 – C->G induced, Lane 3 – C-
>G un-induced, Lane 4 – G->A induced, Lane 5 G->A un-induced, Lane 6 DHFRL1 GST 24 h 
induced, Lane 7 – DHFRL1 GST 24 h un-induced, Lane 8 – DHFR His 24 h induced, Lane 9 – 
DHFR His 24 h un-induced, Lane 10 – untransformed control 
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GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGGTTGGTAGCCTGAACT
GCATTGTCGCGGTATCTCAGAATATGGGCATTGGCAAAAACGGCGACTTACCGTGGCCGCCGTTGCGTAAT
GAATTTCGCTATTTTCAGCGTATGACGACTACTTCATCAGTTGAAGGGAAACAAAACCTCGTGATTATGGGC
AAGAAGACCTGGTTCTCTATTCCCGAGAAAAATCGTCCGTTAAAGGGCCGTATTAACCTTGTGTTATCTCGC
GAGCTGAAGGAGCCGCCGCAGGGGGCCCATTTCTTATCCCGTTCCCTGGATGACGCACTGAAGCTGACCGA
ACAACCTGAACTGGCTAATAAAGTCGACATGGTGTGGATTGTAGGCGGTAGCTCGGTTTATAAAGAAGCGA
TGAACCACCCCGGGCACTTAAAACTGTTCGTAACTCGCATCATGCAAGACTTTGAAAGTGATACGTTTTTCC
CCGAAATCGACCTGGAAAAGTATAAACTGCTGCCGGAATATCCGGGGGTTTTGTCCGATGTTCAGGAGGAA
AAAGGTATCAAATACAAGTTTGAGGTGTATGAAAAGAACGATTAAGACCCAGCTTTCTTGTACAAAGTGGT
GGGG 
 
 
Figure 6.21. DHFR sequence optimised for rare codon usage. The bases highlighted in yellow 
represent the G-clamp, the bases highlighted in pink represent the attB sites and the bases 
highlighted in green represent the TEV Cleavage site. 
 
Organism Escherichia 
CDS length 564 
Codon Adaptation Index (CAI) 
Escherichia  
 
CAI : 0.75 
Figure 6.22. The distribution of codon usage frequency along the length of the DHFR gene to 
be expressed in the target host organism. The Codon Adaptation Index (CAI) is a value that is 
correlated with the possibility of high protein expression level in a desired expression organism, 
where a CAI of 1.0 is considered ideal.  Our gene has a CAI value of 0.75. The lower the CAI 
number, the higher the chance that the gene of interest will be expressed poorly 
(www.genscript.com).  
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GC curve 
 
Average GC content: 47.90 
 
Figure 6.23. A curve showing the average GC content of the DHFR gene. The GC content of the 
DHFR gene is 47.90%. The ideal % range of GC content is between 30% and 70%. Any peaks 
outside of this range can adversely affect transcriptional and translational efficiency 
(www.genscript.com). 
 
Escherichia  
 
 
Figure 6.24. The percentage distribution of codons in computed codon quality groups. The 
value of 100 is set for the codon with the highest usage frequency for a given amino acid in the 
desired expression organism. Codons with values lower than 30 are likely to hamper the expression 
efficiency. The percentage of low frequency (<30%) codons based on our target host organism is 
6 % (www.genscript.com). 
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GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGTTTCTGCTGTTAAATT
GCATCGTTGCCGTCTCCCAGAACATGGGCATTGGTAAGAATGGTGACCTGCCACGCCCGCCGCTGCGCAAC
GAATTTCGTTACTTTCAACGGATGACAACTACCAGTTCTGTAGAAGGCAAACAGAACTTGGTGATCATGGG
CCGTAAAACCTGGTTCAGTATCCCGGAAAAGAACCGCCCGTTAAAAGATCGGATTAATCTGGTGTTGAGTC
GCGAACTTAAGGAACCACCGCAGGGGGCACACTTTCTGGCCCGTTCACTGGATGATGCTCTGAAATTAACA
GAACGTCCAGAATTAGCGAACAAAGTCGATATGATCTGGATTGTCGGTGGGAGTAGCGTCTACAAAGAGG
CGATGAATCATCTGGGCCACTTGAAGCTCTTTGTCACCCGGATCATGCAGGATTTTGAGTCAGATACATTCT
TTTCTGAAATCGATCTGGAAAAATATAAACTTCTGCCGGAATACCCGGGCGTTCTCAGTGACGTCCAGGAA
GGTAAGCACATCAAATATAAATTTGAGGTGTGCGAAAAAGACGATTAAGACCCAGCTTTCTTGTACAAAGT
GGTGGGG 
 
Figure 6.25. DHFRL1 sequence optimised for rare codon usage. The bases highlighted in yellow 
represent the G-clamp, the bases highlighted in pink represent the attB sites and the bases 
highlighted in green represent the TEV Cleavage site. 
 
Organism Escherichia 
CDS length 564 
Codon Adaptation Index (CAI) 
Escherichia  
 
CAI : 0.76 
Figure 6.26. The distribution of codon usage frequency along the length of the DHFRL1 gene 
to be expressed in the target host organism. The Codon Adaptation Index (CAI) is a value that is 
correlated with the possibility of high protein expression level in a desired expression organism, 
where a CAI of 1.0 is considered ideal.  Our gene has a CAI value of 0.76. The lower the CAI 
number, the higher the chance that the gene of interest will be expressed poorly 
(www.genscript.com). 
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GC curve 
 
Average GC content: 47.72 
 
Figure 6.27. A curve showing the average GC content of the DHFR gene. The GC content of the 
DHFR gene is 47.72%. The ideal % range of GC content is between 30% and 70%. Any peaks 
outside of this range can adversely affect transcriptional and translational efficiency 
(www.genscript.com). 
Escherichia  
 
 
Figure 6.28. The percentage distribution of codons in computed codon quality groups. The 
value of 100 is set for the codon with the highest usage frequency for a given amino acid in the 
desired expression organism. Codons with values lower than 30 are likely to hamper the expression 
efficiency. The percentage of low frequency (<30%) codons based on our target host organism is 
7 % (www.genscript.com). 
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Figure 6.29. Gel Electrophoresis of amplified DHFR and DHFRL1 PCR products. Lane 1 – 
100 bp DNA ladder, Lane 2 – DHFR PCR product, Lane 3 – DHFRL1 PCR product, Lane 4 – 
negative control. PCR products of the correct size (646 bp) were obtained indicating that the DNA 
samples have been amplified.  
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Figure 6.30. An example of an SDS-PAGE gel showing numerous proteins of the same size 
being expressed. Lane 1 – PAGE Ruler Plus protein ladder, Lane 2 – 1 h induced soluble, Lane 3 – 
1 h induced insoluble, Lane 4 – 1 h un-induced soluble,  Lane 5 – 1 h un-induced insoluble. 
Cultures were grown at 30°C for 1 h. Numerous bands can be seen at ~ 48 kDa, preventing us to 
identify our protein of interest. 
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Figure 6.31. Western blot analysis of rare codon optimised DHFR clone optimised for protein 
expression probed with the DHFR antibody. Lane 1 – PAGE Ruler Plus protein ladder, Lane 2 – 
blank, Lane 3 – 1 h induced soluble, Lane 4 – blank, Lane 5 – 1 h induced insoluble, Lane 6 – 
blank, Lane 7 – 1 h un-induced soluble, Lane 8 – blank, Lane 9 – 1 h un-induced insoluble, Lane 10 
– blank, Lane 11 – DHFR control (150 ng). Cultures were grown at 30°C for 1 h. A band of the 
correct size is present at ~ 48 kDa, indicating that our protein of interest is in the soluble fraction. 
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Figure 6.32. Western blot analysis of rare codon optimised DHFRL1 clone optimised for 
protein expression probed with the DHFR antibody. Lane 1 – PAGE Ruler Plus protein ladder, 
Lane 2 – blank, Lane 3 – 1 h induced soluble, Lane 4 – blank, Lane 5 – 1 h induced insoluble, Lane 
6 – blank, Lane 7 – 1 h un-induced soluble, Lane 8 – blank, Lane 9 – 1 h un-induced insoluble, 
Lane 10 – blank, Lane 11 – DHFR control (150 ng). Cultures were grown at 30°C for 1 h. A band 
of the correct size is present at ~ 48 kDa, indicating that our protein of interest is in the soluble 
fraction. 
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Figure 6.33. Western blot analysis of the GST tagged DHFRL1 rs61739170 polymorphism 
clone optimised for protein expression probed with the DHFR antibody. Lane 1 – PAGE Ruler 
Plus protein ladder, Lane 2 – blank, Lane 3 – 4 h induced soluble, Lane 4 – blank, Lane 5 – 4 h 
induced insoluble, Lane 6 – blank, Lane 7 – 4 h un-induced soluble, Lane 8 – blank, Lane 9 – 4 h 
un-induced insoluble, Lane 10 – blank, Lane 11 – DHFR control (150 ng). Cultures were grown at 
30°C for 4 h. A band of the correct size is present at ~ 48 kDa, indicating that our protein of interest 
is in the soluble fraction. 
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Figure 6.34. Western blot analysis of the GST tagged DHFRL1 rs17855824 polymorphism 
clone optimised for protein expression probed with the DHFR antibody. Lane 1 – PAGE Ruler 
Plus protein ladder, Lane 2 – blank, Lane 3 – 4 h induced soluble, Lane 4 – blank, Lane 5 – 4 h 
induced insoluble, Lane 6 – blank, Lane 7 – 4 h un-induced soluble, Lane 8 – blank, Lane 9 – 4 h 
un-induced insoluble, Lane 10 – blank, Lane 11 – DHFR control (150 ng). Cultures were grown at 
30°C for 4 h. A band of the correct size is present at ~ 48 kDa, indicating that our protein of interest 
is in the soluble fraction. 
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Figure 6.35. Western blot analysis of the DHFRL1 protein purification fractions probed with 
the DHFR antibody. Lane 1 – PAGE Ruler Plus protein ladder, Lane 2 – DHFRL1 optimised 
soluble fraction, Lane 3 - DHFRL1 optimised concentrated soluble fraction, Lane 4 – DHFRL1 
optimised clarified soluble fraction, Lane 5 - DHFRL1 optimised flow through, Lane 6 – DHFRL1 
optimised wash, Lane 7 – blank, Lane 8 – PAGE Ruler Plus protein ladder, Lane 9 – DHFRL1 
optimised concentrated elution 1, Lane 10 – DHFRL1 optimised concentrated elution 2, Lane 11 – 
DHFR control. Bands of the correct size (48 kDa) were seen in the elution fraction, indicating that 
the GST-tagged fusion protein is present.  
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Figure 6.36. Western blot analysis of the DHFRL1 rs61739170 polymorphism protein 
purification fractions probed with the DHFR antibody. Lane 1 – PAGE Ruler Plus protein 
ladder, Lane 2 – DHFRL1 rs61739170 optimised soluble fraction, Lane 3 - DHFRL1 rs61739170 
optimised concentrated soluble fraction, Lane 4 – DHFRL1 rs61739170 optimised clarified soluble 
fraction, Lane 5 - DHFRL1 rs61739170 optimised flow through, Lane 6 – DHFRL1 rs61739170 
optimised wash, Lane 7 – blank, Lane 8 – PAGE Ruler Plus protein ladder, Lane 9 – DHFRL1 
rs61739170 optimised concentrated elution 1, Lane 10 – DHFRL1 rs61739170 optimised 
concentrated elution 2, Lane 11 – DHFR control. Bands of the correct size (48 kDa) were seen in 
the elution fraction, indicating that the GST-tagged fusion protein is present.  
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Figure 6.37. Western blot analysis of the DHFRL1 rs17855824 polymorphism protein 
purification fractions probed with the DHFR antibody. Lane 1 – PAGE Ruler Plus protein 
ladder, Lane 2 – DHFRL1 rs17855824 optimised soluble fraction, Lane 3 - DHFRL1 rs17855824 
optimised concentrated soluble fraction, Lane 4 – DHFRL1 rs17855824 optimised clarified soluble 
fraction, Lane 5 - DHFRL1 rs17855824 optimised flow through, Lane 6 – DHFRL1 rs17855824 
optimised wash, Lane 7 – blank, Lane 8 – PAGE Ruler Plus protein ladder, Lane 9 – DHFRL1 
rs17855824 optimised concentrated elution 1, Lane 10 – DHFRL1 rs17855824 optimised 
concentrated elution 2, Lane 11 – DHFR control. Bands of the correct size (48 kDa) were seen in 
the elution fraction, indicating that the GST-tagged fusion protein is present.  
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Figure 6.38. SDS-PAGE gel of the DHFRL1 rs17855824 polymorphism purified eluted protein 
fractions. Lane 1 – PAGE Ruler Plus protein ladder, Lane 2 - DHFRL1 rs17855824 optimised 
concentrated elution 1, Lane 3 – DHFRL1 rs17855824 optimised concentrated elution 2, Lane 4 – 
DHFR control. A strong glutathione band, our band of interest (48 kDa) as well as other bands were 
observed on the Coomassie stained SDS-PAGE gel. 
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Figure 6.39. Quantification of purified protein samples via Image J using Western blot 
analysis of the DHFRL1 and DHFRL1 polymorphism protein purification fractions probed 
with the DHFR antibody. Recombinant proteins were quantified by normalising against a known 
concentration of DHFR control. (A) Lane 1 – PAGE Ruler Plus protein ladder, Lane 2 – DHFRL1 
optimised concentrated elution 1, Lane 3 – DHFRL1 optimised concentrated elution 2, Lane 4 – 
176 ng DHFR control. (B) Lane 1 - PAGE Ruler Plus protein ladder, Lane 2 – DHFRL1 
rs61739170 optimised concentrated elution 1, Lane 3 – DHFRL1 rs61739170 optimised 
concentrated elution 2, Lane 4 – 176 ng DHFR control, Lane 5 – DHFRL1 rs17855824 optimised 
concentrated elution 1, Lane 6 – DHFRL1 rs17855824 optimised concentrated elution 2.  
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ΔOD/Min = 0.0008 
 
Figure 6.40. DHFR Control without DHF (substrate). The graph above was obtained by plotting 
the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that there is 
no DHFR activity, indicated by the roughly straight horizontal line, i.e., when one of the key 
components of the reaction, DHF, which is the substrate for DHFR, is absent, the reaction cannot 
take place.   
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ΔOD/Min = 0.0002 
 
Figure 6.41. DHFR control without NADPH (cofactor). The graph above was obtained by 
plotting the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that 
there is no DHFR activity, indicated by the straight horizontal line, i.e., when one of the key 
components of the reaction, NADPH, which is a cofactor for DHFR, is absent, the reaction cannot 
take place.   
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ΔOD/Min = 0.0116 
 
Figure 6.42. DHFR Control. The graph above was obtained by plotting the 340 nm absorbance 
measurement vs. time in s. From the graph, it can be confirmed that once all the necessary 
components that are involved in the DHFR pathway are present, there is DHFR activity, indicated 
by the decrease in absorbance over time. The decrease in ΔOD over the 2.5 min was measured as 
ΔOD/min. An R2 value of over 0.98 indicated good linearity of the assay and precision of the 
standard preparation. 
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ΔOD/Min = 0.0012 
 
Figure 6.43. DHFR control plus methotrexate. The graph above was obtained by plotting the 340 
nm absorbance measurement vs. time in s. The graph above demonstrates that the change in 
NADPH absorbance that we observed in Figure 6.40 is due to reductase activity as the majority of 
activity is lost in the presence of the dihydrofolate reductase inhibitor, Methotrexate. From the 
graph, it can be confirmed that methotrexate (40 nM) is inhibiting DHFR activity and that the 
concentration of methotrexate used is high enough to inhibit all DHFR enzyme activity, indicated 
by the straight horizontal line. 
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ΔOD/Min = 0.004 
 
Figure 6.44. Purified DHFRL1 protein sample. The graph above was obtained by plotting the 
340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that our purified 
DHFRL1 protein is active, indicated by the decrease in absorbance over time. The decrease in ΔOD 
over the 5 min was measured as ΔOD/min. An R2 value of over 0.98 indicated good linearity of the 
assay and precision of the standard preparation. 
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ΔOD/Min = 0.0007 
 
Figure 6.45. Purified DHFRL1 protein sample plus Methotrexate. The graph above was 
obtained by plotting the 340 nm absorbance measurement vs. time in s. The graph above 
demonstrates that the change in NADPH absorbance that we observed in Figure 6.42 is due to 
reductase activity as the majority of activity is lost in the presence of the dihydrofolate reductase 
inhibitor, Methotrexate, which is also known to inhibit DHFRL1 (at a higher concentration) based 
on previous experiments carried out in the laboratory. From the graph, it can be confirmed that 
methotrexate (40 nM) is inhibiting DHFR activity and that the concentration of methotrexate used is 
high enough to inhibit all DHFR / DHFRL1 enzyme activity, indicated by the straight horizontal 
line. 
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ΔOD/Min = 0.0136 
 
Figure 6.46. Purified DHFRL1 rs61739170 protein sample. The graph above was obtained by 
plotting the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that 
our purified DHFRL1 rs61739170 protein is active, indicated by the decrease in absorbance over 
time. The decrease in ΔOD over the 5 min was measured as ΔOD/min. An R2 value of over 0.98 
indicated good linearity of the assay and precision of the standard preparation. 
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ΔOD/Min = 0.0007 
 
Figure 6.47. Purified DHFRL1 rs61739170 protein sample plus Methotrexate. The graph above 
was obtained by plotting the 340 nm absorbance measurement vs. time in s. The graph above 
demonstrates that the change in NADPH absorbance that we observed in Figure 6.44 is due to 
reductase activity as the majority of activity is lost in the presence of the dihydrofolate reductase 
inhibitor, Methotrexate, which is also known to inhibit DHFRL1 (at a higher concentration) based 
on previous experiments carried out in the laboratory. From the graph, it can be confirmed that 
methotrexate (40 nM) is inhibiting DHFR activity and that the concentration of methotrexate used is 
high enough to inhibit all DHFR / DHFRL1 enzyme activity, indicated by the straight horizontal 
line. 
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ΔOD/Min = 0.0066 
 
Figure 6.48. Purified DHFRL1 rs17855824 protein sample. The graph above was obtained by 
plotting the 340 nm absorbance measurement vs. time in s. From the graph, it can be confirmed that 
our purified DHFRL1 rs17855824 protein is active, indicated by the decrease in absorbance over 
time. The decrease in ΔOD over the 5 min was measured as ΔOD/min. An R2 value of over 0.98 
indicated good linearity of the assay and precision of the standard preparation. 
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ΔOD/Min = 0.001 
 
Figure 6.49. Purified DHFRL1 rs17855824 protein sample plus Methotrexate. The graph above 
was obtained by plotting the 340 nm absorbance measurement vs. time in s. The graph above 
demonstrates that the change in NADPH absorbance that we observed in Figure 6.46 is due to 
reductase activity as the majority of activity is lost in the presence of the dihydrofolate reductase 
inhibitor, Methotrexate, which is also known to inhibit DHFRL1 (at a higher concentration) based 
on previous experiments carried out in the laboratory. From the graph, it can be confirmed that 
methotrexate (40 nM) is inhibiting DHFR activity and that the concentration of methotrexate used is 
high enough to inhibit all DHFR / DHFRL1 enzyme activity, indicated by the straight horizontal 
line. 
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Figure 6.50. Specific activity of DHFRL1 and DHFRL1 polymorphisms. The bar chart above 
shows specific enzyme activity fold difference with respect to the DHFRL1 wild type. The 
DHFRL1 rs61739170 polymorphism has a 3.36 fold increase in comparison to the wild type and the 
DHFRL1 rs17855824 polymorphism has a 1.64 fold increase when compared to the DHFRL1.   
 
DHFRL1 Protein Sequence (187 aa):  
MFLLLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKT
WFSIPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWI
VGGSSVYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEG
KHIKYKFEVCEKDD 
 
Figure 6.51. DHFRL1 Protein Sequence. The four motifs that are required for DHFRL1 catalytic 
activity are highlighted in yellow. Specific residues important for folate, NADPH and/or MTX 
binding are underlined. Specific amino acids important for DHFR mRNA binding are shown in red. 
Image adapted from (McEntee et al., 2011). P shows the location of the DHFRL1 rs61739170 
polymorphism and the V shows the location of the DHFRL1 rs17855824 polymorphism. 
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Figure 6.52. Overview of Enzyme Kinetics. Vmax is the maximum velocity of the enzyme and 
measures the amount of time it takes for the substrate to bind all the enzymes active sites. Km 
(Michaelis-Menten constant) measures the substrate concentration required to reach half the Vmax. 
The Km characterises the enzyme’s affinity for the substrate. 
 
 
Table 6.1. Purified Protein Quantification via Image J Software. 
 
  Quantification 
for protein 
Quantification 
for control  
(176 ng) 
Fold 
Difference 
Amount of 
protein (ng) 
loaded (18 µL) 
Amount of 
protein 
(ng) in 1 
µL 
DHFRL1 7084 15691 2.21 79.84 4.4 
rs61739170 8689 24542 2.82 62.4 3.5 
rs17855824 13928 24542 1.76 100 5.55 
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7.1  Introduction   
The term proteomics generally refers to the large-scale analysis of proteins and it is 
often specifically used to refer to protein purification and mass spectrometry. Proteomic tools 
have been used to help us to extend our knowledge of disease mechanisms, by helping us to 
develop novel biomarkers for diagnosing disease, to identify new targets for therapeutics and to 
study altered protein expression (Hanash, 2003). DHFRL1, as mentioned in Section 1.12 is a 
newly discovered gene and therefore, studies on the gene have only recently begun in order to 
determine its functionality. Therefore, there is not much knowledge on how it may affect the 
expression of other genes or what effect it has on health and disease, though preliminary data 
and analysis obtained in Chapter 5 and Chapter 6, did show that polymorphisms within the 
coding region of DHFRL1 are associated with NTDs and that they can alter the activity of the 
gene. Therefore the aim of this chapter is to investigate the impact of up-regulating and down-
regulating DHFRL1 expression by proteomic analysis, namely LC-MS. This will hopefully 
allow us to have a better understanding of DHFRL1 and help us to determine whether DHFRL1 
expression levels could have an impact on human health and disease.  
 
7.1.1 Liquid Chromatography–Mass Spectrometry (LC-MS) 
LC-MS is a powerful analytical technique that combines HPLC with MS. As the name 
suggests, the first part of LC-MS is HPLC. Reversed phase liquid chromatography is used for 
most cases of LC-MS, whereby the chemicals in the samples are separated by forcing the 
sample through a column that is packed with a hydrophilic solvent by a liquid at high pressure 
in order to allow the sample to bind to the column. The different metabolites are then eluted off 
the column by a more hydrophobic solvent such as methanol. Once the chemicals have been 
separated physically by RP-LC, the metabolites enter the mass detector, where MS takes place. 
MS is a technique that measures the mass-to-charge ratio of charged particles. Therefore, once 
the metabolites enter the mass detector, the solvents are removed and the metabolites are 
ionised. Solvents need to be removed as ions only fly through a very good vacuum. The mass 
detector then scans the molecules it sees by mass and produces a full high-resolution spectrum, 
separating all ions that have different masses (Pitt, 2009).  
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7.1.2 Objectives  
In this chapter, the role of altered DHFRL1 expression was examined. Assessment of 
the impact of altered DHFRL1 expression levels were examined using the following 
methodology: 
 Confirmation of DHFRL1 down-regulation in DHFRL1 down-regulated cells by 
RT-qPCR and Western blot. 
 Generation of DHFRL1 over-expressing cell pools. 
 Confirmation of DHFRL1 over-expression by RT-qPCR and Western blot. 
 Examination of altered DHFRL1 expression by LC-MS. 
 Proteomic Analysis of LC-MS data by Progenesis 3.1 Software. 
 Pathway analysis of genes affected by altered DHFRL1 expression by the Ingenuity 
Pathway Analysis (IPA) software. 
 
7.2 Results  
7.2.1 Confirmation of DHFRL1 Down-Regulation   
A stably transfected cell pool model of targeted DHFRL1 knock-downs (shRNA B1 
and shRNA C1) in HEK 293 cells were previously generated in the lab by Dr. Stefano 
Minguzzi, using the MISSIONTM TRC lentiviral shRNA vectors. As severe down-regulation 
may have a detrimental effect on the cells, inducible IPTG vectors were used in order to allow a 
certain control on the down-regulation of DHFRL1. Five shRNA constructs (Table 7.1) were 
originally tested with various concentrations of IPTG and the two shRNAs that showed the best 
down-regulation were selected, i.e. shRNA B1 and shRNA C1 for the down-regulation 
experiments. First of all, in order to confirm down-regulation of these cell pools before 
proteomic analysis was carried out, the cells were cultured as described in Section 2.6.3 and 
Section 2.6.4 and RNA was extracted from the DHFRL1 down-regulated cells as well as those 
from parental HEK 293 cells and HEK 293 shRNA control cell lines as described in Section 
2.6.9 and run on an agarose gel in order to ensure that the RNA was intact (Figure 7.1). RNA 
was then quantified and cDNA was synthesised as described in Section 2.6.13 
 
Once cDNA was synthesised, down-regulation by the two shRNA constructs was 
confirmed at the mRNA level by RT-qPCR as described in Section 2.6.15 (Figure 7.2 and 
Figure 7.3). Figure 7.2 shows that when the DHFRL1 down-regulated samples are normalised 
to the non-targeting shRNA control or to the normal parental HEK 293 cells, they do not show 
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a lower expression of DHFRL1 as expected, i.e., the induced shRNA cells showed a similar 
level of DHFRL1 expression to the shRNA control and the parental HEK 293 cells. The un-
induced cells appeared to have a higher level of DHFRL1 expression compared to the other 
cells and therefore, it was decided to compare our IPTG induced samples to our un-induced 
samples (Figure 7.3). Figure 7.3 shows that when the IPTG induced DHFRL1 down-regulated 
samples are normalised to their un-induced controls, both DHFRL1 shRNA B1 and shRNA C1 
cells are down-regulated by 24 % and 57 % respectively.  
 
Mitochondrial protein fractions were also isolated from the cells as described in Section 
2.3.15 and Western blot analysis was carried in order to determine DHFRL1 down-regulation at 
the protein level. However Western blot failed to confirm DHFRL1 down-regulation at the 
protein level, with only very subtle changes seen between the induced and un-induced samples. 
Quantification of DHFRL1 at the protein level however, has been complicated by recent 
findings in the Parle-McDermott lab. Up until now, DHFR has been considered to be entirely 
cytoplasmic. However, the Parle-McDermott lab have recently shown that both DHFR and 
DHFRL1 fused GFP proteins localise to the mitochondria by Western blotting and confocal 
microscopy, though whether the GFP is driving the localisation is yet to be determined. 
Therefore, quantification of DHFRL1 at the protein level is complicated by the likely cross-
reactivity of the antibody between DHFRL1 and its paralogue DHFR as DHFRL1 and DHFR 
differ only in a total of 16 amino acids. An antibody that can specifically distinguish between 
the two proteins is difficult to produce.  
 
7.2.2 Generation of DHFRL1 Over-expressing Cell Lines 
DHFRL1 was cloned into the mammalian expression vector pcDNA3.2/V5-DEST via 
Gateway cloning as described in Section 2.2.8 and plasmid DNA was isolated and sequenced to 
ensure the correct sequence. Once the correct sequence was confirmed, HEK 293 cells were 
transfected with pcDNATM3.2-DHFRL1 and pcDNATM3.2/V5-DEST in a 6-well plate as 
described in Section 2.6.8 The DHFRL1 HEK 293 over-expressed cells attached and grew on 
the plates. However, the pcDNATM3.2/V5-DEST (empty vector) was not compatible with the 
cells and the cells died after transfection and were therefore abandoned. After 48 h of 
transfection, the medium was replaced with DMEM containing 500 µg/mL G418 antibiotic and 
the resistant cells were selected for two weeks. The stably transfected cells were then cultured 
for a further three passages before stocks were made / before they were used in experiments. 
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Un-transfected HEK 293 cells were also treated with DMEM with 500 µg/mL G418 antibiotic. 
All these cells died within ten days.  
 
7.2.3 Confirmation of DHFRL1 Up-Regulation 
The DHFRL1 over-expressed and the HEK 293 cells were selected for the proteomics 
experiment. First of all, in order to confirm up-regulation of the DHFRL1 over-expressing cell 
pool before proteomic analysis was carried out, cells were cultured as described in Section 
2.6.3.2 and Section 2.6.4.2 and RNA was extracted from the DHFRL1 over-expressed cells as 
well as those from the HEK 293 control cells as described in Section 2.6.9 and the RNA 
samples were run on an agarose gel (Figure 7.4). RNA was then quantified and cDNA was 
synthesised as described in Section 2.6.13. 
 
Once cDNA was synthesised, DHFRL1 over-expression was confirmed at the mRNA 
level by RT-qPCR as described in Section 2.6.15 (Figure 7.5). Figure 7.5 shows that when the 
DHFRL1 over-expressed samples are normalised to the HEK 293 control cells, the DHFRL1 
over-expressed cells are up-regulated by ~ 5.5 fold. 
 
Mitochondrial protein fractions were also isolated from the DHFRL1 over-expressed 
HEK 293 and HEK 293 cells as described in Section 2.3.15 and Western blot analysis was 
carried out as described in Section 2.3.11 to determine the over-expression of DHFRL1 at the 
protein level. Western blots were probed with both the DHFR and PDH antibody in order to 1) 
confirm the presence of DHFRL1 in the mitochondria and 2) so that the DHFRL1 expression 
levels could be determined. Western blots were analysed using the Image J software, which 
confirmed a 1.5 fold increase in DHFRL1 expression at the protein level (Figure 7.6). However, 
as mentioned earlier (Section 7.2.1), the localisation of DHFR to the mitochondria complicates 
our protein quantification. Therefore, quantification of DHFRL1 via Image J may not be highly 
accurate, and the utilisation of Image J at the level of a 1.5 fold difference may not be 
considered truly quantitative.  
 
7.2.4 Sample Preparation of Cell Lysates for Proteomic analysis  
Once DHFRL1 down-regulation and over-expression was confirmed by RT-qPCR / 
Western blot, the DHFRL1 HEK 293 knock-down cells, the DHFRL1 HEK 293 over-expressed 
cells and the control cells were set up for proteomic analysis. For the DHFRL1 HEK 293 down-
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regulated cells, six flasks were seeded with 2 x 106 cells. Half of the flasks were induced with 
500 µM IPTG. All six flasks were incubated at 37ºC with CO₂ 5 %, humidified air 95 % and 
the cells were left to grow for five days. For the DHFRL1 HEK 293 over-expressed and the 
HEK 293 control cells, three flasks were seeded with 2 x 106 cells. The flasks were incubated at 
37ºC with CO₂ 5 %, humidified air 95 % and the cells were left to grow for five days. After five 
days, cell pellets were collected from all flasks, were washed with 1 mL of sterile PBS five 
times and were then stored at -80°C until they were processed for proteomic analysis.  
 
7.2.5 Proteomic analysis on the effects of altering DHFRL1 expression  
DHFRL1 down-regulated and over-expressed whole cell lysates were analysed by LC-
MS by our collaborators Dr. Paula Meleady and Mr. Michael Henry from the National Institute 
for Cellular Biology (NICB) in DCU. Label-free LC-MS analysis was carried out using the 
Progenesis label-free LC-MS software version 3.1 (NonLinear Dynamics), as recommended by 
the manufacturer (see www.nonlinear.com for more information on alignment, normalisation, 
calculation of peptide abundance, etc.). The raw data was processed by the software in two 
main steps. First of all, each sample run was subjected to an alignment, which involves aligning 
the data based on the LC retention time of each of the samples, compensating for any between-
run variation. The sample run that yielded the most features (i.e. peptide ions) was used as the 
reference run, to which retention of all of the other runs were aligned and peak intensities were 
normalised. The Progenesis peptide quantification algorithm calculates the abundance of the 
peptides as the sum of the peak area within its isotope boundaries. Each abundance value is 
then transformed to a normalised abundance value by applying a global scaling factor. Protein 
abundance was calculated as the sum of the abundances of all the peptide ions, which have 
been identified as coming from the same protein. A number of criteria were used to filter the 
data before exporting the MS/MS output files to MASCOT (www.matrixscience.com) for 
protein identification; peptide features with ANOVA < 0.05 between experimental groups, 
mass peaks with charge states from +1 to +3, and greater than three isotopes per peptide. All 
MS/MS spectra were exported from the Progenesis software as a MASCOT generic file (mgf) 
and used for peptide identification with MASCOT (version 2.2) searched against the 
UniProKB-SwissProt database (taxonomy, Mammals). The search parameters that were used 
are as follows: peptide mass tolerance set to 20 ppm, MS/MS mass tolerance set at 0.5 Da; up 
to two missed cleavages allowed, carbamidomethylation set as a fixed modification and 
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methionine oxidation set as a variable modification. Only peptides with ion scores of 30 and 
above were considered and re-imported back into the Progenesis LC-MS software for further 
analysis. An ANOVA p-value of ≤ 0.05 between experimental groups was used as a cut-off.  
  
7.2.5.1 Proteomic Analysis on the DHFRL1 Down-Regulation Experiment 
LC-MS data analysed with the Progenesis 3.1 software reported a large number of 
proteins to be up-regulated and down-regulated when DHFRL1 was knocked-down. A total of 
310 significant proteins were found for the DHFRL1 shRNA B1 construct (Table 7.2) and 24 
significant proteins for the DHFRL1 shRNA C1 construct (Table 7.3). Network analysis was 
performed on these proteins using the IPA software (Qiagen). Network analysis identified 
many of these proteins to be associated with cell morphology and embryonic development 
(Figure 7.7). Protein analysis of the data set also identified a large number of the proteins to be 
associated with nucleic acid metabolism, cell cycle, DNA replication, recombination and repair 
and cell death and survival (Table 7.4) as well as with glycolysis, oxidative phosphorylation, 
electron transport, ATP synthesis and the malate / aspartate shuttle (Table 7.9). 
 
However, when the data sets from the two different DHFRL1 shRNA constructs were 
combined and analysed together, the majority of the proteins proved not to be consistent 
between the two sample sets. This could be due to the fact that the two shRNA constructs 
down-regulated DHFRL1 to different extents or it may be due to off-target effects of shRNA 
regulation. When both data sets were analysed together, a total of six proteins were found to be 
present in both sets. However, of these, only three were found to have similar effects. The three 
proteins that were seen to alter protein expression in the same direction in both sets of samples 
were Serpin H1 (SERPINH1), which was found to be up-regulated, heterogeneous nuclear 
ribonucleoprotein K (HNRNPK), which was found to be down-regulated and dihydrolipoyl 
dehydrogenase, mitochondria (DLD), which was also found to be down-regulated (Table 7.5). 
Although the XRCC5, the RPL8 and the RPL18a proteins were also found in both samples sets 
they had opposing effects and were therefore removed.  
 
7.2.5.2 Proteomic Analysis on the DHFRL1 Over-Expression Experiment 
LC-MS data analysed with the Progenesis 3.1 software reported a large number of 
proteins to be up-regulated and down-regulated when DHFRL1 was over-expressed. The 
software reported a total of 79 significant proteins of which 48 were up-regulated (Table 7.6) 
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and 31 were down-regulated (Table 7.7). Protein function and network analysis was performed 
on these proteins using the IPA software. The proteins which appeared in our dataset were 
analysed and matched for different networks in which they are involved / associated in. The 
two networks generated, which included the most number of our proteins are shown in Figure 
7.8 and Figure 7.9. The figures show that DHFRL1 over-expression has an impact on proteins 
that are associated with cell proliferation, cancer, cell cycle, cell death and survival and DNA 
replication, recombination and repair. Using the IPA software, proteins which are of interest to 
us, i.e. those involved in DNA replication, recombination and repair, nucleic acid metabolism, 
cell death and survival, cell proliferation and cell cycle (Table 7.8) as well as those involved in 
glycolysis, oxidative phosphorylation, electron transport, ATP synthesis and the malate / 
aspartate shuttle (Table 7.9) could also be identified. 
 
7.2.5.3 Proteomic Analysis on the DHFRL1 Down-Regulation and Over-Expression 
Experiment Analysed Together  
When the proteomics data from both the DHFRL1 down-regulation and over-
expression experiments were examined together, numerous proteins were found to be present in 
both data sets, with some proteins having opposing effects, while others having similar effects 
(Table 7.10). 
 
7.3 Discussion 
The aim of this chapter was to analyse the effects of down-regulating and up-regulating 
DHFRL1 in HEK 293 cells in order to determine the effects that altered DHFRL1 expression 
has on the expression of other proteins by proteomic analysis, namely LC-MS, a method which 
is being highly used in order to produce databases in order to help us broaden and strengthen 
our knowledge of disease mechanisms. This is of great interest to us as, as mentioned earlier 
(Section 1.12), DHFRL1 is a newly discovered member of the DHFR gene family and plays an 
important role in de novo thymidylate biosynthesis in the mitochondria along with SHMT2 and 
TYMS (Anderson et al., 2011). This would suggest that like DHFR, DHFRL1 plays an 
important role in DNA replication and repair / cell proliferation. In order for us to examine 
what effects DHFRL1 has on other proteins, we first had to generate stable cell pools, in which, 
DHFRL1 was either down-regulated or over-expressed. These were generated by transfection 
of HEK 293 cells (Section 2.6.8). 
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In the case of our DHFRL1 down-regulated stable cell pools, inducible shRNA constructs 
were used in order to down-regulate DHFRL1. As DHFRL1 is involved in DNA replication 
and repair, knocking-out the gene completely may have had severe consequences on cell 
stability. Therefore, it was important not to completely knock-out DHFRL1 but to down-
regulate it enough so that substantial proteomic changes could be observed. When we examined 
the down-regulation of the DHFRL1 down-regulated cells, we found that when we normalised 
the DHFRL1 down-regulated samples to the non-targeting shRNA control or to the normal 
HEK 293 cells, the down-regulated cells were not down-regulated, with the non-targeting 
shRNA control and the normal HEK 293 cells having similar / lower DHFRL1 gene expression 
in comparison to both induced and un-induced DHFRL1 down-regulated shRNA constructs 
(Figure 7.2). However, when we normalised the IPTG induced down-regulated samples against 
the un-induced samples, down-regulation was observed with the DHFRL1 shRNA B1 samples 
down-regulated by 24 % and the shRNA C1 samples down-regulated by 57 % (Figure 7.3). 
Although this model is not 100 % ideal, as the insertion of the shRNA constructs appears to 
increase the level of DHFRL1 expression, as the shRNA constructs have been transfected into 
both induced and un-induced samples, we are still examining like with like with the only 
difference being the induction of the DHFRL1 shRNA so that it is being down-regulated in one 
of the samples and not the other. Therefore, we can say that an artificial DHFRL1 down-
regulated system has been generated that will allow us to gather preliminary data on the 
relevance of DHFRL1 expression level for global cellular functions. The increase in DHFRL1 
expression levels observed by the insertion of the shRNA constructs may be due to the fact that 
DHFRL1 is involved in DNA synthesis as mentioned above. The insertion of the shRNA 
construct may cause damage to the cells and therefore, DHFRL1 expression may be up-
regulated as a result in order to repair the damage caused; an interesting observation in itself. In 
order to try and avoid the change in DHFRL1 expression levels after transfection, one could try 
transfecting the HEK 293 cells with shRNA constructs in different vectors so as to try and 
obtain one that does not alter the expression levels of DHFRL1 or switch to a completely 
different system such as the newly developed genome editing approaches as discussed in 
Section 5.3. This will have to be carried out in the future in order to confirm our findings that 
we obtained from our preliminary analysis. 
 
For our DHFRL1 over-expressed experiments, the over-expressed cells (pcDNATM3.2-
DHFRL1) were normalised against HEK 293 cells. Although it would have been more ideal to 
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normalise our DHFRL1 over-expressed cells with HEK 293 cells in which the empty vector 
(pcDNATM3.2/V5-DEST) had been transfected into, as mentioned in Section 7.2.2, the empty 
vector was not compatible with the cells and therefore, HEK 293 cells were used as our control. 
The reason why the HEK 293 cells transfected with the empty vector died may be due to the 
fact that the empty vector contains the ccdB gene, a toxic gene for bacteria (See Appendix AJ 
for vector map), whose product may also inhibit mammalian cell division (Hiraga et al., 1985). 
In order to try and resolve this problem and in order to confirm our preliminary findings, it may 
be possible to remove the ccdB gene from the vector using a restriction enzyme approach in the 
future. 
 
Despite the fact that altered DHFRL1 expression could not be determined conclusively at 
the protein level by Western blot analysis as mentioned in Section7.2.1 and 7.2.3, due to the 
possible confounding localisation of DHFR to the mitochondria, as altered DHFRL1 was 
confirmed by RT-qPCR, whole cell lysates were collected and analysed by LC-MS. 
 
Once LC-MS data was obtained, analysis was first carried out with the Progenesis 3.1 
software for both DHFRL1 down-regulated and over-expressed protein samples, in order to 
apply cut offs of p<0.05. After careful analysis of the data, we found numerous genes that are 
involved in DNA replication, recombination and repair, cell death and survival, cell cycle, cell 
proliferation and nucleic acid metabolism to be affected when DHFRL1 was both down-
regulated (Table 7.4) and over-expressed (Table 7.8). This is not surprising as, as mentioned 
earlier, DHFRL1 plays a major role in DNA replication and repair (Anderson et al., 2011). 
Although many of the effects that we observed were minor, i.e. only a small up-regulation or 
down-regulation, many of the proteins that were observed function in the same pathway or in 
pathways which are interconnected with each other, and therefore the combinational effect of 
these proteins together may have a large impact on pathway function. These minor effects 
however, may also be random effects and therefore, further analysis is required in order to 
confirm these findings. A number of proteins, however, such as PARP1, an enzyme involved in 
the base excision repair pathway (Beck et al., 2014), TRIM28, a gene known as the master 
regulator of the genome, involved in mediating gene silencing, cell growth, apoptosis and DNA 
repair (Iyengar and Farnham, 2011), MYH9, an ATP hydrolysis site, DHX9, an enzyme that 
catalyses the ATP-dependent unwinding of double-stranded DNA and RNA (Chakraborty and 
Grosse, 2011) and XRCC6, an enzyme involved in non-homologous end joining required for 
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the repair of double-strand breaks (Ramsden and Gellert, 1998) were seen to be highly down-
regulated by over-expressing DHFRL1 and proteins such as SEPT9, HINT1 and SOD1, all of 
which play a role in cell growth or cell death were found to be up-regulated when DHFRL1 
was down-regulated. A protein of great interest to us, serine hydroxymethyltransferase, 
mitochondrial (SHMT2), a protein that is involved in the de novo thymidylate biosynthesis 
pathway, as well as the inter-conversion of serine and glycine (Anderson et al., 2011) was also 
found to be up-regulated when DHFRL1 was over-expressed and down-regulated when 
DHFRL1 was knocked-down (Table 7.10). It was also interesting to see that the majority of 
proteins that were affected by both knocking-down and over-expressing DHFRL1 were 
involved in DNA replication, recombination and repair, cell death and survival and the cell 
cycle (Table 7.10).  
 
As we know, DHFR plays a critical role in the folate mediated one-carbon metabolism 
pathway, playing an important role in the regulation of the amount of THF in the cell (Figure 
1.1). THF is essential DNA synthesis, which in turn is required for cell proliferation and cell 
growth. As folate / THF are required by rapidly dividing cells, such as cancer cells, DHFR has 
been targeted in the treatment of cancer (Schweitzer et al., 1990). As DHFRLI also regulates 
the level of THF in the cell, inhibiting / targeting DHFRL1 with drugs, such as a modified 
version of methotrexate could prevent / reduce the growth and proliferation of cells that are 
characteristic of cancer. As DHFRL1 takes the place of DHFR in the mitochondria, it is likely 
that DHFRL1 plays a similar role to DHFR. Therefore, it is not surprising that a large number 
of genes that were altered after over-expressing DHFRL1 are involved in cancer (Figure 7.9), 
with many of the genes involved in apoptosis in cancer being down-regulated (DHX9, GPI, 
MYH9, PARP1, XRCC6, YWHAG, PRKDC and RPA1) and those involved in proliferation / 
nucleotide biosynthesis / replication being up-regulated (ALDOA1, FUBP1, GNB2L1, BSG, 
IMPDH2, CSNK2B, PDIA3, SHMT2, and GAPDH) in response to DHFRL1 over-expression. 
 
From the findings obtained in the previous chapters, DHFRL1 is also thought to be 
associated with NTDs, birth defects that occur during the first trimester of pregnancy. 
Therefore, it was highly interesting to observe numerous proteins that are involved in cell 
morphology and embryonic development to be altered when DHFRL1 was down-regulated 
(Figure 7.7). Examination of the proteins that were identified to be involved in embryonic 
development showed that the majority of the genes that were shown to be down-regulated are 
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involved in growth regulation (STIM1, PA2G4, ITGB1, PHB, SMG1, SLC3A2, BSG and 
EIF2S1). These proteins, in association with those identified to be involved in DNA replication, 
recombination and repair, nucleic acid metabolism and cell death and survival further support 
our theory that DHFRL1 is associated with NTDs. 
 
It has recently been shown that folate metabolism also plays a role in NADPH production 
in both the cytoplasm and the mitochondria (Fan et al., 2014). Tracing of one-carbon 
metabolism by LC-MS and carbon-labelling by Fan et al., (2014) showed that the oxidation of 
methylene-THF to 10-formyl-THF is coupled with the reduction of NADP+ to NADPH. In 
order to confirm this finding, they also knocked-down the MTHFD genes, in both the 
cytoplasm and the mitochondria. Depletion of either of the MTHFD isoenzymes resulted in the 
reduction of cellular NADPH / NADP+, indicating a clear connection between the folate 
pathway and the NADPH pathways. Therefore, it was interesting to see that a number of 
proteins that are involved in glycolysis, oxidative phosphorylation, electron transport, ATP 
synthesis and the malate / aspartate shuttle to be affected by both down-regulating and over-
expressing DHFRL1 (Table 7.9).  
 
Finally, when the two DHFRL1 down-regulated shRNA construct data was analysed 
together, as mentioned in Section 7.2.5.1, we found three genes, SERPINH1, HNRNPK and 
DLD to be affected (Table 7.5). Of these three genes, the DLD gene, which was observed to be 
down-regulated, is of interest to us. As mentioned in Section 1.3, one of the functions of folate 
metabolism in the mitochondria is the inter-conversion of glycine and serine (Fox and Stover, 
2008) (Figure 1.1). The DLD gene plays a major role in the glycine cleavage system (GCS) 
(Kikuchi et al., 2008) as well as a vital role in energy metabolism (Vaubel et al., 2011). The 
GCS is a reversible system where a series of enzymes are triggered in response to high glycine 
concentrations in order to catalyse the degradation of glycine (Kikuchi et al., 2008) and is made 
up of three enzymes, the P protein (GLDC), the T protein (AMT) and the L protein (DLD) as 
well as a carrier protein, the H protein. These proteins form an enzyme complex that is loosely 
associated with the mitochondrial inner membrane in order to break down glycine (Kikuchi et 
al., 2008). Glycine catabolism involves the oxidative cleavage of glycine to CO2, NH4
+ and 
CH2, a methylene group, which is accepted by THF to form 5,10-methylene-THF, which is a 
one-carbon donor for the biosynthesis of a number of cellular molecules such as purines, 
thymidylate and methionine (Figure 1.1). Therefore, it was highly interesting that when 
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DHFRL1 was down-regulated, that the DLD protein was also down-regulated. As DHFRL1 is 
known to be involved in thymidylate biosynthesis in the mitochondria, down-regulation of this 
gene would suggest a reduction at the rate in which thymidylate is synthesised, and therefore, a 
reduced need for one-carbon donors. As a result, there would be less of a requirement for 
glycine degradation to occur and therefore, it is not surprising that the DLD protein is down-
regulated when DHFRL1 is down-regulated. However, how the mechanism of loss of 
expression of DLD in response to DHFRL1 down-regulation is open to be elucidated. Why 
DHFRL1 down-regulation is affecting the other two proteins is not clear but the HNRNPK 
protein is thought to play a role in cell cycle progression by acting as a transcriptional co-
activator of p53 for cell-cycle arrest (Lee et al., 2012) as well as apoptosis in the mitochondria 
(Marchenko et al., 2000). In response to apoptosis inducing stress signals, p53 is known to 
translocate to the mitochondria, where it interacts with anti- and pro-apoptotic Bcl-two family 
members to either inhibit or activate apoptosis, resulting in the permeabilisation of the outer 
mitochondrial membrane, releasing enzymes such as caspases that are involved in apoptosis 
(Marchenko et al., 2000). These findings are of interest as it has recently been shown that the 
enzymes involved in nuclear thymidylate biosynthesis form a complex and translocate to the 
nuclear lamina in a cell cycle dependent manner, with translocation occurring during the S and 
G2/M phase of the cell cycle (Anderson et al., 2012b), with the complex also shown to be 
enriched at sites of DNA replication and repair, suggesting that thymidylate biosynthesis occurs 
at the sites of DNA synthesis (Anderson et al., 2012b).  
 
 All in all, these preliminary novel findings above indicate that down-regulating or over-
expressing DHFRL1 can have an impact on altering the expression levels of a numerous 
number of proteins, particularly those that are involved in DNA replication, recombination and 
repair, cancer and embryonic development as well as those involved in NADPH pathways. We 
have pointed out the connection between DHFRL1 and many of the proteins identified, 
however, the relationship between DHFRL1 and the other proteins remain to be elucidated. 
Although these novel findings will provide a basis for future work that will be carried out in 
this area, there were a number of issues associated with both generating the DHFRL1 down-
regulated and over-expressed stable cell pools and confirming the altered DHFRL1 expression 
levels. Therefore, the data obtained from our proteomic analysis will have to repeated / carried 
out and confirmed by another system. 
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Figure 7.1. Gel Electrophoresis of extracted RNA on a 1 % agarose gel. Lane 1 – HEK 293 
DHFRL1 knock down un-induced RNA, Lane 2 – HEK 293 DHFRL1 knock down induced 
RNA, Lane 3 – HEK 293 shRNA 1-1 control RNA, Lane 4 – HEK 293 RNA. A 1 µg 
concentration of RNA was loaded into each well. Sharp, clear 28S and 18S rRNA bands can be 
seen for all samples, with the 28S rRNA band having a stronger intensity that the 18S rRNA 
band, indicating that the RNA is intact. 
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Figure 7.2. Validation of DHFRL1 down-regulation by RT-qPCR in HEK 293 stable 
transfected cell pools. DHFRL1 gene expression was analysed in two cell pools that differed 
by shRNA used to target DHFRL1, i.e., shRNA B1 and shRNA C1, at the mRNA level by RT-
qPCR to confirm its down-regulation. Relative DHFRL1 gene expression was analysed and 
normalised to cDNA generated from the control cell line, i.e., cells transfected with a non-
specific shRNA control. Relative expression was calculated using GUS as the reference gene. 
The bar chat shows that when the DHFRL1 down-regulated samples are normalised to the non-
targeting shRNA control or to the normal parental HEK 293 cells, they do not show a lower 
expression of DHFRL1 as expected, i.e., the induced shRNA cells showed a similar level of 
expression of DHFRL1 compared to the shRNA control line and the parental HEK 293 line. UI 
= un-induced, I = induced   
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Figure 7.3. Validation of DHFRL1 down-regulation by RT-qPCR in HEK 293 stable 
transfected cell pools. DHFRL1 gene expression was analysed in two cell pools that differed 
by shRNA used to target DHFRL1, i.e., shRNA B1 and shRNA C1, at the mRNA level by RT-
qPCR to confirm its down-regulation. Relative DHFRL1 gene expression regulation was 
analysed and confirmed by comparing the un-induced (UI) (negative control) samples to the 
induced (I) samples, normalising to the un-induced DHFRL1 samples. The B1 cells show a 
down-regulation of 24 % and the C1 cells show a down-regulation of 57 %. Relative expression 
was calculated using GUS as the reference gene. UI = un-induced, I = induced   
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Figure 7.4. Gel Electrophoresis of extracted RNA on a 1 % agarose gel. Lane 1 – HEK 293 
DHFRL1 over-expressed RNA, Lane 2 – HEK 293 control RNA. A 1 µg concentration of RNA 
was loaded into each well. Sharp, clear 28S and 18S rRNA bands can be seen for all samples, 
with the 28S rRNA band having a stronger intensity that the 18S rRNA band, indicating that 
the RNA is intact. 
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Figure 7.5. Validation of DHFRL1 over-expression by RT-qPCR in HEK 293 stable 
transfected cell pools. DHFRL1 gene expression was analysed in both HEK 293 and DHFRL1 
over-expressed cells at the mRNA level by RT-qPCR to confirm up-regulation. The over-
expressed cells show an up-regulation of ~ 5.5 fold. Relative expression was normalised against 
the HEK 293 cells. GUS was used as the reference gene. 
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Figure 7.6. Validation of DHFRL1 over-expression by Western blot analysis for 
proteomic analysis. (A) Western blot of HEK 293 and DHFRL1 over-expressed 
mitochondrial protein fractions probed with the DHFR antibody. Lane 1 – protein ladder, 
Lane 2 – HEK 293 mitochondrial protein sample, Lane 3 – DHFRL1 over-expressed HEK 293 
mitochondrial sample. All samples were equally loaded. Bands of the correct size (21 kDa) 
were seen for all of the mitochondrial protein samples. (B) Western blot of HEK 293 and 
DHFRL1 over-expressed mitochondrial protein fractions probed with the PDH antibody. 
Lane 1 – protein ladder, Lane 2 – HEK 293 mitochondrial protein sample, Lane 3 – DHFRL1 
over-expressed HEK 293 mitochondrial sample. All samples were equally loaded. Bands of the 
correct size (43 kDa) were seen for all of the mitochondrial protein samples. 
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Figure 7.7. Network Analysis of Proteins Classified as Involved in Cell Morphology and 
Embryonic Development Drawn Using the IPA Software. Molecules in green represent 
those that are down-regulated, molecules in light green represent those that are slightly down-
regulated, molecules in red represent those that are up-regulated, molecules in light red 
represent those that are slightly up-regulated and molecules in white represent those that were 
added from the Ingenuity Knowledge Base. Molecules represented by vertical diamonds are 
enzymes, those represented by horizontal diamonds are peptidases, those represented by 
horizontal ovals are transcription regulators, those represented by triangles are phosphatases, 
those represented by inverted triangles are kinases, those represented by squares are cytokines, 
those represented by rectangles are G-protein coupled receptors, those represented by 
trapezoids are transporters, those represented by double circles are complexes and those 
represented by circles are other. 
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Figure 7.8. Network Analysis of Proteins Classified as Involved in Cellular Growth and 
Proliferation, Cancer and Cell Cycle Drawn Using the IPA Software. Molecules in green 
represent those that are down-regulated, molecules in light green represent those that are 
slightly down-regulated, molecules in light red represent those that are slightly up-regulated 
and molecules in white represent those that were added from the Ingenuity Knowledge Base. 
Molecules represented by vertical diamonds are enzymes, those represented by horizontal 
diamonds are peptidases, those represented by horizontal ovals are transcription regulators, 
those represented by triangles are kinases, those that are represented by squares are cytokines, 
those that are represented by double circles are complexes and those represented by circles are 
other. 
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Figure 7.9. Network Analysis of Proteins Classified as Involved in Cell Death and 
Survival, Cell Cycle and DNA Replication, Recombination and Repair Using the IPA 
Software. Molecules in green represent those that are down-regulated, molecules in light green 
represent those that are slightly down-regulated, molecules in light red represent those that are 
slightly up-regulated and molecules in white represent those that were added from the Ingenuity 
Knowledge Base. Molecules represented by vertical diamonds are enzymes, those represented 
by horizontal ovals are transcription regulators, those represented by vertical ovals are 
transmembrane receptors, those that are represented by squares are cytokines and those 
represented by circles are other. 
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7.1 shRNA constructs used to generate DHFRL1 down-regulated cell pools. 
 
 shRNA Construct Vector Mismatches with DHFR 
1 Control pLKO.1  
A 28 base shRNA
† 1 x Lac O 7 
B 19 base shRNA
† 3 x Lac O 7 
C TRCN0000160428 3 x Lac O 4 
D TRCN0000161799
‡ 3 x Lac O 0 
E TRCN00001658880 1 x Lac O 5 
 
† custom shRNA 
‡selected to target both DHFR and DHFRL1 
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Table 7.2. List of proteins which altered in expression following down-regulation of DHFRL1 by shRNA B1 construct in HEK 
293 cells. 
 
Accession  Gene Description Peptides Score 
Anova 
(p) Fold 
P07311 ACYP1 Acylphosphatase-1 1 2.99 9.28E-05 1.41 
P50454 SERPINH1 Serpin H1 1 3.64 0.00015 1.26 
O95793 STAU1 Double-stranded RNA-binding Staufen homolog 1 1 3.61 0.00018 1.7 
Q96HE7 ERO1L ERO1-like protein alpha 1 4.77 0.00043 1.28 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 3 13.17 0.00066 1.47 
P28072 PSMB6 Proteasome subunit beta type-6 2 5.59 0.00078 1.38 
P37802 TAGLN2 Transgelin-2 2 6.66 0.00104 1.53 
P20962 PTMS Parathymosin 1 3.53 0.00135 1.7 
O43852 CALU Calumenin 1 2.62 0.00147 1.54 
P14854 COX6B1 Cytochrome c oxidase subunit 6B1 1 2.73 0.00168 1.2 
P16949 STMN1 Stathmin 4 10.87 0.00175 1.62 
P15531 NME1 Nucleoside diphosphate kinase A 1 2.65 0.00236 1.48 
P30085 CMPK1 UMP-CMP kinase 1 3.14 0.00243 1.39 
P60174 TPI1 Triosephosphate isomerase 9 33.03 0.00244 1.37 
P60174 PIWIL1  Piwi-like protein 1 1 2.28 0.00354 1.6 
P06744 GPI Glucose-6-phosphate isomerase 1 4.02 0.00372 1.29 
Q9NZL9 MAT2B Methionine adenosyltransferase 2 subunit beta 1 5.19 0.00381 1.3 
P67936 TPM4 Tropomyosin alpha-4 chain 2 9.9 0.00388 1.52 
P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 5 16.91 0.00451 1.23 
Q13263 TRIM28 Transcription intermediary factor 1 beta 6 18.44 0.00499 1.4 
P13489 RNH1 Ribonuclease inhibitor 2 7.74 0.00523 1.24 
Q13347 EIF3I Eukaryotic translation initiation factor 1 3.15 0.00536 1.28 
Q96CT7 CCDC124 Coiled-coil domain-containing protein 124 2 5.65 0.00607 1.46 
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O94760 DDAH1 N[G], N[G]-dimethylarginine dimethylaminohydrolase 1 1 3.38 0.00611 1.2 
P49327 FASN Fatty acid synthase 2 6.53 0.00668 1.27 
Q99615 DNAJC7 Dna J homolog subfamily C member 7 2 5.8 0.00673 1.38 
P49915 GMPS GMP synthase (glutamine hydrolysing) 1 2.75 0.00695 1.52 
P15259 PGAM2 Phosphoglycerate mutase 2 1 3.83 0.00727 1.48 
O00299 CLIC1 Chloride intracellular channel protein 1 1 3.01 0.00786 1.42 
P55327 TPD52 Tumour protein D52 1 3.93 0.00867 1.61 
Q6ZQQ2 SPATA31D1 Spermatogenesis associated protein 1 2.22 0.0089 1.24 
O75390 CS Citrate synthase, mitochondrial 1 2.56 0.00909 1.41 
O43399 TPD52L2 Tumour protein D54 1 2.57 0.00933 1.45 
P40925 MDH1 Malate dehydrogenase, cytoplasmic 2 8.22 0.00955 1.18 
P54577 YARS Tyrosine-tRNA ligase, cytoplasmic 1 2.32 0.01 1.68 
O00170 AIP AH receptor-interacting protein  1 2.52 0.01 1.51 
O60664 PLIN3 Perilipin-3 1 3.38 0.01 1.36 
O43423 ANP32C Acidic leucine-rich nuclear phosphoprotein 32 family member C 2 6.55 0.01 1.36 
P43487 RANBP1  Ran-specific GTPase-activating protein  1 2.77 0.01 1.42 
P08107 HSPA1A Heat shock 70kDa protein 1A/1B 3(2) 9.73 0.01 1.27 
P14625 HSP90B1 Endoplasmin 2 5.4 0.01 1.26 
Q9H444 CHMP4B Charged multivescular body protein 4b 2 5.95 0.01 1.65 
P15374 UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3 1 2.27 0.01 1.69 
Q99832 CCT7 T-complex protein 1 subunit eta 1 3.94 0.01 1.2 
P52907 CAPZA1 F-actin capping protein subunit alpha-1 1 3.9 0.01 1.41 
P61956 SUMO2 Small ubiquitin-related modifier 2 2 6.31 0.01 1.25 
O00154 ACOT7 Cytosolic acyl coenzyme A thioester hydrolase 1 5.26 0.01 1.39 
P07900 HSP90AA1 Heat shock protein HSP90-alpha 5(4) 14.17 0.01 1.23 
P29692 EEF1D Elongation factor 1-delta 1 4.32 0.01 1.3 
O75533 SF3B1 Splicing factor 3B subunit 1 1 2.99 0.01 1.52 
Q02790 FKBP4 Peptidyl-prolyl cis-trans isomerase 2(1) 7.25 0.01 1.3 
P32119 PRDX2 Peroxiredoxin 2 1 2.62 0.02 1.53 
P13667 PDIA4 Protein disulfide isomerase A4 3 10.17 0.02 1.24 
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P62826 RANBP1  GTP-binding nuclear protein Ran 1 2.71 0.02 1.21 
P14314 PRKCSH Glucosidase 2 subunit beta 2 10.75 0.02 1.46 
Q04637 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 1 2.73 0.02 1.66 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit 2 7.05 0.02 1.75 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 1 4.14 0.02 1.48 
P08238 HSP90AB1 Heat shock protein HSP90-beta 2(1) 6.48 0.02 1.28 
P07737 PFN1 Profilin 1 2 5.57 0.02 1.33 
P00390 GSR Glutathione reductase, mitochondrial 1 2.87 0.02 1.18 
P08240 SRPR Signal recognition particle receptor subunit alpha 1 2.43 0.02 1.56 
P48643 CCT5 T-complex protein 1 subunit epsilon 1 3.48 0.02 1.33 
P14618 PKM Pyruvate kinase isozymes M1/M2 1 4.73 0.02 1.96 
P60709 ACTB Actin, cytoplasmic 1 1 2.28 0.02 1.87 
P29401 TKT Transketolase 1 2.4 0.02 1.52 
C9JLR9 C11orf95 Uncharacterised protein C11 or95 1 1.92 0.02 1.76 
P34932 HSPA4 Heat shock 70kDA protein 4 3(2) 12.66 0.02 1.28 
P04075 ALDOA Fructose bisphosphate aldolase A 1 2.81 0.02 1.49 
Q9UNN5 FAF1 FAS-associated factor 1 1 2.63 0.02 1.46 
Q15773 MLF2 Myeloid leukeia factor 2 1 2.37 0.02 1.48 
P48147 PREP Prolyl endopeptidase  1 3.19 0.02 1.18 
P07108 DBI Acyl-CoA binding protein 1 2.74 0.02 9.69 
P18206 VCL Vinculin 2 5.98 0.02 1.26 
Q8TAW3 ZNF671 Zinc finger protein 671 1 2.33 0.02 3.16 
P23396 RPS3 40S ribosomal protein S3 1 2.41 0.03 1.55 
P49321 NASP Nuclear autoantigenic sperm protein 1 3.24 0.03 1.33 
Q9NTK5 OLA1 Obg-like ATPase 1 1 3.47 0.03 1.18 
P50990 CCT8 T-complex protein 1 subunit theta 2 6.45 0.03 1.27 
Q8WUW1 BRK1 Protein BRICK1 1 2.53 0.03 1.72 
P06733 ENO1 Alpha-enolase 2 8.03 0.03 1.77 
P31150 GDI1 Rab GDP dissocation inhibitor alpha 1 3.11 0.03 1.41 
O15355 PPM1G Protein phosphatase 1G 1 3.33 0.03 1.47 
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P35244 RPA3 Replcation protein A 14kDa subunit 1 2.47 0.03 1.25 
Q16181 SEPT7 Septin 7 1 3.27 0.03 1.38 
Q9H773 DCTPP1 dCTP pyrophosphatase 1 1 2.96 0.03 1.44 
Q15019 SEPT2 Septin 2 1 4.84 0.03 1.25 
P61626 LYZ Lysozyme C 1 2.07 0.03 3267.94 
Q15293 RCN1 Reticulocalbin-1 2 8.52 0.03 1.44 
P11021 HSPA5 78kDa glucose-regulated protein 2(1) 7.97 0.03 1.13 
P62633 CNBP Cellular nucleic acid binding protein 1 2.48 0.03 1.45 
O43665 RGS10 Regulator of G-protein signaling 10 1 2.34 0.03 1.73 
Q9UHR4 BAIAP2L1 
Brain-specific angiogenesis inhibitoyr 1-associated protein 2-like 
protein 1 1 2.05 0.03 1.17 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit B 1 4.15 0.03 1.25 
P42167 TMPO Lamina-assocaited polypeptide 2, isoforms beta/gamma 2 6.74 0.03 1.38 
P04406 GAPDH Glyceraldehyde 3-phosphate dehydrogenase 2 8.72 0.03 1.29 
P21333 FLNA Filamin-A 1 2.53 0.03 1.25 
P11586 MTHFD1 C-1-tetrahydrofolate sybthase, cytoplasmic 1 2.21 0.03 1.2 
Q9UHD8 SEPT9 Septin-9 2(1) 5.36 0.03 2.24 
P47756 CAPZB F-actin-capping protein subunit beta 1 3.76 0.03 1.54 
P55036 PSMD4 26S proteasome non ATPase regulatory subunit 4 1 2.35 0.03 1.38 
Q9UGP8 SEC63 Translocation protein SEC63 homolog 1 2.47 0.04 1.77 
P07237 P4HB Protein disulfide isomerase 1 5.06 0.04 1.4 
P49773 HINT1 Histidine triad nuceotide-binding protein 1 1 3.04 0.04 2.86 
Q01105 SET Protein SET 1 2.94 0.04 1.82 
P62258 YWHAE 14-3-3 protein epsilon 1 2.4 0.04 1.13 
P40227 CCT6A T-complex protein 1 subunit zeta 1 4.48 0.04 2.02 
P61758 VBP1 Prefoldin subunit 3 1 2.82 0.04 1.46 
O43242 PSMD3 26S proteasome non ATPase regulatory subunit 3 1 2.8 0.04 1.92 
P33176 KIF5B Kinesin-1 heavy chain 1 3.8 0.04 1.57 
P36873 PPP1CC Serine/threonine protein phosphatase PP1-gamma catalytic subunit 1 2.64 0.04 1.15 
Q15056 EIF4H Eukaryotic translation initiation factor 4H 1 2.21 0.04 1.83 
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Q13162 PRDX4 Peroxiredoxin-4 1 6.29 0.04 1.41 
P35579 MYH9 Myosin-9 2 6.99 0.04 1.43 
O43765 SGTA Small glutamine-rich tetratricopeptide repeat-containing protein alpha 1 2.39 0.04 1.25 
P13796 LCP1 Plastin-2 2 6.15 0.04 1.28 
P00441 SOD1 Superoxide dismutase [Cu-Zn] 1 3.76 0.04 4.08 
Q8WW12 PCNP PEST proteolytic signal-containing nuclear protein 1 2.79 0.04 1.44 
P61981 YWHAG 14-3-3 protein gamma 1 3.01 0.04 4.4 
P35080 PFN2 Profilin-2 1 4.17 0.04 1.18 
P35580 MYH10 Myosin-10 1 4.48 0.05 1.51 
Q32MZ4 LRRFIP1 Leucine-rich repeat flightless-interacting protein 1 1 2.58 0.05 1.43 
P68104 EEF1A1 Elongation factor 1-alpha 1 1 4.04 0.05 1.17 
O95747 OXSR1 Serine/threonine protein kinase OSR1 1 3.88 0.05 1.22 
O75874 IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic 1 2.45 0.05 1.41 
Q9H2E6 SEMA6A Semaphorin-6A 1 2.25 0.05 1.79 
Q99471 PFDN5 Prefoldin subunit 5 1 5.72 0.05 1.59 
Q9UKY7 CDV3 Protein CDV3 homolog 1 4.69 0.05 1.38 
P27816 MAP4 Microtubule-associaed protein 4 1 2.58 0.05 1.39 
P00338 LDHA L-lactate dehydrogenase A chain 1 3.91 0.05 1.19 
Q13247 SRSF6 Serine/arginine rich splicing factor 6 2 5.38 6.45E-05 1.29 
Q96PK6 RBM14 RNA-binding protein 14 3 7.35 0.000138 1.3 
Q15007 WTAP Pre-mRNA splicing regulator WTAP 1 3.19 0.00022 1.57 
Q9Y5B9 SUPT16H FACT complex subunit SPT16 5 14.67 0.000243 1.51 
O00148 DDX39A ATP-dependent RNA helicase DDX39A 6 17 0.000248 1.44 
Q8NBN7 RDH13 Retinol dehydrogenase 13 2 6.66 0.00115 1.34 
P31040 SDHA Succinate dehydrogenase flavopotein subunit, mitochondrial 2 6.52 0.00144 1.22 
Q14108 SCARB2 Lysosome membrane protein 2 1 2.59 0.00145 1.39 
Q9BPW8 NIPSNAP1 Protein NipSnap homolg 1 1 3.31 0.0015 1.17 
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 5 13.74 0.00159 1.51 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1 5 13.13 0.00163 1.37 
Q9NVX2 NLE1 Notchless protein homolg 1 1 2.47 0.00167 1.3 
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P00505 GOT2 Aspartate aminotransferase, mitochondrial 1 2.33 0.00174 1.38 
Q9P032 NDUFAF4 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex assembly 
factor 4 1 3.04 0.00208 1.33 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 2 4.82 0.00226 1.31 
P51659 HSD17B4 Peroxisoma multifunctional enzyme type 2 3 10.41 0.00275 1.29 
Q96TA2 YME1L1 ATP-dependent zinc metalloprotease 2 6.88 0.00309 1.24 
Q15393 SF3B3 Splicing factor 3B subunit 3 3 10.89 0.00326 1.24 
O75439 PMPCB Mitochondrial-processing peptidase subunit beta 2 6.3 0.00327 1.25 
Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1 6(5) 17.26 0.00355 1.38 
P30049 ATP5D ATP synthase subunit delta, mitochondrial 1 4.18 0.00374 1.19 
P23246 SFPQ Splicing factor, proline and glutamine rich 6 22.63 0.00376 1.61 
P21796 VDAC1 Voltage-dependent anion selective channel protein 1 3 12.56 0.00437 1.21 
P09622 DLD Dihydrolipoyl dehydrogenase, mitochondrial 1 3.79 0.00441 1.4 
O75955 FLOT1 Flotillin 1 3.63 0.00453 1.26 
P05388 RPLP0 60S acidic ribosomal protein P0 1 3.18 0.00457 1.32 
Q15233 NONO Non-POU domain-containing octamer-binding protein 10(9) 28.47 0.00506 1.56 
O00571 DDX3X ATP-dependent RNA helicase DDX3X 4 13.23 0.00507 1.29 
P18085 ARF4 ADP-ribosyltaion factor 4 1 2.75 0.0052 1.47 
O95218 ZRANB2 Zinc finger Ran-binding domain-containing protein 2 1 4.89 0.00539 3.96 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M 4 8.51 0.00541 1.44 
P22087 FBL rRNA 2'-O-methyltransferase fibrillarin 1 4.67 0.00582 1.44 
P05556 ITGB1 Integrin beta-1 1 3.8 0.00601 1.39 
P50213 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 1 2.81 0.00615 1.11 
P20700 LMNB1 Lamin-B1 3 8.2 0.00622 1.54 
Q06265 EXOSC9 Exosome complex component RRP45 1 2.33 0.0064 1.44 
P61353 RPL27 60S ribosomal protein L27 1 2.78 0.00643 1.44 
Q9UMS4 PRPF19 Pre-mRNA processing factor 19 1 2.72 0.00701 1.29 
P55072 VCP Transitional endoplasmic reticulum ATPase 1 3.34 0.00756 1.17 
P35637 FUS RNA-binding protein FUS 3 11.02 0.00768 1.44 
O43707 ACTN4 Alpha-actinin-4 2 5.96 0.0078 1.27 
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Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 1 1.92 0.00825 1.31 
P14866 HNRNPL Heterogeneous nuclear ribonucleoprotein L 3 12.14 0.00828 1.3 
P42704 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 2 5.86 0.00832 1.19 
Q15029 EFTUD2 116 kDa US small nuclear ribonucleoprotein component 1 2.32 0.00839 1.29 
Q92547 TOPBP1 DNA topoisomerase 2-binding protein 1 1 2.05 0.0085 1.78 
Q00610 CLTC Clathrin heavy chain 1 1 4.83 0.00885 1.29 
Q9Y2W1 THRAP3 Thyroid hormone receptor-associated protein 3 3 8.31 0.00901 1.76 
Q9BZE1 MRPL37 39S ribosomal protein L37, mitochondrial 1 5.07 0.00911 1.26 
Q92552 MPPS27 28S ribosomal protein S27, mitochondrial 1 6.4 0.00927 1.18 
Q12788 TBL3 Transducin beta-like protein 3 1 2.68 0.00937 1.44 
Q96JB5 CDK5RAP3 CDK5 regulatory subunit-associated protein 3 1 3.61 0.00937 1.24 
P46776 RPL27A 60S ribosomal protein L27a 2 4.97 0.00962 1.44 
O94905 ERLIN2 Erlin-2 1 3.5 0.00969 1.28 
Q9P2R7 SUCLA2 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 1 3.34 0.00974 1.16 
P53582 METAP1 Methionine aminopeptidase 1 1 2.98 0.01 1.33 
Q92945 KHSRP Far upstream element-binding protein 2 3 14.16 0.01 1.55 
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 1 4.54 0.01 1.29 
P28838 LAP3 Cytosol aminopeptidase 1 3.5 0.01 1.07 
Q13423 NNT NAP(P) transhydrogenase, mitochondrial 2 7.29 0.01 1.2 
Q9UKV3 ACIN1 Apoptotic chromatin condensation inducer in the nucleus 1 3.52 0.01 1.38 
Q15075 EEA1 Early endosome antigen 1 1 2.77 0.01 1.37 
Q9UQ80 PA2G4 Proliferation-associated protein 2G4 1 2.21 0.01 1.76 
Q12931 TRAP1 Heat shock protein 75kDa, mitochondrial 1 3.49 0.01 1.23 
Q9HB40 SCPEP1 Retinoid-inducible serine carboxypeptidase 1 3.28 0.01 1.15 
Q9BVP2 GNL3 Guanine nucleotide-binding protein-like3 1 5.52 0.01 1.54 
Q9UHB6 LIMA1 LIM domain and actin-binding protein 1 1 3.26 0.01 1.48 
O00410 IPO5 Importin 5 1 2.44 0.01 1.18 
P19338 NCL Nucleolin 4 9.87 0.01 1.46 
Q16891 IMMT Mitochondrial inner membrane protein 3 10.28 0.01 1.24 
Q9Y277 VDAC3 Voltage-dependent anion selective channel protein 3 3 9.42 0.01 1.3 
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Q5JTZ9 AARS2 Alanine-tRNA ligase, mitochondrial 1 2.99 0.01 1.2 
P62917 RPL8 60S ribosomal protein L8 1 4.38 0.01 1.85 
P20340 RAB6A Ras-related protein Rab-6A 4 11.16 0.01 1.3 
P25705 ATP5A1 ATP synthase subunit alpha, mitochondrial 2 6.72 0.01 1.31 
Q9UQ35 SRRM2 Serine/arginine repetitve matrix protein 2 5 15.03 0.01 1.48 
Q8NFH5 NUP35 Nucleoporin 1 2.51 0.01 1.26 
P08195 SLC3A2 4F2 cll-surface antigen heavy chain 1 4.06 0.01 1.41 
P28331 NDUFS1 NADH-ubiquinone oxidoreductase 75kDa subunit, mitochondrial 2 6.44 0.01 1.29 
P06239 LCK Tyrosine-protein kinase Lck 1 3.23 0.01 1.34 
P08134 RHOC Rho-related GTP-binding protein RhoC 1 1.98 0.01 1.35 
O00422 SAP18 Histone deacetylase complex subunit SAP18 1 2.59 0.01 1.39 
Q7Z4V5 HDGFRP2 Hepatoma derived growth factor-related protein 2 1 4.34 0.01 1.33 
Q96DI7 SNRNP40 U5 small nuclear ribonucleoprotein 40kDa protein 1 3.19 0.02 1.4 
Q2TAY7 SMU1 WD40 repeat-containing protein SMU1 1 2.25 0.02 1.6 
Q96I24 FUBP3 Far upstream element-binding protein 3 1 4.06 0.02 1.32 
Q02543 RPL18A 60S ribosomal protein L18a 1 2.98 0.02 1.53 
Q08211 DHX9 ATP-dependent RNA helicase A 3 10.61 0.02 1.32 
P35613 BSG Basigin 1 5.63 0.02 1.23 
P20339 RAB5A Ras-related protein Rab-5A 1 2.83 0.02 1.51 
Q9UJS0 SLC25A13 Calcium-bindin mitochondrial carrier protein Aralar 2 1 3.82 0.02 1.2 
P38432 COIL Coilin 1 3.22 0.02 2.36 
P31937 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 1 3.34 0.02 1.11 
Q12905 ILF2 Interleukin enhancer-binding factor 2 2 6.61 0.02 1.26 
P00367 GLUD1 Glutamate dehydrogenase 1, mitochondrial 1 2.74 0.02 1.17 
Q96A26 FAM162A Protein FAM162A 1 2.96 0.02 1.4 
Q9H1E3 NUCKS1 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 6.28 0.02 2.3 
Q8N1F7 NUP93 Nuclear pore complex protein Nup93 1 2.2 0.02 1.21 
O95831 AIFM1 Apoptosis-inducing factor 1, mitochondrial 1 2.16 0.02 1.29 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 2 5.14 0.02 1.36 
P27144 AK$ Adenylate kinase isoenzyme 4, mitochondrial 1 2.57 0.02 1.29 
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P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha 1 3.44 0.02 1.28 
O95167 NDUFA3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 1 1.94 0.02 1.35 
P35250 RFC2 Replication factor C subunit 2 1 4.12 0.02 1.17 
P51149 RAB7A Ras-related protein Rab-7a 1 2.98 0.02 1.66 
Q96SB4 SRPK1 SRSF protein kinase 1 1 4.11 0.02 1.57 
Q8IYB3 SRRM1 Serine/arginine repetitve matrix protein 1 1 2.89 0.02 1.36 
P0C0S5 H2AFZ Histone H2A.Z 1 2.12 0.02 1.29 
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 2 5.06 0.02 1.19 
O43684 BUB3 Mitotic checkpoint protein 1 3.91 0.02 1.16 
Q14978 NOLC1 Nucleolar and coiled-body phosphprotein 1 2 5.78 0.02 1.55 
O96008 TOMM40 Mitochondrial import receptor subunit TOM40 homolog 1 4.65 0.02 1.29 
Q07955 SRSF1 Serine/arginine-rich splicing factor 1 3 8.2 0.02 1.39 
Q9Y3B9 RRP15 RRP15-like protein 1 3.16 0.02 1.14 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta 2-like 1 3 12.49 0.02 1.31 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 2 1 2.35 0.03 1.47 
P31930 UQCR1 Cytochrome b-c1 complex subunit 1, mitochondrial 1 3.13 0.03 1.21 
Q15717 ELAVL1 ELAV-like protein 1 1 3.51 0.03 1.18 
P35232 PHB Prohibition 1 2.28 0.03 1.3 
P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial 2 7.1 0.03 1.27 
P03247 E1B E1B protein, small T-antigen 1 2.35 0.03 1.22 
Q9NUJ1 ABHD10 Mycophenoic acid acyl-glucuronide esterase, mitochondrial 1 4.86 0.03 1.25 
P84095 RHOG Rho-related GTP-binding protein RhoG 1 4.15 0.03 1.87 
P34897 SHMT2 Serine hydroxymethyltransferase, mitochondrial 1 3.12 0.03 1.24 
O75643 SNRNP200 U5 small nuclear ribonucleoprotein 200kDa helicase 1 3.11 0.03 1.31 
Q9Y305 ACOT9 Acyl-coenzyme A thioesterase 9, mitochondrial 1 2.97 0.03 1.44 
Q01130 SRSF2 Serine/arginine-rich splicing factor 2 2 4.18 0.03 1.65 
Q92667 AKAP1 A-kinase anchor protein 1, mitochondrial 1 3.87 0.03 1.44 
O00541 PES1 Pescadillo homlog 1 2.97 0.03 1.52 
Q9H3P7 ACBD3 Golgi resident protein GCP60 1 4.44 0.03 1.19 
P49755 TMED10 Transmembrane emp24 domain-containing protein 10 1 3.8 0.03 1.44 
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P13804 ETFA Electron transfer flavoprotein subunit alpha, mitochondrial 1 2.74 0.03 1.09 
Q8TEV9 SMCR8 
Smith-Magenis syndrome chromosomal region candidate gene 8 
protein 1 2.29 0.03 1.59 
P04181 OAT Ornithine aminotransferase, mitochondrial 2 7.55 0.03 1.23 
Q15800 MSMO1 Methylsterol monooxygenase 1 1 5.02 0.03 1.3 
P02545 LMNA Prelamin-A/C 1 3.18 0.03 1.31 
P46777 RPL5 60S ribosomal protein L5 1 2.8 0.03 1.28 
Q07065 CKAP4 Cytoskeleton-associated protein 4 1 2.31 0.03 1.28 
P31942 HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 1 3.87 0.03 1.13 
Q969V3 NCLN Nicalin 1 4.18 0.03 1.27 
P40926 MDH2 Malate dehydrogenase, mitochondrial 1 3.42 0.03 1.34 
P48735 IDH2 Isocitrate dehydrogenase [NADP], mitochondrial 1 3.06 0.03 1.27 
P13010 XRCC5 X-ray repair cross-complementing protein 5 1 2.27 0.04 1.19 
Q96Q15 SMG1 Serine/threonine protein kinase SMG1 1 2.35 0.04 1.22 
Q9H074 PAIP1 Polyadenylate-binding protein interacting protein 1 1 2.96 0.04 1.27 
Q9UKL3 CASP8AP2 CASP8-assocaited protein 2 1 2.21 0.04 1.69 
P11498 PC Pyruvate carboxylase, mitochondrial 1 3.52 0.04 1.28 
P38117 ETFB Electron transfer flavoprotein subunit beta, mitochondrial 1 2.08 0.04 1.38 
P38646 HSPA9 Stress-70 protein, mitochondrial 1 3.44 0.04 1.13 
Q9NS69 TOMM22 Mitochondrial import receptor subunit TOM22 homolog 1 4.14 0.04 1.33 
P11177 PDHB Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 1 2.72 0.04 1.35 
P46778 RPL21 60S ribosomal protein L21 1 2.76 0.04 1.24 
Q14444 CAPRIN1 Caprein-1 1 3.2 0.04 1.45 
Q8WXF0 SRSF12 Serine/arginine-rich splicing factor 12 1 3.06 0.04 1.18 
P53992 SEC24C Protein transport protein Sec24C 1 3.37 0.04 1.33 
P09543 CNP 2',3'-cyclic-nucleotide 3'-phosphodiesterase 1 3.7 0.04 1.43 
A6NIZ1 
 
Ras-related protein Rap-1-b like protein 1 2.37 0.04 1.39 
P54709 ATP1B3 Sodium/potassium-transporting ATPase subunit beta 1 3.01 0.04 1.23 
P39023 RPL3 60S ribosomal protein L3 2 5.37 0.04 1.34 
P63092 GNAS Guanine nucleotide-binding protein G(s) subunit alpha isoforms short 1 3.68 0.04 1.23 
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Q99714 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 1 2.01 0.04 1.81 
P62316 SNRPD2 Small nuclear ribonucleoprotein Sm D2 1 3.15 0.04 1.31 
P52815 MRPL12 39S ribosomal protein L12, mitochondrial 1 2.86 0.04 1.09 
P11233 RALA Ras-related protein Ral-A 1 4.1 0.04 1.32 
P62306 SNRPF Small nuclear ribonucleoprotein F 1 3.36 0.04 1.53 
P51649 ALDH5A1 Succinate semialdehyde dehydrogenase, mitochondrial 1 3.04 0.04 1.24 
Q9NYF0 DACT1 Dapper homolog 1 1 2.53 0.05 1.64 
Q8WWY3 PRPF31 U4/U6 small nuclear ribonucleoprotein Prp31 1 4.39 0.05 1.16 
Q13586 STIM1 Stromal interation molecule 1 1 2.73 0.05 1.6 
P08670 VIM Vimentin 1 2.25 0.05 1.35 
Q15365 PCBP1 Poly(rC)-binding protein 1 1 2.49 0.05 1.55 
O75964 ATP5L ATP synthase subunit g, mitochondrial 1 2.56 0.05 1.93 
Q8WZ42 TTN Titin 1 1.99 0.05 1.71 
P32969 RPL9 60S ribosomal protein L9 1 3.13 0.05 1.32 
P37268 FDFT1 Squalene synthase 1 3.27 0.05 1.23 
Q9NYF8 BCLAF1 Bcl-2-associated transcription factor 1 1 3.34 0.05 1.3 
Q13535 ATR Serine/threonine protein kinase ATR 1 2.34 0.05 1.17 
Q6PIW4 FIGNL1 Fidgetin-like protein 1 1 2.74 0.05 1.15 
P05198 EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 1 3.35 0.05 1.21 
P62910 RPL32 60S ribosomal protein L32 1 5.12 0.05 1.31 
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Table 7.3. List of proteins which altered in expression following down-regulation of DHFRL1 by shRNA C1 construct in HEK 
293 cells. 
 
Accession  Gene Description Peptides Score Anova (p) Fold 
Q02878 RPL6 60S ribosomal protein L6 2 4.08 0.00634 1.42 
Q02543 RPL18A 60S ribosomal protein L18a 1 2.05 0.00848 1.54 
P30050 RPL12 60S ribosomal protein L12 1 2.1 0.00969 1.23 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 1 2.26 0.01 1.09 
Q6ZU65 UBN2 Ubinuclein-2 1 2.3 0.02 1.89 
P15880 RPS2 40S ribosomal protein S2 1 2.03 0.02 1.32 
P62917 RPL8 60S ribosomal protein L8 1 3.14 0.03 1.35 
P13010 XRCC5 X-ray repair cross-complementing protein 5 1 3.17 0.04 1.39 
P50454 SERPINH1 Serpin H1 1 3.21 0.04 1.24 
Q14684 RRP1B Ribosomal RNA processing protein 1 homolog B 1 2.73 0.04 1.29 
P09622 DLD Dihydrolipoyl dehydrogenase, mitochondrial 1 3.19 0.04 1.36 
Q14684 RRP1B Ribosomal RNA processing protein 1 homolog B 1 2.73 0.04 1.29 
Q9UQE7 SMC3 Structural maintenance of chromosomes protein 3 1 2.98 0.0076 1.22 
Q7Z3U7 MON2 Protein MON2 homolog 1 2.57 0.01 1.9 
Q9UBQ0 VPS29 Vacuolar protein sorting-associated protein 29 1 3.77 0.01 1.63 
P49756 RBM25 RNA-binding protein 25 1 3.09 0.02 1.15 
P62993 GRB2 Growth factor receptor-bound protein 2 1 2.71 0.02 1.07 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 1 3.39 0.02 1.4 
O95782 AP2A1 AP-2 complex subunit alpha-1 1 2.61 0.03 1.33 
Q99536 VAT1 Synaptic vesicle membrane protein VAT-a homolog 1 3.95 0.03 1.17 
Q9NYF3 FAM53C Protein FAM53C 1 2.22 0.04 1.44 
Q9BQE3 TUBA1C Tubulin alpha-1C chain 1 2.03 0.04 1.17 
Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 1 3.11 0.04 1.23 
Q8NI60 ADCK3 Chaperone activity of bc1 complex-like, mitochondrial 1 2.41 0.05 1.16 
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Table 7.4. List of proteins that are involved in DNA Replication, Recombination and Repair, Nucleic Acid Metabolism, Cell 
Death and Survival and Cell Cycle that are affected by down-regulating DHFRL1 in HEK 293 cells. 
 
Gene Function  Fold 
TXNDC5 Cell Death & Survival 1.47 
TAGLN2 Cell Death & Survival 1.53 
STMN1 DNA Replication, Recombination & Repair / Cell Death & Survival 1.62 
NME1 DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival 1.48 
GPI Cell Death & Survival 1.29 
UBA1 Cell Death & Survival 1.23 
TRIM28 DNA Replication, Recombination & Repair / Cell Death & Survival 1.4 
FASN Cell Cycle / Cell Death & Survival 1.27 
TPD52 Cell Death & Survival 1.61 
YARS Cell Death & Survival 1.68 
PLIN3 DNA Replication, Recombination & Repair 1.36 
HSP90B1 Cell Death & Survival 1.26 
SUMO2 DNA Replication, Recombination & Repair 1.25 
HSP90AA1 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival 1.23 
SF3B1 DNA Replication, Recombination & Repair 1.52 
PRDX2 Cell Death & Survival 1.53 
EIF4G1 Cell Death & Survival 1.66 
PRKDC DNA Replication, Recombination & Repair / Cell Death & Survival 1.75 
PPIA DNA Replication, Recombination & Repair 1.48 
HSP90AB1 Cell Death & Survival 1.28 
PFN1 Cell Cycle 1.33 
GSR Cell Death & Survival 1.18 
CCT5 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair 1.33 
PKM Nucleic Acid Metabolism / Cell Death & Survival 1.96 
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HSPA4 Cell Death & Survival 1.28 
ALDOA Cell Death & Survival 1.49 
FAF1 Cell Death & Survival 1.46 
OLA1 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair 1.18 
CCT8 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair 1.27 
ENO1 Cell Death & Survival 1.77 
PPM1G Cell Death & Survival 1.47 
RPA3 DNA Replication, Recombination & Repair 1.25 
SEPT7 Cell Cycle 1.38 
LYZ Cell Death & Survival 3267.94 
HSPA5 Cell Death & Survival 1.13 
GAPDH Cell Death & Survival 1.29 
FLNA Cell Cycle / Cell Death & Survival 1.25 
SEPT9 Cell Cycle 2.24 
P4HB Cell Death & Survival 1.4 
HINT1 Cell Death & Survival 2.86 
SET Cell Death & Survival 1.82 
YWHAE Cell Death & Survival 1.13 
PPP1CC Cell Cycle / Cell Death & Survival 1.15 
MYH9 Cell Cycle / Cell Death & Survival 1.43 
SOD1 DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival 4.08 
YWHAG Cell Cycle / Cell Death & Survival 4.4 
MYH10 Cell Cycle 1.51 
EEF1A1 DNA Replication, Recombination & Repair 1.17 
OXSR1 DNA Replication, Recombination & Repair 1.22 
SEMA6A Cell Death & Survival 1.79 
LDHA Nucleic Acid Metabolism / Cell Death & Survival 1.19 
WTAP Cell Death & Survival -1.57 
RDH13 Cell Death & Survival -1.34 
SDHA Cell Death & Survival -1.22 
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DDX17 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.51 
SPTAN1 Cell Cycle -1.37 
NDUFAF4 Cell Death & Survival -1.33 
HNRNPK Cell Death & Survival -1.31 
SFPQ DNA Replication, Recombination & Repair / Cell Death & Survival -1.61 
VDAC1 Cell Death & Survival -1.21 
RPLP0 Cell Death & Survival -1.32 
DDX3X Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.29 
ARF4 Cell Death & Survival -1.47 
ITGB1 Cell Cycle / Cell Death & Survival -1.39 
LMNB1 Cell Cycle / Cell Death & Survival -1.54 
PRPF19 DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival -1.29 
VCP Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.17 
FUS DNA Replication, Recombination & Repair / Cell Cycle -1.44 
HNRNPU DNA Replication, Recombination & Repair / Cell Death & Survival -1.31 
TOPBP1 Cell Cycle / Cell Death & Survival -1.78 
TBL3 DNA Replication, Recombination & Repair -1.44 
CDK5RAP3 Cell Cycle / Cell Death & Survival -1.24 
RPL27A Cell Death & Survival -1.44 
ACIN1 DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival -1.38 
TRAP1 Cell Death & Survival -1.23 
GNL3 Cell Cycle -1.54 
NCL DNA Replication, Recombination & Repair / Cell Death & Survival -1.46 
IMMT Cell Death & Survival -1.24 
VDAC3 Nucleic Acid Metabolism -1.3 
ATP5A1 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.31 
SRRM2 DNA Replication, Recombination & Repair -1.48 
SLC3A2 Cell Death & Survival -1.41 
NDUFS1 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair -1.29 
LCK DNA Replication, Recombination & Repair / Cell Death & Survival -1.34 
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RHOC Cell Cycle / Cell Death & Survival -1.35 
SAP18 Cell Death & Survival -1.39 
SMU1 DNA Replication, Recombination & Repair -1.6 
DHX9 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair -1.32 
BSG DNA Replication, Recombination & Repair / Cell Death & Survival -1.23 
RAB5A Cell Death & Survival -1.51 
SLC25A13 Nucleic Acid Metabolism -1.2 
ILF2 Cell Death & Survival -1.26 
GLUD1 Cell Death & Survival -1.17 
FAM162A Cell Death & Survival -1.4 
NUP93 Cell Death & Survival -1.21 
AIFM1 DNA Replication, Recombination & Repair / Cell Death & Survival -1.29 
ATP1A1 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.36 
AK4 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair -1.29 
GNAI3 Cell Cycle -1.28 
SRPK1 DNA Replication, Recombination & Repair / Cell Death & Survival -1.57 
EIF4A3 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair / Cell Death & Survival -1.19 
SRSF1 Cell Death & Survival -1.39 
GNB2L1 Cell Death & Survival -1.31 
VDAC2 Cell Death & Survival -1.47 
ELAVL1 Cell Cycle / Cell Death & Survival -1.18 
PHB Cell Death & Survival -1.3 
RHOG Cell Death & Survival -1.87 
SNRNP200 Nucleic Acid Metabolism / DNA Replication, Recombination & Repair -1.31 
SRSF2 Cell Death & Survival -1.65 
TMED10 Cell Death & Survival -1.44 
LMNA Cell Cycle / Cell Death & Survival -1.31 
RPL5 Cell Cycle -1.28 
XRCC5 DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival -1.19 
SMG1 Cell Death & Survival -1.22 
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CASP8AP2 Cell Cycle / Cell Death & Survival -1.69 
HSPA9 Cell Death & Survival -1.13 
GNAS Cell Death & Survival -1.23 
HSD17B10 Cell Death & Survival -1.81 
RALA Cell Cycle / Cell Death & Survival -1.32 
SNRPF DNA Replication, Recombination & Repair -1.53 
STIM1 Cell Death & Survival -1.6 
ATP5L Nucleic Acid Metabolism / DNA Replication, Recombination & Repair -1.93 
FDFT1 Cell Death & Survival -1.23 
BCLAF1 DNA Replication, Recombination & Repair / Cell Death & Survival -1.3 
ATR DNA Replication, Recombination & Repair / Cell Cycle / Cell Death & Survival -1.17 
FIGNL1 DNA Replication, Recombination & Repair -1.15 
EIF2S1 Cell Death & Survival -1.21 
SMC3 DNA Replication, Recombination & Repair -1.22 
RBM25 Cell Death & Survival -1.15 
 
 
 Table 7.5. List of proteins that had altered expression following down-regulation of DHFRL1 in HEK 293 cells with both 
shRNA constructs. 
Accession  Gene Description Peptides Score Anova (p) Fold 
 
Average 
P50454 SERPINH1 Serpin H1 1 3.64 0.000158 +1.26 +1.24 1.25 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 2 4.82 0.00226 -1.31 -1.4 -1.355 
P09622 DLD Dihydrolipoyl dehydrogenase, mitochondrial 1 3.79 0.00441 -1.4 -1.36 -1.38 
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Table 7.6. List of proteins which increased in expression following over-expression of DHFRL1 in HEK293 cells. 
 
Accession  Gene Description Peptides Score Anova (p) Fold 
Q96AE4 FUBP1 Far upstream element-binding protein 1 1 56.66 1.46E-03 1.27 
Q92598 HSPH1 Heat shock protein 105 kDa  1 43.57 2.92E-03 1.64 
O75947 ATP5H ATP synthase subunit d, mitochondrial  1 40.01 3.26E-03 1.59 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M 3 191.01 3.85E-03 1.23 
P04075 ALDOA  Fructose-bisphosphate aldolase A 1 53.39 4.50E-03 1.36 
 P11142 HSPA8 Heat shock cognate 71 kDa protein 2 97.21 8.70E-03 1.67 
Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic 1 62.45 8.94E-03 1.47 
O60637 TSPAN3 Tetraspanin-3 1 43.83 9.26E-03 1.59 
P10599 TXN Thioredoxin 1 41.28 0.01 1.26 
P63220 RPS21 40S ribosomal protein S21 1 61.29 0.01 1.27 
P55036 PSMD4 26S proteasome non-ATPase regulatory subunit 4 1 113.48 0.01 1.35 
P34897 SHMT2 Serine hydroxymethyltransferase, mitochondrial 1 64.09 0.01 1.37 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 1 41.38 0.01 1.35 
 O60884 DNAJA2 DnaJ homolog subfamily A member 2 1 59.92 0.01 1.42 
P28072 PSMB6 Proteasome subunit beta type-6 1 72.19 0.02 1.2 
 P00505 GOT2 Aspartate aminotransferase, mitochondrial 1 59.43 0.02 1.23 
P18669 PGAM1 Phosphoglycerate mutase 1 1 48.01 0.02 2.36 
O15511 ARPC5 Actin-related protein 2/3 complex subunit 5 1 53.7 0.02 1.43 
P40926 MDH2 Malate dehydrogenase, mitochondrial 1 45.23 0.02 1.13 
 P10809 HSPD1 60 kDa heat shock protein, mitochondrial 1 51.44 0.02 1.37 
P13639 EEF2 Elongation factor 2  1 41.69 0.02 1.45 
P19338 NCL Nucleolin 1 46.9 0.03 1.19 
P46060 RANGAP1 Ran GTPase-activating protein 1 1 44.04 0.03 1.61 
Q04837 SSBP1 Single-stranded DNA-binding protein, mitochondrial 1 55.65 0.03 1.19 
P67870 CSNK2B  Casein kinase II subunit beta 1 60.17 0.03 1.37 
P09497 CLTB Clathrin light chain B 1 59.61 0.03 1.33 
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P31948 STIP1 Stress-induced-phosphoprotein 1 1 53.35 0.03 1.22 
P23588 EIF4B Eukaryotic translation initiation factor 4B  1 43.02 0.03 1.35 
P62805 HIST1H4A Histone H4 1 58.13 0.03 13.58 
P62633 CNBP Cellular nucleic acid-binding protein 1 61.27 0.03 1.46 
Q04760 GLO1 Lactoylglutathione lyase 2 86 0.03 1.16 
Q9UQ35 SRRM2  Serine/arginine repetitive matrix protein 2 1 66.77 0.03 1.53 
O95218 ZRANB2 Zinc finger Ran-binding domain-containing protein 2 1 45.24 0.03 1.98 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 1 91.59 0.03 1.22 
P43243 MATR3 Matrin-3 1 53.14 0.03 1.23 
Q4VXU2 PABPC1L Polyadenylate-binding protein 1-like 1 42.91 0.04 1.33 
P12268 IMPDH2 Inosine-5'-monophosphate dehydrogenase 2 1 73.26 0.04 1.29 
Q01581 HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 1 44.52 0.04 1.28 
P35613 BSG Basigin 1 61.47 0.04 1.32 
 P16152 CBR1 Carbonyl reductase [NADPH] 1  1 62.77 0.04 1.35 
Q8TF72 SHROOM3 Protein Shroom3 1 41.96 0.04 2.85 
P08865 RPSA 40S ribosomal protein SA 1 55.38 0.04 1.41 
Q15417 CNN3 Calponin-3 1 79 0.05 1.38 
P30101 PDIA3  Protein disulfide-isomerase A3 1 46.78 0.05 1.35 
Q9NQ29 LUC7L Putative RNA-binding protein Luc7-like 1 1 54.59 0.05 1.2 
P62993 GRB2 Growth factor receptor-bound protein 2 1 40.88 0.05 1.26 
Q9UQ80 PA2G4  Proliferation-associated protein 2G4 1 45.05 0.05 1.09 
Q99832 CCT7 T-complex protein 1 subunit eta 1 67.22 0.05 1.33 
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Table 7.7. List of proteins which decreased in expression following over-expression of DHFRL1 in HEK 293 cells. 
 
 
Accession  Gene Description Peptides Score Anova (p) Fold 
P07196 NEFL Neurofilament light polypeptide 3 154.41 6.62E-05 -1.31 
Q8NC51 SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 1 49.12 1.79E-03 -1.46 
P07197 NEFM Neurofilament medium polypeptide 2 109.91 1.98E-03 -1.45 
P31040 SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mt 1 67.27 2.84E-03 -1.18 
P09874 PARP1 Poly [ADP-ribose] polymerase 1 1 66.55 3.67E-03 -6.84 
Q13263 TRIM28 Transcription intermediary factor 1-beta 1 89.53 4.42E-03 -2.62 
O75131 CPNE3 Copine-3 1 41.58 6.23E-03 -2.08 
Q9UQE7 SMC3 Structural maintenance of chromosomes protein 3 1 52.08 7.36E-03 -1.5 
Q08211 DHX9 ATP-dependent RNA helicase A 1 64.9 7.53E-03 -2.38 
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 1 49.66 7.89E-03 -1.23 
P06744 GPI Glucose-6-phosphate isomerase 1 43.91 8.89E-03 -1.76 
P52209 PGD 6-phosphogluconate dehydrogenase, decarboxylating 1 58.61 9.96E-03 -1.21 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit 1 315.64 0.01 -1.95 
Q8NE71 ABCF1 ATP-binding cassette sub-family F member 1 1 46.9 0.01 -1.86 
P62316 SNRPD2 Small nuclear ribonucleoprotein Sm D2 1 67.05 0.01 -3.12 
Q14980 NUMA1 Nuclear mitotic apparatus protein 1 2 98.73 0.01 -1.55 
Q12906 ILF3 Interleukin enhancer-binding factor 3 1 40.31 0.02 -1.24 
P35579 MYH9 Myosin-9 1 47.87 0.02 -2.23 
P35637 FUS  RNA-binding protein FUS 1 40.54 0.03 -1.66 
Q13428 TCOF1  Treacle protein 1 45.91 0.03 -3.04 
P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  1 41.19 0.03 -1.25 
P27694 RPA1 Replication protein A 70 kDa DNA-binding subunit 1 61.31 0.03 -1.4 
P61981 YWHAG 14-3-3 protein gamma 1 43.44 0.03 -1.52 
Q3ZCQ8 TIMM50 Mitochondrial import inner membrane translocase subunit TIM50  1 60.98 0.04 -1.37 
P12956 XRCC6 X-ray repair cross-complementing protein 6 1 40.08 0.04 -5.87 
 P60468 SEC61B  Protein transport protein Sec61 subunit beta 1 51.98 0.04 -2.98       
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 P55084 HADHB Trifunctional enzyme subunit beta, mitochondrial  1 64.52 0.04 -1.23 
O95831 AIFM1  Apoptosis-inducing factor 1, mitochondrial  1 44.13 0.04 -1.4 
P56182 RRP1 Ribosomal RNA processing protein 1 homolog A 1 44.02 0.05 -1.86 
 Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1  1 48.34 0.05 -1.73 
P30419 NMT1  Glycylpeptide N-tetradecanoyltransferase 1 1 61.54 0.05 -5.08 
 
 
      
 
Table 7.8. List of proteins that are involved in DNA Replication, Recombination and Repair, Nucleic Acid Metabolism, Cell 
Death and Survival, Cellular Growth and Proliferation and Cell Cycle that are affected by over-expressing DHFRL1 in HEK 
293 cells. 
 
Gene Function Fold 
FUBP1 Cell Death & Survival / Cell Cycle 1.27 
ATP5H Nucleic Acid Metabolism 1.59 
HNRNPM Cellular Growth & Proliferation 1.23 
ALDOA  Nucleic Acid Metabolism / Cell Death & Survival 1.36 
HSPA8 DNA Replication, Recombination & Repair / Cell Death & Survival 1.67 
TXN DNA Replication, Recombination & Repair / Cell Death & Survival / Cellular Growth & Proliferation 1.26 
GNB2L1 Cell Death & Survival / Cellular Growth & Proliferation 1.35 
DNAJA2 Cellular Growth & Proliferation 1.42 
HSPD1 Nucleic Acid Metabolism / Cell Death & Survival / Cellular Growth & Proliferation 1.37 
NCL Cell Death & Survival / Cellular Growth & Proliferation 1.19 
SSBP1 DNA Replication, Recombination & Repair / Cellular Growth & Proliferation 1.19 
CSNK2B  Cellular Growth & Proliferation 1.37 
STIP1 Nucleic Acid Metabolism 1.22 
EIF4B Cell Death & Survival / Cellular Growth & Proliferation 1.35 
GLO1 Cell Death & Survival 1.16 
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GAPDH Cell Death & Survival 1.22 
IMPDH2 Cell Death & Survival / Cellular Growth & Proliferation 1.29 
BSG DNA Replication, Recombination & Repair / Cell Death & Survival / Cellular Growth & Proliferation 1.32 
CBR1 Cell Death & Survival 1.35 
RPSA Cellular Growth & Proliferation 1.41 
PDIA3  Cellular Growth & Proliferation 1.35 
GRB2 Cellular Growth & Proliferation 1.26 
PA2G4  Cellular Growth & Proliferation 1.09 
CCT7 Cellular Growth & Proliferation 1.33 
NEFL Cell Cycle -1.31 
SDHA Cell Death & Survival -1.18 
PARP1 
DNA Replication, Recombination & Repair / Cell Death & Survival / Cellular Growth & Proliferation / 
Cell Cycle -6.84 
TRIM28 DNA Replication, Recombination & Repair / Cell Death & Survival / Cellular Growth & Proliferation -2.62 
SMC3 DNA Replication, Recombination & Repair -1.5 
DHX9 DNA Replication, Recombination & Repair / Nucleic Acid Metabolism -2.38 
IGF2BP3 Cellular Growth & Proliferation -1.23 
GPI Cell Death & Survival / Cellular Growth & Proliferation -1.76 
PGD Nucleic Acid Metabolism -1.21 
PRKDC DNA Replication, Recombination & Repair / Cell Death & Survival / Cell Cycle -1.95 
NUMA1 Cellular Growth & Proliferation / Cell Cycle -1.55 
ILF3 Cellular Growth & Proliferation -1.24 
MYH9 Cell Death & Survival / Cellular Growth & Proliferation -2.23 
FUS  DNA Replication, Recombination & Repair / Cellular Growth & Proliferation / Cell Cycle -1.66 
ACAT1 Cellular Growth & Proliferation -1.25 
RPA1 
DNA Replication, Recombination & Repair / Nucleic Acid Metabolism / Cell Death & Survival / Cell 
Cycle -1.4 
YWHAG Cell Death & Survival / Cellular Growth & Proliferation -1.52 
TIMM50 Cell Death & Survival -1.37 
XRCC6 DNA Replication, Recombination & Repair / Cell Death & Survival / Cellular Growth & Proliferation -5.87 
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HADHB Cellular Growth & Proliferation -1.23 
AIFM1  DNA Replication, Recombination & Repair / Cell Death & Survival -1.4 
 
Table 7.9. List of proteins that are involved in glycolysis, oxidative phosphorylation, electron transport, ATP synthesis, and 
malate / aspartate shuttle that are affected by altering DHFRL1 expression in HEK 293 cells. 
      
Gene Description Function  DHFRL1 KD
+
  DHFRL1 OEˠ 
ATP5H ATP synthase subunit d, mitochondrial ATP synthesis   1.59 
NDUFAF4 NADH dehydrogenase 1 alpha subcomplex assembly factor 4 ATP synthesis  -1.33  
NDUFS1 NADH-ubiquinone oxidoreductase 75kDa subunit, mitochondrial ATP synthesis  -1.29  
NDUFA3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 ATP synthesis  -1.35  
ATP5L ATP synthase subunit G, mitochondrial ATP metabolism  -1.93  
DLD Dihydrolipoyl dehydrogenase, mitochondrial Glycine Cleavage System  -1.36  
ALDOA Fructose-bisphosphate aldolase A Glycolysis   1.36 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Glycolysis  1.29 1.22 
GPI Glucose-6-phosphate isomerase Glycolysis   -1.76 
TPI1 Triosephosphate isomerase Glycolysis  1.37  
PGAM1 Phosphoglycerate mutase 1 Glycolysis   2.36 
MDH2 Malate dehydrogenase, mitochondrial Malate / aspartate shuttle   1.13 
GOT2 Aspartate aminotransferase, mitochondrial Malate / aspartate shuttle  -1.38 1.23 
SDHA Succinate dehydrogenase flavoprotein subunit, mitochondrial Electron transport   -1.18 
ALDH5A1 Succinate semialdehyde dehydrogenase, mitochondrial Electron transport  -1.24  
COX6B1 Cytochrome c oxidase subunit 6B1 Electron transport  1.2  
ACAT1 Acetyl-CoA acetyltransferase, mitochondrial Oxidative phosphorylation  -1.27 -1.25 
 
+
KD = knocked-down 
ˠ
OE = over-expressed 
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Table 7.10. List of proteins that showed that showed altered expression (some opposing, some similar effects) in both DHFRL1 
over-expressing and DHFRL1 down-regulated HEK 293 cells. 
 
Gene Description L1 OE L1 KD 
GPI Glucose-6-phosphate isomerase -1.76 1.29 
TRIM28 Transcription intermediary factor 1-beta -2.62 1.4 
PRKDC DNA-dependent protein kinase catalytic subunit -1.95 1.75 
MYH9 Myosin-9 -2.23 1.43 
YWHAG 14-3-3 protein gamma -1.52 4.4 
GOT2 Aspartate aminotransferase, mitochondrial 1.23 -1.38 
ZRANB2 Zinc finger Ran-binding domain-containing protein 2 1.98 -3.96 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 1.23 -1.44 
PA2G4 Proliferation-associated protein 2G4 1.09 -1.76 
NCL Nucleolin 1.19 -1.46 
SRRM2 Serine/arginine repetitive matrix protein 2 1.53 -1.48 
BSG Basigin 1.32 -1.23 
GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 1.35 -1.31 
SHMT2 Serine hydroxymethyltransferase, mitochondrial 1.37 -1.24 
MDH2 Malate dehydrogenase, mitochondrial 1.13 -1.34 
GRB2 Growth factor receptor-bound protein 2 1.26 -1.07 
    SMC3 Structural maintenance of chromosomes protein 3 -1.5 -1.22 
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial -1.18 -1.22 
SPTBN1 Spectrin beta chain, non-erythrocytic 1  -1.73 -1.38 
FUS RNA-binding protein FUS -1.66 -1.44 
DHX9 ATP-dependent RNA helicase A -2.38 -1.32 
AIFM1 Apoptosis-inducing factor 1, mitochondrial  -1.4 1.29 
ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  -1.25 -1.27 
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SNRPD2 Small nuclear ribonucleoprotein Sm D2 -3.12 -1.31 
PSMB6 Proteasome subunit beta type-6 1.2 1.38 
CCT7 T-complex protein 1 subunit eta 1.33 1.2 
ALDOA Fructose-bisphosphate aldolase A 1.36 1.49 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 1.22 1.29 
PSMD4 26S proteasome non-ATPase regulatory subunit 4 1.35 1.38 
CNBP Cellular nucleic acid-binding protein 1.46 1.45 
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8.1 Discussion 
This project focused on investigating the molecular mechanism of the role of folate in 
human health by 1) examining the impact of folic acid supplementation on gene-specific DNA 
methylation patterns during pregnancy; 2) exploring the functional relevance of specific 
polymorphisms from the DHFR gene family and 3) investigating the effect of altered DHFRL1 
expression on genes / proteins. A schematic representation of the project is shown in Figure 1.8. 
As mentioned earlier (Section 1.3), the folate mediated one-carbon metabolism pathway is a 
complex biochemical pathway that is compartmentalised between the cytoplasm, the 
mitochondria and the nucleus (Section 1.4) (Figure 1.1) (Tibbetts and Appling, 2010, Stover and 
Field, 2011). It involves numerous enzymes and is essential to the cell and is made up of three 
main interdependent metabolic pathways; the de novo dTMP biosynthesis pathway, the de novo 
purine biosynthesis pathway, which are involved in DNA synthesis and the homocysteine re-
methylation pathway (Figure 1.1). All three of these pathways use the cofactor THF to carry the 
one carbon units that are required for biosynthetic reactions within the cell (Stover, 2004).  
 
 The first part of my project focused on the homocysteine re-methylation pathway, 
which uses 5-methyltetrahydrofolate for the re-methylation of homocysteine to methionine. 
Methionine is then converted to SAM, which serves as a cofactor for numerous methylation 
reactions, such as DNA methylation (Anderson et al., 2012c). DNA methylation patterns have 
been shown to be capable of changing throughout a person’s lifetime, especially during 
reprogramming events associated with development and aging (Waterland and Jirtle, 2003, 
Fraga et al., 2005, Martin, 2005, Faulk and Dolinoy, 2011), as well as cancer (Feinberg, 2007). 
Increasing evidence shows that the human in utero environment can impact DNA methylation 
patterns and disease risk of the subsequent offspring. This relates back to the “fetal origins of 
adult disease” theory originally proposed by Barker (Barker et al., 1989) (Section 1.8). As DNA 
methylation is dependent on several enzymes and the presence of dietary micronutrients such as 
folate as cofactors (Anderson et al., 2012c), there is a key association between the two. 
Therefore, nutri-genetics is emerging as an area of great interest and the role of dietary 
influences on gene expression is an area of large research interest as DNA methylation events 
and dietary practices, particularly micronutrient intake may ultimately influence disease 
phenotype.  
 
 Due to this, we examined the DNA methylation patterns of pregnant women, half of 
whom had taken folic acid supplements throughout their entire pregnancy and those who had 
only taken folic acid for their first trimester. In our study, we chose to examine a small number 
of genes, which had previously been shown to be candidates that could potentially be altered in 
response to folate as well as two genes, DHFR and DHFRL1 that are known to play a major role 
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in the folate mediated one-carbon metabolism pathway. However, when we examined the 
DHFRL1 gene and those genes that had been previously shown to be folate-sensitive in our 
FASSTT samples, we found that the CpG sites that we examined in these genes were not folate 
sensitive / were 100 % unmethylated and no DNA methylation pattern differences were seen 
between the samples. Nonetheless, we examined only a small number of genes and the CpG 
sites that we examined were not the same as those that had been examined previously. The 
DHFR gene also showed not to be folate sensitive in regards to methylation, however 
methylation changes were observed between individuals as well as between themselves, pre- 
and post- intervention, indicating that DNA methylation patterns can change within individuals 
(Fraga et al., 2005).  
 
 Gene-specific methylation studies are a relatively new area of research and have only 
recently begun to be carried out with very few studies carried out to date examining the 
relationship between folate and DNA methylation patterns of specific genes. In order for us to 
examine the relationship between folate and the DNA methylation of specific genes, novel 
assays were designed using newly developed DNA methylation profiling techniques such as 
MS-HRM and SMART-MSP. Although the results we obtained from our methylation assays 
were negative, i.e., no correlation was found between women who took folic acid throughout 
their entire pregnancy and those who only took folic acid for their first trimester, for the gene 
regions we examined, these techniques only allow for the analysis of a small region of the gene 
at a time, ~100-200 bp, and therefore are not perfect assays. As mentioned in Chapter 1, 
epigenetics is a new a field of science that is emerging and examining the epigenome / DNA 
methylation is of vital importance in order to help us understand and to account for the diversity 
observed between the population, in addition to the genome, as well as its relevance for human 
health and disease. Therefore, new techniques are currently being developed in order to try and 
assess DNA methylation in the best possible manner. Although, there is no gold standard as of 
yet, it is most likely to be a sequenced based assay, which would allow genes to be examined at 
single base resolution. Once these techniques have been developed, it would be of great interest 
to examine the FASSTT study samples for a large number of genes in order to determine if any 
DNA methylation differences exist between the samples, allowing us to elucidate the effects of 
folate on DNA methylation patterns. 
 
The other part of my project focused on the DNA synthesis pathway, which is made up 
of the de novo dTMP biosynthesis pathway and the de novo purine biosynthesis pathway 
(Figure 1.1). As previously discussed (Section 1.11), DHFR is one of the most important 
enzymes that is involved in the folate-mediated one carbon metabolism pathway and plays a 
major role in purine and dTMP synthesis. Therefore, any polymorphisms found within this gene 
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are often hypothesised to have severe consequences on the folate pathway, which in turn may 
impact on an individual’s risk to health and disease. Although no polymorphisms have been 
found within the DHFR coding region to date (Litwack, 2008), a 19 bp deletion / insertion 
polymorphism, located in intron-1 has been studied at length and has been associated with 
NTDs (Johnson et al., 2004, van der Linden et al., 2007, Parle-McDermott et al., 2007). 
However, the biological function of this polymorphism as well as its association with 
circulating metabolites has been controversial throughout the years, and has yet to be 
determined (Gellekink et al., 2007, Stanisławska-Sachadyn et al., 2008). Therefore, we 
examined the effect of this 19 bp deletion / insertion polymorphism on circulating folate 
metabolites and folate intake in the largest population yet to be examined. In our study, we 
found that the polymorphism was not associated with any of the circulating folate metabolite 
levels or with folate intake. The reason behind why there are no polymorphisms located within 
the DHFR coding region is likely to relate to the critical role this enzyme plays in cellular 
function and a dramatic impact on enzyme activity will have severe consequences. This theory 
is further supported by two recent studies that have identified rare coding mutations (not 
polymorphisms) in DHFR as causative for megaloblastic anaemia and cerebral folate deficiency 
(Banka et al., 2011, Cario et al., 2011). In relation to the 19 bp deletion / insertion 
polymorphism; previous work from the laboratory suggested that it might impact on mRNA 
levels (Parle-McDermott et al., 2007), although the effect was marginal. The lack of any impact 
on circulating metabolites may indicate that the effect of this polymorphism is not dramatic 
enough to impact on the overall one carbon balance but doesn’t rule out an influence on 
maternal supply to the embryo during very early development. Further investigation is required 
to elucidate this. However, a recent finding has shown that individuals with the combined 
genotype of the DHFR 19 bp deletion and the SHMT C1420T TT genotypes have increased 
folate concentrations (Mendes et al., 2013), suggesting that it may be important to examine the 
combination effects of gene polymorphisms rather than examining them individually.    
 
It has also recently been shown that there is an almost five-fold variation in DHFR 
activity between individuals (Bailey and Ayling, 2009). However, the cause of this variability is 
yet unknown. Several factors that are thought to be associated with the cause of this variability 
are MDM2 and DHFR polymorphisms. The oncogene product MDM2 has been shown to 
decrease DHFR activity, by binding to and mono-ubiquitinating DHFR. This was shown in cell 
lines that either over-expressed MDM2 or were transiently transfected with MDM2 (Bailey and 
Ayling, 2009). Polymorphisms within the DHFR promoter region as well as the 19 bp deletion / 
insertion polymorphism have also been candidates and at present, combinations of these non-
coding variants in addition to the post-translational modification, ubiquitination are thought to 
be sufficient in explaining the variability of DHFR activity among individuals (Bailey and 
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Ayling, 2009). DHFR promoter methylation may also be a mechanism which may cause 
variability in DHFR activity. DHFR promoter methylation was investigated in Chapter 3 and 
our findings indicated that individuals do differ in their DHFR promoter methylation patterns. 
This could be interesting in itself as it may contribute to the variability of DHFR activity among 
individuals but will have to be investigated further.   
 
On the other hand, the discovery of DHFRL1 as a functional gene (Anderson et al., 
2011, McEntee et al., 2011) has opened up a window of opportunities for investigating the 
effects of polymorphisms within another folate related gene. de novo dTMPs are synthesised 
through the catalytic conversion of dUMPs to dTMPs by three folate enzymes, SHMT, TYMS 
and DHFR (Appling, 1991). This reaction takes place in the nucleus during the S phase of the 
cell cycle (Woeller et al., 2007). dTMP synthesis is required for DNA replication in both the 
nucleus and the mitochondria and up until recently it was thought that dTMP synthesis in the 
cytoplasm supported both. However Anderson et al. (2011), recently identified that DHFRL1 
takes the place of DHFR in the de novo thymidylate biosynthesis pathway in the mitochondria 
(Anderson et al., 2011)  
 
Although it is not yet known how DHFRL1 is transported and enters the mitochondria, 
it highlights the importance of mitochondrial folate mediated one-carbon metabolism. The 
DHFRL1 gene has similar properties to DHFR but in contrast has been shown to have much 
lower activity in comparison to the DHFR gene in a recombinant system (McEntee et al., 2011). 
However, unlike DHFR, examination of the NCBI SNP database indicated that there are non-
synonymous polymorphisms within the coding region of DHFRL1, which is of great interest. 
Therefore, we examined two of these polymorphisms, the rs61739170 proline to alanine (C->G) 
polymorphism and the DHFRL1 rs17855824 valine to isoleucine (G->A) polymorphism in 
detail. Analysis of these two DHFRL1 non-synonymous polymorphisms indicated that they 
have the ability to impact enzyme activity, with both polymorphisms increasing the specific 
enzyme activity of the protein in comparison to that of the WT DHFRL1 protein.  
 
The novel finding of the existence of non-synonymous polymorphisms within the 
DHFRL1 gene is highly interesting in itself, but the fact that the polymorphisms can alter the 
enzyme activity of the gene is of great significance, as the majority of polymorphisms found 
within the coding region of a gene are typically synonymous. This suggests that the 
polymorphisms that we examined could be functional polymorphisms, which could have major 
impacts on the function of the gene at the transcriptional and / or the translational level. This 
theory is further supported by our protein structure prediction (Section 6.2.1), which showed the 
polymorphisms to alter the 3D structure / folding of DHFRL1. As mentioned earlier, as the 
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activity of DHFR is highly variable among individuals, the same may be the case for DHFRL1 
and these polymorphisms may play a role in this variability. The newly discovered 
polymorphisms may also help us predict an individual’s response to certain drugs, susceptibility 
to environmental factors such as toxins as well as the risk of developing a particular disease. 
However, the exact function of these polymorphisms remains to be elucidated.    
 
These polymorphisms may also play a role in relation to disease risk and in Chapter 5, 
the rs17855824 SNP along with two other DHFRL1 SNPs were shown to be associated with 
NTDs in an Irish cohort by our collaborators in the NIH and TCD for the first time. This novel 
finding is of great significance, especially as the polymorphisms that were examined were found 
to be frequent in the Caucasian population, and will hopefully help us to elucidate the 
mechanisms behind NTDs. It also further implicates the importance of looking at genetic 
variation as a risk factor for diseases such as NTDs, with genes involved in the folate-mediated 
one-carbon metabolism pathway as prime candidates for association studies. Although the 
mechanism behind how these polymorphisms are affecting NTDs are yet unknown, the 
polymorphisms may affect NTDs by altering the expression of the gene / protein or as already 
shown it may be due to the fact the polymorphisms altering the activity of the enzyme. In order 
to try and determine the functions of the polymorphisms and to elucidate their association with 
NTDs, they will be investigated further in relation to their function in the laboratory and they 
will also be screened for risk of NTDs in an UK NTD cohort in collaboration with the NIH and 
TCD in order to confirm our findings observed in the Irish NTD cohort. 
 
The final part of my project involved the generation of stable DHFRL1 knocked-down 
and over-expressed cell pools for the first time so that the effects of altered DHFRL1 expression 
could be examined by proteomic analysis. Data obtained from the proteomic analysis, 
demonstrated that altered DHFRL1 expression level has an effect on numerous proteins, with a 
large number of proteins that were identified as being involved in DNA replication, 
recombination and repair, cell growth and cell death as well as those involved in cancer. 
Numerous proteins that are involved in embryonic development were also discovered, further 
supporting our theory that DHFRL1 is associated with NTDs. Proteins that are also involved in 
NADPH pathways were also identified, strengthening the recent finding by Fan et al. (2014), 
that folate metabolism also plays a role in NADPH production in both the cytoplasm and the 
mitochondria (Fan et al., 2014). As NADPH and its derivatives play an important role in energy 
metabolism (Atkinson, 1977), our findings will hopefully help us to identify the relationship 
between folate metabolism and NADPH pathways. These novel findings have demonstrated that 
altering the expression of DHFRL1 not only has an effect on proteins that are involved in the 
folate mediated one carbon metabolism pathway but also on numerous proteins that are 
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involved in a large number of different biological pathways, signifying the importance of 
examining the relationship of proteins in numerous pathways. 
 
In conclusion, we have investigated for the first time, the DNA methylation patterns in 
candidate folate sensitive genes as well as in DHFR and DHFRL1 in order to determine whether 
prolonged exposure to folic acid supplementation during pregnancy can result in changes in 
DNA methylation patterns, finding out that the regions we examined are not folate-sensitive and 
how folate polymorphisms as well as altering the expression of a gene could have an impact in 
human health and disease by altering the activity / expression of other proteins.  
  
8.2 Future Work 
Future work to be carried out in the laboratory will focus on the following areas: 
 Further functional characterization of DHFRL1 polymorphisms 
As mentioned in Chapter 6, the two DHFRL1 polymorphism proteins examined showed 
to have an increase in specific activity when compared to the WT DHFRL1 protein. The 
next step would be to determine the Km and Vmax’s of the two polymorphisms and 
compare them to that of the WT in order to further characterise the function of the 
polymorphisms. 
 Impact of recombinant DHFRL1 polymorphic variants on anti-folates, such as 
methotrexate and aminopterin – what impact do they have on treatment. 
Previous studies that have been carried out in the Parle-McDermott laboratory have 
shown that DHFRL1 has a lower binding capacity to the anti-folate drug, methotrexate 
in comparison to DHFR (unpublished data). Therefore, it would be interesting to see 
whether DHFRL1 polymorphisms have an effect on the binding of methotrexate by 
enzyme inhibition assays. If the polymorphisms are found to alter the binding affinity of 
the drugs, this may have a large impact on treating cancer patients with anti-folates in 
the future.  
 How DHFRL1 localises to the mitochondria 
Neither DHFR nor DHFRL1 have mitochondrial targeting sequences. Aligning DHFR 
and DHFRL1 protein sequences show 16 amino acid differences between the two 
proteins (Figure 8.1). Mutating these amino acids back to those of DHFR one at a time / 
in combination may determine how DHFRL1 is localised to the mitochondria. Post- 
translational modifications such as sumoylation and acetylation could also be examined. 
 Examination of  thymidylate biosynthesis complexes in the mitochondria 
It has recently been shown that SHMT1, TYMS, DHFR and other proteins in the 
nucleus form a thymidylate biosynthesis complex that is associated with the nuclear 
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lamina (Anderson et al., 2012a). It would be interesting to determine whether a similar 
complex is also formed in the mitochondria. This could be carried out by using co-
immunoprecipitation and tandem affinity purification assays, using monoclonal 
antibodies for DHFRL1 to pull down DHFRL1 / DHFRL1 enzyme complexes. These 
complexes could then be analysed by LC-MS in order to identify proteins which have 
formed a complex. 
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DHFR            MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 60 
DHFRL1          MFLLLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKTWFS 60 
                *.  ******************** *****************************:***** 
 
DHFR            IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS 120 
DHFRL1          IPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWIVGGSS 120 
                *********.********************:***********:*********:******* 
 
DHFR            VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF 180 
DHFRL1          VYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEGKHIKYKF 180 
                ******** ********************.********************** * ***** 
 
DHFR            EVYEKND 187 
DHFRL1          EVCEKDD 187 
                ** **:* 
 
Figure 8.1. A protein sequence alignment of human DHFR and DHFRL1 generated using clustalW2. Amino acids highlighted in yellow indicate 
those that differ between the two proteins. 
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Appendix A. Vector map for pDONR 221. Image taken from Invitrogen   
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Appendix B. Vector map for pDEST15. Image taken from Invitrogen   
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ATM 5’ flanking sequence(1000 bp) 
TTGGTCCCAACACTGAACCAAGGAAATTGCGCCCAAGGTTGAAGCACACGCAATCCGTCCGTCA
TGCAGACAAATGCTCTTTCAGGGGTCCTAATTAAGTGTGGAGGCCTGACTTTCCTTCCGAATCC
GCCCCAGGTGTTCCACCCCGAGCTTCCCCTCGGGCTTCCCCTCGCCACGCAGCCTCTGAAGAGA
GGAGCATCTACATACAAAGAGGCTTAAACTGCCCAGAACCTCCGAATGACGAAGAATCACCGCC
AGTCTCAACTCGTAAGCTGGGAGGCAAAACCCCAAAGCTTCCCTACCAAGGGAAAACCTTTGGC
CTCAAAGGTCCTTCTGTCCAGCATAGCCGGGTCCAATAACCCTCCATCCCGCGTCCGCGCTTAC
CCAATACAAGCCGGGCTACGTCCGAGGGTAACAACATGATCAAAACCACAGCAGGAACCACAAT
AAGGAACAAGACTCAGGTTAAAGCAAACACAGCGACAGCTCCTGCGCCGCATCTCCTGGTTCCA
GTGGCGGCACTGAACTCGCGGCAATTTGTCCCGCCTCTTTCGCTTCACGGCAGCCAATCGCTTC
CGCCAGAGAAAGAAAGGCGCCGAAATGAAACCCGCCTCCGTTCGCCTTCGGAACTGTCGTCACT
TCCGTCCTCAGACTTGGAGGGGCGGGGATGAGGAGGGCGGGGAGGACGACGAGGGCGAAGAGGG
TGGGTGAGAGCCCCGGAGCCCGAGCCGAAGGGCGAGCCGCAAACGCTAAGTCGCTGGCCATTGG
TGGACATGGCGCAGGCGCGTTTGCTCCGACGGGCCGAATGTTTTGGGGCAGTGTTTTGAGCGCG
GAGACCGCGTGATACTGGATGCGCATGGGCATACCGTGCTCTGCGGCTGCTTGGCGTTGCTTCT
TCCTCCAGAAGTGGGCGCTGGGCAGTCACGCAGGGTTTGAACCGGAAGCGGGAGTAGGTAGCTG
CGTGGCTAACGGAGAAAAGAAGCCGTGGCCGCGGGAGGAG 
 
ATM primers used for MS-HRM in Wojdacz paper 
 
Fwd primer: CGAAGAGGGTGGGTGAGAGTTT (22) 58.8°C 
 NON CpG Cs CONVERTED TO Ts 
ATM sequence: CGAAGAGGGTGGGTGAGAGCCC 
 
Rev primer: ACGCCATATCCACCAATAACCAAC (24) 57.5°C 
Rev complement: GTTGGTTATTGGTGGATATGGCGT 
 NON CpG Cs CONVERTED TO Ts 
ATM sequence: GCTGGCCATTGGTGGACATGGCGC 
 
PCR PRODUCT = 85 bp 
 
 
 
 
  
 
 
 
 
 
 
Appendix C. ATM MS-HRM primer sequence and location 
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RASSF1A 5’ Flanking Sequence (1000 bp) 
 
TTTGTGATGTCCTCTTGTACCGGATGAGAGGGTCTCCATGCACACACAGACCTGGGACACTATC
CATCCACAAGTTCCTAAATAGGCCAGAGCAGTGATGCTCAACCCAGACTCCATGTTACAATAAT
TTGGGGAGTTTTTAAAATTTACTGATGCCTAGGGTCCACTCCCAGCAGTTGATTCAACAGGTCT
GCGGTGGGATCCAGGCTAGCGGGGAGGACTGTAAAAGCACCCCTGGTGATTCCAGCTGGTGTCT
ACCCAGGGGAGAGCAACCTTTGCTTGCTGGCGATTCCCAGGGGTGCAGAAGGACTGCTGGGTGT
GTGGCTGCGTGCATATTTTAGCATCTGATTCACTGGGTCAGAAAAGGGTGTTTGCTAAATAAAG
ACTCAACAAAACTCCTGCTTGCAGGGGGCCCACCAAAGGTTCTAAATTTTTCCAGGCTCCCTCC
CATAGGTGGTAATTTCCCTTCACCCTAAAGGTTCTGGAGGGGGTCATGAGTGTTTGAGAAGAGG
CAAGCCTGGGAAGATGGACTCCGAGGACAGTAGGCACAAACCCTTTCTCAAGAAGGGCCAAGGC
ATTTTAAAGATAAGAAACTTAAAATCAGCGTATTTTTACATATAAGCAGCCACCTCTGCTCATC
TGTGGCCCAGATACGAGTGGAGTGCGACAAGGGATAAACCATTTTCGCGCACTCTTCAGCGATG
GGGCGAAAGTAACGGACCTAGTCCTCGGGAGCTGTCCCCGCCGACCCCCTCTGCCGCGACTTGA
CCCGCGGCGACTGCGCTGCCCCTTGGCTGCCCCTTCCGCTCTCGTAGGCGCGCGGGGCCACTAC
TCACGCGCGCACTGCAGGCCTTTGCGCACGACGCCCCAGATGAAGTCGCCACAGAGGTCGCACC
ACGTGTGCGTGGCGGGCCCCGCGGGCTGGAAGCGGTGGCCACGGCCAGGGACCAGCTGCCGTGT
GGGGTTGCACGCGGTGCCCCGCGCGATGCGCAGCGCGTTG 
 
 
Fwd primer:  GTTTTAGATGAAGTCGTTATAGAGGT (26) 52.5°C 
NON CpG Cs CONVERTED TO Ts 
RASSF1A sequence: GCCCCAGATGAAGTCGCCACAGAGGT 
 
 
Rev primer:  CCCCACACGACAACTAATCCCTAA (24) 56.3°C 
Rev complement: TTAGGGATTAGTTGTCGTGTGGGG 
NON CpG Cs CONVERTED TO Ts 
RASSF1A sequence: CCAGGGACCAGCTGCCGTGTGGGG 
 
PCR PRODUCT = 100 bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D. RASSF1A MS-HRM primer sequence and location 
 315 
 
EIF2C3 5’ flanking sequence (1000bp) 
 
TCTCAGATGTCTTTCGTTGAGACGCAAAAAAAAGCTGTGGGGTAGGGCGTAAGGGGAGGGTGGA
GAAGAGAGAGAGGGTTCCTGGCCAAGGGAACCAAAAGCAGAGAAGCTCCAAGTCAGAAAAAAGC
AGCGGTTGGCCCGTTGGGAGAATTGGAAGCCAACCAGTATAGCTGTAGCACAGGCGGGGCCCAT
TTACGCCGTGCGTTTTCACCCTGGAAAGGAGTTTGGGTTTTCAAGTGTGACGAGGCGCTATTAA
AGAGTTTTAAACATGGAAATTACTCGATCTGATGTTTGTGTAGTGTCCTGTTTGTTAGTCATCT
TTTCCAAACTATAATACATTTTTTTTTTCCTAAAAATGGTCGTTAAAGCAGCCTAGGACTTAGG
TCAATTGCGGTGGTCACTTGACCGCCTGTGAGGAGGCGGCGCGTGGGGTGGATCGGACTGGGCG
TGGCGGGGGCTCAGGAAGGAGGGTGGCCCTACCCCAGCGGGCTCGGCTCGGGGCCTCCGCGGCA
GTTCGGGGTCCTTCACCCGCCGGCTCCAGGTAGGCTACTCCTCAGGTAAGCCCCGCCGCCAGCC
GCGACGTCGTCGCAGACAGGCACCGCCCCCACTCGTGCGGCGCGAGTAGTCCTGCCCCTCCGCG
TTGTCTCCGGCCGGCACGGCCCGGCGGGGTACGGCCGAGCCCGCCGCATGTGGCCCGGCTCCCG
GACACCTCCCCGGCGTCCTCCGCGCCGGCCGCTCCTGCCCCGACGTCGCTCCGGCACGGCTCGG
GGCCCAGAGGCGAGGCGAGGACGCCGGGCAAGCCAGGCAGCGGAACTGACGCCGGCGAGCTTCC
GGGGCGGCCCCGGGCAGGTCGGCGGCGGCGGCCCGCAGTCGTGGAGGAGCGGTGGGAGCGTCGG
CGGCCGCGGGCGATGCAACTTCCGGACGGGACTCCCCTCTGTCCGCGCCTCACATCTCCCCTTC
CTCTCGCCTAGTCCTGTGCCGTTTTCCGTCCGCGACTCTT 
 
Fwd primer:  TTAGGAAGGAGGGTGGTTTTATT (23) 53.7°C 
NON CpG Cs CONVERTED TO Ts 
EIF2C3 sequence: TCAGGAAGGAGGGTGGCCCTACC 
 
Rev primer:  AAACTTACCTAAAAAATAACCTACCTAAA (29) 51.5°C 
Rev complement: TTTAGGTAGGTTATTTTTTAGGTAAGTTT 
NON CpG Cs CONVERTED TO Ts 
EIF2C3 sequence: TCCAGGTAGGCTACTCCTCAGGTAAGCCC 
 
PCR PRODUCT = 107 bp 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix E. EIF2C3 MS-HRM primer sequence and location 
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ATP5F1 5’ flanking sequence (1000 bp) 
TTAACACTTCCCCAATATTTGGACACTAGTAAGTATTTGCTGAACTAGTTGAATAAATGTCTTG
CAGAGTCTTTAAAAATATGTTGAATAATTGAACGTCTTGCACAGTGACTGGTTAAGTATAGAGA
ATCCGCCAAAAGTTGTCTTGATTATGTAGTGTTCAAGCTCAACTGTCAGAGAGGTTAAATCTAT
CAAAAACTGGGACTTTAAACTTCCATGCAATGCCGGCCAACTTCCAAATTCTGATTTTAAAAAA
AAAAAAAGCCAAAGCCTGCATCGCTAAGCCTAACAGTCAACAAAAAGAAAGCAGAATGAAGACA
AGAAAGCGGTAAGAAATGGGAAGAGACATGTAGCACAGATTGGCTTCAATGTCATCTTAAAATC
AAGATTATGCTTGGTCTGGGCTGTGGGGGTTAAGGGGCAGGTTACACAGAAGAAAAATGGTTCC
AATCCGTTGCTTAATTTTGTTACGGATTTTTCTAGGAAATCTCACCAGACAATTTAGAATTTTA
GAAAAGGTATTTCCCACCTACACAAGAGTTTGCATTCGGGGCCAACACTCTCAGGCTCCTCCAA
GCACTGAGTATAGGACGTTAGATATTGAGCTCAACCCTACGGTACCCCAAGTCTCCATTCTACC
GTTCCACCCGGGGGTGGGGGTGGATAATGGGATAGTGACTCACCTGAATCGGAGGCCACTAGAA
TACCTCTCTCCCCAACCCAAGTGAGGTCAGCCACTCCAGCCTCCGTTTGGACTCCGGCGGAGCA
GAAGCCTTCGTTGGGGGCGGCACAGGGGTCCTTAAAAAGCCAGAGGGAGCCGGCCCAGCAGCGC
CCACTCAGGCTGGAGGCCCCGAGGAGAAGCGCCCCATCTACGGGGGGTACAAGCTGTCAGCGCG
TGAAGGGTAGAAGGGTTCGCCTCCATGGAGACCGCACAGAACAGCGTTCCGGCCGGGTCTGGAT
CTGAGCTCAGGAACGCGGGGCAGGGCTGGGGACAGCTCGG 
 
Fwd sequence: CGTTGGGGGCGGTATAGGGG  62.8°C  
NON CpG Cs CONVERTED TO Ts 
ATP5F1 sequence: CGTTGGGGGCGGCACAGGGG 
 
Rev sequence: CCGAACTATCCCCAACCCTACCC  60.9°C 
Rev complement: GGGTAGGGTTGGGGATAGTTCGG 
NON CpG Cs CONVERTED TO Ts 
ATP5F1 sequence: GGGCAGGGCTGGGGACAGCTCGG 
 
PCR PRODUCT = 223 bp 
 
 
 
 
 
 
 
 
 
 
 
Appendix F. ATP5F1 MS-HRM primer sequence and location 
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DHFR 5’ Upstream Sequence ~ intron 1-2 
ttataatctaaactacaaaaagagttcactggggaactgcacaatatgactgcttttaa
ccgtagtgatttcaaatattgagccatgctgttgcagtcttaaaaactggagacctaag
ggcagctttcttctagtcacccaatccagcacttttttaaaaaatcagtaaaactcttc
gaccaccaaggaaaaaaaaaaaggatggaggttaaaagacgcaccccttgcccacaagc
cccctcatcagaatgggagtcaggagacctgagttcctgtctcaggcctgccattaaaa
acctgcataacctttgcctatctcctcaaacggaagtactaaaacctcagcgcttcacc
caatttgtagccccggctgggctcttcccaccttccccttcttcagcccgccccttcct
cctccagccctatcatcgggcggagggtccccgcctccgcccgccttacccacaagccc
cgcccccccagccccgatggccctgcccAGTCCCAGACAGAACCTACTATGTGCGGCGG
CAGCTGGGGCGGGAAGGCGGGAGCTGGGGGCGCTGGGGGCGCTGCGGCCGCTGCGGCCG
CTGCAGCCGCTGCAGCGCCAGGGTCCACCTGGTCGGCTGCACCTGTGGAGGAGGAGGTG
GATTTCAGGCTTCCCGTAGACTGGAAGAATCGGCTCAAAACCGCTTGCCTCGCAGGGGC
TGAGCTGGAGGCAGCGAGGCCGCCCGACGCAGGCTTCCGGCGAGACATGGCAGGGCAAG
GATGGCAGCCCGGCGGCAGGGCCTGGCGAGGAGCGCGAGCCCGCGGCCGCAGTTCCCAG
GCGTCTGCGGGCGCGAGCACGCCGCGACCCTGCGTGCGCCGGGGCGGGGGGGCGGGGCC
TCGCCTGCACAAATGGGGACGAGGGGGGCGGGGCGGCCACAATTTCGCGCCAAACTTGA
CCGCGCGTTCTGCTGTAACGAGCGGGCTCGGAGGTCCTCCCGCTGCTGTCATGGTTGGT
TCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGGGGACCT
GCCCTGGCCACCGCTCAGgtatctgccgggccggggcgatgggacccaaacgggcgcag
gctgcccacggtcggggtACCTGGGCGGGACGCGCCAggccgactcccggcgagaggat
ggggccagacttgcggtctgcgctggcaggaagggtgggcccgactggattcccctttt
ctgctgcgcgggaggcccagttgctgatttctgcccggattctgctgcccggtgaggtc
tttgccctgcggcgccctcgcccagggcaaagtcccagccctggagaaaacacctcacc
cctacccacagcgctccgtttgtcaggtgccttagagctcgagcccaagggataatgtt
tcgagtaacgctgtttctctaacttgtag 
 
5’ Upstream Sequence 
Exon 1 
Intron 1 
19 bp deletion 
 
Fwd sequence: GAGGGTCCCCGCCTCCGCCCG  54.6°C  
NON CpG Cs CONVERTED TO Ts 
DHFR sequence: GAGGGTTTTCGTTTTCGTTCG 
 
Rev sequence: CGCTGCAGCGCCAGGGTCCACCTG 54.4°C 
Rev complement: CGTTGTAGCGTTAGGGTTTATTTG 
NON CpG Cs CONVERTED TO Ts 
DHFR sequence: CAAATAAACCCTAACGCTACAACG 
PCR PRODUCT = 186 bp 
 
 
Appendix G. DHFR SMART-MSP primer sequence and location 
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DHFRL1 transcripts - multiple sequence alignment 
 
DHFRL1_Transcript1 
ATCCCAGCACCCTCCCTCGCCACCTCGGCCGCGTCCAGAAGCGTCTCATTCAGATAGAGGTACCCAGCCGGGCCCCAGGTCTCACCTGGGTCAGCATTGTCCCGC
TGAGAGCTTTCAAACAACAGGTGTACGCGAATCAGTATCAAAAAGCCTCCAGGGAACTGAAAAAAACAGTCTGACTTCCGGGATTCGCGGGCATCCACTTTCATT
CTCACGTTTCCTCTTCAATTTCTCGC 
 
DHFRL1_Transcript1      GAGATACTGATTTGCTCGCGCTATAGAATTCTTGTCGAAGAGGCTTAGCTCCCGCGGGAG 60 
DHFRL1_Transcript2      GAGATACTGATTTGCTCGCGCTATAGAATTCTTGTCGAAGAGGCTTAGCTCCCGCGGGAG 60 
                        ************************************************************ 
 
DHFRL1_Transcript1      ATTTCGTGCGCAGTTACTTCCGGTAGCTGGTAAAGGCTGATACTTCCCAGGACGCGGAG- 119 
DHFRL1_Transcript2      ATTTCGTGCGCAGTTACTTCCGGTAGCTGGTAAAGGCTGATACTTCCCAGGACGCGGAGG 120 
                        ***********************************************************  
 
DHFRL1_Transcript1      ------------------------------------------------------------ 
DHFRL1_Transcript2      TAACGGGCCAGGGCCAAAGCGACTTTCGCTACTTGGATTGGTCGGCGTAGCTTTGGGCGG 180 
                                 
                                                     
DHFRL1_Transcript1      ------------------------------------------------------------ 
DHFRL1_Transcript2      CCGGACCTTAGAAAGTCACACATCTGCGCGCCTGTGCGGCCCCTGCTTCTGCGGATGCTG 240 
 
                                                                                     
DHFRL1_Transcript1      --GCACGTAAAAAAATTTGAAGAAGGGAATTTCGCGGCATTCTTGGCCTGGCTTCCTGGC 177 
DHFRL1_Transcript2      AGGCACGTAAAAAAATTTGAAGAAGGGAATTTCGCGGCATTCTTGGCCTGGCTTCCTGGC 300 
                          ********************************************************** 
 
DHFRL1_Transcript1      GTAGCCAGCAAGTTCGGAGGTGTTAACCGCTGCTGTCATGTTTCTTTTGCTAAACTGCAT 237 
DHFRL1_Transcript2      GTAGCCAGCAAGTTCGGAGGTGTTAACCGCTGCTGTCATGTTTCTTTTGCTAAACTGCAT 360 
                        ************************************************************ 
 
DHFRL1_Transcript1      CGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCT 297 
DHFRL1_Transcript2      CGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCT 420 
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                        ************************************************************ 
 
 
DHFRL1_Transcript1      CAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACA 357 
DHFRL1_Transcript2      CAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACA 480 
                        ************************************************************ 
 
 
Fwd sequence: GGGCCAGGGCCAAAGCGACTTTCGC 57.5°C  
NON CpG Cs CONVERTED TO Ts 
DHFR sequence: GGGTTAGGGTTAAAGCGATTTTCGT 
 
Rev sequence: CGCCTGTGCGGCCCCTGCTT 58.0°C 
Rev complement: CGCGTTTGTGCGGTTTTTGTTT 
NON CpG Cs CONVERTED TO Ts 
DHFR sequence: AAACAAAAACCGCACAAACGCG 
PCR PRODUCT = 81 bp 
 
 
 
 
 
 
Appendix H. DHFRL1 Transcript Alignment and SMART-MSP primer sequence and location 
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TUBE 
NUMBER PCR 
COL2A1  
Mean Cp 
DHFR  
Mean Cp 
DHFR Cp  
[100%(target - control)] 
DHFR ΔCp  
(target - control) DHFR ΔΔCp 
DHFR  
2^-ΔΔCp 
DHFR % 
methylation 
1 FIP-1074 A 28.21 30.54 -0.56 2.33 2.89 0.135 13.49 
2 FIP-1074 B 28.13 30.14 -1.54 2.01 3.55 0.085 8.54 
3 FIP-1085 A 27.84 30.32 -0.56 2.48 3.04 0.122 12.16 
4 FIP-1085 B 28.42 30.57 -0.56 2.15 2.71 0.153 15.28 
5 FIP-1010 A 28.32 30.14 -0.56 1.82 2.38 0.192 19.21 
6 FIP-1010 B - 37.45           
7 FIP-1156 A 31.34 33.24 -0.56 1.9 2.46 0.182 18.17 
8 FIP-1156 B 25.7 27.61 -0.98 1.91 2.89 0.135 13.49 
9 FIP-1099 A 28.66 30.54 -1.54 1.88 3.42 0.093 9.34 
10 FIP-1099 B 25.75 28.24 -0.56 2.49 3.05 0.121 12.07 
11 FIP-1061 A 29.6 31.76 -0.56 2.16 2.72 0.152 15.18 
12 FIP-1061 B 25.53 28.04 -0.56 2.51 3.07 0.119 11.91 
13 FIP-1069 A 31.27 34.82 -0.4 3.55 3.95 0.065 6.47 
14 FIP-1069 B 26.01 34.93 -0.4 8.92 9.32 0.002 0.16 
15 FIP-1160 A 32.66 32.96 -0.4 0.3 0.7 0.616 61.56 
16 FIP-1160 B 28.04 29.7 -0.4 1.66 2.06 0.240 23.98 
17 FIP-1092 A 31.68 33.33 -0.4 1.65 2.05 0.241 24.15 
18 FIP-1092 B 28.84 31.73 -0.4 2.89 3.29 0.102 10.22 
19 FIP-1123 A 27.15 36.76 -0.4 9.61 10.01 0.001 0.10 
20 FIP-1123 B 34.42 35.48 -0.4 1.06 1.46 0.363 36.35 
21 FIP-1132 A 29.76 33.35 0.12 3.59 3.47 0.090 9.02 
22 FIP-1132 B 25.76 29.66 -0.4 3.9 4.3 0.051 5.08 
23 FIP-1157 A 29.96 31.48 -0.4 1.52 1.92 0.264 26.43 
24 FIP-1157 B 27.47 31.08 -0.4 3.61 4.01 0.062 6.21 
25 FIP-1082 A 30.85 34.45 -0.82 3.6 4.42 0.047 4.67 
26 FIP-1082 B 27.86 31.46 -0.4 3.6 4 0.062 6.25 
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27 FIP-1168 A 30.24 35.21 -0.4 4.97 5.37 0.024 2.42 
28 FIP-1168 B 25.09 28.9 -0.82 3.81 4.63 0.040 4.04 
29 FIP-1174 A 34.88 40 -0.4 5.12 5.52 0.022 2.18 
30 FIP-1174 B 25.8 28.8 -0.82 3 3.82 0.071 7.08 
31 FIP-1180 A 25.07 37.26 -0.4 12.19 12.59 0.000 0.02 
32 FIP-1180 B 27.76 29.38 -0.82 1.62 2.44 0.184 18.43 
33 FIP-1222 A 32.65 34.24 -0.4 1.59 1.99 0.252 25.17 
34 FIP-1222 B 25.91 29.12 -0.4 3.21 3.61 0.082 8.19 
35 FIP-1224 A 31.24 33.68 -0.4 2.44 2.84 0.140 13.97 
36 FIP-1224 B 26.41 30.64 -0.4 4.23 4.63 0.040 4.04 
37 FIP-1003 A 30.96 32.18 -0.09 1.22 1.31 0.403 40.33 
38 FIP-1003 B 27.56 29.34 -0.09 1.78 1.87 0.274 27.36 
39 FIP-1004 A 34.04? 31.05 -1.62 #VALUE! #VALUE! #VALUE! #VALUE! 
40 FIP-1004 B 26.04 28.85 -0.09 2.81 2.9 0.134 13.40 
41 FIP-1005 A 29.47 28.9 -3.3 -0.57 2.73 0.151 15.07 
42 FIP-1005 B 31.28 29.81 -3.3 -1.47 1.83 0.281 28.13 
43 FIP-1007 A 29.05 27.5 -3.3 -1.55 1.75 0.297 29.73 
44 FIP-1007 B 28.93 29.74 -3.3 0.81 4.11 0.058 5.79 
45 FIP-1008 A 29.78 29.23 -3.3 -0.55 2.75 0.149 14.87 
46 FIP-1008 B 27.1 29.66 -0.09 2.56 2.65 0.159 15.93 
47 FIP-1009 A 28.76 30.27 -3.3 1.51 4.81 0.036 3.56 
48 FIP-1009 B 29.2 29.84 -3.3 0.64 3.94 0.065 6.52 
49 b FIP-1012 A 28.4 30.93 -0.34 2.53 2.87 0.137 13.68 
50 FIP-1012 B 27.9 29.31 -3.3 1.41 4.71 0.038 3.82 
51 FIP-1018 A 27.63 28.82 -3.3 1.19 4.49 0.045 4.45 
52 FIP-1018 B 25.87 29.97 -0.09 4.1 4.19 0.055 5.48 
53 FIP-1019 A               
54 FIP-1019 B 25.77 28.55 -0.09 2.78 2.87 0.137 13.68 
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55 FIP-1020 A 28.81 28.87 -3.3 0.06 3.36 0.097 9.74 
56 FIP-1020 B 30.56 32.27 -3.3 1.71 5.01 0.031 3.10 
57 FIP-1022 A 28.11 30.68 -3.3 2.57 5.87 0.017 1.71 
58 FIP-1022 B 29.72 33.44 -3.55 3.72 7.27 0.006 0.65 
59 FIP-1023 A 28.59 31.49 -3.3 2.9 6.2 0.014 1.36 
60 FIP-1023 B 26.64 30.32 -0.09 3.68 3.77 0.073 7.33 
61 b FIP-1024 A 28.48 32.64 -0.34 4.16 4.5 0.044 4.42 
62 FIP-1024 B 30.62 31.11 -3.3 0.49 3.79 0.072 7.23 
63 FIP-1028 A 32.39 31.29 -3.3 -1.1 2.2 0.218 21.76 
64 FIP-1028 B 31.18 30.19 -3.3 -0.99 2.31 0.202 20.17 
65 FIP-1030 A 23.58 28.21 -0.09 4.63 4.72 0.038 3.79 
66 FIP-1030 B 28.22 31.05 -0.09 2.83 2.92 0.132 13.21 
67 b FIP-1031 A 29.75 33.36 -0.09 3.61 3.7 0.077 7.69 
68 FIP-1031 B               
69 FIP-1032 A               
70 FIP-1032 B               
71 FIP-1033 A 25.7 29.38 -0.73 3.68 4.41 0.047 4.70 
72 FIP-1033 B 27.1 31.12 -0.73 4.02 4.75 0.037 3.72 
73 FIP-1035 A 29.8 32.63 -0.34 2.83 3.17 0.111 11.11 
74 FIP-1035 B 27.04 30.18 -0.34 3.14 3.48 0.090 8.96 
75 FIP-1037 A 33.19 35.29 -1.54 2.1 3.64 0.080 8.02 
76 FIP-1037 B 27.7 31.63 -0.34 3.93 4.27 0.052 5.18 
77 FIP-1041 A 29.59 32.6 -0.34 3.01 3.35 0.098 9.81 
78 FIP-1041 B 29.11 32.67 -0.34 3.56 3.9 0.067 6.70 
79 FIP-1042 A 30.86 34.71 -0.34 3.85 4.19 0.055 5.48 
80 FIP-1042 B 29.04 33.12 -0.34 4.08 4.42 0.047 4.67 
81 FIP-1043 A 29.46 31.65 -0.34 2.19 2.53 0.173 17.31 
82 FIP-1043 B 27.25 31.87 -0.34 4.62 4.96 0.032 3.21 
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83 FIP-1050 A 29.05 31.15 -0.34 2.1 2.44 0.184 18.43 
84 FIP-1050 B 25.16 28.3 -0.34 3.14 3.48 0.090 8.96 
85 FIP-1052 A 27.37 30.76 -0.34 3.39 3.73 0.075 7.54 
86 FIP-1052 B 27.65 30.16 -0.34 2.51 2.85 0.139 13.87 
87 FIP-1053 A 28.26 30.64 -1.54 2.38 3.92 0.066 6.61 
88 FIP-1053 B 27.7 30.49 -0.34 2.79 3.13 0.114 11.42 
89 FIP-1062 A 26.81 29.72 -0.34 2.91 3.25 0.105 10.51 
90 FIP-1062 B 27.59 30.64 -0.34 3.05 3.39 0.095 9.54 
91 FIP-1063 A 31.32 32.67 -0.34 1.35 1.69 0.310 30.99 
92 FIP-1063 B 27.58 30.37 -0.34 2.79 3.13 0.114 11.42 
93 FIP-1064 A 29.5 32.83 -0.34 3.33 3.67 0.079 7.86 
94 FIP-1064 B 27.27 30.26 -0.34 2.99 3.33 0.099 9.94 
95 FIP-1066 A 30.25 34 -0.34 3.75 4.09 0.059 5.87 
96 FIP-1066 B 28.93 30.46 -1.91 1.53 3.44 0.092 9.21 
97 FIP-1067 A 29.42 31.32 0.28 1.9 1.62 0.325 32.53 
98 FIP-1067 B 30.17 33.7 0.28 3.53 3.25 0.105 10.51 
99 FIP-1070 A 24.76 26.94 -1.42 2.18 3.6 0.082 8.25 
100 FIP-1070 B 27.23 29.72 -1.42 2.49 3.91 0.067 6.65 
101 FIP-1076 A 30.19 31.9 0.28 1.71 1.43 0.371 37.11 
102 FIP-1076 B 28.51 30.26 0.28 1.75 1.47 0.361 36.10 
103 FIP-1077 A 30.17 31.87 0.28 1.7 1.42 0.374 37.37 
104 FIP-1077 B 27.8 30.32 0.16 2.52 2.36 0.195 19.48 
105 FIP1078 A 28.29 30.19 0.28 1.9 1.62 0.325 32.53 
106 FIP-1078 B 27.05 29.71 0.28 2.66 2.38 0.192 19.21 
107 FIP1087 A 30.43 32.27 0.28 1.84 1.56 0.339 33.92 
108 FIP-1090 A 29.74 32.11 0.28 2.37 2.09 0.235 23.49 
109 FIP-1090 B 29.28 32.07 0.28 2.79 2.51 0.176 17.56 
110 FIP-1091 A 27.73 31.08 0.28 3.35 3.07 0.119 11.91 
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111 FIP-1091 B 25.82 29.15 0.28 3.33 3.05 0.121 12.07 
112 FIP-1093 A 29.57 31.07 0.28 1.5 1.22 0.429 42.93 
113 FIP-1093 B 24.75 28.69 0.28 3.94 3.66 0.079 7.91 
114 FIP-1095 A 30.52 33.49 0.28 2.97 2.69 0.155 15.50 
115 FIP-1095 B 28.43 30.72 -1.42 2.29 3.71 0.076 7.64 
116 FIP-1100 A 28.74 30.87 0.28 2.13 1.85 0.277 27.74 
117 FIP-1100 B 30.37 32.57 0.28 2.2 1.92 0.264 26.43 
118 FIP-1102 A 27.82 30.33 0.28 2.51 2.23 0.213 21.32 
119 FIP-1102 B 27.98 30.37 0.28 2.39 2.11 0.232 23.16 
120 FIP-1107 A 27.98 30.96 -1.42 2.98 4.4 0.047 4.74 
121 FIP-1107 B 28.29 30.39 0.28 2.1 1.82 0.283 28.32 
122 FIP-1108 A 28.49 32.2 0.28 3.71 3.43 0.093 9.28 
123 FIP-1108 B 27.79 36.82 0.28 9.03 8.75 0.002 0.23 
124 FIP-1109 A 29.96 31.67 -1.42 1.71 3.13 0.114 11.42 
125 FIP-1109 B 26.9 29.17 -1.54 2.27 3.81 0.071 7.13 
126 FIP-1110 A 29.51 31.98 0.28 2.47 2.19 0.219 21.92 
127 FIP-1110 B 26.95 29.64 0.28 2.69 2.41 0.188 18.82 
128 FIP-1112 A 30.26 32.34 0.28 2.08 1.8 0.287 28.72 
129 FIP-1112 B 24.94 28.02 0.28 3.08 2.8 0.144 14.36 
130 FIP-1113 A 27.15 30.46 0.28 3.31 3.03 0.122 12.24 
131 FIP-1113 B 27.47 30.82 0.28 3.35 3.07 0.119 11.91 
132 FIP-1114 A 29.74 32.72 0.28 2.98 2.7 0.154 15.39 
133 FIP-1114 B 27.22 30.67 0.28 3.45 3.17 0.111 11.11 
134 FIP-1114 B 27.28 27.95 -2.55 0.67 3.22 0.107 10.73 
135 FIP-1115 A 31.04 31.54 -1.54 0.5 2.04 0.243 24.32 
136 FIP-1115 B 25.88 28.09 0.28 2.21 1.93 0.262 26.24 
137 FIP-1116 A 29.95 31.52 0.16 1.57 1.41 0.376 37.63 
138 FIP-1116 B 28.07 29.39 0.16 1.32 1.16 0.448 44.75 
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139 FIP-1118 A 29.28 31.08 0.16 1.8 1.64 0.321 32.09 
140 FIP-1118 B 22.64 26.52 0.16 3.88 3.72 0.076 7.59 
141 FIP-1119 A 27.5 29.18 0.16 1.68 1.52 0.349 34.87 
142 FIP-1119 B 26.3 28.3 0.16 2 1.84 0.279 27.93 
143 FIP-1120 A 28.75 31.1 0.16 2.35 2.19 0.219 21.92 
144 FIP-1120 B 27.4 28.87 0.16 1.47 1.31 0.403 40.33 
145 FIP-1122 A 29.59 30.9 0.16 1.31 1.15 0.451 45.06 
146 FIP-1122 B 26.91 28.27 0.16 1.36 1.2 0.435 43.53 
147 FIP-1126 A 29.91 31.91 0.16 2 1.84 0.279 27.93 
148 FIP-1126 B 28.04 29.66 0.16 1.62 1.46 0.363 36.35 
149 FIP-1127 A 26.68 29.49 0.16 2.81 2.65 0.159 15.93 
150 FIP-1127 B 26.76 31.68 0.16 4.92 4.76 0.037 3.69 
151 FIP-1131 A 27.63 29.28 -1.86 1.65 3.51 0.088 8.78 
152 FIP-1131 B 28.57 39.66 -3.44 11.09 14.53 0.000 0.00 
153 FIP-1134 B 28.58 29.61 0.16 1.03 0.87 0.547 54.71 
154 FIP-1135 A 28.32 30.17 0.16 1.85 1.69 0.310 30.99 
155 FIP-1136 A 30.37 32.4 0.16 2.03 1.87 0.274 27.36 
156 FIP-1136 B 27.69 29.37 0.16 1.68 1.52 0.349 34.87 
157 FIP-1138 A 29.75 31.99 0.16 2.24 2.08 0.237 23.65 
158 FIP-1138 B 25.21 25.57 -2.87 0.36 3.23 0.107 10.66 
159 FIP-1139 A 30.51 32.23 0.16 1.72 1.56 0.339 33.92 
160 FIP-1139 B 27.81 29.08 0.16 1.27 1.11 0.463 46.33 
161 FIP-1141 A 30.91 32.21 0.16 1.3 1.14 0.454 45.38 
162 FIP-1141 B 24.99 27.65 0.16 2.66 2.5 0.177 17.68 
163 FIP-1144 A 24.1 26.99 0.16 2.89 2.73 0.151 15.07 
164 FIP-1144 B 27.75 34.19 0.16 6.44 6.28 0.013 1.29 
165 FIP-1145 A 29.27 32.49 0.16 3.22 3.06 0.120 11.99 
166 FIP-1145 B 26.91 29.01 0.16 2.1 1.94 0.261 26.06 
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167 FIP-1151 A 28.81 31.38 -1.86 2.57 4.43 0.046 4.64 
168 FIP-1151 B 29.88 31.23 0.16 1.35 1.19 0.438 43.83 
169 FIP-1152 A 30.03 32.81 0.16 2.78 2.62 0.163 16.27 
170 FIP-1152 B 27.65 31.28 0.16 3.63 3.47 0.090 9.02 
171 FIP-1153 A 30.39 33.02 0.16 2.63 2.47 0.180 18.05 
172 FIP-1153 B 26.84 28.45 0.16 1.61 1.45 0.366 36.60 
173 FIP-1154 A 31.24 33.55 0.16 2.31 2.15 0.225 22.53 
174 FIP-1154 B 25.44 28.52 0.16 3.08 2.92 0.132 13.21 
175 FIP-1155 A 28.09 29.94 0.16 1.85 1.69 0.310 30.99 
176 FIP-1155 B 27.58 30.16 0.16 2.58 2.42 0.187 18.69 
177 FIP-1161 A 31.37 32.95 -0.02 1.58 1.6 0.330 32.99 
178 FIP-1161 B 26.44 29.39 -0.02 2.95 2.97 0.128 12.76 
179 FIP-1163 A 31.08 33.41 -0.02 2.33 2.35 0.196 19.61 
180 FIP-1163 B 27.26 30.68 -0.02 3.42 3.44 0.092 9.21 
181 FIP-1166 A 25.61 29.3 -0.02 3.69 3.71 0.076 7.64 
182 FIP-1166 B 27.68 30.2 -0.02 2.52 2.54 0.172 17.19 
183 FIP-1171 A 26.97 29.74 -0.02 2.77 2.79 0.145 14.46 
184 FIP-1171 B 27.64 30.11 -0.02 2.47 2.49 0.178 17.80 
185 FIP-1173 A 26.03 28.45 -0.02 2.42 2.44 0.184 18.43 
186 FIP-1173 B 27.25 29.49 -0.02 2.24 2.26 0.209 20.88 
187 FIP-1177 A 27.75 30.81 -0.02 3.06 3.08 0.118 11.83 
188 FIP-1177 B 27.34 30.03 -0.02 2.69 2.71 0.153 15.28 
189 FIP-1183 A 29.86 32.02 -0.11 2.16 2.27 0.207 20.73 
190 FIP-1183 B 28.91 31.14 -0.02 2.23 2.25 0.210 21.02 
191 FIP-1185 A 27.72 29.89 -0.02 2.17 2.19 0.219 21.92 
192 FIP-1185 B 29.44 30.57 -1 1.13 2.13 0.228 22.85 
193 FIP-1185 B 26.17 29.51 -0.02 3.34 3.36 0.097 9.74 
194 FIP-1187 A 29.77 31.93 -0.11 2.16 2.27 0.207 20.73 
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195 FIP-1187 B 26.17 29.96 -0.02 3.79 3.81 0.071 7.13 
196 FIP-1188 A 31.14 33.37 -0.11 2.23 2.34 0.198 19.75 
197 FIP-1188 B 27.65 31 -0.02 3.35 3.37 0.097 9.67 
198 FIP-1189 A 33.22 34.96 -0.02 1.74 1.76 0.295 29.52 
199 FIP-1189 B 29.29 32.34 -0.02 3.05 3.07 0.119 11.91 
200 FIP-1190 A 30.14 32.08 -0.02 1.94 1.96 0.257 25.70 
201 FIP-1190 B 29.72 32.11 -0.02 2.39 2.41 0.188 18.82 
202 FIP-1192 A 32.43 34.86 -0.02 2.43 2.45 0.183 18.30 
203 FIP-1192 B 28.91 32.51 -0.02 3.6 3.62 0.081 8.13 
204 FIP-1193 A 33 35.94 -0.02 2.94 2.96 0.129 12.85 
205 FIP-1193 B 29.22 32.02 -0.02 2.8 2.82 0.142 14.16 
206 FIP-1194 A 31.67 34.37 -0.02 2.7 2.72 0.152 15.18 
207 FIP-1194 B 30.31 32.64 -0.02 2.33 2.35 0.196 19.61 
208 FIP-1195 A 31.29 33.28 -0.02 1.99 2.01 0.248 24.83 
209 FIP-1195 B 28.94 32.51 -0.02 3.57 3.59 0.083 8.30 
210 FIP-1197 A 31.64 35.05 -0.02 3.41 3.43 0.093 9.28 
211 FIP-1197 B 29.98 33.87 -0.02 3.89 3.91 0.067 6.65 
212 FIP-1198 A 30.57 34.09 -0.02 3.52 3.54 0.086 8.60 
213 FIP-1199 A 32.91 35.86 -0.02 2.95 2.97 0.128 12.76 
214 FIP-1199 B 32.6 34.84 -0.02 2.24 2.26 0.209 20.88 
215 FIP-1200 A         0     
216 FIP-1200 B 30.2 32.67 -0.02 2.47 2.49 0.178 17.80 
217 FIP-1201 A 32.81 28.65 -6.19 -4.16 2.03 0.245 24.49 
218 FIP-1201 B 31.42 27.93 -6.19 -3.49 2.7 0.154 15.39 
219 FIP-1203 A         0     
220 FIP-1203 B 31.77 28.06 -6.19 -3.71 2.48 0.179 17.92 
221 FIP-1204 A               
222 FIP-1204 B 31.55 29.01 -6.19 -2.54 3.65 0.080 7.97 
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223 FIP-1205 A               
224 FIP-1205 B 30.61 26.5 -6.19 -4.11 2.08 0.237 23.65 
225 FIP-1206 A 29.48 26.56 -6.19 -2.92 3.27 0.104 10.37 
226 FIP-1206 B 29.65 27.09 -6.19 -2.56 3.63 0.081 8.08 
227 FIP-1209 A 32.68 29.43 -6.19 -3.25 2.94 0.130 13.03 
228 FIP-1209 B 30.91 28.18 -6.19 -2.73 3.46 0.091 9.09 
229 FIP-1210 B 30.66 28.5 -6.19 -2.16 4.03 0.061 6.12 
230 FIP-1211 A               
231 FIP-1211 B 31.12 28.47 -6.19 -2.65 3.54 0.086 8.60 
232 FIP-1212 A 32.77 28.93 -6.19 -3.84 2.35 0.196 19.61 
233 FIP-1212 B 30.34 27.13 -6.19 -3.21 2.98 0.127 12.67 
234 FIP-1214 A 31.18 28.25 -6.19 -2.93 3.26 0.104 10.44 
235 FIP-1214 B 29.92 27.66 -6.19 -2.26 3.93 0.066 6.56 
236 FIP-1215 A 32.36 29.45 -6.19 -2.91 3.28 0.103 10.29 
237 FIP-1215 B 26.66 27.08 -6.19 0.42 6.61 0.010 1.02 
238 FIP-1216 A 30.68 28.12 -6.19 -2.56 3.63 0.081 8.08 
239 FIP-1216 B 28.37 27.61 -6.19 -0.76 5.43 0.023 2.32 
240 FIP-1217 A 30.06 26.83 -6.19 -3.23 2.96 0.129 12.85 
241 FIP-1217 B 31.42 27.96 -6.19 -3.46 2.73 0.151 15.07 
242 FIP-1218 A 33.73 31.53 -6.19 -2.2 3.99 0.063 6.29 
243 FIP-1218 B               
244 FIP-1219 A 33.87 31.21 -6.19 -2.66 3.53 0.087 8.66 
245 FIP-1219 B 31.06 29.3 -6.19 -1.76 4.43 0.046 4.64 
246 FIP-1220 A 32.79 30.89 -6.19 -1.9 4.29 0.051 5.11 
247 FIP-1220 B 31.8 29.81 -6.19 -1.99 4.2 0.054 5.44 
248 FIP-1225 A 33.73 30.47 -6.19 -3.26 2.93 0.131 13.12 
249 FIP-1225 B 31.34 28.61 -6.17 -2.73 3.44 0.092 9.21 
250 FIP-1226 A 30.55 28.95 -6.19 -1.6 4.59 0.042 4.15 
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251 FIP-1226 B 30.16 28.36 -6.17   6.17 0.014 1.39 
252 FIP-2001 A 31.52 29.67 -6.19 -1.85 4.34 0.049 4.94 
253 FIP-2002 A               
254 FIP-2003 A 30.88 29.82 -6.19 -1.06 5.13 0.029 2.86 
255 FIP-2003 A 25.53 26.38 -3.44 0.85 4.29 0.051 5.11 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix I. Raw Cp values and analysis for the COL2A1 and DHFR SMART-MSP Assays 
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TUBE 
NUMBER PCR 
COL2A1 Mean 
Cp L1 Mean Cp 
L1 Cp  
[100%(target - control)] 
L1 ΔCp  
(target - control) L1 ΔΔCp L1 2^ΔΔCp 
L1 % 
methylation 
1 FIP-1074 A 28.21 35.88 1.17 7.67 6.5 0.011 1.10 
2 FIP-1074 B 28.13 34.88 1.17 6.75 5.58 0.021 2.09 
3 FIP-1085 A 27.84 35.01 1.17 7.17 6 0.016 1.56 
4 FIP-1085 B 28.42 36.5 1.17 8.08 6.91 0.008 0.83 
5 FIP-1010 A 28.32 34.14 1.17 5.82 4.65 0.040 3.98 
6 FIP-1010 B 
 
37.65 
    
0.00 
7 FIP-1156 A 31.34 37.54 1.17 6.2 5.03 0.031 3.06 
8 FIP-1156 B 25.7 32.18 1.17 6.48 5.31 0.025 2.52 
9 FIP-1099 A 28.66 35.15 1.17 6.49 5.32 0.025 2.50 
10 FIP-1099 B 25.75 32.82 1.17 7.07 5.9 0.017 1.67 
11 FIP-1061 A 29.6 36.61 1.17 7.01 5.84 0.017 1.75 
12 FIP-1061 B 25.53 32.66 1.17 7.13 5.96 0.016 1.61 
13 FIP-1069 A 31.27 40 1.33 8.73 7.4 0.006 0.59 
14 FIP-1069 B 26.01 39.39 1.33 13.38 12.05 0.000 0.02 
15 FIP-1160 A 32.66 37.45 1.33 4.79 3.46 0.091 9.09 
16 FIP-1160 B 28.04 34.18 1.33 6.14 4.81 0.036 3.56 
17 FIP-1092 A 31.68 38.32 1.33 6.64 5.31 0.025 2.52 
18 FIP-1092 B 28.84 35.67 1.33 6.83 5.5 0.022 2.21 
19 FIP-1123 A 27.15 38.6 1.33 11.45 10.12 0.001 0.09 
20 FIP-1123 B 34.42 40 1.33 5.58 4.25 0.053 5.26 
21 FIP-1132 A 29.76 38.85 -1.13 9.09 10.22 0.001 0.08 
22 FIP-1132 B 25.76 37.38 1.33 11.62 10.29 0.001 0.08 
23 FIP-1157 A 29.96 38.1 1.33 8.14 6.81 0.009 0.89 
24 FIP-1157 B 27.47 36.02 1.33 8.55 7.22 0.007 0.67 
25 FIP-1082 A 30.85 40 1.33 9.15 7.82 0.004 0.44 
26 FIP-1082 B 27.86 37.03 1.33 9.17 7.84 0.004 0.44 
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27 FIP-1168 A 30.24 40 1.33 9.76 8.43 0.003 0.29 
28 FIP-1168 B 25.09 34.13 1.33 9.04 7.71 0.005 0.48 
29 FIP-1174 A 34.88 40 0.12 5.12 5 0.031 3.13 
30 FIP-1174 B 25.8 34.03 1.33 8.23 6.9 0.008 0.84 
31 FIP-1180 A 25.07 40 1.33 14.93 13.6 0.000 0.01 
32 FIP-1180 B 27.76 34.22 1.33 6.46 5.13 0.029 2.86 
33 FIP-1222 A 32.65 40 1.33 7.35 6.02 0.015 1.54 
34 FIP-1222 B 25.91 33.76 1.33 7.85 6.52 0.011 1.09 
35 FIP-1224 A 31.24 40 1.33 8.76 7.43 0.006 0.58 
36 FIP-1224 B 26.41 36.65 1.33 10.24 8.91 0.002 0.21 
37 FIP-1003 A 30.96 39.39 -4.82 8.43 13.25 0.000 0.01 
38 FIP-1003 B 27.56 34.27 -4.82 6.71 11.53 0.000 0.03 
39 FIP-1004 A 34.04? 33.81 -3.14 #VALUE! #VALUE! #VALUE! #VALUE! 
40 FIP-1004 B 26.04 34.69 -4.82 8.65 13.47 0.000 0.01 
41 FIP-1005 A 29.47 33.96 -4.82 4.49 9.31 0.002 0.16 
42 FIP-1005 B 31.28 37.01 -4.82 5.73 10.55 0.001 0.07 
43 FIP-1007 A 29.05 33.19 -4.82 4.14 8.96 0.002 0.20 
44 FIP-1007 B 28.93 34.71 -4.82 5.78 10.6 0.001 0.06 
45 FIP-1008 A 29.78 36.04 -4.82 6.26 11.08 0.000 0.05 
46 FIP-1008 B 27.1 35.99 -4.82 8.89 13.71 0.000 0.01 
47 FIP-1009 A 28.76 37.84 -4.82 9.08 13.9 0.000 0.01 
48 FIP-1009 B 29.2 34.8 -4.82 5.6 10.42 0.001 0.07 
49 b FIP-1012 A 28.4 38.5 -4.82 10.1 14.92 0.000 0.00 
50 FIP-1012 B 27.9 34.18 -4.82 6.28 11.1 0.000 0.05 
51 FIP-1018 A 27.63 34.5 -4.82 6.87 11.69 0.000 0.03 
52 FIP-1018 B 25.87 37.8 -4.82 11.93 16.75 0.000 0.00 
53 FIP-1019 A 
       54 FIP-1019 B 25.77 35.2 -4.82 9.43 14.25 0.000 0.01 
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55 FIP-1020 A 28.81 36.09 -4.82 7.28 12.1 0.000 0.02 
56 FIP-1020 B 30.56 35.82 -4.82 5.26 10.08 0.001 0.09 
57 FIP-1022 A 28.11 37.48 -4.82 9.37 14.19 0.000 0.01 
58 FIP-1022 B 29.72 40 -4.82 10.28 15.1 0.000 0.00 
59 FIP-1023 A 28.59 39.16 -4.82 10.57 15.39 0.000 0.00 
60 FIP-1023 B 26.64 36.97 -4.82 10.33 15.15 0.000 0.00 
61 b FIP-1024 A 28.48 36.91 -4.82 8.43 13.25 0.000 0.01 
62 FIP-1024 B 30.62 39.38 -4.82 8.76 13.58 0.000 0.01 
63 FIP-1028 A 32.39 38.55 -4.82 6.16 10.98 0.000 0.05 
64 FIP-1028 B 31.18 37.35 -4.82 6.17 10.99 0.000 0.05 
65 FIP-1030 A 23.58 36.44 -4.82 12.86 17.68 0.000 0.00 
66 FIP-1030 B 28.22 40 -4.82 11.78 16.6 0.000 0.00 
67 b FIP-1031 A 29.75 40 -4.82 10.25 15.07 0.000 0.00 
68 FIP-1031 B 
       69 FIP-1032 A 
       70 FIP-1032 B 
       71 FIP-1033 A 25.7 36.39 -2.25 10.69 12.94 0.000 0.01 
72 FIP-1033 B 27.1 38.87 -2.25 11.77 14.02 0.000 0.01 
73 FIP-1035 A 29.8 37.88 0.6 8.08 7.48 0.006 0.56 
74 FIP-1035 B 27.04 35.64 0.6 8.6 8 0.004 0.39 
75 FIP-1037 A 33.19 40 0.6 6.81 6.21 0.014 1.35 
76 FIP-1037 B 27.7 35.57 0.6 7.87 7.27 0.006 0.65 
77 FIP-1041 A 29.59 37.19 0.6 7.6 7 0.008 0.78 
78 FIP-1041 B 29.11 37.86 0.6 8.75 8.15 0.004 0.35 
79 FIP-1042 A 30.86 40 0.6 9.14 8.54 0.003 0.27 
80 FIP-1042 B 29.04 36.52 0.6 7.48 6.88 0.008 0.85 
81 FIP-1043 A 29.46 36.49 0.6 7.03 6.43 0.012 1.16 
82 FIP-1043 B 27.25 37.25 0.6 10 9.4 0.001 0.15 
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83 FIP-1050 A 29.05 36.54 0.6 7.49 6.89 0.008 0.84 
84 FIP-1050 B 25.16 32.76 0.6 7.6 7 0.008 0.78 
85 FIP-1052 A 27.37 35.58 0.6 8.21 7.61 0.005 0.51 
86 FIP-1052 B 27.65 36.03 0.6 8.38 7.78 0.005 0.45 
87 FIP-1053 A 28.26 35.91 0.6 7.65 7.05 0.008 0.75 
88 FIP-1053 B 27.7 33.64 0.6 5.94 5.34 0.025 2.47 
89 FIP-1062 A 26.81 34.2 0.6 7.39 6.79 0.009 0.90 
90 FIP-1062 B 27.59 35.97 0.6 8.38 7.78 0.005 0.45 
91 FIP-1063 A 31.32 40 0.6 8.68 8.08 0.004 0.37 
92 FIP-1063 B 27.58 36.39 0.6 8.81 8.21 0.003 0.34 
93 FIP-1064 A 29.5 37.65 0.6 8.15 7.55 0.005 0.53 
94 FIP-1064 B 27.27 35.35 0.6 8.08 7.48 0.006 0.56 
95 FIP-1066 A 30.25 39.77 0.6 9.52 8.92 0.002 0.21 
96 FIP-1066 B 28.93 37.74 0.6 8.81 8.21 0.003 0.34 
97 FIP-1067 A 29.42 33.49 -1.49 4.07 5.56 0.021 2.12 
98 FIP-1067 B 30.17 36.67 -1.49 6.5 7.99 0.004 0.39 
99 FIP-1070 A 24.76 28.91 -1.49 4.15 5.64 0.020 2.01 
100 FIP-1070 B 27.23 32.63 -1.49 5.4 6.89 0.008 0.84 
101 FIP-1076 A 30.19 33.46 -1.49 3.27 4.76 0.037 3.69 
102 FIP-1076 B 28.51 31.86 -1.49 3.35 4.84 0.035 3.49 
103 FIP-1077 A 30.17 33.5 -1.49 3.33 4.82 0.035 3.54 
104 FIP-1077 B 27.8 32.78 -1.61 4.98 6.59 0.010 1.04 
105 FIP1078 A 28.29 31.88 -1.49 3.59 5.08 0.030 2.96 
106 FIP-1078 B 27.05 31.08 -1.49 4.03 5.52 0.022 2.18 
107 FIP1087 A 30.43 34.38 -1.49 3.95 5.44 0.023 2.30 
108 FIP-1090 A 29.74 33.89 -1.49 4.15 5.64 0.020 2.01 
109 FIP-1090 B 29.28 35.03 -1.49 5.75 7.24 0.007 0.66 
110 FIP-1091 A 27.73 33.04 -1.49 5.31 6.8 0.009 0.90 
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111 FIP-1091 B 25.82 31.29 -1.49 5.47 6.96 0.008 0.80 
112 FIP-1093 A 29.57 33.34 -1.49 3.77 5.26 0.026 2.61 
113 FIP-1093 B 24.75 30.06 -1.49 5.31 6.8 0.009 0.90 
114 FIP-1095 A 30.52 35.14 -1.49 4.62 6.11 0.014 1.45 
115 FIP-1095 B 28.43 33.65 -1.49 5.22 6.71 0.010 0.96 
116 FIP-1100 A 28.74 33.29 -1.49 4.55 6.04 0.015 1.52 
117 FIP-1100 B 30.37 37.39 0.08 7.02 6.94 0.008 0.81 
118 FIP-1102 A 27.82 32.55 -1.49 4.73 6.22 0.013 1.34 
119 FIP-1102 B 27.98 32.61 -1.49 4.63 6.12 0.014 1.44 
120 FIP-1107 A 27.98 32.99 -1.49 5.01 6.5 0.011 1.10 
121 FIP-1107 B 28.29 32.15 -1.49 3.86 5.35 0.025 2.45 
122 FIP-1108 A 28.49 35.34 -1.49 6.85 8.34 0.003 0.31 
123 FIP-1108 B 27.79 37.55 0.6 9.76 9.16 0.002 0.17 
124 FIP-1109 A 29.96 34.64 -1.49 4.68 6.17 0.014 1.39 
125 FIP-1109 B 26.9 31.88 0.81 4.98 4.17 0.056 5.56 
126 FIP-1110 A 29.51 33.98 -1.49 4.47 5.96 0.016 1.61 
127 FIP-1110 B 26.95 31.19 -1.49 4.24 5.73 0.019 1.88 
128 FIP-1112 A 30.26 34.87 -1.49 4.61 6.1 0.015 1.46 
129 FIP-1112 B 24.94 29.87 -0.51 4.93 5.44 0.023 2.30 
130 FIP-1113 A 27.15 31.13 -0.51 3.98 4.49 0.045 4.45 
131 FIP-1113 B 27.47 32.47 -0.51 5 5.51 0.022 2.19 
132 FIP-1114 A 29.74 34.55 -0.51 4.81 5.32 0.025 2.50 
133 FIP-1114 B 27.22 33.66 -0.51 6.44 6.95 0.008 0.81 
134 FIP-1114 B 27.28 33.27 -0.63 5.99 6.62 0.010 1.02 
135 FIP-1115 A 31.04 35.05 -0.51 4.01 4.52 0.044 4.36 
136 FIP-1115 B 25.88 30.27 -0.51 4.39 4.9 0.033 3.35 
137 FIP-1116 A 29.95 34.92 -0.95 4.97 5.92 0.017 1.65 
138 FIP-1116 B 28.07 32.23 -0.95 4.16 5.11 0.029 2.90 
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139 FIP-1118 A 29.28 34.74 -0.95 5.46 6.41 0.012 1.18 
140 FIP-1118 B 22.64 30.8 -0.95 8.16 9.11 0.002 0.18 
141 FIP-1119 A 27.5 32.18 -0.95 4.68 5.63 0.020 2.02 
142 FIP-1119 B 26.3 31.17 -0.95 4.87 5.82 0.018 1.77 
143 FIP-1120 A 28.75 34.87 -0.95 6.12 7.07 0.007 0.74 
144 FIP-1120 B 27.4 32.21 -0.95 4.81 5.76 0.018 1.85 
145 FIP-1122 A 29.59 34.19 -0.95 4.6 5.55 0.021 2.13 
146 FIP-1122 B 26.91 31.92 -0.95 5.01 5.96 0.016 1.61 
147 FIP-1126 A 29.91 36.78 -0.95 6.87 7.82 0.004 0.44 
148 FIP-1126 B 28.04 33.59 -0.95 5.55 6.5 0.011 1.10 
149 FIP-1127 A 26.68 33.01 -0.95 6.33 7.28 0.006 0.64 
150 FIP-1127 B 26.76 32.81 -0.95 6.05 7 0.008 0.78 
151 FIP-1131 A 27.63 32.92 -0.95 5.29 6.24 0.013 1.32 
152 FIP-1131 B 28.57 31.64 -3.14 3.07 6.21 0.014 1.35 
153 FIP-1134 B 28.58 32.65 -0.95 4.07 5.02 0.031 3.08 
154 FIP-1135 A 28.32 33.3 -0.95 4.98 5.93 0.016 1.64 
155 FIP-1136 A 30.37 36.23 -0.95 5.86 6.81 0.009 0.89 
156 FIP-1136 B 27.69 32.71 -0.95 5.02 5.97 0.016 1.60 
157 FIP-1138 A 29.75 38.23 -0.95 8.48 9.43 0.001 0.14 
158 FIP-1138 B 25.21 32.3 -0.95 7.09 8.04 0.004 0.38 
159 FIP-1139 A 30.51 38 -0.95 7.49 8.44 0.003 0.29 
160 FIP-1139 B 27.81 33.08 -0.95 5.27 6.22 0.013 1.34 
161 FIP-1141 A 30.91 36.35 -0.95 5.44 6.39 0.012 1.19 
162 FIP-1141 B 24.99 31.76 -0.95 6.77 7.72 0.005 0.47 
163 FIP-1144 A 24.1 30.99 -0.95 6.89 7.84 0.004 0.44 
164 FIP-1144 B 27.75 36.1 -0.95 8.35 9.3 0.002 0.16 
165 FIP-1145 A 29.27 35.92 -0.95 6.65 7.6 0.005 0.52 
166 FIP-1145 B 26.91 33.11 -0.95 6.2 7.15 0.007 0.70 
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167 FIP-1151 A 28.81 35.99 -0.95 7.18 8.13 0.004 0.36 
168 FIP-1151 B 29.88 34.95 -0.95 5.07 6.02 0.015 1.54 
169 FIP-1152 A 30.03 37.4 -1.93 7.37 9.3 0.002 0.16 
170 FIP-1152 B 27.65 34.28 -0.36 6.63 6.99 0.008 0.79 
171 FIP-1153 A 30.39 35.46 -1.93 5.07 7 0.008 0.78 
172 FIP-1153 B 26.84 30.65 -1.93 3.81 5.74 0.019 1.87 
173 FIP-1154 A 31.24 36.26 -1.93 5.02 6.95 0.008 0.81 
174 FIP-1154 B 25.44 30.38 -1.93 4.94 6.87 0.009 0.85 
175 FIP-1155 A 28.09 32.5 -1.93 4.41 6.34 0.012 1.23 
176 FIP-1155 B 27.58 32.18 -1.93 4.6 6.53 0.011 1.08 
177 FIP-1161 A 31.37 34.31 -2.54 2.94 5.48 0.022 2.24 
178 FIP-1161 B 26.44 31.14 -2.54 4.7 7.24 0.007 0.66 
179 FIP-1163 A 31.08 40 3.29 8.92 5.63 0.020 2.02 
180 FIP-1163 B 27.26 32.22 -2.54 4.96 7.5 0.006 0.55 
181 FIP-1166 A 25.61 35.73 3.29 10.12 6.83 0.009 0.88 
182 FIP-1166 B 27.68 35.33 3.29 7.65 4.36 0.049 4.87 
183 FIP-1171 A 26.97 35.84 3.29 8.87 5.58 0.021 2.09 
184 FIP-1171 B 27.64 36.04 3.29 8.4 5.11 0.029 2.90 
185 FIP-1173 A 26.03 29.69 -2.54 3.66 6.2 0.014 1.36 
186 FIP-1173 B 27.25 36.45 3.29 9.2 5.91 0.017 1.66 
187 FIP-1177 A 27.75 36.77 3.29 9.02 5.73 0.019 1.88 
188 FIP-1177 B 27.34 37.09 3.29 9.75 6.46 0.011 1.14 
189 FIP-1183 A 29.86 39.25 3.2 9.39 6.19 0.014 1.37 
190 FIP-1183 B 28.91 36.84 3.29 7.93 4.64 0.040 4.01 
191 FIP-1185 A 27.72 36.11 3.29 8.39 5.1 0.029 2.92 
192 FIP-1185 B 29.44 35.07 2.31 5.63 3.32 0.100 10.01 
193 FIP-1185 B 26.17 33.43 3.29 7.26 3.97 0.064 6.38 
194 FIP-1187 A 29.77 38.17 3.2 8.4 5.2 0.027 2.72 
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195 FIP-1187 B 26.17 37.01 3.29 10.84 7.55 0.005 0.53 
196 FIP-1188 A 31.14 40 3.2 8.86 5.66 0.020 1.98 
197 FIP-1188 B 27.65 36.72 3.29 9.07 5.78 0.018 1.82 
198 FIP-1189 A 33.22 40 3.29 6.78 3.49 0.089 8.90 
199 FIP-1189 B 29.29 38.71 3.29 9.42 6.13 0.014 1.43 
200 FIP-1190 A 30.14 34.06 -2.54 3.92 6.46 0.011 1.14 
201 FIP-1190 B 29.72 36.41 3.29 6.69 3.4 0.095 9.47 
202 FIP-1192 A 32.43 40 3.29 7.57 4.28 0.051 5.15 
203 FIP-1192 B 28.91 40 3.29 11.09 7.8 0.004 0.45 
204 FIP-1193 A 33 40 3.29 7 3.71 0.076 7.64 
205 FIP-1193 B 29.22 32.42 -2.54 3.2 5.74 0.019 1.87 
206 FIP-1194 A 31.67 40 3.29 8.33 5.04 0.030 3.04 
207 FIP-1194 B 30.31 37.95 3.29 7.64 4.35 0.049 4.90 
208 FIP-1195 A 31.29 33.98 -2.54 2.69 5.23 0.027 2.66 
209 FIP-1195 B 28.94 37.04 3.29 8.1 4.81 0.036 3.56 
210 FIP-1197 A 31.64 40 3.29 8.36 5.07 0.030 2.98 
211 FIP-1197 B 29.98 38.6 3.29 8.62 5.33 0.025 2.49 
212 FIP-1198 A 30.57 40 3.29 9.43 6.14 0.014 1.42 
213 FIP-1199 A 32.91 40 3.29 7.09 3.8 0.072 7.18 
214 FIP-1199 B 32.6 40 3.29 7.4 4.11 0.058 5.79 
215 FIP-1200 A 
       216 FIP-1200 B 30.2 36.12 3.29 5.92 2.63 0.162 16.15 
217 FIP-1201 A 32.81 32.68 -5.13 -0.13 5 0.031 3.13 
218 FIP-1201 B 31.42 32.3 -5.13 0.88 6.01 0.016 1.55 
219 FIP-1203 A 
       220 FIP-1203 B 31.77 32.03 -5.13 0.26 5.39 0.024 2.38 
221 FIP-1204 A 
   
0 
   222 FIP-1204 B 31.55 32.65 -5.13 1.1 6.23 0.013 1.33 
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223 FIP-1205 A 
       224 FIP-1205 B 30.61 31.04 -5.13 0.43 5.56 0.021 2.12 
225 FIP-1206 A 29.48 29.79 -5.13 0.31 5.44 0.023 2.30 
226 FIP-1206 B 29.65 30.85 -5.13 1.2 6.33 0.012 1.24 
227 FIP-1209 A 32.68 33.69 -5.13 1.01 6.14 0.014 1.42 
228 FIP-1209 B 30.91 32.04 -5.13 1.13 6.26 0.013 1.30 
229 FIP-1210 B 30.66 32.48 -5.13 1.82 6.95 0.008 0.81 
230 FIP-1211 A 
       231 FIP-1211 B 31.12 32.44 -5.13 1.32 6.45 0.011 1.14 
232 FIP-1212 A 32.77 33.41 -5.13 0.64 5.77 0.018 1.83 
233 FIP-1212 B 30.34 30.04 -5.13 -0.3 4.83 0.035 3.52 
234 FIP-1214 A 31.18 32.01 -5.13 0.83 5.96 0.016 1.61 
235 FIP-1214 B 29.92 31.52 -5.13 1.6 6.73 0.009 0.94 
236 FIP-1215 A 32.36 33.3 -5.13 0.94 6.07 0.015 1.49 
237 FIP-1215 B 26.66 30.86 -5.13 4.2 9.33 0.002 0.16 
238 FIP-1216 A 30.68 32.13 -5.13 1.45 6.58 0.010 1.05 
239 FIP-1216 B 28.37 31.89 -5.13 3.52 8.65 0.002 0.25 
240 FIP-1217 A 30.06 30.71 -5.13 0.65 5.78 0.018 1.82 
241 FIP-1217 B 31.42 31.66 -5.13 0.24 5.37 0.024 2.42 
242 FIP-1218 A 33.73 34.85 -5.13 1.12 6.25 0.013 1.31 
243 FIP-1218 B 
       244 FIP-1219 A 33.87 36.05 -5.13 2.18 7.31 0.006 0.63 
245 FIP-1219 B 31.06 32.81 -5.13 1.75 6.88 0.008 0.85 
246 FIP-1220 A 32.79 35.08 -5.13 2.29 7.42 0.006 0.58 
247 FIP-1220 B 31.8 33.73 -5.13 1.93 7.06 0.007 0.75 
248 FIP-1225 A 33.73 33.99 -5.13 0.26 5.39 0.024 2.38 
249 FIP-1225 B 31.34 31.75 -5.13 0.41 5.54 0.021 2.15 
250 FIP-1226 A 30.55 32.95 -5.13 2.4 7.53 0.005 0.54 
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251 FIP-1226 B 30.16 32.64 -5.13 2.48 7.61 0.005 0.51 
252 FIP-2001 A 31.52 33.2 -5.13 1.68 6.81 0.009 0.89 
253 FIP-2002 A 
       254 FIP-2003 A 30.88 33.58 -5.13 2.7 7.83 0.004 0.44 
255 FIP-2003 A 25.53 29.78 -2.4 4.25 6.65 0.010 1.00 
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DHFR 19bp Deletion 
 
CTGCAGCGCCAGGGTCCACCTGGTCGGCTGCACCTGTGGAGGAGGAGGTGGATTTCAGGCTTCC
CGTAGACTGGAAGAATCGGCTCAAAACCGCTTGCCTCGCAGGGGCTGAGCTGGAGGCAGCGAGG
CCGCCCGACGCAGGCTTCCGGCGAGACATGGCAGGGCAAGGATGGCAGCCCGGCGGCAGGGCCC
GGCGAGGAGCGCGAACCCGCGGCCGCAGTTCCCAGGCGTCTGCGGGCGCGAGCACGCCGCGACC
CTGCGTGCGCCGGGGCGGGGGGGCGGGGCCTCGCCTGCACAAATAGGGACGAGGGGGCGGGGCG
GCCACAATTTCGCGCCAAACTTGACCGCGCGTTCTGCTGTAACGAGCGGGCTCGGAGGTCCTCC
CGCTGCTGTCATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGC
AAGAACGGGGACCTGCCCTGGCCACCGCTCAGGTATCTGCCGGGCCGGGGCGATGGGACCCAAA
CGGGCGCAGGCTGCCCACGGTCGGGGTACCTGGGCGGGACGCGCCAGGCCGACTCCCGGCGAGA
GGATGGGGCCAGACTTGCGGTCTGCGCTGGCAGGAAGGGTGGGCCCGACTGGATTCCCCTTTTC
TGCTGCGCGGGAGGCCCAGTTGCTGATTTCTGCCCGGATTCTGCTGCCCGGTGAGGTCTTTGCC
CTGCGGCGCCCTCGCCCAGGGCAAAGTCCCAGCCCTGGAGAAAACACCTCACCCCTACCCACAG
CGCTCCGTTTGTCAGGTGCCTTAGAGCTCGAGCCCAAGGGATAATGTTTCGAGTAACGCTGTTT
CTCTAACTTGTAGGAATGAATTCAGATATTTCCAGAGAATGACCACAACCTCTTCAGTAGAAGG
TAATGTGGGATTAAGTAGGGTCTTGCTTGATGAAGTTTACCAGTGCAAATGTTAGTTAAATGGA
AAGTTTTCCGTGTTAATCTGGGACCTTTTCTCTTATTATGGATCTGTATGATCTGTATGCAGTT
CCCAAGGTTCATTTACCATTATTAAAAAATTTTTGTCTTAGAAATTTTATGTATGTCAACGCAC
GAGCAAATTATCAGGCATGGGGCAGAATTGGCAACTGGGTGGAGGCTTCGGTGGAGGTTAGCAC
TCCGAAAGGAAAACAGAGTAGGCCTTTGGAACAGCTGCTGGAAGAGATAAGGCCTGAACAAGGG
CAGTGGAGAAGAGAGGGTAAAAATTTTTTAAGGTTACATGACCCTGGATTTTGGAGATC 
 
ATG – translational start site 
Primers 
Sensor probe 
Anchor probe 
19 bp insertion / deletion         
 
 
 
 
 
 
 
 
Appendix K. Sequence of DHFR gene indicating the location of primers and 
probes used for genotyping the DHFR 19 bp deletion / insertion polymorphism.   
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DHFR Gene Family Multiple Sequence Alignment 
 
 
DHFR            TCCCAGACAGAACCTACTATGTGCGGCGGCAGCTGGGGCGGGAAGGCGGGAGCTGGGGGC 60 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            GCTGGGGGCGCTGCGGCCGCTGCGGCCGCTGCAGCCGCTGCAGCGCCAGGGTCCACCTGG 120 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            TCGGCTGCACCTGTGGAGGAGGAGGTGGATTTCAGGCTTCCCGTAGACTGGAAGAATCGG 180 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            CTCAAAACCGCTTGCCTCGCAGGGGCTGAGCTGGAGGCAGCGAGGCCGCCCGACGCAGGC 240 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            TTCCGGCGAGACATGGCAGGGCAAGGATGGCAGCCCGGCGGCAGGGCCTGGCGAGGAGCG 300 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            CGAGCCCGCGGCCGCAGTTCCCAGGCGTCTGCGGGCGCGAGCACGCCGCGACCCTGCGTG 360 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          ------------------------------------------------------------ 
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DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            CGCCGGGGCGGGGGGGCGGGGCCTCGCCTGCACAAATGGGGACGAGGGGGGCGGGGCGGC 420 
DHFRP1          ------------------------------------------------------------ 
DHFRL1          -------------------------------AAAAATTTGAAGAAGGG------------ 17 
DHFRP2          ------------------------------------------------------------ 
                                                                             
 
DHFR            CACAATTTCGCGCCAAACTTGACCGCGCGTTCTGCTGTAACGAGCGGGCTCGGAGGTCCT 480 
DHFRP1          -ACAATTTCGCGCCAAACTTGACCGCGCGTTCTGCTGTAACGAGCGGGCTCGGAGGTCCT 59 
DHFRL1          ---AATTTCGCGGCATTCTTGGCCTGGCTTCCTGGCGTAGCCAGCAAGTTCGGAGGTGTT 74 
DHFRP2          -----TTCCG-GCCAATCTTGGCCGCGCGTCCTGGTGTAGCGAGCGGGCTTGGAGGAGCT 54 
                     ** ** * **  **** **  ** * ***  *** * ***  * * *****   * 
 
DHFR            C-CCGCTGCTGTCATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGG 539 
DHFRP1          C-CCGCTGCTGTCATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGG 118 
DHFRL1          AACCGCTGCTGTCATGTTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGG 134 
DHFRP2          CACCGCTGCTGTCATGGTTCGTTTGCTAAACTGCATCGTCGCTGTGTCTCAGAACATGGG 114 
                  ************** **  ** ************************ ** ******** 
 
DHFR            CATCGGCAAGAACGGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCA 599 
DHFRP1          CATCGGCAAGAACGGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCA 178 
DHFRL1          CATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCA 194 
DHFRP2          CATCGGCAAGAACGGGGACCTGCCCTGACCGCCGCTCAGGAATGAATTTAGGTATTTCCA 174 
                ************************* * ** ***************** ** ******** 
 
DHFR            GAGAATGACCACAACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAA 659 
DHFRP1          GAGAATGACCACAACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAA 238 
DHFRL1          GAGAATGACCACAACTTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAA 254 
DHFRP2          GAGAATGAC-ACAATCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTTTGTGTAGGAA 233 
                ********* ****  *********** ********************* ** *** *** 
 
DHFR            GACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCT 719 
DHFRP1          GACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCT 298 
DHFRL1          GACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCT 314 
DHFRP2          GACCTGGTTCTCCATTCCTGGGAAGAATCGACCTTCAAAGGATAGAATTAATTTAGTTCT 293 
 343 
 
                ******************** ************** ***** ****************** 
 
 
DHFR            CAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGA 779 
DHFRP1          CAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGA 358 
DHFRL1          CAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGA 374 
DHFRP2          CAGCAGAGAACTCAAGGAACCTCCACAACGAGCTCATTTTCTTGCCAGAAGTCTGGTTGA 353 
                **************************** ************** ******** * * *** 
 
DHFR            TGCCTTAAAACTTACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGT 839 
DHFRP1          TGCCTTAAAACTTACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGT 418 
DHFRL1          TGCCTTAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGT 434 
DHFRP2          GATCTTAAAACTTACTTAACAACCAGAATTAGCAAATAGAGTAGACATGATTTGGATAGT 413 
                   ************* *** ***************** ********** * ******** 
 
DHFR            TGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGT 899 
DHFRP1          TGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGT 478 
DHFRL1          TGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGT 494 
DHFRP2          TGGTGGCAGTTCTGTTTATAAGGAAGCCATGAGTCGCCCAGGCCATCTTAAACTATTTGT 473 
                ******************************** ** ** ********************* 
 
DHFR            GACAAGGATCATGCAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAA 959 
DHFRP1          GACAAGGATCATGCAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAA 538 
DHFRL1          GACAAGGATCATGCAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAA 554 
DHFRP2          GACAAAGATCATGCAGGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAA 533 
                ***** ********* ************************ ********** ******** 
 
DHFR            ATATAAACTTCTGCCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCAT 1019 
DHFRP1          ATATAAACTTCTGCCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCAT 598 
DHFRL1          ATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACAT 614 
DHFRP2          ATATAAAATTCTGCCAGAATATCCAGGCGTTCTCTCGGATGT----------------AT 577 
                ******* ******* ***** ***** ******** *****                ** 
 
DHFR            TAAGTACAAATTTGAAGTATATGAGAAGAATGATTAATATGAAGGTGTTTTCTAGTTTA- 1078 
DHFRP1          TAAGTACAAATTTGAAGTATATGAGAAGAATGATTAATATGAAGGTGTTTTCTAGTTTA- 657 
DHFRL1          CAAGTACAAATTTGAAGTATGTGAGAAGGATGATTAATATGAAGGTGTTTTCTGGTTTA- 673 
DHFRP2          TAAGTACAAATTTCAAGTATATGAGAAGAATGATTAATATGAAGGTGTTTTCTGGTTTAT 637 
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                 ************ ****** ******* ************************ *****  
 
DHFR            ----AGTTGTTCCCCCTCCCTCTGAAAAAA-GTATGTATTTTTACATTAGAAAAGG-T-T 1131 
DHFRP1          ----AGTTGTTCCCCCTCCCTCTGAAAAAA-GTATGTATTTTTACATTAGAAAAGG-T-T 710 
DHFRL1          ----AGTTGTTCCCCCTCCCTCTGAGAAAA-GTATGCATTTTTACATTAGAAAAGG-GAC 727 
DHFRP2          TTTAAGTTGTTCCCCCTCCCTCTGAAAAAAAGTTTATATTTTTACATTAGAAAAAAAGAC 697 
                    ********************* **** ** *  *****************       
 
DHFR            TTTTGTTGACTTTAGATCTAT----AATTATTTCTAAGCAACTAGTTTTTATTCCCCACT 1187 
DHFRP1          TTTTGTTGACTTTAGATCTAT----AATTATTTCTAAGCAACTAGTTTTTATTCCCCACT 766 
DHFRL1          TTTTGTTGACTTCAGATCTATGGATAATTATTTCTAAGCAACGTGTTTTTATTCCTCACT 787 
DHFRP2          TTTTGTTGACTTTAGATCTTTGGATAATTATTTCTAAGCAACATGTTTTTACTCCCCACT 757 
                ************ ****** *    *****************  ******* *** **** 
 
DHFR            ACTCTTGTCTCTATCAGATACCATTTATGAGACATTCTTGCTATAACTAAGTGCTTCTCC 1247 
DHFRP1          ACTCTTGTCTCTATCAGATACCATTTATGAGACATTCTTGCTATAACTAAGTGCTTCTCC 826 
DHFRL1          AATCTTGGCTATATCAGATACCATTTATGAAACATTCTTGCTATAACT----GTCTCTCC 843 
DHFRP2          AATCTTGACTATATCAGATACCACTTATGAAATATTCTTGCTATAATTAAGTGCCTCTCC 817 
                * ***** ** ************ ****** * ************* *    *  ***** 
 
DHFR            AAGACCCCAACTGAGTCCCCAGCACCTGCTACAGTGAGCTGCCATTCCACACCCATCACA 1307 
DHFRP1          AAGACCCCAACTGAGTCCCCAGCACCTGCTATAGTGAGCTGCCATTCCACACCCATCACA 886 
DHFRL1          AAGACCCCGACTGAGTCCCCAGCACCTGCTACAGTGAGCT-------------------- 883 
DHFRP2          AAGACCCTGACTGAGTCCCCAGCACCTGCTACAGTGAGCTGCCATTCCACACCCATCGCA 877 
                *******  ********************** ********                     
 
DHFR            TGTGGCACTCTTGCCAGTCCTTGACATTGTCGGGCTTTTCACATGTTGGTAATATTTATT 1367 
DHFRP1          TGTGGCACTCTTGCCAGTCCTTGACATTGTCGGGCTTTTCACATGTTGGTAATATTTATT 946 
DHFRL1          ------------------------------------------------------------ 
DHFRP2          TATGGGACTCTTGCCAGTCCTTGACATTGTCGGGCTTTTCAAATGTTGGTAGTATTTCTT 937 
                                                                             
DHFR            AAAGATGAAGATCCACATACCCTTCAACTGAGCAGTTTCACTAGTGGAAAT 1418 
DHFRP1          AAAGATGAAGATCCACATAC------------------------------- 966 
DHFRL1          --------------------------------------------------- 
DHFRP2          AAAGATGAAGATGCACATACCCTCCAACT---------------------- 966 
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GTT->ATT Val->Ile SNP rs17855824 primers 
 
CCT->GCT Pro->Ala SNP rs61739170 primers 
 
ATG->ATT Met->Ile SNP rs114936057 primers 
 
SNPS IN RED 
 
Appendix L. A Multiple Sequence Alignment of the DHFR Gene Family and the location of the DHFRL1 polymorphisms and primers 
used. 
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Genotyping Sequence Alignments for the 3 DHFRL1 polymorphisms in the Coriell samples examined  
 
SNP1 rs17855824 polymorphism  
 
D               -NNNNNNNNNNNNNNNNNNNNNNNTGCNGGNCTTTGAAGTGACACGTTTTTTTCNGAAAT 59 
E               ---NNNNNNNNNNNNNNNNNNNCATGCNGGNCTTTGAAGTGACACGTTTTTTTCNGAAAT 57 
G               -NNNNNNNNNNNNNNNNNNNNNCATGCAGGACTTTGAAGTGACACGTTTTTTTCNGAAAT 59 
C               ----NNNNNNNNNNNNNNNNNNCATGCAGGNNTTTGAAGTGACACGTTTTTTTCNGAAAT 56 
F               -NNNNNNNNNNNNNNNNNNNNNCATGCAGGNNTTTGAAGTGACACGTTTTTTTCNGAAAT 59 
B               NNNNNNNNNNNNNNNNNNNGNNCATGCAGGNNTTTGAAGTGACACGTTTTTTTCAGAAAT 60 
H               --NNNNNNNNNNNNNNNNNGNNCATGCAGGNNTTTGAAGTGACACGTTTTTTTCAGAAAT 58 
A               -NNNNNNNNNNNNNNNNNNGNNCATGCAGGNCTTTGAAGTGACACGTTTTTTTCAGAAAT 59 
I               ----NNNNNNNNNGNNNNNGANCATGCAGGACTTTGAAGTGACACGTTTTTTTCAGAAAT 56 
J               ----NNNNNNNNNGNNNNNGANCATGCAGGACTTTGAAGTGACACGTTTTTTTCAGAAAT 56 
                    ********* *****  *  *** **  ********************** ***** 
 
D               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 119 
E               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 117 
G               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 119 
C               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 116 
F               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 119 
B               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 120 
H               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 118 
A               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 119 
I               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 116 
J               TGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGA 116 
                ************************************************************ 
 
D               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 151 
E               GGGGAAACACATCAAGTACAAATTTGAAGTAAN 150 
G               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 151 
C               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 148 
F               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 151 
B               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 152 
H               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 150 
A               GGGGAAACACATCAAGTACAAATTTGAAGTAA- 151 
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I               GGGGAAACACATCAAGTACAAATTTGAANNA-- 147 
J               GGGGAAACACATCAAGTACAAATTTGAANNA-- 147 
                ****************************  *   
 
SNP 2 rs61739170 polymorphism 
 
A               --NNNNNNNNNNNTTCNNANNNATCGACCTTTAAGGNTAGAATTAATTTAGTTCTCAGCA 58 
E               --NNNNNNNNNNNNTCNNNNNNATCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 58 
G               ---CNNNNNNNCNNNCNNNNNNATCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 57 
I               ---CNNNNNNN-NNTCNNNNANATCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 56 
D               ---NNNNNNNNNNNNNNNNNAGATCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 57 
H               -NNNNNNNNNNNNNNNNNNNNNATCGACCTTTAAGGANAGAATTAATTTAGTTCTCAGCA 59 
J               CNNNNNNNNNCNNTNCNNNNNNATCGACCTTTAAGGANAGAATTAATTTAGTTCTCAGCA 60 
F               NNNNNNNNNNNNNNNCNNANNNATCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 60 
B               ---NNNNNNNNNNNNCNGANNNANCGACCTTTAAGGATAGAATTAATTTAGTTCTCAGCA 57 
C               ---NNNNNNNNNNNNCNNANNNATCGACCTTTAAGGANAGAATTAATTTAGTTCTCAGCA 57 
                    ******  *.. *. * .*.************ .********************** 
 
A               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 118 
E               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 118 
G               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 117 
I               GAGAACTCAAGGAAGCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 116 
D               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 117 
H               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 119 
J               GAGAACTCAAGGAAGCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 120 
F               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 120 
B               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTCTGGATGATGCCT 117 
C               GAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCT 117 
                ************** ******************************** ************ 
 
A               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGNTNTGGATAGTTGGTG 178 
E               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGGTNTGGATAGTTGGTG 178 
G               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 177 
I               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 176 
D               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGGTTTGGATAGTTGGTG 177 
H               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 179 
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J               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 180 
F               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 180 
B               TAAAACTTACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTG 177 
C               TAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTG 177 
                ***************.**************************** * ************* 
 
 
 
A               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTAN 229 
E               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTAN 229 
G               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTAN 228 
I               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTAA 227 
D               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTN- 227 
H               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTAN 230 
J               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAANN-- 229 
F               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAANN-- 229 
B               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAANNN-- 226 
C               GCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTNNNNNNNN 228 
                *******************************************.    .   
 
 
SNP 3 rs114936057 polymorphism  
 
A               -------NNNNNNNNNNNNNCNCNNNNNNNNNNCATGGGCATCGGCAAGAACGGGGACCT 53 
G               -------NNNNNNNNNCNNNNNCNNNGTNNNANCATGGGCATCGGCAAGAACGGGGACCT 53 
C               NNNNNNNNNNNNNNNNNNNNNNCNNNNNNNNAACATGGGCATCGGCAAGAACGGGGACCT 60 
J               ------NNNNNNNNNNNNNNCNCNNNNNCNNAACATGGGCATCGGCAG-AACGGGGACCT 53 
D               -NNNNNNNNNNNNNNNNNNNNNCNNNNN-NNAACATGGGCATCGGCAAGAACGGGGACCT 58 
E               -------NNNNNNNNNNNNNNNCNNNGNCNAAACATGGGCATCGGCAG-AACGGGGACCT 52 
I               ------NNNNNNNNNNNNNNNNCNNNGNCNAAACATGGGCATCGGCAG-AACGGGGACCT 53 
F               -----NNNNNNNNNNNNCNNNNCNNNNTCNAAACATGGGCATCGGCAAGAACGGGGACCT 55 
B               ---NNNNNNNNNNNNTNNNNNNCNNNNNCNAAACATGGGCATCGGCAAGAACGGGGACCT 57 
H               ----NNNNNNNTNNNNNTNNNNNGCTGTGNCAACATGGGCATCGGCAG-AACGGGGACCT 55 
                       ****.***.  ** * . ... *   **************. *********** 
 
A               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 113 
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G               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 113 
C               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 120 
J               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 113 
D               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 118 
E               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 112 
I               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 113 
F               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 115 
B               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 117 
H               GCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTC 115 
                ************************************************************ 
 
A               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 173 
G               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 173 
C               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 180 
J               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 173 
D               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 178 
E               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 172 
I               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 173 
F               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 175 
B               AGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 177 
H               AGTAGAGGGTAN-CAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGA 174 
                ***********  *********************************************** 
 
A               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACC 233 
G               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACC 233 
C               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACC 240 
J               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAANC 233 
D               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAAGC 238 
E               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAAGC 232 
I               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAANC 233 
F               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACC 235 
B               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACC 237 
H               GAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGANAACTCAAGGAACC 234 
                **********************************************.*********** * 
 
A               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGN-- 290 
G               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGN-- 290 
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C               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAA- 298 
J               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGN-- 290 
D               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAN- 296 
E               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAN- 290 
I               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAN- 291 
F               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAN- 293 
B               TCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAN- 295 
H               TCCNCAAGGAGCTCANTTTCTNGNCAGAANNTTNNATGATGCCTN-AAACNTACNNNNN 292 
                *** ***********.*****.* *****..**..*********. ****.***..    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix M. Examples of Genotyping Sequence Alignments for the three DHFRL1 polymorphisms in the Coriell samples examined
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Chromatogram of DHFRL1 G->A (rs17855824) polymorphism. The arrow indicates the 
SNP position. 
 
 
 
 
Chromatogram of DHFRL1 C->G (rs61739170) polymorphism. The arrow indicates the 
SNP position. 
 
 
 
 
Chromatogram of DHFRL1 G->T (rs114936057) polymorphism. The arrow indicates 
the SNP position. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix N. Chromatograms for the 3 DHFRL1 polymorphisms that were Sanger 
sequenced to determine the genotypes of the samples 
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Chromatogram from a sequencing run of one of the successful DHFRL1 G->A 
(rs17855824) mutant clones. The arrow indicates the SNP position. 
 
 
 
 
 
Chromatogram from a sequencing run of one of the successful DHFRL1 C->G 
(rs61739170) mutant clones. The arrow indicates the SNP position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix O. Chromatograms from Sanger sequencing runs of the two DHFRL1 
mutant clones to verify that the correct mutation had been inserted into the DNA 
samples after site directed mutagenesis. 
 353 
 
DHFR_HIS_TAG               -------------------------------------------------- 
DHFR_HIS_TAG_BP_CLONE      NNNNNNNNNGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAA 50 
                                                                              
 
DHFR_HIS_TAG               ----------------------GGGGACAAGTTTGTACAAAAAAGCAGGC 28 
DHFR_HIS_TAG_BP_CLONE      TTGATGAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCAGGC 100 
                                                 .. *.*** ******************* 
 
DHFR_HIS_TAG               TTCGAAAATCTGTACTTCCAGGGGATGGTTGGTTCGCTAAACTGCATCGT 78 
DHFR_HIS_TAG_BP_CLONE      TTCGAAAATCTGTACTTCCAGGGGATGGTTGGTTCGCTAAACTGCATCGT 150 
                           ************************************************** 
 
DHFR_HIS_TAG               CGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGGGGACCTGCCCTGGC 128 
DHFR_HIS_TAG_BP_CLONE      CGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGGGGACCTGCCCTGGC 200 
                           ************************************************** 
 
DHFR_HIS_TAG               CACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACAACCTCT 178 
DHFR_HIS_TAG_BP_CLONE      CACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACAACCTCT 250 
                           ************************************************** 
 
DHFR_HIS_TAG               TCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTT 228 
DHFR_HIS_TAG_BP_CLONE      TCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTT 300 
                           ************************************************** 
 
DHFR_HIS_TAG               CTCCATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTC 278 
DHFR_HIS_TAG_BP_CLONE      CTCCATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTC 350 
                           ************************************************** 
 
DHFR_HIS_TAG               TCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGA 328 
DHFR_HIS_TAG_BP_CLONE      TCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGA 400 
                           ************************************************** 
 
DHFR_HIS_TAG               AGTCTAGATGATGCCTTAAAACTTACTGAACAACCAGAATTAGCAAATAA 378 
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DHFR_HIS_TAG_BP_CLONE      AGTCTAGATGATGCCTTAAAACTTACTGAACAACCAGAATTAGCAAATAA 450 
                           ************************************************** 
 
DHFR_HIS_TAG               AGTAGACATGGTCTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCA 428 
DHFR_HIS_TAG_BP_CLONE      AGTAGACATGGTCTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCA 500 
                           ************************************************** 
 
DHFR_HIS_TAG               TGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAAGAC 478 
DHFR_HIS_TAG_BP_CLONE      TGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAAGAC 550 
                           ************************************************** 
 
DHFR_HIS_TAG               TTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACT 528 
DHFR_HIS_TAG_BP_CLONE      TTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACT 600 
                           ************************************************** 
 
DHFR_HIS_TAG               TCTGCCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCA 578 
DHFR_HIS_TAG_BP_CLONE      TCTGCCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCA 650 
                           ************************************************** 
 
DHFR_HIS_TAG               TTAAGTACAAATTTGAAGTATATGAGAAGAATGATCATCATCATCATCAT 628 
DHFR_HIS_TAG_BP_CLONE      TTAAGTACAAATTTGAAGTATATGAGAAGAATGATCATCATCATCATCAT 700 
                           ************************************************** 
 
DHFR_HIS_TAG               CATTAGGACCCAGCTTTCTTGTACAAAGTGG------------------- 659 
DHFR_HIS_TAG_BP_CLONE      CATTAGGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCATTG 750 
                           ***************************** *                    
 
DHFR_HIS_TAG               -------------------------------------------------- 
DHFR_HIS_TAG_BP_CLONE      CTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATAAAATCA 800 
                                                                              
 
                                                                              
Appendix P. Clustal Sequence Alignment of the DHFR BP Clone Incorporating the HIS Tag  
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Appendix Q. Chromatogram Sequence of the DHFR BP Clone Incorporating the 
HIS Tag  
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DHFRL1_HIS_TAG               -------------------------------------------------- 
DHFRL1_HIS_TAG_BP_Clone      NNNNNNNNNNNNGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAAC 50 
                                                                                
 
DHFRL1_HIS_TAG               -----------------------------ACAAGTTTGTACAAAAAAGCA 21 
DHFRL1_HIS_TAG_BP_Clone      AAATTGATGAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCA 100 
                                                          .*** **************** 
 
DHFRL1_HIS_TAG               GGCTTCGAAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCAT 71 
DHFRL1_HIS_TAG_BP_Clone      GGCTTCGAAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCAT 150 
                             ************************************************** 
 
DHFRL1_HIS_TAG               CGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCA 121 
DHFRL1_HIS_TAG_BP_Clone      CGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCA 200 
                             ************************************************** 
 
DHFRL1_HIS_TAG               GGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACT 171 
DHFRL1_HIS_TAG_BP_Clone      GGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACT 250 
                             ************************************************** 
 
DHFRL1_HIS_TAG               TCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTG 221 
DHFRL1_HIS_TAG_BP_Clone      TCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTG 300 
                             ************************************************** 
 
DHFRL1_HIS_TAG               GTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAG 271 
DHFRL1_HIS_TAG_BP_Clone      GTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAG 350 
                             ************************************************** 
 
DHFRL1_HIS_TAG               TTCTCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCC 321 
DHFRL1_HIS_TAG_BP_Clone      TTCTCAGCAGAGAACTAAAGGAACCTCCACAAGGAGCTCATTTTCTTGCC 400 
 
                             ****************.********************************* 
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DHFRL1_HIS_TAG               AGAAGTTTGGATGATGCCTTAAAACTTACTGAACGACCAGAATTAGCAAA 371 
DHFRL1_HIS_TAG_BP_Clone      AGAAGTTTGGATGATGCCTTAAAACTTACTGAACGACCAGAATTAGCAAA 450 
                             ************************************************** 
 
DHFRL1_HIS_TAG               TAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAG 421 
DHFRL1_HIS_TAG_BP_Clone      TAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAG 500 
                             ************************************************** 
 
DHFRL1_HIS_TAG               CCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAG 471 
DHFRL1_HIS_TAG_BP_Clone      CCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAG 550 
                             ************************************************** 
 
DHFRL1_HIS_TAG               GACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAA 521 
DHFRL1_HIS_TAG_BP_Clone      GACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAA 600 
                             ************************************************** 
 
DHFRL1_HIS_TAG               ACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAAC 571 
DHFRL1_HIS_TAG_BP_Clone      ACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAAC 650 
                             ************************************************** 
 
DHFRL1_HIS_TAG               ACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATCATCAT 621 
DHFRL1_HIS_TAG_BP_Clone      ACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATCATCAT 700 
                             ************************************************** 
 
DHFRL1_HIS_TAG               CATCATTAGGACCCAGCTTTCTTGTACAAAGTGGT--------------- 656 
DHFRL1_HIS_TAG_BP_Clone      CATCATTAGGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCA 750 
                             ******************************** *                 
 
DHFRL1_HIS_TAG               -------------------------------------------------- 
DHFRL1_HIS_TAG_BP_Clone      TTGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATAAAA 800                                                                                
                                                                     
 
Appendix R. Clustal Sequence Alignment of the DHFRL1 BP Clone Incorporating the HIS Tag  
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Appendix S. Chromatogram Sequence of the DHFRL1 BP Clone Incorporating 
the HIS Tag  
 363 
 
DHFR_HIS_TAG            ------------------------------------------------------------ 
DHFR_HIS_TAG_Clone      TGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCAC 480 
                                                                                     
 
DHFR_HIS_TAG            ------------------------------------------------------------ 
DHFR_HIS_TAG_Clone      GTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTCCATGGTCGAATCA 540 
                                                                                     
 
DHFR_HIS_TAG            ------TTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGGTTGGTTC 54 
DHFR_HIS_TAG_Clone      AACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGGTTGGTTC 600 
                              ****************************************************** 
 
DHFR_HIS_TAG            GCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGGGGACCTGCC 114 
DHFR_HIS_TAG_Clone      GCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGGGGACCTGCC 660 
                        ************************************************************ 
 
DHFR_HIS_TAG            CTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACAACCTCTTCAGT 174 
DHFR_HIS_TAG_Clone      CTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACAACCTCTTCAGT 720 
                        ************************************************************ 
 
DHFR_HIS_TAG            AGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCCATTCCTGAGAA 234 
DHFR_HIS_TAG_Clone      AGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCCATTCCTGAGAA 780 
                        ************************************************************ 
 
DHFR_HIS_TAG            GAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACCTCC 294 
DHFR_HIS_TAG_Clone      GAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACCTCC 840 
                        ************************************************************ 
 
DHFR_HIS_TAG            ACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTTACTGAACAACC 354 
DHFR_HIS_TAG_Clone      ACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTTACTGAACAACC 900 
                        ************************************************************ 
 
DHFR_HIS_TAG            AGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCTGTTTATAAGGA 414 
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DHFR_HIS_TAG_Clone      AGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCTGTTTATAAGGA 960 
                        ************************************************************ 
 
DHFR_HIS_TAG            AGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAAGACTTTGA 474 
DHFR_HIS_TAG_Clone      AGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAAGACTTTGA 1020 
                        ************************************************************ 
 
DHFR_HIS_TAG            AAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTGCCAGAATACCC 534 
DHFR_HIS_TAG_Clone      AAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTGCCAGAATACCC 1080 
                        ************************************************************ 
 
DHFR_HIS_TAG            AGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTTGAAGTATATGA 594 
DHFR_HIS_TAG_Clone      AGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTTGAAGTATATGA 1140 
                        ************************************************************ 
 
DHFR_HIS_TAG            GAAGAATGATCATCATCATCATCATCATTAGGACCCAGCTTTCTTGTACAAAGT------ 648 
DHFR_HIS_TAG_Clone      GAAGAATGATCATCATCATCATCATCATTAGGACCCAGCTTTCTTGTACAAAGTGGTTTG 1200 
                        ******************************************************       
 
DHFR_HIS_TAG            ------------------------------------------------- 
DHFR_HIS_TAG_Clone      ATTCGACCCGGGATCCGGCTGCTAACAAAGCCCGAANGANNNNNNNNNN 1249 
                                                                          
 
 
 
 
 
 
 
 
Appendix T. Clustal Sequence Alignment of Recombinant DHFR (LR clone) showing that the HIS Tag has Been Incorporated after 
Gateway Cloning  
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Appendix U. Chromatogram Sequence of Recombinant DHFR (LR clone) showing 
that the HIS Tag has Been Incorporated after Gateway Cloning  
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DHFRL1_HIS_TAG            ------------------------------------------------------------ 
DHFRL1_HIS_TAG_Clone      NTACTNTNGNNNACGCTAGCATGGATGTTTNCCCAGTCNNGACGTNGTAAACGACNNCCA 300 
                                                                                       
 
DHFRL1_HIS_TAG            ------------------------------------------------------------ 
DHFRL1_HIS_TAG_Clone      GTCTTAAGCTCGGNCCCCAAATAATGATTTNATTTTGACTGNNAGNNACCTGTNNGTTGC 360 
                                                                                       
 
DHFRL1_HIS_TAG            --------------------------------ACAAGTTTGTACAAAAAAGCAGGCTTCG 28 
DHFRL1_HIS_TAG_Clone      AACAAATTGATGAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAG-CAGGCTTCG 419 
                                                          .*** ************. ********* 
 
DHFRL1_HIS_TAG            AAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAA 88 
DHFRL1_HIS_TAG_Clone      AAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAA 479 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            ACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGT 148 
DHFRL1_HIS_TAG_Clone      ACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGT 539 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            ATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGG 208 
DHFRL1_HIS_TAG_Clone      ATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGG 599 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            GTAGGAAGACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATT 268 
DHFRL1_HIS_TAG_Clone      GTAGGAAGACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATT 659 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            TAGTTCTCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTT 328 
DHFRL1_HIS_TAG_Clone      TAGTTCTCAGCAGAGAACTAAAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTT 719 
                          *******************.**************************************** 
 
DHFRL1_HIS_TAG            TGGATGATGCCTTAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTT 388 
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DHFRL1_HIS_TAG_Clone      TGGATGATGCTCTAAAACTTACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTT 779 
                          **********  ************************************************ 
 
DHFRL1_HIS_TAG            GGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAAC 448 
DHFRL1_HIS_TAG_Clone      GGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAAC 839 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            TATTTGTGACAAGGATCATGCAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACT 508 
DHFRL1_HIS_TAG_Clone      TATTTGTGACAAGGATCATGCAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACT 899 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            TGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGA 568 
DHFRL1_HIS_TAG_Clone      TGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGA 959 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            AACACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATCATCATCATCATT 628 
DHFRL1_HIS_TAG_Clone      AACACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATCATCATCATCATT 1019 
                          ************************************************************ 
 
DHFRL1_HIS_TAG            AGGACCCAGCTTTCTTGTACAAAGTGGT-------------------------------- 656 
DHFRL1_HIS_TAG_Clone      AGGACCCAGCTTTCTTGTACAAAGTGGTTTGATTCGACCCGGGATCCGGCTGCTAACAAA 1079 
                          ****************************                                 
 
DHFRL1_HIS_TAG            --------------------- 
DHFRL1_HIS_TAG_Clone      GCCCGAAAGNAGNNNNNNNNN 1100 
 
 
 
 
 
 
Appendix V. Clustal Sequence Alignment of Recombinant DHFRL1 (LR clone) showing that the HIS Tag has Been Incorporated after 
Gateway Cloning  
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Appendix W. Chromatogram Sequence of Recombinant DHFRL1 (LR clone) 
showing that the HIS Tag has Been Incorporated after Gateway Cloning  
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DHFRL1_HIS_TAG        ------------------------------------------------------------ 
DHFRL1_G-A_Clone      AATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAAT 600 
                                                                                   
 
DHFRL1_HIS_TAG        ------------------------------------------------------------ 
DHFRL1_G-A_Clone      CCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACC 660 
                                                                                   
 
DHFRL1_HIS_TAG        --------------------------------------------ACAAGTTTGTACAAAA 16 
DHFRL1_G-A_Clone      ATCCTCCAAAATCGGATCTGGTTCCGCGTCCATGGTCGAATCAAACAAGTTTGTACAAAA 720 
                                                                  **************** 
 
DHFRL1_HIS_TAG        AAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCATCGTCG 76 
DHFRL1_G-A_Clone      AAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATGTTTCTTTTGCTAAACTGCATCGTCG 780 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        CTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCTCAGGA 136 
DHFRL1_G-A_Clone      CTGTGTCCCAAAACATGGGCATCGGCAAGAACGGGGACCTGCCCAGGCCGCCGCTCAGGA 840 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        ATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACAGAATC 196 
DHFRL1_G-A_Clone      ATGAATTCAGGTATTTCCAGAGAATGACCACAACTTCTTCAGTAGAGGGTAAACAGAATC 900 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        TGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGG 256 
DHFRL1_G-A_Clone      TGGTGATTATGGGTAGGAAGACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGG 960 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        ATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTC 316 
DHFRL1_G-A_Clone      ATAGAATTAATTTAGTTCTCAGCAGAGAACTAAAGGAACCTCCACAAGGAGCTCATTTTC 1020 
                      *******************************.**************************** 
 
DHFRL1_HIS_TAG        TTGCCAGAAGTTTGGATGATGCCTTAAAACTTACTGAACGACCAGAATTAGCAAATAAAG 376 
 374 
 
DHFRL1_G-A_Clone      TTGCCAGAAGTTTGGATGATGCTCTAAAACTTACTGAACGACCAGAATTAGCAAATAAAG 1080 
                      **********************  ************************************ 
 
DHFRL1_HIS_TAG        TAGACATGATTTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAG 436 
DHFRL1_G-A_Clone      TAGACATGATTTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCTAG 1140 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GCCATCTTAAACTATTTGTGACAAGGATCATGCAGGACTTTGAAAGTGACACGTTTTTTT 496 
DHFRL1_G-A_Clone      GCCATCTTAAACTATTTGTGACAAGGATCATGCAGGACTTTGAAAGTGACACGTTTTTTT 1200 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        CAGAAATTGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTGTTCTCTCTGATG 556 
DHFRL1_G-A_Clone      CAGAAATTGACTTGGAGAAATATAAACTTCTGCCTGAATACCCAGGTATTCTCTCTGATG 1260 
                      ***********************************************.************ 
 
DHFRL1_HIS_TAG        TCCAGGAGGGGAAACACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATC 616 
DHFRL1_G-A_Clone      TCCAGGAGGGGAAACACATCAAGTACAAATTTGAAGTATGTGAGAAGGATGATCATCATC 1320 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        ATCATCATCATTAGGACCCAGCTTTCTTGTACAAAGTGGT-------------------- 656 
DHFRL1_G-A_Clone      ATCATCATCATTAGGACCCAGCTTTCTTGTACAAAGTGGTTTGATTCGACCCGGGATCCG 1380 
                      ****************************************                     
 
DHFRL1_HIS_TAG        ----------------------------------- 
DHFRL1_G-A_Clone      GCTGCTAACAAAGCNCGAANGNNGNNNNNNNNNNN 1415 
 
 
 
 
 
 
Appendix X. Clustal Sequence Alignment of Recombinant DHFRL1 clone showing that the G->A rs17855824 (Valine->Isoleucine) SNP 
has Been Incorporated by SDM   
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Appendix Y. Chromatogram Sequence of Recombinant DHFRL1 showing that the 
G->A rs17855824 (Valine->Isoleucine) SNP has Been Incorporated by SDM   
 378 
 
DHFRL1_HIS_TAG        ------------------------------------------------------------ 
DHFRL1_C-G_Clone      GAGCCTTTCGTTTTATTTGATGCCTGGCAGTTCCCTACTCTCGCGTTAACGCTAGCATGG 180 
                                                                                   
 
DHFRL1_HIS_TAG        ------------------------------------------------------------ 
DHFRL1_C-G_Clone      ATGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCTTAAGCTCGGGCCCCAAATA 240 
                                                                                   
 
DHFRL1_HIS_TAG        ------------------------------------------------------------ 
DHFRL1_C-G_Clone      ATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTGATGAGCAATGCTTT 300 
                                                                                   
 
DHFRL1_HIS_TAG        ---------ACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATG 51 
DHFRL1_C-G_Clone      TTTATAATGCCAACTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACTTCCAGGGGATG 360 
                               .*** ********************************************** 
 
DHFRL1_HIS_TAG        TTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGG 111 
DHFRL1_C-G_Clone      TTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAACGGG 420 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACT 171 
DHFRL1_C-G_Clone      GACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACAACT 480 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        TCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATT 231 
DHFRL1_C-G_Clone      TCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCCATT 540 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        CCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAG 291 
DHFRL1_C-G_Clone      CCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTCAAG 600 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTTACT 351 
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DHFRL1_C-G_Clone      GAAGCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCTCTAAAACTTACT 660 
                      *** *******************************************  *********** 
 
DHFRL1_HIS_TAG        GAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCTGTT 411 
DHFRL1_C-G_Clone      GAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCTGTT 720 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        TATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAG 471 
DHFRL1_C-G_Clone      TATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATGCAG 780 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAAACTTCTGCCT 531 
DHFRL1_C-G_Clone      GACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAAACTTCTGCCT 840 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACATCAAGTACAAATTTGAA 591 
DHFRL1_C-G_Clone      GAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACATCAAGTACAAATTTGAA 900 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GTATGTGAGAAGGATGATCATCATCATCATCATCATTAGGACCCAGCTTTCTTGTACAAA 651 
DHFRL1_C-G_Clone      GTATGTGAGAAGGATGATCATCATCATCATCATCATTAGGACCCAGCTTTCTTGTACAAA 960 
                      ************************************************************ 
 
DHFRL1_HIS_TAG        GTGGT------------------------------------------------------ 656 
DHFRL1_C-G_Clone      GTGGTTTGATTCGACCCGGGATCCGGCTGCTAACAAAGCCCGNNTNNNNGNNNNNNNNN 1019 
                      *****           
 
 
 
 
 
Appendix Z. Clustal Sequence Alignment of Recombinant DHFRL1 showing that the C->G rs6139170 (Proline->Alanine) SNP has Been 
Incorporated by SDM   
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Appendix AA. Chromatogram Sequence Alignment of Recombinant DHFRL1 
showing that the C->G rs6139170 (Proline->Alanine) SNP has Been Incorporated 
by SDM   
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DHFR    ------------------------------------------------------------ 
DHFR_BP         NNNNNNNNNNNNNGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTGATG 60 
                                                                             
 
DHFR            ----------------GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACT 44 
DHFR_BP         AGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTACT 120 
                                .. *.*** *********************************** 
 
DHFR            TCCAGGGGATGGTTGGTAGCCTGAACTGCATTGTCGCGGTATCTCAGAATATGGGCATTG 104 
DHFR_BP         TCCAGGGGATGGTTGGTAGCCTGAACTGCATTGTCGCGGTATCTCAGAATATGGGCATTG 180 
                ************************************************************ 
 
DHFR            GCAAAAACGGCGACTTACCGTGGCCGCCGTTGCGTAATGAATTTCGCTATTTTCAGCGTA 164 
DHFR_BP         GCAAAAACGGCGACTTACCGTGGCCGCCGTTGCGTAATGAATTTCGCTATTTTCAGCGTA 240 
                ************************************************************ 
 
DHFR            TGACGACTACTTCATCAGTTGAAGGGAAACAAAACCTCGTGATTATGGGCAAGAAGACCT 224 
DHFR_BP         TGACGACTACTTCATCAGTTGAAGGGAAACAAAACCTCGTGATTATGGGCAAGAAGACCT 300 
                ************************************************************ 
 
DHFR            GGTTCTCTATTCCCGAGAAAAATCGTCCGTTAAAGGGCCGTATTAACCTTGTGTTATCTC 284 
DHFR_BP         GGTTCTCTATTCCCGAGAAAAATCGTCCGTTAAAGGGCCGTATTAACCTTGTGTTATCTC 360 
                ************************************************************ 
 
DHFR            GCGAGCTGAAGGAGCCGCCGCAGGGGGCCCATTTCTTATCCCGTTCCCTGGATGACGCAC 344 
DHFR_BP         GCGAGCTGAAGGAGCCGCCGCAGGGGGCCCATTTCTTATCCCGTTCCCTGGATGACGCAC 420 
                ************************************************************ 
 
DHFR            TGAAGCTGACCGAACAACCTGAACTGGCTAATAAAGTCGACATGGTGTGGATTGTAGGCG 404 
DHFR_BP         TGAAGCTGACCGAACAACCTGAACTGGCTAATAAAGTCGACATGGTGTGGATTGTAGGCG 480 
                ************************************************************ 
 
DHFR            GTAGCTCGGTTTATAAAGAAGCGATGAACCACCCCGGGCACTTAAAACTGTTCGTAACTC 464 
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DHFR_BP         GTAGCTCGGTTTATAAAGAAGCGATGAACCACCCCGGGCACTTAAAACTGTTCGTAACTC 540 
                ************************************************************ 
 
DHFR            GCATCATGCAAGACTTTGAAAGTGATACGTTTTTCCCCGAAATCGACCTGGAAAAGTATA 524 
DHFR_BP         GCATCATGCAAGACTTTGAAAGTGATACGTTTTTCCCCGAAATCGACCTGGAAAAGTATA 600 
                ************************************************************ 
 
DHFR            AACTGCTGCCGGAATATCCGGGGGTTTTGTCCGATGTTCAGGAGGAAAAAGGTATCAAAT 584 
DHFR_BP         AACTGCTGCCGGAATATCCGGGGGTTTTGTCCGATGTTCAGGAGGAAAAAGGTATCAAAT 660 
                ************************************************************ 
 
DHFR            ACAAGTTTGAGGTGTATGAAAAGAACGATTAAGACCCAGCTTTCTTGTACAAAGTGG--- 641 
DHFR_BP         ACAAGTTTGAGGTGTATGAAAAGAACGATTAAGACCCAGCTTTCTTGTACAAAGTTGGCA 720 
                ******************************************************* *    
 
DHFR            ---TGGGG---------------------------------------------------- 646 
DHFR_BP         TTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATA 780 
                   *..*.                                                     
 
DHFR            ------------------------------------------------------------ 
DHFR_BP         AAATCATTATTTGCCATCCAGCTGATATCCCCTATAGTGAGTCGTATTACATGGTCATAG 840 
                                                                             
 
 
 
 
 
 
 
 
 
 
Appendix AB. Clustal Sequence Alignment of the Rare Codon Optimised DHFR BP Clone  
 385 
 
 
 
 
 
 
 
 
 
 386 
 
 
 
 
 
 
 
 
 
 387 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix AC. Chromatogram Sequence Alignment of the Rare Codon 
Optimised DHFR BP Clone  
 388 
 
DHFRL1          ------------------------------------------------------------ 
DHFRL1_BP       NNNNNNNNNNNNNTGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTGAT 60 
                                                                             
 
DHFRL1          -----------------GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTAC 43 
DHFRL1_BP       GAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCAGGCTTCGAAAATCTGTAC 120 
                                 .. *.*** ********************************** 
 
DHFRL1          TTCCAGGGGATGTTTCTGCTGTTAAATTGCATCGTTGCCGTCTCCCAGAACATGGGCATT 103 
DHFRL1_BP       TTCCAGGGGATGTTTCTGCTGTTAAATTGCATCGTTGCCGTCTCCCAGAACATGGGCATT 180 
                ************************************************************ 
 
DHFRL1          GGTAAGAATGGTGACCTGCCACGCCCGCCGCTGCGCAACGAATTTCGTTACTTTCAACGG 163 
DHFRL1_BP       GGTAAGAATGGTGACCTGCCACGCCCGCCGCTGCGCAACGAATTTCGTTACTTTCAACGG 240 
                ************************************************************ 
 
DHFRL1          ATGACAACTACCAGTTCTGTAGAAGGCAAACAGAACTTGGTGATCATGGGCCGTAAAACC 223 
DHFRL1_BP       ATGACAACTACCAGTTCTGTAGAAGGCAAACAGAACTTGGTGATCATGGGCCGTAAAACC 300 
                ************************************************************ 
 
DHFRL1          TGGTTCAGTATCCCGGAAAAGAACCGCCCGTTAAAAGATCGGATTAATCTGGTGTTGAGT 283 
DHFRL1_BP       TGGTTCAGTATCCCGGAAAAGAACCGCCCGTTAAAAGATCGGATTAATCTGGTGTTGAGT 360 
                ************************************************************ 
 
DHFRL1          CGCGAACTTAAGGAACCACCGCAGGGGGCACACTTTCTGGCCCGTTCACTGGATGATGCT 343 
DHFRL1_BP       CGCGAACTTAAGGAACCACCGCAGGGGGCACACTTTCTGGCCCGTTCACTGGATGATGCT 420 
                ************************************************************ 
 
DHFRL1          CTGAAATTAACAGAACGTCCAGAATTAGCGAACAAAGTCGATATGATCTGGATTGTCGGT 403 
DHFRL1_BP       CTGAAATTAACAGAACGTCCAGAATTAGCGAACAAAGTCGATATGATCTGGATTGTCGGT 480 
                ************************************************************ 
 
DHFRL1          GGGAGTAGCGTCTACAAAGAGGCGATGAATCATCTGGGCCACTTGAAGCTCTTTGTCACC 463 
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DHFRL1_BP       GGGAGTAGCGTCTACAAAGAGGCGATGAATCATCTGGGCCACTTGAAGCTCTTTGTCACC 540 
                ************************************************************ 
 
DHFRL1          CGGATCATGCAGGATTTTGAGTCAGATACATTCTTTTCTGAAATCGATCTGGAAAAATAT 523 
DHFRL1_BP       CGGATCATGCAGGATTTTGAGTCAGATACATTCTTTTCTGAAATCGATCTGGAAAAATAT 600 
                ************************************************************ 
 
DHFRL1          AAACTTCTGCCGGAATACCCGGGCGTTCTCAGTGACGTCCAGGAAGGTAAGCACATCAAA 583 
DHFRL1_BP       AAACTTCTGCCGGAATACCCGGGCGTTCTCAGTGACGTCCAGGAAGGTAAGCACATCAAA 660 
                ************************************************************ 
 
DHFRL1          TATAAATTTGAGGTGTGCGAAAAAGACGATTAAGACCCAGCTTTCTTGTACAAAGTGG-- 641 
DHFRL1_BP       TATAAATTTGAGGTGTGCGAAAAAGACGATTAAGACCCAGCTTTCTTGTACAAAGTTGGC 720 
                ******************************************************** *   
 
DHFRL1          ----TGGGG--------------------------------------------------- 646 
DHFRL1_BP       ATTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAAT 780 
                    *..*.                                                    
 
DHFRL1          ------------------------------------------------------------ 
DHFRL1_BP       AAAATCATTATTTGCCATCCAGCTGATATCCCCTATAGTGAGTCGTATTACATGGTCATA 840 
                                                                             
 
 
 
 
 
 
 
 
 
 
Appendix AD. Clustal Sequence Alignment of the Rare Codon Optimised DHFRL1 BP Clone  
 390 
 
 
 
 
 
 
 
 
 
 391 
 
 
 
 
 
 
 
 
 
 392 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix AE. Chromatogram Sequence Alignment of the Rare Codon 
Optimised DHFRL1 BP Clone  
 
 393 
 
DHFR            ------------------------------------------------------------ 
DHFR_Clone      TTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAA 480 
                                                                             
 
DHFR            -------------------------------------------GGGG------------- 4 
DHFR_Clone      GTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCC 540 
                                                           ** *              
 
DHFR            -------------------------------------ACAAGTTTGTACAAAAAAGCAGG 27 
DHFR_Clone      AAAATCGGATCTGGTTCCGCGTCCATGGTCGAATCAAACAAGTTTGTACAAAAAAGCAGG 600 
                                                     *********************** 
 
DHFR            CTTCGAAAATCTGTACTTCCAGGGGATGGTTGGTAGCCTGAACTGCATTGTCGCGGTATC 87 
DHFR_Clone      CTTCGAAAATCTGTACTTCCAGGGGATGGTTGGTAGCCTGAACTGCATTGTCGCGGTATC 660 
                ************************************************************ 
 
DHFR            TCAGAATATGGGCATTGGCAAAAACGGCGACTTACCGTGGCCGCCGTTGCGTAATGAATT 147 
DHFR_Clone      TCAGAATATGGGCATTGGCAAAAACGGCGACTTACCGTGGCCGCCGTTGCGTAATGAATT 720 
                ************************************************************ 
 
DHFR            TCGCTATTTTCAGCGTATGACGACTACTTCATCAGTTGAAGGGAAACAAAACCTCGTGAT 207 
DHFR_Clone      TCGCTATTTTCAGCGTATGACGACTACTTCATCAGTTGAAGGGAAACAAAACCTCGTGAT 780 
                ************************************************************ 
 
DHFR            TATGGGCAAGAAGACCTGGTTCTCTATTCCCGAGAAAAATCGTCCGTTAAAGGGCCGTAT 267 
DHFR_Clone      TATGGGCAAGAAGACCTGGTTCTCTATTCCCGAGAAAAATCGTCCGTTAAAGGGCCGTAT 840 
                ************************************************************ 
 
DHFR            TAACCTTGTGTTATCTCGCGAGCTGAAGGAGCCGCCGCAGGGGGCCCATTTCTTATCCCG 327 
DHFR_Clone      TAACCTTGTGTTATCTCGCGAGCTGAAGGAGCCGCCGCAGGGGGCCCATTTCTTATCCCG 900 
                ************************************************************ 
 
DHFR            TTCCCTGGATGACGCACTGAAGCTGACCGAACAACCTGAACTGGCTAATAAAGTCGACAT 387 
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DHFR_Clone      TTCCCTGGATGACGCACTGAAGCTGACCGAACAACCTGAACTGGCTAATAAAGTCGACAT 960 
                ************************************************************ 
 
DHFR            GGTGTGGATTGTAGGCGGTAGCTCGGTTTATAAAGAAGCGATGAACCACCCCGGGCACTT 447 
DHFR_Clone      GGTGTGGATTGTAGGCGGTAGCTCGGTTTATAAAGAAGCGATGAACCACCCCGGGCACTT 1020 
                ************************************************************ 
 
DHFR            AAAACTGTTCGTAACTCGCATCATGCAAGACTTTGAAAGTGATACGTTTTTCCCCGAAAT 507 
DHFR_Clone      AAAACTGTTCGTAACTCGCATCATGCAAGACTTTGAAAGTGATACGTTTTTCCCCGAAAT 1080 
                ************************************************************ 
 
DHFR            CGACCTGGAAAAGTATAAACTGCTGCCGGAATATCCGGGGGTTTTGTCCGATGTTCAGGA 567 
DHFR_Clone      CGACCTGGAAAAGTATAAACTGCTGCCGGAATATCCGGGGGTTTTGTCCGATGTTCAGGA 1140 
               ************************************************************ 
 
DHFR            GGAAAAAGGTATCAAATACAAGTTTGAGGTGTATGAAAAGAACGATTAAGACCCAGCTTT 627 
DHFR_Clone      GGAAAAAGGTATCAAATACAAGTTTGAGGTGTATGAAAAGAACGATTAAGACCCAGCTTT 1200 
                ************************************************************ 
 
DHFR            CTTGTACAAAGTGGTGGGG----------------------------------------- 646 
DHFR_Clone      CTTGTACAAAGTGGTTTGATTCGACCCGGGATCCGGNGNGNGNNNNNNNNNNNNNNNNNG 1260 
                ***************  *.                                          
 
DHFR            ------------ 
DHFR_Clone      NNNNNNNNNNNN 1272 
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DHFRL1            ------------------------------------------------------------ 
DHFRL1_Clone      TTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATA 480 
                                                                               
 
DHFRL1            --------------------------------------GGGG------------------ 4 
DHFRL1_Clone      TAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAAT 540 
                                                        ** *                   
 
DHFRL1            --------------------------------ACAAGTTTGTACAAAAAAGCAGGCTTCG 32 
DHFRL1_Clone      CGGATCTGGTTCCGCGTCCATGGTCGAATCAAACAAGTTTGTACAAAAAAGCAGGCTTCG 600 
                                                  **************************** 
 
DHFRL1            AAAATCTGTACTTCCAGGGGATGTTTCTGCTGTTAAATTGCATCGTTGCCGTCTCCCAGA 92 
DHFRL1_Clone      AAAATCTGTACTTCCAGGGGATGTTTCTGCTGTTAAATTGCATCGTTGCCGTCTCCCAGA 660 
                  ************************************************************ 
 
DHFRL1            ACATGGGCATTGGTAAGAATGGTGACCTGCCACGCCCGCCGCTGCGCAACGAATTTCGTT 152 
DHFRL1_Clone      ACATGGGCATTGGTAAGAATGGTGACCTGCCACGCCCGCCGCTGCGCAACGAATTTCGTT 720 
                  ************************************************************ 
 
DHFRL1            ACTTTCAACGGATGACAACTACCAGTTCTGTAGAAGGCAAACAGAACTTGGTGATCATGG 212 
DHFRL1_Clone      ACTTTCAACGGATGACAACTACCAGTTCTGTAGAAGGCAAACAGAACTTGGTGATCATGG 780 
                  ************************************************************ 
 
DHFRL1            GCCGTAAAACCTGGTTCAGTATCCCGGAAAAGAACCGCCCGTTAAAAGATCGGATTAATC 272 
DHFRL1_Clone      GCCGTAAAACCTGGTTCAGTATCCCGGAAAAGAACCGCCCGTTAAAAGATCGGATTAATC 840 
                  ************************************************************ 
 
DHFRL1            TGGTGTTGAGTCGCGAACTTAAGGAACCACCGCAGGGGGCACACTTTCTGGCCCGTTCAC 332 
DHFRL1_Clone      TGGTGTTGAGTCGCGAACTTAAGGAACCACCGCAGGGGGCACACTTTCTGGCCCGTTCAC 900 
                  ************************************************************ 
 
DHFRL1            TGGATGATGCTCTGAAATTAACAGAACGTCCAGAATTAGCGAACAAAGTCGATATGATCT 392 
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DHFRL1_Clone      TGGATGATGCTCTGAAATTAACAGAACGTCCAGAATTAGCGAACAAAGTCGATATGATCT 960 
                  ************************************************************ 
 
DHFRL1            GGATTGTCGGTGGGAGTAGCGTCTACAAAGAGGCGATGAATCATCTGGGCCACTTGAAGC 452 
DHFRL1_Clone      GGATTGTCGGTGGGAGTAGCGTCTACAAAGAGGCGATGAATCATCTGGGCCACTTGAAGC 1020 
                  ************************************************************ 
 
DHFRL1            TCTTTGTCACCCGGATCATGCAGGATTTTGAGTCAGATACATTCTTTTCTGAAATCGATC 512 
DHFRL1_Clone      TCTTTGTCACCCGGATCATGCAGGATTTTGAGTCAGATACATTCTTTTCTGAAATCGATC 1080 
                  ************************************************************ 
 
DHFRL1            TGGAAAAATATAAACTTCTGCCGGAATACCCGGGCGTTCTCAGTGACGTCCAGGAAGGTA 572 
DHFRL1_Clone      TGGAAAAATATAAACTTCTGCCGGAATACCCGGGCGTTCTCAGTGACGTCCAGGAAGGTA 1140 
                  ************************************************************ 
 
DHFRL1            AGCACATCAAATATAAATTTGAGGTGTGCGAAAAAGACGATTAAGACCCAGCTTTCTTGT 632 
DHFRL1_Clone      AGCACATCAAATATAAATTTGAGGTGTGCGAAAAAGACGATTAAGACCCAGCTTTCTTGT 1200 
                  ************************************************************ 
 
DHFRL1            ACAAAGTGGTGGGG---------------------------------------------- 646 
DHFRL1_Clone      ACAAAGTGGTTTGATTCGACCCGGGATNNNNNNNNNNNNNNNNNNNCNNNCNNNNNNNNN 1260 
                  **********  *.                                               
 
DHFRL1            ------------ 
DHFRL1_Clone      NNNNNNNNNNNN 1272 
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Appendix AK. Vector map for pcDNA / V5-DEST. Image taken from Invitrogen   
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Appendix AL. DNA Ladders. Image taken from New England BioLabs (NEB). A. 
100 bp ladder. B. 1 kb ladder. The DNA ladders were loaded on to the agarose gels 
in order to determine the sizes of the PCR products and plasmid preps. Ladder 
used for each case depended on the size of the products. 
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Appendix AM. ColorBurst Electrophoresis Marker (Protein Ladder). Image taken 
from Sigma-Aldrich. The protein ladder was loaded on to SDS-PAGE gels in order 
to determine the sizes of the proteins for SDS-PAGE and Western blotting analysis.  
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The Impact of Nutrition on Differential Methylated
Regions of the Genome1
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ABSTRACT
Nutrition has always played an important role in health and disease, ranging from common diseases to its likely contribution to the fetal origins
of adult disease. However, deciphering the molecular details of this role is much more challenging. The impact of nutrition on the methylome,
i.e., DNA methylation, has received particular attention in more recent years. Our understanding of the complexity of the methylome is evolving
as efforts to catalog the DNA methylation differences that exist between different tissues and individuals continue. We review selected examples
of animal and human studies that provide evidence that, in fact, speciﬁc genes and DNA methylation sites are subject to change during
development and during a lifetime as a direct response to nutrition. Investigation of the methyl donors folate, choline, and methionine provide
the most compelling evidence of a role in mediating DNA methylation changes. Although a number of candidate regions/genes have been
identiﬁed to date, we are just at the beginning in terms of cataloging so-called nutrient-sensitive methylation variable positions in humans. Adv.
Nutr. 2: 463–471, 2011.
Introduction
The methylome describes the modiﬁcations to DNA that
potentially exist within a given genome without changes to
the DNA sequence itself. In humans, traditionally these
modiﬁcations mostly referred to methylation of cytosine
residues (5mC),2 usually in the context of a CpG. However,
more recent work indicates that non-CpG methylation (1)
and 5-hydroxymethylcytosine (2,3) also form part of the hu-
man methylome. Methylation of DNA falls under the um-
brella term epigenetics, which describes heritable changes
to DNA and chromatin that are passed on to daughter cells
either mitotically or meiotically. Although histone modifica-
tions and their impact on chromatin remodeling are highly
relevant and interplay with DNA modifications, they are not
the focus of this review [see Choi and Friso (4)].
Research interest in DNA methylation gained momen-
tum in the past 10 years and focused on its effect on gene
expression and its association with various disease states,
most notably cancer (5). Methylation of DNA in the region
of a gene is generally associated with gene expression being
switched off, whereas unmethylated DNA is associated with
gene expression being switched on. The exact mechanism is
not fully elucidated but is believed to involve the interference
of methylated cytosine with binding of the RNA polymerase
complex and associated transcription factors through an in-
teraction with chromatin (6) (Fig. 1). Although this has
been the prevailing mechanism, more recent research indi-
cates that DNA methylation is not always associated with
transcriptional repression, particularly when it occurs in
gene bodies rather than in the promoters of genes (7). Cells
use DNA methylation as a mechanism to control gene ex-
pression in a number of different ways. The types of DNA
methylation changes as they relate to specific functions as
we currently understand them range from tissue-specific
gene expression to inactivation of imprinted genes, the
X-chromosome, and transposable elements. DNA methyla-
tion changes have also been associated with a range of dis-
ease states including imprinting disorders (8), tumorigenesis
(5), neurological disorders (9), cardiovascular disease (10),
and autoimmune diseases (11). Apart from definitive patho-
logically induced changes, evidence to date suggests that there
are also regions of the methylome that are subject to change in
response to the environment including nutrition. A compre-
hensive overview of the type of sites that are subject to this
is not currently available, but preliminary work on this indi-
cates that it is likely to include regions that silence transpos-
able elements, possibly some imprinted genes and other site
types that have yet to be identified. A definitive term has
not been assigned to describe these sites that are subject to
1 Author disclosures: M. Ozaki and A. Parle-McDermott, no conflicts of interest.
* To whom correspondence should be addressed. E-mail: anne.parle-mcdermott@dcu.ie
2 Abbreviations used: CGI, CpG island; DVR, differentially methylated region; 5hmC,
5-hydroxymethylcytosine; 5mC, 5-methylcytosine; IUGR, intrauterine growth restriction;
MTHFR, methyltetrahydrofolate reductase; MVP, methylation variable position.
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environmental influence, but they have been referred to as
metastable alleles or epialleles (12). The Human Epigenome
Project (13) uses the term MVP to describe individual
DNA methylation sites that show tissue-specific changes or
changes in response to a disease state. Others refer to a group
of such sites as DMRs (14). Our focus is on those DNAmeth-
ylation sites that are influenced by nutritional status—so-called
nutrient-sensitive MVPs.
Current status of knowledge
The human methylome
Efforts such as the 1000 Genomes Project (15) have pro-
vided a comprehensive catalog of the genetic variation that
exists between human individuals, but what about the meth-
ylome? It is clear that DNA methylation patterns will vary
not only among tissues but also among individuals, but
the extent and variability of these patterns have yet to be es-
tablished. The Human Epigenome Project (13) and the NIH
Roadmap Epigenomics (16) projects are bids to bridge the
gap in our current knowledge of the variation in DNAmeth-
ylation patterns that exist among individuals. In the same
way that single nucleotide polymorphisms provide a catalog
of human genetic variation, these projects aim to catalog
a variety of epigenetic marks including MVPs, i.e., those
DNA methylation sites that vary in different tissues, among
individuals, and in disease states.
Extensive human methylome data across a number of
different populations and disease states are currently being
generated, as alluded to previously. Although such data
sets will provide us with a unique insight into human meth-
ylome patterns, we rely on recently completed analyses to
give us a glimpse of what might be revealed. The ﬁrst most
detailed human methylome, i.e., at single-base-resolution,
was published in 2009 by Lister et al. (1). The DNA methyl-
ation patterns of human stem cells and fetal ﬁbroblasts
were assessed, and a number of interesting patterns were
identiﬁed that challenged some of the previous assumptions
regarding DNA methylation patterns. Previously, most cyto-
sine methylation was thought to occur in the context of CG
(or CpG). High-density CG regions are referred to as CGIs,
can occur in the promoter regions of genes, and, when they
do, are often unmethylated (17). The analysis by Lister et al.
(1) revealed that in stem cells, one-fourth of cytosinemethyl-
ation occurred in a non-CG context and were enriched in the
coding regions of genes. Highly expressed genes tended to
have a 3-fold higher level of non-CG methylation density
than nonexpressed genes. However, this non-CG methylation
started to be lost on cellular differentiation and appeared to be
a speciﬁc feature of stem cells. In human ﬁbroblasts, they
noted that reduced methylation levels were associated with
decreased transcriptional activity for some genes. Thus, un-
methylated cytosines are not always associated with a high
level of gene expression, and their impact on transcriptional
activity appears to depend on their location within the gene.
5mC was always considered to be the ﬁfth DNA base, but
it appears that there is also a sixth base in the form of 5hmC.
Although the existence of 5hmC in mammals was originally
suggested in 1972 (18), it was only deﬁnitively shown in
2009 by Kriaucionis and Heintz (2) and Tahiliani et al.
(3). The enzyme that catalyzes the conversion of 5mC to
5hmC was identiﬁed as TET1 (3). TET1 is a 2-oxoglutarate
and Fe(II)-dependent enzyme that has been shown to bind
throughout the genome in embryonic stem cells but partic-
ularly at high-density CpG sites in the promoters of genes
and within speciﬁc genes (19). Modiﬁcations of 5hmC
showed a pattern similar to that of TET1 binding, i.e., found
particularly at high- and intermediate-density CpG sites,
which is in contrast to 5mC, which is found predominantly
at low-density CpG sites. Similarly to 5mC, however, 5hmC
is thought to have a role in transcriptional repression, also
mediated through TET1 (19). However, additional roles for
5hmC include the ability to “prime” specific genes for rapid
activation when required (20), and it is also thought to have
a role in the regulation of DNA methylation patterns (19).
Despite the rapid recent advances in interrogating the
methylome, it is clear that understanding the relevance of
these methylation marks and how they might vary among
tissues and individuals is far from complete. We describe
the current evidence demonstrating that nutrition has an im-
pact on 5mC patterns in the following paragraphs, but there
are no studies to date that have addressed this speciﬁcally at
FIGURE 1 The role of CGI methylation in the control of gene
transcription. Unmethylated and methylated CGIs in the
promoter region of a given gene are shown. Open circle
lollipops indicate unmethylated cytosines; closed circle lollipops
indicate methylated cytosines. The nucleosomes of chromatin
are not shown. (A) Unmethylated CGIs are usually in a
transcriptionally permissive state in tandem with specific histone
modifications. TFs recognize specific DNA motifs in the
promoter and facilitate binding of the RNA polymerase II
(RNApolII) complex to initiate transcription at the transcription
start site (curved arrow). (B) Methylated CGIs are associated with
a transcriptionally repressed state. This is thought to be due to
the binding of MBP, which recognizes methylated cytosines,
which subsequently recruit co-repressor complexes that influence
the chromatin state via histone deacetylases and ultimately
prevent binding by TFs. An alternative mechanism is that
methylated cytosines directly prevent binding of TFs. CGI, CpG
island; MBP, methyl-binding protein; TFs, transcription factors.
464 Parle-McDermott and Ozaki
the 5hmC level. It is likely that nutritional inﬂuences are
equally relevant for 5hmC given that its formation appears
to depend on the presence of 5mC (19). However, the ma-
jority of DNA methylation techniques to date are unable
to distinguish between 5mC and 5hmC. Therefore, previous
studies may need to be reassessed to consider the newly
identiﬁed sixth DNA base.
Nutrition as a mediator of DNA
methylation changes
The identiﬁcation of veriﬁed nutrient-sensitive MVPs is of
particular interest because it offers a potential mechanism
to explain the observations that relate to the fetal origins
of adult disease theory and the role of nutrition in a range
of common diseases. The fetal origins of adult disease theory
was originally proposed by Barker et al. (21,22) and states
that the in utero environment of the embryo can have an im-
pact on the adult disease risk of the offspring. It has also
been proposed that some effects are transgenerational, i.e.,
can be passed on to subsequent generations. This theory
was based on initial studies that demonstrated an association
between fetal growth impairment and adult cardiovascular
disease, diabetes, and insulin resistance (23–27). Fetal un-
dernutrition is believed to be the key mitigating factor,
and DNA methylation is one of the mechanisms that may
mediate these effects. Additional studies such as the Dutch
Hunger Winter found that in utero exposure to famine
was associated with increased risks of obesity (men) (28)
and schizophrenia (29), increased prevalence of obstructive
airways disease (30) and impaired glucose and lipid homeo-
stasis, an increase in coronary heart disease later in life, an
increased risk of breast cancer (women), and reduced renal
function in a manner that is dependent on gestational age at
the time of exposure to famine (31). Evidence to support the
fetal origins of adult disease theory has been reviewed exten-
sively elsewhere (32). However, whether it is the changes to
the methylome that are mediating these effects remains to be
proven.
Apart from in utero exposure, DNA methylation patterns
have been shown to change during one’s lifetime. The most
striking evidence of this was a twin study by Fraga et al. (33)
that showed how the methylome of identical twins became
more divergent as they aged. They also correlated this with
changes in the expression of a range of genes. It is likely
that nutrition is one of the environmental influences that
have an impact on these methylome changes. Another
twin study by Kaminksy et al. (34) suggested that the pheno-
typic similarity of monozygotic twins is attributed not only
to their identical genomes, but also to sharing a similar epi-
genome compared with dizygotic twins. Further evidence of
age-dependent DNA methylation changes has recently been
reported for a number of specific genes (35).
It is clear that DNAmethylation patterns can change dur-
ing our development and as we age, but a role in disease de-
velopment and progression has received particular focus in
recent years. The most intensely studied has been changes as-
sociated with cancer (5). However, it is difﬁcult to disentangle
the sites relevant to nutrition given the complexity and mu-
tational nature of cancer development. Other diseases that
exhibit dramatic gene-speciﬁc DNAmethylation changes in-
clude dementia and systemic lupus erythematosus (36).
While we await high-resolution methylome proﬁles of
different tissues from a variety of populations, it is clear
that there are regions of the genome that are subject to
DNA methylation changes during development, cellular dif-
ferentiation, or one’s lifetime. These may be distinct or over-
lap with disease-associated DNA methylation changes. The
challenge now is to actually identify those nutrient-sensitive
MVPs that have relevance to a phenotype. For the remainder
of this review, we describe the current evidence of nutrient-
sensitive MVPs both in animal models and human studies.
Nutrient-sensitive MVPs
Animal models
The evidence to date suggests that the impact of nutrition on
DNA methylation patterns can happen at the level of the or-
ganism, probably in a tissue-speciﬁc fashion or transgenera-
tionally, i.e., can have an impact on the subsequent progeny.
Examples of those nutrients that have been shown to inﬂu-
ence DNA methylation patterns are described in the follow-
ing and are summarized in Table 1. Mutant animal models
are not included because they complicate the relevance of
nutrition on the methylome in these animals.
Methyl donors: folate, methionine, and choline. The fo-
late metabolic pathway consists of a plethora of enzymes
and is compartmentalized between the cytoplasm, nucleus,
and mitochondria (37). Folate metabolism provides the
1-carbons necessary for a number of reactions involving the
synthesis of DNA and in methylation reactions (Fig. 2).
S-adenosylmethionine is particularly relevant for DNA meth-
ylation because it provides the actual methyl group (CH3)
that is added onto cytosine to produce 5mC. S-adenosylho-
mocysteine is the product formed after donation of the
methyl group from S-adenosylmethionine and is an inhibitor
of methyltransferases including DNA methyltransferases.
Thus, the suggestion that folate supply and other methyl do-
nors such as methionine and choline can influence DNA
methylation patterns of an organism has strong biological
plausibility. This was elegantly demonstrated in the agouti
mouse model (38). This mouse model is probably one of
the most widely cited animal models in support of the fetal
origins of adult disease theory, i.e., transgenerational effects.
This study showed how a maternal diet supplemented with
methyl-donating vitamins, including folic acid, resulted in hy-
permethylation of a specific region of the mouse genome,
producing an altered coat color phenotype in the mice off-
spring that were genetically identical (39). Inappropriate
expression at the viable yellow agouti locus (Avy) due to
changes in the methylation status of a cryptic gene pro-
moter led to the variable observable phenotypes. This was
one of the first studies that provided experimental evidence
in support of DNA methylation as one of the molecular
mechanisms mediating maternal diet-related phenotypic
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changes in offspring (39). These DNA methylation changes
were also seen to persist in offspring born in the next gener-
ation who were not exposed to methyl-donating vitamins in
utero (40). Decreased methylation at the Avy locus was also
observed in response to the chemical Bisphenol A but was
reversed by supplementation of the diet with methyl donors
or the phytoestrogen genistein (41). A similar finding was
also observed at an additional locus, i.e., the cdk5 activator
binding protein (41). Methyl-donating supplementation
transgenerational effects have been reported in other animal
models including increased methylation at the AxinFu gene
in offspring (42). Hollingsworth et al. (43) identified 82 po-
tentially differentially methylated genes in the lung tissue of
mouse progeny whose mothers were supplemented with
methyl donors compared with controls. Among these, addi-
tional convincing evidence identified Runx3 as being exces-
sively methylated. Apart from rodent supplementation,
studies have also considered methyl donor deficiency diets
in other animal models. Female sheep were fed a vitamin
B-12, folate, and methionine–restricted diet periconception-
ally (44). Their offspring were heavier and fatter and had an
altered immune response and insulin resistance, and males
particularly had elevated blood pressure compared with
controls. Methylation of 1400 CGIs was assessed by restric-
tion landmark genome scanning in the fetal liver of the off-
spring, and 4% of sites showed altered methylation status.
Studies investigating the effect of methyl donor deficiency
to the individual organism rather than the offspring have
also been conducted. The cancer-relevant p53 gene was de-
methylated at specific sites in F344 rats fed a diet deficient
in the methyl donors choline, methionine, and folic acid
for 9 wk. However, it was also noted that some CpG sites
were resistant to demethylation (45). Mice subjected to a
postweaning methyl donor–deficient diet demonstrated a
loss of imprinting of the Igf2 gene compared with those
mice fed the control diet (46). This study also highlights
the relevance of the postnatal diet and how it can also influ-
ence nutrient-sensitive MVPs. A more recent study (47) as-
sessed the impact of a folate-deficient diet on female mice
before and during pregnancy and lactation. DNA methyla-
tion patterns of three genes including Esr1, Igf2, and
Slc39a4CC were assessed in the dam’s blood, liver, and
FIGURE 2 A simplified view of cytoplasmic 1C folate
metabolism. Not all enzymes are shown. The reactions in blue
supply the 1Cs required for DNA synthesis. The reactions in red
form part of the folate pathway that produces the methyl donor
SAM. A range of methyltransferase enzymes catalyze the transfer
of the methyl group (CH3) from SAM to a number of substrates
including DNA, i.e., methylation reactions. SAH is an inhibitor of
methyltransferase enzymes. MTHFR, methyltetrahydrofolate
reductase enzyme; SAH, S-adenosylhomocysteine; SAM,
S-adenosylmethionine THF, tetrahydrofolate.
TABLE 1. Summary of selected studies investigating nutrient sensitive DNA methylation sites in animal models1
Nutrient Model
DNA methylation
site(s) examined References
Methyl donor supplementation Maternal mouse offspring Agouti gene 38–41
Cdk5 activator binding protein 41
AxinFu gene 42
82 genes including runx3 43
Methyl donor deficiency Maternal sheep offspring 1400 CpG islands 44
Adult rats p53 45
Postweaning mouse Igf2 46
Pregnant mice Esr1, Igf2, Slc39a4CC 47
Rat brain Global methylation 48
Choline deficiency Maternal mouse offspring Cdkn3, global methylation 49
Maternal rat offspring Dnmt1, Ifg2, global methylation 50
Protein restriction Adult rats, F2 offspring PPARa 52, 53
Maternal mouse offspring CpG islands including Lxra 54
Cultured mouse blastocysts H19 55
Paternal rat offspring PPARa: CpG island 50kb upstream 58
Adult mice Leptin promoter 60
Maternal rat offspring/leptin injections PPARa, glucocorticoid receptor 61
High-fat diet Adult rats Leptin promoter 59
Genistein Adult mice Differential method including ribosomal DNA
and desmin-binding fragment
64
Genistein supplementation Maternal mouse offspring Agouti gene 65
1 Methyl donors include folate, methionine, and choline.
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kidney. Although the focus of many studies has been on the
offspring, this study highlights the relevance of nutrient-
sensitive MVPs in pregnant mothers, particularly during a
period of high demand for methyl-donating nutrients.
DNA methylation changes were observed but were found
to be gene and tissue specific. The tissue specificity of
DNA methylation changes was also reported in rats fed a
diet lacking methionine, choline, and folic acid (48). Global
DNA methylation was assessed by HPLC–MS/MS and showed
hypermethylation in rat brain and hypomethylation in rat
liver compared with controls. However, the biological rele-
vance and sensitivity of measuring global DNA methylation
patterns (as opposed to genomewide DNA methylation
changes) are not clear. Global DNA methylation by im-
munohistochemistry (49) and HPLC (50) were also as-
sessed in animal models assessing the transgenerational
impact of choline specifically. Dietary choline during em-
bryonic development is thought to have a significant role
in memory function in subsequent adults (49,51). A choline-
deficient diet was introduced to mouse dams during days
12–17 of pregnancy. Fetal brains were isolated on embryonic
day 17, and global DNA methylation was decreased in a spe-
cific region of the brain (49). Gene-specific DNA methyla-
tion was also assessed by bisulfite sequencing and showed
that choline deficiency decreased DNA methylation of the
Cdkn3 gene but had no effect on Cdkn2b and Calb2 (49).
A rat study also assessed choline specifically but addressed
both supplementation and deficiency. Female rats were fed
a diet consisting of varying levels of choline during preg-
nancy, and the impact of this on DNA methylation of the fe-
tal liver and brain was assessed. Exposure to choline
deficiency resulted in reduced methylation of the DNA
methyltransferase enzyme Dnmt1 with a corresponding in-
creased level of mRNA. This appeared to lead to increased
global DNA methylation and hypermethylation of Igf2 (50).
These studies illustrate that dietary methyl-donor content
can inﬂuence DNA methylation patterns, both transgenera-
tionally and at the level of the organism. The propensity to
change appears to be gene speciﬁc, CpG site speciﬁc, and tis-
sue speciﬁc. Moreover, changes to global gene expression
patterns appear to have little relevance to what is happening
at the DNA site–specific level, and, therefore, the relevance
of such measurements is questionable. As already men-
tioned, the link with methyl-donor supply and DNA meth-
ylation follows a plausible path, but what about the supply of
other nutrients?
Protein and amino acids. Protein restriction is thought to
mimic fetal undernutrition, a key factor associated with the
fetal origins of adult disease concept. A protein-restricted
diet in rats during pregnancy showed loss of DNA methyla-
tion in the promoters of glucocorticoid receptor and the
PPARa by methyl-sensitive PCR (52). The loss of DNA
methylation correlated with an increase in mRNA levels. In-
terestingly, folic acid supplementation prevented the meth-
ylation changes mediated by protein restriction. However,
again, gene-specificity is at play here because no change in
the promoter of PPARg, an isoform of PPARa, was ob-
served. A follow-up of this study also showed that the hypo-
methylation state of the target genes observed in the F1
generation is passed onto the F2 offspring, even when the
F1 offspring were fed a normal diet (53). Maternal protein
restriction was also observed to affect DNA methylation of
a range of genes by CGI microarray analysis in fetal livers
shortly after birth (54). Further analysis of one of these
genes, i.e., liver-X-receptor alpha (Lxra), showed hyperme-
thylation in protein-restricted pups that correlated with a
drop in mRNA levels. Loss of imprinting has also been ob-
served in cultured mouse blastocysts at the maternally ex-
pressed H19 gene (55). Demethylation at the normally
hypermethylated paternal allele was dependent on the cul-
ture medium used. Medium containing extra amino acids
did not display loss of imprinting, highlighting the relevance
of the nutritional environment for the preservation of im-
printing patterns. Again, gene specificity is observed because
another imprinted gene, Snrpn, did not display loss of im-
printing in either medium. In addition to maternal transge-
nerational nutritional effects, evidence of paternal effects has
also been shown (56,57), which highlights the importance of
considering alternative mechanisms beyond maternal ef-
fects. Offspring livers of male rats on a low protein-diet
showed a significant increase in DNA methylation at an in-
tragenic CGI,w50 kb upstream of the PPARa gene by bisul-
fite sequencing. Because the global methylation levels in
low-protein and control offspring were similar, this further
demonstrates the relevance of gene specificity (58).
Fat. Leptin is an adipokine that is involved in the regulation
of body weight and food intake. A recent study describes
how a speciﬁc CpG site within the leptin promoter showed
signiﬁcant methylation differences in rats fed a high-fat diet
compared with controls. The change in methylation was as-
sociated with circulating leptin levels (59). Changes in the
leptin promoter, i.e., the removal of methyl groups at CpG
sites within the promoter, was also shown in mice fed a
low-protein diet (60). The impact of leptin on DNA meth-
ylation was further investigated by Gluckman et al. (61).
Adult rats that were previously injected with leptin after
birth to well-nourished mothers demonstrated a differential
methylation change in PPARa and glucocorticoid receptor
compared with those born to undernourished mothers.
This article highlights how maternal diet history can influ-
ence subsequent neonatal and adult cellular responses.
Genistein. Soy products are known to reduce the risk of car-
diovascular disease and carcinogenesis (62,63). Genistein is a
soy phytoestrogen that may mediate these risk reductions
and was investigated for an impact on DNA methylation.
Day et al. (64) used differential methylation hybridization
arrays to investigate DNAmethylation in mice on a genistein
diet. Liver, brain, and prostate tissues were examined, but
only changes in the prostate were detected using this tech-
nique. These included three novel sequences, ribosomal
DNA, and a desmin-binding fragment. However, conﬁrmation
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of these changes with an additional technique was not per-
formed, and, therefore, their relevance is unclear. Genistein
supplementation did, however, increase methylation at the
Avy locus in the agoutimouse model offspring (65) in a fash-
ion similar to methyl donor supplementation, as described
previously.
Animal models have provided substantial evidence that
fetal undernutrition, or indeed overnutrition, can inﬂuence
DNA methylation patterns of an individual or their off-
spring. Are humans susceptible to the same types of changes
in response to nutritional status? It is much more challeng-
ing to address this in humans.
Human studies
Although there is a wealth of literature supporting the role of
nutrition in health and disease including the fetal origins of
human disease concept (32), the identiﬁcation of nutrient-
sensitive MVPs in humans has only been a recent focus of
attention. The Dutch Hunger Winter from 1944 to 1945
provided an excellent opportunity to investigate this further.
Food restrictions were in place in the western part of the
Netherlands toward the end of World War II. Despite this,
medical records and registries were maintained, which al-
lowed prenatally exposed individuals to be traced. Heijmans
et al. (66) showed that prenatally exposed individuals dis-
played signiﬁcantly less DNA methylation at the imprinted
IGF2 locus compared with their unexposed, same-sex sib-
lings 60 y later. This appeared to be an early developmental
effect because individuals exposed during late gestation
showed no effect. The susceptibility of the IGF2 locus to
in utero exposure in humans correlates with similar findings
in animal models already described. Additional loci for this
cohort of samples were examined in a subsequent study that
found that INSIGF showed decreased methylation, whereas
IL10, LEP, ABCA1, GNASAS, and MEG3 showed increased
methylation in individuals exposed prenatally to the famine
(67). Late gestational exposure showed DNA methylation
changes in just GNASAS and LEP in men only. Thus,
nutrition-induced changes appeared to be particularly rele-
vant but not limited to the periconceptional period, showed
both increased and decreased methylation, and displayed
some sex specificity. Apart from the Dutch Hunger Winter
samples, a number of both observational and intervention
studies have been conducted in humans, focusing for the
most part on methyl donors, particularly folate. We did
not include those studies involving cancer tissues because
epigenetic dysregulation is well documented as contributing
to tumorigenesis and may cloud the role of nutrients in me-
diating DNA methylation changes. Friso et al. (68) reported
a correlation between folate status and global DNA methyl-
ation levels in peripheral blood mononuclear DNA mea-
sured by HPLC/MS. Again, the relevance of measuring
global DNA methylation without site-specific information
is not clear, but the authors did report the interesting
observation that individuals who were MTHFR 677 TT
homozygous had a significantly lower level of global
DNA methylation compared with 677 CC individuals. The
MTHFR gene encodes a key enzyme in the folate metabolic
pathway (Fig. 2), i.e., 5,10-methyltetrahydrofolate reductase.
The MTHFR 677C > T polymorphism is a well-accepted,
disease-associated variant that is thermolabile and converts
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate
at a reduced rate, particularly when the folate status is low
(69,70). Thus, the supply of methyl groups may be compro-
mised in MTHFR 677 TT individuals, and this appears to
correlate with global DNA methylation patterns. Additional
observational studies focusing on folic acid include an ex-
amination of promoter methylation of estrogen receptor a
and MLH1 (71). This study found no correlation between
serum and red cell folate and DNA methylation but did
find a correlation between vitamin B-12 and estrogen recep-
tor a methylation in colon tissue. Steegers-Theunissen et al.
(72) found a 4.5% increase in the DNA methylation of IGF2
DMR in the children of mothers who consumed 400 mg
of folic acid periconceptionally compared with those who
had not. Folic acid intervention studies of postmenopausal
women showed decreased global DNA methylation in
women consuming a low-folate diet measured by incorpora-
tion of a tritiated methyl group using SssI methyltransferase
(73,74). However, one study reported recovery of DNA
methylation in folate-replete subjects (73) but no change
in another (74). Again, we question the validity of measur-
ing global DNA methylation levels as opposed to a genome-
wide analysis. A more recent report by Fryer et al. (75)
applied the Illumina Infinium Methylation 27K BeadArray
system to human cord blood samples in which folate and
homocysteine levels were also measured. Homocysteine is
inversely correlated with folate levels (Fig. 2). This allows
analysis of 27,578 CpG loci associated with 14,496 genes
and is a large step toward a genomewide analysis. Similar
to previous findings [reviewed by Deaton and Bird (17)],
the general pattern observed was that the majority of
CpGs within CGIs were found to be hypomethylated,
whereas those outside CGIs were methylated at a mid to
high level. They specifically identified that DNAmethylation
of 12 genes (EIF2C3, ZBTB11, BDH2, ZNF187, RUNX1T1,
C9orf64, PDE2A, MGC33486, AMN, ZPBP2, FBN3, PVRL2)
directly correlated with homocysteine levels, whereas themeth-
ylation of 5 genes (ATP5F1, CYP26C1, FSTL3,MDS032, BMX)
displayed an inverse correlation with homocysteine levels. Be-
cause cord blood samples were taken at term, it supports late
gestation as also representing a window of opportunity for
nutrition-induced DNA methylation changes. However, the
methylation patterns observed by the Illumina InfiniumMeth-
ylation 27K beadchip were not confirmed by another method,
and, therefore, these genes require further validation. The lim-
ited number of human studies described here does implicate
folate status and its associated metabolites in influencing
DNA methylation patterns both in utero and in adults. Assess-
ment of other nutrients has been limited. An intervention
study of soy isoflavones in 34 healthy premenopausal women
showed that the promoter region of RARb2 and CCND2 in
breast tissue showed hypermethylation post-treatment but
no effect on p16, RASSF1A, or ER (76). The relevance of
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gene specificity is again highlighted here. DNA methylation
patterns and IUGR were considered using a microarray
DNA methylation assay known as HELP (HpaII tiny frag-
ment Enrichment by ligation Mediated PCR) (77). Although
specific nutrients were not examined, nutrient status has
been implicated as a contributing factor to IUGR (77). A
modest change of 6% DNA methylation difference was ob-
served consistently in HNF4A, ATGS, and TADA3L in the
cord blood of IUGR neonates compared with controls. These
genes were previously linked with type 2 diabetes.
The identiﬁcation of nutrient-sensitive MVPs in humans
is limited by sample availability and ethical issues. Despite
this, a number of observational and intervention studies
found DNAmethylation changes in response to nutrient sta-
tus, particularly in response to folate status (summarized in
Table 2). The more relevant studies examined gene-specific
DNA methylation patterns (66,67,71,72,76) or a narrow ge-
nomewide approach (75). Candidate methylation sites have
emerged, but we are at the beginning in terms of decipher-
ing the human methylome and identifying those nutrient-
relevant DNA methylation sites.
Conclusions
Efforts in the past 10 y provide us with a glimpse of the com-
plexity of the human methylome. We now know that the
simple association of DNA methylation and repressed gene
expression is not always the case. Mammalian DNA methyl-
ation can occur outside the CG context and within the cod-
ing regions of genes. Methylcytosine can also be converted to
hydroxymethylcytosine and is recognized by a speciﬁc set of
molecules that are just starting to be understood. Data just
published (78) have ﬁnally begun to shed light on how de-
methylation of DNA occurs, i.e., by conversion of 5mC
and 5hmC to 5-carboxylcytosine with subsequent process-
ing by thymine-DNA glycosylase. Cataloging the methylo-
mic differences between tissues and individuals has just
begun, but what is clear is that nutrition has a distinct role
to play in mediating DNA methylation changes during de-
velopment or one’s lifetime. Currently there is no compre-
hensive list of which sites are nutrient sensitive, but
studies to date, some which are described here, provide po-
tential candidates. These studies highlighted how it is not
simply about methyl group supply because both supplemen-
tation and deficiency studies observe both increases and de-
creases in DNA methylation. The pattern that is emerging so
far is that nutrient-mediated DNA methylation changes are
gene specific, site specific, tissue specific, and age specific. In
light of this, it is much more meaningful to examine specific,
known regions of the genome or, indeed, a genomewide
screen rather than measuring global DNA methylation pat-
terns that have limited relevance. The technology is now
available to do this, and the identification of nutrient-sensitive
MVPs is likely to explode in the next few years.
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